White v. Novartis Pharmaceuticals Corp.

Full title: CHERYL J. WHITE, SUCCESSOR TO WILLIAM WHITE, Plaintiff, v. NOVARTIS…

Court: UNITED STATES DISTRICT COURT EASTERN DISTRICT OF CALIFORNIA

Date published: Aug 24, 2011

NO. CIV. 06-665 WBS GGH (E.D. Cal. Aug. 24, 2011)

Opinion

NO. CIV. 06-665 WBS GGH

08-24-2011

CHERYL J. WHITE, SUCCESSOR TO WILLIAM WHITE, Plaintiff, v. NOVARTIS PHARMACEUTICALS CORPORATION, Defendant.

WILLIAM B. SHUBB

FINAL PRETRIAL ORDER

A Final Pretrial Conference was held in this matter, pursuant to the provisions of Rule 16(d) of the Federal Rules of Civil Procedure and Local Rule 282, on August 22, 2011. John Girardi and John Vecchione appeared as counsel for plaintiff; Martin Calhoun and James Bruen appeared as counsel for defendant. Following the hearing, the court enters this Final Pretrial Order:

I. Jurisdiction-Venue

Jurisdiction is predicated upon diversity jurisdiction, 28 U.S.C. § 1332. Venue is undisputed and is hereby found to be proper.

II. Jury-Nonjury

The parties have requested a jury trial. Accordingly, the action shall be tried, pursuant to Federal Rule of Civil Procedure 48, before a jury consisting of no less than six and no more than twelve members.

III. Jury Instructions and Proposed Form of Verdict No later than ten court days before the trial date, counsel for plaintiff shall lodge and serve, pursuant to Local Rule 163, copies of all jury instructions that plaintiff requests be given on plaintiff's claims. At that time, counsel for plaintiff shall also file and serve a copy of a proposed form of verdict.

No later than seven court days before the trial date, counsel for defendant shall file and serve any objections to the instructions proposed by plaintiff. At the same time, counsel for defendant shall lodge and serve, pursuant to Local Rule 163, copies of any and all jury instructions not already proposed by plaintiff, which defendant requests be given. Also at that time, counsel for defendant shall file and serve a copy of any proposed form of verdict and shall also file any objections to plaintiff's proposed form of verdict.

No later than four court days before the trial date, counsel for plaintiff shall file and serve any objections to the instructions proposed by defendant and to any proposed form of verdict.

Pursuant to Local Rule 163, any other instructions thereafter presented will be refused unless it is shown either: (1) that the necessity for the request arose in the course of trial; could not reasonably have been anticipated prior to trial from the pleadings, discovery or nature of the action; and the request for such additional instructions is presented to the court as promptly as possible; or (2) that the refusal to give such instructions would constitute plain error.

Likewise, any objections to proposed instructions not made in accordance with this Order will be overruled as untimely unless it is shown either: (1) that the grounds therefor arose in the course of trial and the intention to make such objections is communicated to the court as promptly as possible, or (2) that the giving of such instructions would constitute plain error.

IV. Voir Dire Questions

No later than fourteen days before the trial date, counsel for each party shall submit all proposed jury voir dire questions.

V. Trial Briefs/Motions in Limine

No later than fourteen days before the trial date, each party shall file trial briefs, which shall include any additional¹ motions in limine, pursuant to Local Rule 285. No later than seven days before trial, the parties may file oppositions, if any, to the motions in limine.

1 The parties have already filed numerous motions in limine. (See Docket Nos. 54, 68, 71, 74, 76, 79, 84, 87, 89, 91, and 162.) Many of these motions relate to experts. As the court previously ordered following the initial Pretrial Conference, "[a]ny challenges to proffered expert testimony based on Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999), shall be raised and resolved outside the presence of the jury just prior to when the challenged expert will be called to give testimony. Any challenged expert shall be present for such a challenge, and shall be available for questioning." (Feb. 8, 2011, Order at 2:5-12 (Docket No. 166).) The court also "informed counsel that it is disinclined to decide defendant's motions with respect to punitive damages and recovery of the cost of the drug prior to trial." (Id. at 2:3-5.)

VI. Remaining Claims

The remaining claims for trial are (1) strict liability, (2) negligence, (3) negligent failure to warn, and (4) breach of implied warranty of fitness for purpose.

VII. Witnesses

(A) Plaintiff anticipates calling the witnesses identified at Exhibit "A" attached hereto. Plaintiff states that this list includes "'Case Wide' witnesses who may be called in person or (more likely) by video-tape deposition." (Pl.'s Amended Pretrial Statement at 11 (Docket No. 169).)

(B) Defendant anticipates calling the witnesses identified at Exhibit "B" attached hereto. Defendant's list includes witnesses that it "expects" to call or "may" call.

(C) Except for retained experts, each party may call any witness designated by any other party.

(D) No other witnesses will be permitted to testify at trial unless:

(1) all parties stipulate that the witness may testify;

(2) the party offering the witness demonstrates that the witness is for the purpose of rebutting evidence which could not have been reasonably anticipated at the time of the Pretrial Conference; or

(3) the witness was discovered after the Pretrial Conference.

(E) Testimony of a witness not designated in this Order, which is offered under paragraph VII(D)(3), above, upon the grounds that the witness was discovered after the Pretrial Conference, will not be permitted unless:

(1) the testimony of the witness could not reasonably have been discovered prior to the Pretrial Conference;

(2) the court and opposing counsel were promptly notified upon discovery of the testimony; and

(3) counsel proffered the witness for deposition if time permitted or provided the opposing counsel a reasonable summary of the testimony if time did not permit a deposition.

VIII. Exhibits

(A) Plaintiff intends to offer the exhibits identified at Exhibit "C" attached hereto. Exhibit C includes a list of "Case Wide" exhibits, "White specific" exhibits, and learned treatises.

(B) Defendant intends to offer the exhibits identified at Exhibit "D" attached hereto.

(C) Each party may offer any exhibit designated by any other party.

(D) No other exhibits will be received in evidence unless:

(1) all parties stipulate that the exhibit may be received in evidence;

(2) the party offering the exhibit demonstrates that the exhibit is for the purpose of rebutting evidence which could not have been reasonably anticipated at the time of the Pretrial Conference; or

(3) the exhibit was discovered after the Pretrial Conference.

(E) An exhibit not designated in this Order, which is offered under paragraph VIII(D)(3), above, upon the grounds that the exhibit was discovered after the Pretrial Conference, will not be received in evidence unless:

(1) the exhibit could not reasonably have been discovered prior to the Pretrial Conference;

(2) the court and the opposing counsel were promptly notified upon discovery of the exhibit; and

(3) counsel provided copies of the exhibit to the opposing counsel if physically possible or made the exhibit reasonably available for inspection by the opposing counsel if copying was not physically possible.

(F) Each party shall exchange copies of all exhibits identified in this Order, or make them reasonably available for inspection by the other party, no later than seven calendar days before the trial date. Any and all objections to such exhibits shall be filed and served not later than four calendar days before the trial date.

(G) The attorney for each party is directed to appear before trial and present an original (and if physically possible one copy) of each exhibit to Deputy Clerk Karen Kirksey Smith at 8:30 a.m. on the date of trial.

(H) Each exhibit which has been designated in this Order and presented on the morning of the date of trial shall be pre-marked by counsel. Plaintiff's exhibits shall bear numbers; defendant's exhibits shall bear letters. If no objection has been made to such exhibit pursuant to paragraph VIII(F), above, such exhibit will require no further foundation and will be received in evidence upon the motion of any party at trial.

IX. Further Discovery and Motions

No further motions shall be brought before trial except upon order of the court and upon a showing of manifest injustice. Fed. R. Civ. P. 16(e). No further discovery will be permitted except by the express stipulation of all parties or upon order of the court and upon a showing of manifest injustice. Id.

X. Use of Depositions or Interrogatories

No later than twenty calendar days before the trial date, counsel for each party shall file and serve a statement designating all answers to interrogatories and all portions of depositions intended to be offered or read into evidence, with the exception of portions to be used only for impeachment or rebuttal. No later than ten calendar days before the trial date, counsel for the opposing party may file and serve a counter-designation of other portions of the same depositions intended to be offered or read into evidence and may file evidentiary objections to the other parties' designation. No later than seven calendar days before the trial date, the parties may file evidentiary objections to the opposing party's counter-designation.

XI. Date and Length of Trial

The trial is set for October 4, 2011, at 9:00 a.m. in Courtroom No. 5. Both sides estimate that the jury trial will last 10 to 13 court days.

XII. Evidence Presentation Equipment

The court has new technical equipment, but may not have all of the "state-of-the-art" audio visual equipment and may not have support personnel necessary for the effective presentation of evidence by electronic means. If any party feels that electronic presentation is necessary, they should contact the Courtroom Deputy prior to trial to determine what equipment the court has and how to use that equipment or bring their own audio visual equipment to the courtroom and be prepared to operate it themselves.

XIII. Settlement Conference

A Settlement Conference is set before Magistrate Judge Dale Drozd at 10:00 a.m. on September 22, 2011.

Each party is ordered to have a principal with full settlement authority present at the conference or be fully authorized to settle the matter on any terms. No later than seven days before the date of the Settlement Conference, each party shall submit a confidential Settlement Conference Statement to the settlement judge. Such statements shall not be filed, but shall be delivered to the chambers of the settlement judge, in hard copy.

XIV. Objections to Pretrial Order

Any objections or suggested modifications to this Pretrial Order shall be filed and served within five court days from the file-stamped date of this Order. All references herein to the date of this Order shall refer to the date the tentative order is filed and not to the date any amended order is filed. If no objections or modifications are made, this Order will become final without further order of the court and shall control the subsequent course of the action, pursuant to Rule 16(e) of the Federal Rules of Civil Procedure.

WILLIAM B. SHUBB

UNITED STATES DISTRICT JUDGE

Exhibit "A": Plaintiff's Witnesses²

2 An asterisk indicates an expert witness.

1. Cheryl White

2. Elliott White

3. Guy Acheson

4. Angela Davies

5. Catherine Alexis Friedman

6. Dr. Richard Jackson*

7. Lauren Jenkins

8. John MacMillan

9. Jon Overholt

10. Carol Richman

11. Robin Robillard

12. Michael Tanaka

13. Talib Najjar, D.D.S.*

14. Robert Marx*

15. Suzanne Parisian*

16. Wayne Ray, Ph.D.*

17. Katalin Csermak-Renner

18. Deborah Dunsire

19. Stefano Fratarcangeli

20. Carsten Goessl

21. Jonathan Green

22. Yong Hei

23. Regina Landesberg

24. Margaret Linguri (Dean)

25. Diogini Maladorno

26. Robin Konecne Sterner

27. Peter Tarassoff

28. Stephanie Petrone

29. Rainer Boehm

30. David Epstein

31. Joanne Machalaba

32. Emily Chee

33. Katarzyna Sablinska

34. Linda Weiss

35. Any Custodian of Records needed to authenticate a document objected to by Defendant.

36. All persons for whom a deposition designation has been submitted.

37. Any person named on Defendant's witness list.

Exhibit "B": Defendant's Witnesses

Witnesses NPC "Expects" to Call:

1. Guy Acheson, D.D.S. (Fact Witness; Non-Retained Expert to the Extent Designated in NPC's Designation of Non-Retained Experts)
American River Dental
10350 Coloma Road
Rancho Cordova, CA 95670
2. Janet Arrowsmith, M.D. (Retained NPC Expert)
185 Eagle Creek Canyon
Ruidoso, NM 88345
3. Warren Browner, M.D. (Retained NPC Expert)
2351 Clay Street, 7th Floor
San Francisco, CA 94115
4. Angela Davies, M.D. (Fact Witness; Non-Retained Expert to the Extent Designated in NPC's Designation of Non-Retained Experts)
OSI Pharmaceuticals
2860 Wilderness Place
Boulder, CO 80301
5. Margaret Dean (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
6. Deborah Dunsire, M.D. (Fact Witness)
8 Highmeadow Road
Weston, MA 02493
7. David Ettinger, M.D. (Retained NPC Expert)
The Johns Hopkins University School of Medicine
401 North Broadway, Suite 1440
Baltimore, MD 21231
8. Alan Felsenfeld, D.D.S. (Retained NPC Expert)
UCLA School of Dentistry
43-085 Le Conte Avenue
Los Angeles, CA 90095
9. Carsten Goessl (Fact Witness)
2683 Night Jasmine Drive
Simi Valley, CA 93065
10. Jonathan Green, Ph.D. (Fact Witness)
Can Be Reached Through NPC Counsel at:
1350 I Street, NW
Washington, DC 20005
11. John MacMillan, Jr., M.D. (Fact Witness; Non-Retained
Expert to the Extent Designated in NPC's Designation of Non-Retained Experts)
UC Davis Medical Center
2315 Stockton Blvd.
Sacramento, CA 95817
12. Dionigi Maladorno, M.D. (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
13. Lynne McGrath, Ph.D. (Fact Witness)
Novartis Pharmaceuticals Corporation
180 Park Avenue, Building 105
Florham Park, NJ 07932
14. Jon Overholt, M.D. (Fact Witness; Non-Retained Expert to the Extent Designated in NPC's Designation of Non-Retained Experts)
4614 New York Avenue
Fair Oaks, CA 95628
15. AnneMarie Petraglia, Pharm.D. (Fact Witness)
55 Challenger Row
Ridgefield Park, NJ 07660
16. Stephanie Petrone (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
17. Brian Royse, D.D.S. (Retained NPC Expert)
Davis Oral Surgery
2035 Lyndell Terrace, Suite 110
Davis, CA 95616
18. Graham Russell, M.D. (Retained NPC Expert)
20 Feilden Grove Headington
Oxford, United Kingdom OX3 0DU
19. Katarzyna Sablinska, Ph.D. (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
20. Nicholas Sauter, M.D. (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
21. Robert Spaet (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
22. Michael Tanaka, M.D. (Fact Witness; Non-Retained Expert
to the Extent Designated in NPC's Designation of Non-Retained Experts)
UC Davis Cancer Center
4501 X Street, Suite 3016
Sacramento, CA 95817
23. Diane Young, M.D. (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936

Witnesses NPC "May" Call:

1. Ephraim Abam (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
2. Raymond Aguilar (Fact Witness)
Can Be Reached Through NPC's Counsel at:
1350 I Street, NW Washington, DC 20005
3. Gordon Douglass, D.D.S. (Fact Witness)
3960 El Camino Avenue
Sacramento, CA 95821
4. David Epstein (Fact Witness)
Novartis AG
CH-4002 Basel
Switzerland
5. Stefano Fratarcangeli (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
6. Yong Hei, M.D., Ph.D. (Fact Witness)
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320
7. John Hohneker, M.D. (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
8. Richard Jackson, D.D.S. (Fact Witness)
Jackson, Heise & Alpha Oral and Maxillofacial Surgery
2525 K Street, Suite 101
Sacramento, CA 95816
9. Jagdish Lallian (Fact Witness)
UC Davis Health System
4900 Broadway
Sacramento, CA 95820
10. Susan MacCharles (Fact Witness)
Can Be Reached Through NPC's Counsel at:
1350 I Street, NW
Washington, DC 20005
11. Robert Miranda (Fact Witness)
Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
12. Talib Najjar, D.M.D. (Retained Plaintiff's Expert)
University of Medicine and Dentistry of New Jersey
110 Bergen Street
Newark, NJ 07103
13. Sharon Pfeiffer (Fact Witness)
UC Davis Health System
4900 Broadway
Sacramento, CA 95820
14. Salvatore Ruggiero, D.M.D., M.D. (Fact Witness)
The New York Center for Orthognathic & Maxillofacial Surgery
474 Montauk Highway West Islip, NY 11795
15. Michael Scott (Fact Witness)
1305 Blackberry Court
Libertyville, IL 60048
16. Robyn Sterner, Pharm.D. (Fact Witness)
920 Route 202
Raritan, NJ 08869
17. Peter Tarassoff, M.D. (Fact Witness)
12 Knights Bridge Drive
Randolph, NJ 07869
18. Brina Wright (Fact Witness)
Can Be Reached Through NPC's Counsel at:
1350 I Street, NW Washington, DC 20005
19. All persons for whom a deposition designation has been submitted.
20. Any Custodian of Records needed to authenticate a document objected to by plaintiff.
21. Any person named on Plaintiff's Witness List.

Exhibit "C": Plaintiff's Exhibits

Plaintiff's "Case Wide" Exhibits

+-----------------------------------------------------------------------------+ ¦Pl. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Exhib ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Date ¦FROM ¦TO ¦SUBJECT ¦Author ¦Title ¦ ¦it ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦No. ¦ ¦ ¦ ¦ ¦ ¦ ¦ +-------+------+---------+----------+------------+--------+-------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Urgent ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cook, ¦Review of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦4/19/ ¦ ¦Dunsire, ¦Pharmacist's¦ ¦ ¦ ¦PX-5000¦ ¦Young ¦ ¦ ¦ ¦ ¦ ¦ ¦2005 ¦ ¦Hei and ¦letter ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦review on ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ due 4/21¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia/Zomet¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦a ¦ ¦ ¦ +-------+------+---------+----------+------------+--------+-------------------¦ ¦ ¦ ¦ ¦Mounier, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dear Dentist¦ ¦ ¦ ¦ ¦ ¦ ¦Cook, ¦ ¦ ¦ ¦ ¦ ¦8/4/2 ¦Lantw ¦ ¦Letter ¦ ¦ ¦ ¦PX-5001¦ ¦icki ¦Csermak- ¦ ¦ ¦ ¦ ¦ ¦005 ¦ ¦ ¦Market ¦ ¦ ¦ ¦ ¦ ¦ ¦Renner and¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Research ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+------+---------+----------+------------+--------+-------------------¦ ¦ ¦ ¦ ¦ ¦Zometa Team ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Receives an ¦ ¦ ¦ ¦ ¦ ¦ ¦Kamal, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦honorable ¦ ¦ ¦ ¦ ¦4/4/2 ¦ ¦Machalaba,¦ ¦ ¦ ¦ ¦PX-5002¦ ¦Boehm ¦ ¦mention at ¦ ¦ ¦ ¦ ¦003 ¦ ¦Miranda ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the 2002 ¦ ¦ ¦ ¦ ¦ ¦ ¦and others¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pharma Team ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Award ¦ ¦ ¦ +-------+------+---------+----------+------------+--------+-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Q1 2007 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rainer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦video ¦ ¦ ¦2007 ¦ ¦ ¦ ¦Boehm ¦ ¦ ¦5003 ¦ ¦ ¦ ¦ ¦ ¦Podcast ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to US ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Organization ¦ +-------+------+---------+----------+------------+--------+-------------------¦ ¦ ¦ ¦ ¦Boehm, ¦Dear Dentist¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Letter ¦ ¦ ¦ ¦PX- ¦8/8/2 ¦ ¦Vanditti, ¦ ¦ ¦ ¦ ¦ ¦ ¦Koukouras¦ ¦Study-Market¦ ¦ ¦ ¦5004 ¦005 ¦ ¦Midwinter ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reaearch ¦ ¦ ¦ ¦ ¦ ¦ ¦and others¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Summary ¦ ¦ ¦ +-------+------+---------+----------+------------+--------+-------------------¦ ¦ ¦ ¦ ¦ ¦Zometa IPT ¦ ¦ ¦ ¦ ¦11/8/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5005¦2005 ¦Niebanck ¦Boehm ¦Objectives ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2006 ¦ ¦ ¦ +-------+------+---------+----------+------------+--------+-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Transmitt ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦al of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Advertisements and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Promotional ¦ ¦PX- ¦11/21 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Labeling ¦ ¦5006 ¦/2006 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for Drugs ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Biologics ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for Human Use ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Reprofile Form¦ ¦ ¦ ¦ ¦ ¦ ¦¦3, Reprofile ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Form 2, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦PRM ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Reprofile ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Forms ¦ ¦ ¦11/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5007¦21 /¦ ¦ ¦ ¦¦Form, BBH ¦ ¦ ¦2006¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Segment D Dr. ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Disc Guide ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ENG/STAG, BBH ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Segment D Dr. ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Disk Guide ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Discourag ed ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Better ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Bone ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Health ¦ ¦PX-5008¦2006¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Doctor ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Discussio ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦n Guide ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦ ¦12/ ¦ ¦ ¦ ¦¦Interacti ve ¦ ¦PX-5009¦31 /¦ ¦ ¦ ¦¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦¦Marketing ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦ ¦11/ ¦ ¦Goessl, ¦Zometa New PI available ¦¦ ¦ ¦PX-5010¦24 /¦Miran¦Dunsire, ¦ ¦¦ ¦ ¦ ¦2003¦da ¦Maladorno and ¦(osteonecros is) ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦PX- ¦7/7/¦ ¦ ¦Re: FDA ¦¦ ¦ ¦ ¦2 ¦Dunsi¦Orloff ¦ ¦¦ ¦ ¦5011 ¦ ¦re ¦ ¦Response to Osteonecrosi s ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦labeling-Zometa and Aredia ¦¦ ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦20 ¦Camin¦ ¦RE: Meeting with Sol ¦¦ ¦ ¦ ¦ ¦is ¦Dunsire ¦Epstein-Brief Summary ¦¦ ¦ ¦5012 ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦ ¦12/ ¦ ¦ ¦Re: Draft ¦¦ ¦ ¦PX- ¦12 ¦Camin¦ ¦ ¦¦ ¦ ¦ ¦ ¦is ¦Maladorno ¦ONJ working for the next ¦¦ ¦ ¦5013 ¦/ ¦ ¦ ¦due Aredia Periodic Report-¦¦ ¦ ¦ ¦2004¦ ¦ ¦Team Review requested ¦¦ ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦Aredia ¦ ¦ ¦2001¦ ¦ ¦ ¦¦National ¦ ¦5014 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦IMS DDD ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦1996-2001 ¦ +-------+----+-----+--------------+---------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Units by ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5015¦2006¦ ¦ ¦ ¦¦State ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2002-2006 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Units by ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5016¦2006¦ ¦ ¦ ¦¦State ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2002-2006 ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Sales ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Force ¦ ¦ ¦2/2/¦ ¦ ¦ ¦¦ ¦ ¦PX-5017¦2 ¦ ¦ ¦ ¦¦Strategy ¦ ¦ ¦004 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Assessmen ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦t ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦ ¦ ¦ ¦Zometa ¦¦ ¦ ¦ ¦11/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5018¦16 /¦Chee ¦Brand ¦Targeting ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Project ¦¦ ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦12/6¦ ¦Johnson, ¦October Sales¦¦ ¦ ¦PX-5019¦/ ¦Vendi ¦Dernaree, ¦contest ¦¦ ¦ ¦ ¦2004¦tti ¦Linguri and ¦results ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦12/ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦15 ¦ ¦ ¦ ¦¦Zoledroni c Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Issue-Management [ZIM] Face¦ ¦5020 ¦/ ¦ ¦ ¦ ¦¦to Face Meeting Summary ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦ ¦ ¦ ¦Final ¦¦ ¦ ¦PX- ¦6/27¦ ¦Epstein, ¦ ¦¦ ¦ ¦ ¦/ ¦Cook ¦Dunsire, Young¦Osteonecrosis¦¦ ¦ ¦5021 ¦ ¦ ¦and others ¦ ¦¦ ¦ ¦ ¦2003¦ ¦ ¦Communication¦¦ ¦ ¦ ¦ ¦ ¦ ¦Strategy ¦¦ ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecr ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦osis and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Bisphosph ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/27¦ ¦ ¦ ¦¦onate ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Therapy, ¦ ¦5022 ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Communica ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦tion ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Strategy, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Version ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦7/7/¦Frata ¦Goldfarb, ¦Osteonecrosi ¦¦ ¦ ¦PX-5023¦2 ¦rcang ¦Konecne and ¦s Mini-NEM ¦¦ ¦ ¦ ¦003 ¦eli ¦others ¦ ¦¦ ¦ +-------+----+------+--------------+-------------++---------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Kick-Off ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦7/8/¦ ¦ ¦ ¦¦Meting, ¦ ¦PX- ¦2 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis ¦ ¦5024 ¦003 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Emergency ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Management Team ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Revised Draft for ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Approval, Standby ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Statement, ¦ ¦ ¦7/30¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦Osteonecrosis and ¦ ¦PX-5025¦ ¦ ¦ ¦ ¦¦Bisphosphonate ¦ ¦ ¦2003¦ ¦ ¦ ¦¦Therapy, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦July 30, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003 ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦ ¦ ¦ ¦Re: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦All ¦Investigator ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2/20¦ ¦Investigators ¦Alert- ¦¦ ¦ ¦PX-5026¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦Participating in ¦Informed Consent ¦¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid ¦of Case Reports ¦¦ ¦ ¦ ¦ ¦ ¦Studies ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦¦ ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦ ¦ ¦ ¦Re: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦All ¦Investigator ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2/20¦ ¦Investigators ¦Alert- ¦¦ ¦ ¦PX-5027¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦Participating in ¦Informed Consent ¦¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid ¦of Case Reports ¦¦ ¦ ¦ ¦ ¦ ¦Studies ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦¦ ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦2/20¦ ¦ ¦ ¦¦ ¦ ¦PX-5028¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦3/8/¦ ¦Zometa ¦ ¦¦ ¦ ¦PX-5029¦2 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦004 ¦ ¦Investigators ¦ ¦¦ ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦ ¦ ¦ ¦Re: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of ¦¦ ¦ ¦PX- ¦3/9/¦ ¦Cook and ¦the Jaws ¦¦ ¦ ¦ ¦2 ¦Bock ¦ ¦ ¦¦ ¦ ¦5030 ¦ ¦ ¦others ¦Informed Consent ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦Change-Final NEM ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Team ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Approved Documents¦¦ ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦5/12¦ ¦ ¦Communications ¦¦ ¦ ¦PX-5031¦/ ¦Cook ¦Petraglia ¦document ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦ ¦ ¦Petraglia, ¦ ¦¦ ¦ ¦ ¦7/8/¦Dunsi¦Goessl, ¦Revised Materials ¦¦ ¦ ¦PX-5032¦2 ¦re ¦ ¦for response to ¦¦ ¦ ¦ ¦004 ¦ ¦Maladorno and ¦the FDA ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+-----+-----------------+------------------++--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Taking Care of ¦ ¦ ¦9/ ¦ ¦ ¦ ¦¦Yourself While ¦ ¦PX- ¦200 ¦ ¦ ¦ ¦¦Living ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5033 ¦4 ¦ ¦ ¦ ¦¦With ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Cancer ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------------+ ¦ ¦6/14¦ ¦ ¦Re; FW: ¦ ¦ ¦ ¦PX-5034¦/ ¦Cook ¦Sablinska ¦media.nejm.org¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦Table of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Contents ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦1/13¦ ¦ ¦of the ¦ ¦ ¦ ¦PX-5035¦/ ¦Csermak-Renner¦Hei ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦jaw- Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and Aredia ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦Re: ¦ ¦ ¦ ¦ ¦2/3/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ ¦PX-5036¦ ¦Csermak-Renner¦Hei ¦of the ¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦jaw- Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and Aredia ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦3/14¦ ¦ ¦Aredia FDA ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Csermak-Renner,¦ ¦ ¦ ¦ ¦ ¦ ¦Maladorno ¦Bess, Close and¦call- ¦ ¦ ¦ ¦5037 ¦2003¦ ¦others ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦7/10¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5038¦/ ¦Goessl ¦Hei ¦FYI ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa, ¦ ¦ ¦ ¦ ¦ ¦ ¦Maladorno,¦Aredia, ¦ ¦PX- ¦12/ ¦ ¦ ¦ ¦ ¦Osteonecrosis¦ ¦ ¦20 ¦ ¦ ¦ ¦Close, ¦of the ¦ ¦5039 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦03 ¦ ¦ ¦ ¦Csermak ¦maxillofacial¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦region ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦Re: San ¦ ¦ ¦ ¦PX- ¦12/1¦Csermak- ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦Malsdorno ¦Antonio ¦ ¦ ¦ ¦5040 ¦ ¦Renner ¦ ¦Osteonecrosi s¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦meeting-Draft ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Slides ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦:cases of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦6/3/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦Csermak- ¦ ¦maxillofacia l¦ ¦ ¦ ¦ ¦ ¦ ¦Malsdorno ¦area of ¦ ¦ ¦ ¦5041 ¦004 ¦Renner ¦ ¦novartisargus ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦database ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦excluding ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦aredia and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦zometa ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦ ¦9/8/¦ ¦ ¦Re: registry ¦ ¦ ¦ ¦PX-5042¦2 ¦Csermak-Renner¦Sablinska ¦study ¦ ¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+--------------+---------------+--------------+----------+-------------¦ ¦PX- ¦1/19¦Csermak- ¦ ¦Re: Agenda for¦ ¦ ¦ ¦ ¦/ ¦ ¦Sauter ¦ONJ Weekly ¦ ¦ ¦ ¦5043 ¦ ¦Renner ¦ ¦Guidelines ¦ ¦ ¦ ¦ ¦2006¦ ¦ ¦Meeting Jan 19¦ ¦ ¦ +-----------------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Spontaneo¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦us ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reporting¦ ¦ ¦2/11¦ ¦ ¦ ¦ ¦of ONJ in¦ ¦PX-5044¦/ ¦ ¦ ¦ ¦Csermak¦the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2006¦ ¦ ¦ ¦ ¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Database ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦ ¦ ¦ ¦Aclasta/Zometa¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2/14¦ ¦Close, ¦Advisory ¦ ¦ ¦ ¦PX-5045¦/ ¦Csermak-Renner¦Wever,Maladorno,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Board- ¦ ¦ ¦ ¦ ¦2006¦ ¦and others ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Preliminary ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦summary ¦ ¦ ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦6/10¦ ¦ ¦Re: Issues ¦ ¦ ¦ ¦PX-5046¦/ ¦Fratarcangeli ¦Dunsire ¦Management ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦7/14¦ ¦ ¦ ¦ ¦NEM ¦ ¦PX-5047¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦Meeting #¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3 ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦8/7/¦ ¦ ¦ ¦ ¦NEM ¦ ¦PX-5048¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦ ¦Meeting #¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦9 ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦9/15¦ ¦ ¦ ¦ ¦NEM ¦ ¦PX-5049¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦Minutes ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦11/ ¦ ¦Epstein, Young, ¦Zometa NEM ¦ ¦ ¦ ¦PX-5050¦10 /¦Dunsi re ¦ ¦Update ¦ ¦ ¦ ¦ ¦2003¦ ¦Hage and others ¦ ¦ ¦ ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦4/2/¦ ¦Petraglia, ¦Minutes for ¦ ¦ ¦ ¦PX-5051¦2 ¦Weiss ¦Goessl, Dunsire ¦NEM Meeting * ¦ ¦ ¦ ¦ ¦004 ¦ ¦and others ¦March 31 2004 ¦ ¦ ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦ ¦ ¦Dunsire, ¦ ¦ ¦ ¦ ¦ ¦4/26¦ ¦ ¦Teleconference¦ ¦ ¦ ¦PX-5052¦/ ¦Tarassoff ¦Fratarcang ¦with Dr. ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦Schwartz ¦ ¦ ¦ ¦ ¦ ¦ ¦eli ¦ ¦ ¦ ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦5/3/¦ ¦Epstein, Young, ¦Osteonecrosis ¦ ¦ ¦ ¦PX-5053¦2 ¦Dunsire ¦ ¦NEM update ¦ ¦ ¦ ¦ ¦004 ¦ ¦Hage and others ¦ ¦ ¦ ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦5/12¦ ¦Petraglia, ¦Minutes for ¦ ¦ ¦ ¦PX-5054¦/ ¦Weiss ¦Goessl, Dunsire ¦NEM Meeting * ¦ ¦ ¦ ¦ ¦2004¦ ¦and others ¦May 10 2004 ¦ ¦ ¦ +-------+----+--------------+----------------+--------------+-------+---------¦ ¦ ¦ ¦ ¦ ¦Update on ¦ ¦ ¦ ¦ ¦5/10¦ ¦ ¦Zometa ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Epstein, Young, ¦ ¦ ¦ ¦ ¦ ¦ ¦Dunsire ¦ ¦Osteonecrosis ¦ ¦ ¦ ¦5055 ¦2004¦ ¦Hage and others ¦of the Jaws ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(attachments) ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦5/23¦ ¦Burke, Young,¦Revision of Action ¦¦ ¦ ¦PX-5056¦/ ¦Dunsi re ¦Bock, ¦Plan for Zometa ¦¦ ¦ ¦ ¦ ¦ ¦Hohneker ¦Briefing Package ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦5/26¦ ¦ ¦ ¦¦Minutes of ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦Zometa NEM ¦ ¦PX-5057¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦Meeting 5/26¦ ¦ ¦ ¦ ¦ ¦ ¦¦/04 ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦7/9/¦ ¦Graves, ¦Re: Time Sensitive ¦¦ ¦ ¦PX-5058¦2 ¦Dunsi re ¦Epstein, ¦Revised materials for ¦¦ ¦ ¦ ¦ ¦ ¦Reinhardt and¦response to the FDA ¦¦ ¦ ¦ ¦004 ¦ ¦others ¦ ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦8/17¦ ¦ ¦ ¦¦NEM ¦ ¦PX-5059¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦Minutes ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦9/17¦ ¦ ¦Re: ¦¦ ¦ ¦PX-5060¦/ ¦Dunsi re ¦Tarassoff ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦Conversation with Dr. ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Marx ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦11/ ¦ ¦Gorsky, ¦No Subject (Dear ¦¦ ¦ ¦PX-5061¦22 /¦Dunsire ¦Epstein, ¦ ¦¦ ¦ ¦ ¦2004¦ ¦Young and ¦Management Colleagues)¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦12/3¦ ¦Gorsky, ¦Re: NEM ¦¦ ¦ ¦PX-5062¦/ ¦Dunsire ¦Epstein, ¦ ¦¦ ¦ ¦ ¦2004¦ ¦Young and ¦Update on ONJ and ASH ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦ ¦ ¦ ¦Re: NEM ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦9/2/¦ ¦ ¦Basel ¦¦ ¦ ¦PX-5063¦2 ¦Kirchhoff ¦Dunsire ¦ ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦members ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦recognition ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦12/ ¦ ¦ ¦ ¦¦Declarati on¦ ¦PX-5064¦16 /¦ ¦ ¦ ¦¦of David R. ¦ ¦ ¦2009¦ ¦ ¦ ¦¦Epstein ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦ ¦ ¦ ¦Zoledronic ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦acid/Zometa ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦closing- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦1/29¦ ¦ ¦sticking ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Epstein ¦Reinhardt ¦with the IMB ¦¦ ¦ ¦5065 ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦approved ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦strategy- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦issue in ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Japan? ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦ ¦5/1/¦ ¦ ¦ ¦¦Zometa SRs ¦ ¦PX-5066¦2 ¦Epstein ¦Burke ¦Osteonecrosis ¦¦Feb 9, 2003 ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+----------------------++------------¦ ¦PX- ¦5/2/¦ ¦Maladorno, ¦Osteonecrosis: ¦¦ ¦ ¦ ¦2 ¦Fratarcangeli¦Stone, ¦Follow-up to today's ¦¦ ¦ ¦5067 ¦ ¦ ¦Linguri and ¦teleconference ¦¦ ¦ ¦ ¦003 ¦ ¦others ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦5/5/¦ ¦Epstein, ¦Osteonecrosis-¦¦ ¦ ¦PX-5068¦2 ¦Fratarcangeli¦Boehm, Guidi ¦Follow-up ¦¦ ¦ ¦ ¦003 ¦ ¦and others ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦5/8/¦ ¦ ¦ ¦¦ ¦ ¦PX-5069¦2 ¦Epstein ¦Ebeling ¦Update ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦6/9/¦ ¦Fratarcang ¦Re: Issues ¦¦ ¦ ¦PX-5070¦2 ¦Epstein ¦eli ¦Management ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦6/10¦ ¦ ¦ ¦¦ ¦ ¦PX-5071¦/ ¦Epstein ¦Ebeling ¦Zometa ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦6/10¦ ¦ ¦ ¦¦ ¦ ¦PX-5072¦/ ¦Epstein ¦Burke ¦Re: Zometa ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦6/10¦ ¦Fratarcang ¦Re: Issues ¦¦ ¦ ¦PX-5073¦/ ¦Dunsire ¦eli ¦Management ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Background ¦ ¦ ¦ ¦ ¦ ¦(No Subject) ¦¦ ¦ ¦PX- ¦6/27¦ ¦ ¦Background on ¦¦Information - ¦ ¦ ¦/ ¦Epstein ¦Vasella ¦reports of ¦¦ ¦ ¦5074 ¦ ¦ ¦ ¦ ¦¦Evaluation- Steps ¦ ¦ ¦2003¦ ¦ ¦Osteonecrosis ¦¦being ¦ ¦ ¦ ¦ ¦ ¦of the Jaw ¦¦taken-Osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦of the Jaw (ON) ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Bisphosphonate ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Therapy ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/29¦ ¦ ¦ ¦¦Communication ¦ ¦PX- ¦/ ¦ ¦ ¦Osteonecrosis ¦¦ ¦ ¦ ¦ ¦Epstein ¦Vasella ¦Q & A As ¦¦Strategy, Zometa, ¦ ¦5075 ¦2003¦ ¦ ¦promised ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Version, 27 June, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003, For ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Internal Use Only ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦7/4/¦ ¦ ¦ ¦¦ ¦ ¦PX-5076¦2 ¦Dunsire ¦Epstein ¦Mini NEM ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦7/7/¦ ¦ ¦ ¦¦ ¦ ¦PX-5077¦2 ¦Epstein ¦Fratarcangeli¦Draft ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+-------------+--------------++--------------------¦ ¦ ¦7/8/¦ ¦ ¦Internal ¦¦ ¦ ¦PX-5078¦2 ¦Epstein ¦Dunsire ¦Speakers ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Kick Off ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦7/8/¦ ¦ ¦ ¦¦Novartis ¦ ¦ ¦2 ¦ ¦ ¦ ¦¦ ¦ ¦PX-5079¦ ¦ ¦ ¦ ¦¦Emergency ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Management Team ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦July 8, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003 ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦7/8/¦ ¦ ¦Re: Zometa websites ¦¦ ¦ ¦PX-5080¦2 ¦Dunsire ¦Machalaba¦vs Avonex.com ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦9/2/¦ ¦ ¦ ¦¦ ¦ ¦PX-5081¦2 ¦Epstein ¦Vasella ¦Zometa Letters ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦Novartis Emergency¦ ¦PX- ¦15 ¦ ¦ ¦Zometa Mini ¦¦Management Team ¦ ¦ ¦ ¦Epstein ¦Ebeling ¦ ¦¦Meeting Minutes, ¦ ¦5082 ¦/ ¦ ¦ ¦NEM Update ¦¦October 1, 2003 ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦ ¦ ¦ ¦FY/Q4 2003 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Investor ¦¦ ¦ ¦ ¦1/16¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦Relations ¦¦ ¦ ¦ ¦ ¦Epste in ¦Hendricks¦ ¦¦ ¦ ¦5083 ¦2004¦ ¦ ¦Backgrounder ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦/Consensus/Q ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦& A ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦1/12¦ ¦ ¦Pharma Award ¦¦ ¦ ¦PX-5084¦/ ¦Fratarcangeli¦Dunsire ¦Nomination ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦2/3/¦ ¦ ¦Re: Zometa NEM ¦¦ ¦ ¦PX-5085¦2 ¦Epstein ¦Vasella ¦Update ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦ ¦ ¦ ¦Re; ¦¦ ¦ ¦PX- ¦3/3/¦ ¦Epstein, ¦ ¦¦ ¦ ¦ ¦2 ¦Dunsire ¦ ¦Questions for Mr. ¦¦ ¦ ¦5086 ¦ ¦ ¦Burke ¦Reinhardt-srooy- one¦¦ ¦ ¦ ¦004 ¦ ¦ ¦question in green ¦¦ ¦ ¦ ¦ ¦ ¦ ¦was missing ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦5/13¦ ¦ ¦Urgent-FDA Request ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦for meeting on ¦¦ ¦ ¦ ¦ ¦Epstein ¦Reinhardt¦Osteonecrosis ¦¦ ¦ ¦5087 ¦2004¦ ¦ ¦reports with Zometa ¦¦ ¦ ¦ ¦ ¦ ¦ ¦and Aredia ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦PX- ¦5/17¦ ¦ ¦(No Subject) See ¦¦ ¦ ¦ ¦/ ¦Epstein ¦Vasella ¦attached update on ¦¦ ¦ ¦5088 ¦ ¦ ¦ ¦Osteonecrosis ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+---------+--------------------++------------------¦ ¦ ¦6/17¦ ¦ ¦ ¦¦ ¦ ¦PX-5089¦/ ¦Epstein ¦Vasella ¦FYI ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦7/15¦ ¦ ¦Zometa:FDA Meeting ¦ ¦ ¦ ¦PX-5090¦/ ¦Epstein ¦Ebeling ¦ONJ (July 15, 04) ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦ ¦ ¦ ¦Summary of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦discussion ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦with J. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦7/22¦ ¦ ¦Reinhardt ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5091¦ ¦Epstein ¦Ebeling ¦regarding ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦coordination of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledronic acid ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦related activities ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦8/4/¦ ¦ ¦Re: NEM ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5092¦ ¦Epste in¦Dunsire ¦Update : FDA ¦ ¦ ¦ ¦ ¦004 ¦ ¦ ¦Labeling outcome on ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦9/23¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5093¦/ ¦Burke ¦Epstein ¦today's discussion ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦11/ ¦ ¦ ¦FDA ¦ ¦ ¦ ¦PX- ¦11 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hoppenot¦Epstein ¦Response-Zometa ¦ ¦ ¦ ¦5094 ¦/ ¦ ¦ ¦Revised PI Submitted¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦10-29-04 ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦12/ ¦ ¦ ¦ ¦ ¦ONJ ¦ ¦PX- ¦16 ¦ ¦ ¦Short ¦ ¦ ¦ ¦ ¦ ¦Dunsire ¦Ebeling ¦ ¦ ¦Overview 16 ¦ ¦5095 ¦/ ¦ ¦ ¦summary ONJ ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦December, 2004 ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦12/ ¦ ¦ ¦MDACC- ¦ ¦ ¦ ¦PX-5096¦22 /¦Epstein ¦Reinhardt ¦ ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦Retrospective study ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦on ONJ ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦12/ ¦ ¦Reinhardt, ¦ ¦ ¦ ¦ ¦PX-5097¦23 /¦Epstein ¦Ebeling ¦Re: ODAC ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates¦ ¦PX- ¦2/3/¦ ¦ ¦For you information ¦ ¦ ¦ ¦ ¦2 ¦Epstein ¦Ebeling ¦-ONJ Reply of Prof. ¦Jacky ¦and ¦ ¦5098 ¦ ¦ ¦ ¦Samson ¦Samson¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of the Jaw ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦ ¦2/22¦ ¦ ¦FDA Mtg. ¦ ¦ ¦ ¦PX-5099¦/ ¦Epstein ¦Ebeling ¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦Zometa ODAC ¦ ¦ ¦ +-------+----+--------+-----------+--------------------+------+---------------¦ ¦PX- ¦3/5/¦ ¦ ¦Re: Todays FDA ¦ ¦ ¦ ¦ ¦2 ¦Ebeli ¦Hukkelhoven¦Advisory Committee ¦ ¦ ¦ ¦5100 ¦ ¦ ¦ ¦meeting on Zometa ¦ ¦ ¦ ¦ ¦005 ¦ ¦ ¦and aredia ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dear ¦ ¦ ¦5/9/¦ ¦ ¦Re: Updateot ¦ ¦ ¦ ¦PX-5101¦2 ¦Epstein ¦Ebeling ¦Dentists ¦ ¦Dentist ¦ ¦ ¦005 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Letter ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦Re: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5/9/¦ ¦ ¦interested in a ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5102¦ ¦Epstein ¦Campbell ¦rehearsal ¦ ¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦pre-ASCO ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦analyst call? ¦ ¦ ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦ ¦6/8/¦ ¦Reinhardt, ¦ ¦ ¦ ¦ ¦PX-5103¦2 ¦Epstein ¦Ebeling ¦NEJM Update ¦ ¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦ ¦7/4/¦ ¦ ¦Re; Fw; NEJM ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦Correspondence on ¦ ¦ ¦ ¦ ¦ ¦Vasella ¦Epstein ¦ONJ to be ¦ ¦ ¦ ¦5104 ¦005 ¦ ¦ ¦published next ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦week ¦ ¦ ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Novartis ¦ ¦ ¦ ¦ ¦ ¦Specialty ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Specialty ¦ ¦ ¦ ¦ ¦ ¦Medicianes ¦ ¦ ¦ ¦PX- ¦8/3/¦ ¦ ¦ ¦David ¦Strategic ¦ ¦ ¦2 ¦Campbell ¦Mallik, ¦BoD ¦ ¦ ¦ ¦5105 ¦ ¦ ¦Ebeling ¦ ¦Epstein¦Plan ¦ ¦ ¦005 ¦ ¦ ¦submissions for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦your advance ¦ ¦20052010, ¦ ¦ ¦ ¦ ¦ ¦review ¦ ¦Presentat ion ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to Board of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Directors ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦PX- ¦9/27¦ ¦Altmeyer, ¦Re: meeting w/ ¦ ¦ ¦ ¦ ¦/ ¦Lantwicki¦Filipovic, ¦David Epstein to ¦ ¦ ¦ ¦5106 ¦ ¦ ¦Mounier and ¦Discuss ¦ ¦ ¦ ¦ ¦2005¦ ¦others ¦ONJ-Confirmed ¦ ¦ ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦PX- ¦10/2¦ ¦ ¦Re: Outcome of the¦ ¦ ¦ ¦ ¦/ ¦Sauter ¦Lantwicki ¦Friday Update to ¦ ¦ ¦ ¦5107 ¦ ¦ ¦ ¦David Epstein ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦2006 Budget ¦ ¦ ¦2006¦ ¦ ¦ ¦ ¦Risks and ¦ ¦5108 ¦ ¦ ¦ ¦ ¦ ¦Opportuni ties¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦ ¦12/7¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5109¦/ ¦Epstein ¦Celera ¦ZIM ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+------------+------------------+-------+--------------¦ ¦ ¦2/23¦ ¦ ¦Re: urgent ¦ ¦ ¦ ¦PX-5110¦/ ¦Kincaid ¦Engelhardt ¦-Epstein Business ¦ ¦ ¦ ¦ ¦2006¦ ¦ ¦review ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mayo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinic: ¦ ¦ ¦ ¦ ¦ ¦Mayo clinic has¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦issued press ¦ ¦New ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/11¦ ¦ ¦release on ¦Mayo ¦recommendations for ¦ ¦PX-5111¦/ ¦Epstein¦Ebeling ¦consensus ¦Clinic¦use of ¦ ¦ ¦2006¦ ¦ ¦statement on ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates¦ ¦bisphosphonates in ¦ ¦ ¦ ¦ ¦ ¦in Myeloma ¦ ¦treatment ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦multiple myeloma ¦ +-------+----+-------+----------+---------------+------+----------------------¦ ¦ ¦ ¦ ¦ ¦Re: US ¦ ¦ ¦ ¦ ¦2/20¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5112¦/ ¦Epstein¦Boehm ¦Points for the ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦MM on February ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦21 ¦ ¦ ¦ +-------+----+-------+----------+---------------+------+----------------------¦ ¦ ¦3/29¦ ¦ ¦2007 Zometa ¦ ¦ ¦ ¦PX-5113¦/ ¦Epstein¦Pizytulski¦Plan.ppt ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------+----------+---------------+------+----------------------¦ ¦ ¦4/11¦ ¦ ¦Oncology Global¦ ¦ ¦ ¦PX-5114¦/ ¦Epstein¦Vasella ¦ESR-March 07 ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------+----------+---------------+------+----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa Turnaroun d ¦ ¦PX- ¦4/16¦ ¦ ¦ ¦ ¦Plan beginning with ¦ ¦ ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦5115 ¦ ¦ ¦ ¦ ¦ ¦ZAED- ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦01701480 ¦ +-------+----+-------+----------+---------------+------+----------------------¦ ¦ ¦ ¦ ¦ ¦Re;FW: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Urgent response¦ ¦ ¦ ¦PX- ¦5/17¦Volan ¦ ¦needed: FDA ¦ ¦ ¦ ¦ ¦/ ¦ ¦Epstein ¦revised Plan ¦ ¦ ¦ ¦5116 ¦ ¦te ¦ ¦ ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦Label21386 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa PI-FDA ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Version ¦ ¦ ¦ +-------+----+-------+----------+---------------+------+----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Normal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦serum ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦7/8/¦ ¦ ¦Re: ¦ ¦bone ¦ ¦PX- ¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Epstein¦Lehrer ¦treatment for ¦ ¦markers ¦ ¦5117 ¦008 ¦ ¦ ¦Zometa induced ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ ¦ ¦in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦bisphosphonate-induced¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦jaws ¦ +-------+----+-------+----------+---------------+------+----------------------¦ ¦ ¦ ¦ ¦ ¦Fw; Alert: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2/17¦ ¦ ¦JAMA letter ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦Long-Term Risks of ¦ ¦ ¦ ¦Epstein¦Jimenez ¦on ¦Kuehn ¦Bisphosphonates Probed¦ ¦5118 ¦2009¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety this ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦week ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦1/24¦ ¦ ¦Fw: Final ¦ ¦ ¦ ¦PX-5119¦/ ¦Kamal ¦Potter, ¦minutes- PMB ¦Kamal¦ ¦ ¦ ¦2007¦ ¦DiTrapani ¦Meeting January ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦15 2007 ¦ ¦ ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Promotional¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Material/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦10/ ¦ ¦ ¦ ¦ ¦Label, ¦ ¦PX-5120¦28 /¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Oncology ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦WebSite ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pages ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦ ¦ ¦ ¦Maladorno, ¦ ¦ ¦ ¦ ¦ ¦4/30¦ ¦ ¦Osteonecrosis: ¦ ¦ ¦ ¦ ¦/ ¦ ¦Stone, ¦Follow-up to ¦ ¦ ¦ ¦PX-5121¦ ¦Fratarcangeli¦ ¦today's ¦ ¦ ¦ ¦ ¦2003¦ ¦Linguri ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦teleconference ¦ ¦ ¦ ¦ ¦ ¦ ¦and others ¦ ¦ ¦ ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦ ¦5/5/¦ ¦Epstein, Boehm,¦ ¦ ¦ ¦ ¦PX-5122¦2 ¦Fratarcangeli¦ ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦003 ¦ ¦Guidi and ¦Follow-up ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦ ¦5/27¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5123¦/ ¦Linguri ¦Zometa Team ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦ ¦6/10¦ ¦ ¦Re: Issues ¦ ¦ ¦ ¦PX-5124¦/ ¦Dunsire ¦Fratarcang eli ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦Management ¦ ¦ ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦PX- ¦7/7/¦ ¦Goldfarb, ¦ ¦ ¦ ¦ ¦ ¦2 ¦Fratarcangeli¦Konecne, ¦Osteonecrosis ¦ ¦ ¦ ¦5125 ¦ ¦ ¦Csermak-Renner ¦Mini NEM ¦ ¦ ¦ ¦ ¦003 ¦ ¦and others ¦ ¦ ¦ ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦Re: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦invitation ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦letters for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦11/ ¦ ¦ ¦faculty and ¦ ¦ ¦ ¦PX- ¦18 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fratarcangeli¦Brant-e ¦Novartis ¦ ¦ ¦ ¦5126 ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦attendees of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonesrosi ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦s Ad Board ¦ ¦ ¦ +-------+----+-------------+---------------+----------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦Invitation ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦letters for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦11/ ¦ ¦ ¦faculty and ¦ ¦ ¦ ¦PX- ¦20 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fratarcangeli¦Brant-e ¦Novartis ¦ ¦ ¦ ¦5127 ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦attendees of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis Ad¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Board ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦11/ ¦ ¦ ¦Invitation letters for ¦¦ ¦ ¦PX-5128¦25 /¦Frata ¦Brant-e ¦faculty and Novartis ¦¦ ¦ ¦ ¦2003¦rcangeli ¦ ¦attendees of Novartis ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosi s Ad Board ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory ¦ ¦ ¦12/5¦ ¦ ¦ ¦¦ ¦ ¦PX-5129¦/ ¦ ¦ ¦ ¦¦Board ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Agenda ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦12/5¦ ¦ ¦ ¦¦Board ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5130¦ ¦ ¦ ¦ ¦¦Executive¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Summary ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Dec 5, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003 ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦12/ ¦ ¦Fratarcangeli,¦RE: ¦¦ ¦ ¦PX-5131¦19 /¦McCormick ¦ ¦ ¦¦ ¦ ¦ ¦2003¦ ¦Linguri ¦Executive Summary ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦1/18¦ ¦ ¦ ¦¦ ¦ ¦PX-5132¦/ ¦Sam Klein ¦Debbie ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦PX- ¦5/1/¦ ¦Abarn, Curtis,¦Product team ¦¦ ¦ ¦ ¦2 ¦Maladorno ¦Meyer and ¦feedback-Aredia and ¦¦ ¦ ¦5133 ¦ ¦ ¦others ¦osteonecrosi s ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦ ¦ ¦ ¦Re Fw ¦¦ ¦ ¦ ¦1/7/¦ ¦ ¦ ¦¦ ¦ ¦PX-5134¦2 ¦Fratarcangeli¦hlousek-h ¦Executive ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Summary ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦ ¦ ¦ ¦Update on ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦12/ ¦ ¦ ¦Zometa ¦¦ ¦ ¦PX- ¦28 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Spaet ¦Hei ¦Ostenecrosis ¦¦ ¦ ¦5135 ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2003¦ ¦ ¦Advisory ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Board ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦2/20¦ ¦Goessl, ¦ ¦¦ ¦ ¦PX-5136¦/ ¦Dunsire ¦Maladorno, ¦Dr. Berenson ¦¦ ¦ ¦ ¦2004¦ ¦Cook and ¦ ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦ ¦ ¦ ¦Re ON issue ¦¦ ¦ ¦ ¦5/3/¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦2 ¦ ¦ ¦in AZURE ¦¦ ¦ ¦ ¦ ¦Fratarcangeli¦Hei ¦ ¦¦ ¦ ¦5137 ¦004 ¦ ¦ ¦Trial ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Newsletter April 2004 ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦6/1/¦ ¦Linguri, ¦ ¦¦ ¦ ¦PX-5138¦2 ¦Fratarcangeli¦stefanidou , ¦Zometa Brand Review at ¦¦ ¦ ¦ ¦004 ¦ ¦Fabiani and ¦the June 24 MMB ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+-------------+--------------+------------------------++---------¦ ¦ ¦ ¦ ¦Gorsky, ¦ ¦¦ ¦ ¦ ¦7/14¦ ¦Epstein, ¦Osteonecrosi s of the ¦¦ ¦ ¦PX-5139¦/ ¦Dunsire ¦ ¦jaw Update ¦¦ ¦ ¦ ¦2004¦ ¦Young and ¦ ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦FDA ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Briefing- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/17¦ ¦ ¦Privileged ¦¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5140¦ ¦Goldfarb¦Petraglia ¦and ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦confidential ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Attorney ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Work Product ¦¦ ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Medical ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Marketing ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting : ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zoledroni ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦c Acid ¦ ¦ ¦28 ¦ ¦ ¦ ¦¦ ¦ ¦PX-5141¦ ¦ ¦ ¦ ¦¦Medical ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦Marketing ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦in ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Vienna, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Austria. ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦6/21¦ ¦ ¦ ¦¦ ¦ ¦PX-5142¦/ ¦ ¦ ¦ ¦¦CV ¦ ¦ ¦2010¦ ¦ ¦ ¦¦ ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦6/20¦ ¦ ¦ ¦¦ ¦ ¦PX-5143¦/ ¦Goessl ¦Hei,Fratarcangeli¦ON ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Kick-Off ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis ¦ ¦PX- ¦7/8/¦ ¦ ¦ ¦¦ ¦ ¦ ¦2 ¦ ¦ ¦ ¦¦Emergency ¦ ¦5144 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦Management¦ ¦ ¦ ¦ ¦ ¦ ¦¦Team, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦July 8, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003 ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦10/8¦ ¦ ¦Re: ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Goessl ¦Maladorno ¦Osteonecrosis: Draft ¦¦ ¦ ¦5145 ¦2003¦ ¦ ¦Aredia Expert Report for ¦¦ ¦ ¦ ¦ ¦ ¦ ¦team review ¦¦ ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦7/10¦ ¦ ¦ ¦¦ ¦ ¦PX-5146¦/ ¦Goessl ¦Hei ¦FYI ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦10/ ¦ ¦ ¦Re: IB ¦¦ ¦ ¦PX-5147¦13 /¦Goessl ¦Urbanowitz ¦ ¦¦ ¦ ¦ ¦2003¦ ¦ ¦Zometa ¦¦ ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecr ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦osis/Oste ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦5/12¦ ¦ ¦Re: Minutes ¦¦omyelitis ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Goessl ¦Weiss ¦for NEM Meeting May 10, ¦¦Spontaneo ¦ ¦5148 ¦2004¦ ¦ ¦2004 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦us ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Reports ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦(cumulati ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ve) ¦ +-------+----+--------+-----------------+-------------------------++----------¦ ¦ ¦3/31¦ ¦ ¦Re: Follow- ¦¦ ¦ ¦PX-5149¦/ ¦Goessl ¦Orloff ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦Osteonecrosis ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Re: FDA ¦ ¦ ¦ ¦ ¦7/7/¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5150¦2 ¦Goessl ¦Dunsire ¦Response to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦004 ¦ ¦ ¦Labeling Zometa and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦5/20¦ ¦Maladorno, ¦ ¦ ¦ON- ¦ ¦ ¦/ ¦ ¦Tarassoff, ¦First Draft of BB ¦ ¦ ¦ ¦PX-5151¦ ¦Goessl ¦Petraglia, ¦'current status' ¦ ¦Current ¦ ¦ ¦2004¦ ¦ ¦section ¦ ¦Status ¦ ¦ ¦ ¦ ¦Weiss ¦ ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦ ¦ ¦Hauser, ¦ ¦ ¦ ¦ ¦ ¦8/30¦ ¦Petraglia, ¦ ¦ ¦ ¦ ¦PX-5152¦/ ¦Hei ¦Goessl and ¦Re: ONJ Manuscript ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦ ¦ ¦ ¦Re: FDA ¦ ¦ ¦ ¦PX- ¦7/8/¦ ¦Petraglia, ¦ ¦ ¦ ¦ ¦ ¦2 ¦Dunsire ¦Goessl, ¦Response to ¦ ¦ ¦ ¦5153 ¦ ¦ ¦Maladorno and¦Osteonecrosis ¦ ¦ ¦ ¦ ¦004 ¦ ¦others ¦labeling Zometa and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Epidemiol¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ogical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Report ¦ ¦ ¦7/18¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦entitled ¦ ¦ ¦ ¦ ¦ ¦ ¦Sablinska¦ ¦ ¦5154 ¦2003¦ ¦ ¦ ¦ ¦Osteonecr¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osis in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patients ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦6/21¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5155¦/ ¦Petraglia¦Pazdur ¦Briefing Package ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦4/5/¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5156¦2 ¦ ¦ ¦ ¦ ¦CV ¦ ¦ ¦008 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦ ¦ ¦ ¦Re; ¦ ¦ ¦ ¦ ¦10/8¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦Osteonecrosis: draft¦ ¦ ¦ ¦ ¦ ¦Maladorno¦Fratarcangeli¦Aredia Expert Report¦ ¦ ¦ ¦5157 ¦2003¦ ¦ ¦for team ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦review-Comments from¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CG and SF ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦6/20¦ ¦Hei, ¦ ¦ ¦ ¦ ¦PX-5158¦/ ¦Goessl ¦ ¦ON ¦ ¦ ¦ ¦ ¦2003¦ ¦Fratarcangeli¦ ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦3/12¦ ¦ ¦Re; Reported cases ¦ ¦ ¦ ¦PX-5159¦/ ¦Ambatlle ¦Weiss ¦of osteonecrosis ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-------------+--------------------+---------+---------¦ ¦ ¦3/31¦ ¦ ¦Re Follow Up ¦ ¦ ¦ ¦PX-5160¦/ ¦Goessl ¦Orloff ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦5/20¦ ¦Maladorno, ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦Tarassoff, ¦First draft of BB ¦¦ ¦ ¦PX-5161¦ ¦Goessl ¦Petraglia, ¦"current status" section¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Weiss ¦ ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5162¦13 /¦Goessl ¦Urbanowitz ¦Re; IB Zometa ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦ ¦7/1/¦ ¦ ¦ ¦¦ ¦ ¦PX-5163¦2 ¦Spaet ¦Linguri, Johnson¦Re; Tough questions ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦PX- ¦7/7/¦ ¦ ¦Re FDA Response to ¦¦ ¦ ¦ ¦2 ¦Goessl ¦Dunsire ¦Osteonecrosi s ¦¦ ¦ ¦5164 ¦ ¦ ¦ ¦labeling-Zometa and ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦Aredia ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦PX- ¦7/8/¦ ¦Petraglia, ¦Re FDA Response to ¦¦ ¦ ¦ ¦2 ¦Dunsire¦Goessl, ¦Osteonecrosis ¦¦ ¦ ¦5165 ¦ ¦ ¦Maladorno and ¦labeling-Zometa and ¦¦ ¦ ¦ ¦004 ¦ ¦others ¦Aredia ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Re ¦¦ ¦ ¦ ¦7/8/¦ ¦Petraglia, ¦ ¦¦ ¦ ¦PX- ¦2 ¦ ¦Dunsire, ¦Osteonecrosis article ¦¦ ¦ ¦ ¦ ¦Goessl ¦Maladorno and ¦from Dr. Bouquot: A ¦¦ ¦ ¦5166 ¦004 ¦ ¦others ¦Multifactorial ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Etiology.pdf ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦ ¦5/12¦ ¦ ¦Re Minutes for NEM ¦¦ ¦ ¦PX-5167¦/ ¦Goessl ¦Weiss ¦Meeting * May 10, 2004 ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦ ¦9/24¦ ¦ ¦Re; case details from ¦¦ ¦ ¦PX-5168¦/ ¦Dunsire¦Maladorno ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦(redacted) ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦PX- ¦9/24¦ ¦ ¦Re FDA Response-Urgent ¦¦ ¦ ¦ ¦/ ¦Goessl ¦Schran ¦input required by noon ¦¦ ¦ ¦5169 ¦ ¦ ¦ ¦(US) Sept 24 ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦ ¦8/30¦ ¦ ¦ ¦¦Zometa ¦ ¦PX-5170¦/ ¦ ¦ ¦ ¦¦Briefing Book¦ ¦ ¦2004¦ ¦ ¦ ¦¦30-Aug-2004 ¦ +-------+----+-------+----------------+------------------------++-------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Research ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦7/16¦ ¦ ¦ ¦¦and ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦Develoment ¦ ¦5171 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Briefing ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Book 16- ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦July-2004 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Project: ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Intern ¦ARD233B/ Bone ¦ ¦ ¦4/23¦ ¦ ¦ ¦ationa ¦Mets ZOL446D/ H ¦ ¦PX-5172¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦l ¦ZOL446E/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Treatment Bone ¦ ¦ ¦ ¦ ¦ ¦ ¦Project ¦Mets ZOL446G/ ¦ ¦ ¦ ¦ ¦ ¦ ¦Team ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Prev Bone Mets ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦6/8/¦ ¦ ¦Re ¦ ¦ ¦ ¦PX-5173¦2 ¦Green ¦Hei ¦Urgent-Osteonecrosis¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦Situation ¦ ¦ ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦ ¦ ¦Dunsire, ¦ ¦ ¦ ¦ ¦ ¦12/1¦ ¦Goessl, ¦ ¦ ¦ ¦ ¦PX-5174¦/ ¦Linguri¦Maladorno¦ON Ad Board Dec 5 ¦ ¦ ¦ ¦ ¦2003¦ ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦12/2¦ ¦ ¦ ¦ ¦Advisory Board ¦ ¦PX-5175¦/ ¦ ¦ ¦ ¦ ¦Executive ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦Summary ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Effect of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dichlorom ethane¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Diphospho nate ¦ ¦ ¦5/ ¦ ¦ ¦ ¦ ¦on ¦ ¦PX- ¦198 ¦ ¦ ¦ ¦Jee, ¦Cortisol-Induced¦ ¦ ¦ ¦ ¦ ¦ ¦Black, ¦Bone Loss in ¦ ¦5176 ¦1 ¦ ¦ ¦ ¦Gotcher ¦Young ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Adult ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rabbits ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦The ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Progress ¦ ¦PX- ¦1/21¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦Gotcher ¦of the ¦ ¦5177 ¦ ¦ ¦ ¦ ¦and Jee ¦ ¦ ¦ ¦1981¦ ¦ ¦ ¦ ¦Peridontal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Syndrome in the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rice Rat ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦The ¦ ¦ ¦1/21¦ ¦ ¦ ¦Gotcher,¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦J.E. ¦Progress of the ¦ ¦ ¦ ¦ ¦ ¦ ¦Jee, ¦Peridontal ¦ ¦5178 ¦1981¦ ¦ ¦ ¦W.S.S. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Syndrome in the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rice Rat ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦1/30¦ ¦ ¦Re ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Csermak ¦ ¦ ¦ ¦ ¦ ¦ ¦Hei ¦ ¦Osteonecrosis of the¦ ¦ ¦ ¦5179 ¦2003¦ ¦Renner ¦jaw- Zometa and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦ +-------+----+-------+---------+--------------------+--------+----------------¦ ¦ ¦6/9/¦ ¦ ¦Task force for ¦ ¦ ¦ ¦PX-5180¦2 ¦Hei ¦Bock ¦Zometa ¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦7/23¦ ¦ ¦Re Zometa & Aredia ¦¦ ¦ ¦PX- ¦/ ¦ ¦Fratarcangeli, ¦Letter to Has on ¦¦ ¦ ¦ ¦ ¦Hei ¦ ¦ ¦¦ ¦ ¦5181 ¦2003¦ ¦Dunsire ¦Osteonecrosis/ Info to¦¦ ¦ ¦ ¦ ¦ ¦ ¦Investigator s ¦¦ ¦ +-------+----+-------+---------------+----------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Revised Draft ¦ ¦ ¦ ¦ ¦ ¦ ¦¦for Approval, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Standby ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Statement ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦7/30¦ ¦ ¦ ¦¦, ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦5182 ¦ ¦ ¦ ¦ ¦¦Osteonecr osis ¦ ¦ ¦2003¦ ¦ ¦ ¦¦and Bisphosph ¦ ¦ ¦ ¦ ¦ ¦ ¦¦onate Therapy, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦July 30, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003 ¦ +-------+----+-------+---------------+----------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦NPC - ¦ ¦ ¦7/31¦ ¦ ¦ ¦¦ ¦ ¦PX-5183¦/ ¦ ¦ ¦ ¦¦Standby ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Statement ¦ +-------+----+-------+---------------+----------------------++----------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦27 ¦ ¦Fratarcangeli, ¦Osteonecrosis - we ¦¦ ¦ ¦ ¦ ¦Hei ¦ ¦should add this to ¦¦ ¦ ¦5184 ¦/ ¦ ¦Dunsire ¦informed consent ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+---------------+----------------------++----------------¦ ¦ ¦ ¦ ¦ ¦Re ¦¦ ¦ ¦PX- ¦4/16¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦Hei ¦Murphy ¦Osteonecrosis- ¦¦ ¦ ¦5185 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦clarification for Mr ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Nigel Parr ¦¦ ¦ +-------+----+-------+---------------+----------------------++----------------¦ ¦ ¦5/12¦ ¦Tarassoff, ¦Re Please comment ¦¦ ¦ ¦PX-5186¦/ ¦Hei ¦Caminis, Hauser¦-short White paper ¦¦ ¦ ¦ ¦2004¦ ¦and others ¦ ¦¦ ¦ +-------+----+-------+---------------+----------------------++----------------¦ ¦ ¦5/13¦ ¦ ¦Re FDA Discussion on ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦reports of ¦¦ ¦ ¦ ¦ ¦Hei ¦Maladorno ¦ ¦¦ ¦ ¦5187 ¦2004¦ ¦ ¦Osteonecrosis with ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa and Aredia ¦¦ ¦ +-------+----+-------+---------------+----------------------++----------------¦ ¦PX- ¦7/8/¦ ¦Petraglia, ¦Re FDA response to ¦¦ ¦ ¦ ¦2 ¦Dunsire¦Goessl, ¦osteonecrosis labeling¦¦ ¦ ¦5188 ¦ ¦ ¦Maladorno, and ¦Zometa and Aredia ¦¦ ¦ ¦ ¦004 ¦ ¦others ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦8/30¦ ¦Hauser, ¦ ¦¦ ¦ ¦PX-5189¦/ ¦Hei ¦Petraglia, ¦Re ONJ Manuscript ¦¦ ¦ ¦ ¦2004¦ ¦Goessl and ¦ ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦9/15¦ ¦ ¦ONJ ¦¦ ¦ ¦PX-5190¦/ ¦Hei ¦Tarassoff ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦abstract.doc ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis- ¦¦ ¦ ¦ ¦6/3/¦ ¦ ¦Treatment duration ¦¦ ¦ ¦PX- ¦2 ¦ ¦ ¦to AE- Grand ¦¦ ¦ ¦ ¦ ¦Maladorno ¦Csermak Renner ¦ ¦¦ ¦ ¦5191 ¦004 ¦ ¦ ¦Total : ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦caculations ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Drug ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Regulatory ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦7/15¦ ¦ ¦ ¦¦Affairs, ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa/ ¦ ¦5192 ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Aredia, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Briefing ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Package ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Dear ¦ ¦ ¦9/24¦ ¦ ¦ ¦¦ ¦ ¦PX-5193¦/ ¦ ¦ ¦ ¦¦Doctor ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Letter ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Dear ¦ ¦ ¦9/24¦ ¦ ¦ ¦¦ ¦ ¦PX-5194¦/ ¦ ¦ ¦ ¦¦Doctor ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Letter ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Dear ¦ ¦ ¦5/5/¦ ¦ ¦ ¦¦ ¦ ¦PX-5195¦2 ¦ ¦ ¦ ¦¦Dentist ¦ ¦ ¦005 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Letter ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5196¦25 /¦Scott ¦Lantwicki ¦Re AAOMS ONJ Survey ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Documents ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦Landesberg ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5197 ¦ ¦ ¦ ¦ ¦¦produced ¦ ¦ ¦ ¦ ¦ ¦ ¦¦pursant to the¦ ¦ ¦ ¦ ¦ ¦ ¦¦subpoena. ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦ ¦ ¦Tarassoff, ¦ ¦¦ ¦ ¦ ¦1/10¦ ¦ ¦Spontaneous report? ¦¦ ¦ ¦PX-5198¦/ ¦Petrone ¦Weiss, ¦Osteonecrosis of the¦¦ ¦ ¦ ¦2002¦ ¦ ¦jaw ¦¦ ¦ ¦ ¦ ¦ ¦Lacerna ¦ ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦1/13¦ ¦ ¦Spontaneous report? ¦¦ ¦ ¦PX-5199¦/ ¦Landesberg¦Petrone ¦Osteonecrosis of the¦¦ ¦ ¦ ¦2003¦ ¦ ¦jaw ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦10/ ¦ ¦ ¦Re: ¦¦ ¦ ¦PX-5200¦21 /¦Slosberg ¦Hei ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦Landesberg $$ ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5201¦25 /¦Slosberg ¦Lantwicki ¦AAOMS ONJ survey ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ +-------+----+----------+----------------+--------------------++--------------¦ ¦ ¦11/9¦ ¦ ¦Re fyi for the ¦¦ ¦ ¦PX-5202¦/ ¦Hei ¦Jung ¦team-ONJ related ¦¦ ¦ ¦ ¦2004¦ ¦ ¦articles ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX- ¦12/10¦ ¦ ¦Re Statement by Kyle on IMF¦¦ ¦ ¦ ¦/2004¦Cook¦Lantwicki ¦ONJ Survey data ¦¦ ¦ ¦5203¦ ¦ ¦ ¦ ¦¦ ¦ +----+-----+----+-------------+---------------------------++------------------¦ ¦ ¦ ¦ ¦Petraglia, ¦ ¦¦ ¦ ¦PX- ¦12/10¦ ¦ ¦E-Mail Subject: Statement ¦¦ ¦ ¦ ¦ ¦Cook¦Goessl, ¦by Kyle on IMF ONJ Survey ¦¦ ¦ ¦5204¦/2004¦ ¦Maladorno and¦data ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +----+-----+----+-------------+---------------------------++------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Pharmaceuticals ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Corporation's ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Response ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦to ¦ ¦5205¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Plaintiffs' ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Steering ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Committee's Sixth ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Set of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Interroga tories ¦ ¦ ¦ ¦ ¦ ¦ ¦¦to Defendant ¦ +----+-----+----+-------------+---------------------------++------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Pharmaceuticals ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Corporation's ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Responses ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦to ¦ ¦5206¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Plaintiffs' ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Steering ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Committee's Second¦ ¦ ¦ ¦ ¦ ¦ ¦¦Request for ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Admission ¦ +----+-----+----+-------------+---------------------------++------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Pharmaceuticals ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Corporation's ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Responses ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦to ¦ ¦5207¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Plaintiffs' ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Steering ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Committee's Sixth ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Set of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Document Requests ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦8/1/¦ ¦ ¦ ¦¦Zometa A ONJ ¦ ¦PX-5208¦2 ¦ ¦ ¦ ¦¦Video ¦ ¦ ¦006 ¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦5/12¦ ¦ ¦Update: Zometa Core ¦¦ ¦ ¦PX-5209¦/ ¦Miranda ¦Petraglia ¦Team 5/12 ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦6/24¦ ¦ ¦ ¦¦ ¦ ¦PX-5210¦/ ¦McClure ¦Linguri ¦RE A quick hello ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦6/17¦ ¦ ¦ ¦¦Defendant's ¦ ¦PX-5211¦/ ¦ ¦ ¦ ¦¦Fact Sheet ¦ ¦ ¦2009¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Amended ¦ ¦ ¦6/4/¦ ¦ ¦ ¦¦ ¦ ¦PX-5212¦2 ¦ ¦ ¦ ¦¦Fact ¦ ¦ ¦010 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Sheet ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦ ¦ ¦Fratarcang eli,¦ ¦¦ ¦ ¦ ¦6/10¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦Tarassoff, ¦Email Subject: Issues ¦¦ ¦ ¦PX-5213¦ ¦Linguri ¦ ¦Management ¦¦ ¦ ¦ ¦2003¦ ¦Weiss, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Machalaba ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦ ¦ ¦Fratarcang eli,¦ ¦¦ ¦ ¦ ¦6/10¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦Tarassoff, ¦Email Subject: Issues ¦¦ ¦ ¦PX-5214¦ ¦Linguri ¦ ¦Management ¦¦ ¦ ¦ ¦2003¦ ¦Weiss, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Machalaba ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5215¦29 /¦ ¦ ¦ ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦11/5¦ ¦ ¦ ¦¦ ¦ ¦PX-5216¦/ ¦Linguri ¦Green ¦Osteonecrosis Ad Board ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦11/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦14 ¦ ¦ ¦Re Draft agenda of the ¦¦ ¦ ¦PX-5217¦ ¦Linguri ¦Maladorno ¦San Antonio meeting ¦¦ ¦ ¦ ¦/ ¦ ¦ ¦-Osteonecrosis ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦12/8¦ ¦Venditti, ¦Update on Zometa ¦¦ ¦ ¦ ¦/ ¦ ¦Johnson, Verma,¦ ¦¦ ¦ ¦PX-5218¦ ¦Linguri ¦Scrudato, ¦Osteonecrosis Advisory ¦¦ ¦ ¦ ¦2003¦ ¦ ¦Board ¦¦ ¦ ¦ ¦ ¦ ¦Barninger ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦4/27¦ ¦ ¦ ¦¦ ¦ ¦PX-5219¦/ ¦Tarassoff¦Hohneker ¦Jim Berenson Call ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦6/16¦ ¦ ¦ ¦¦Memo Field ¦ ¦PX-5220¦/ ¦ ¦ ¦ ¦¦Communication¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦7/1/¦ ¦ ¦Re ¦¦ ¦ ¦PX-5221¦2 ¦Linguri ¦Tarassoff ¦ ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦Discussion with Dr. ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Bouguot ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦7/13¦ ¦ ¦ ¦¦ ¦ ¦PX-5222¦/ ¦Linguri ¦Gericke ¦RE Novartis actions ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+---------------+-----------------------++-------------¦ ¦ ¦5/28¦ ¦ ¦ ¦¦ ¦ ¦PX-5223¦/ ¦ ¦ ¦ ¦¦CV ¦ ¦ ¦2008¦ ¦ ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦9/ ¦¦¦¦ ¦rlnaceeutigcal tional Drug ¦ ¦PX-5224¦199 ¦¦¦¦CIBA Pha Basle, Switze ¦ ¦ ¦ ¦ ¦¦¦¦rland ¦Brochure Orientati on Data/ Aredia ¦ ¦ ¦3 ¦¦¦¦ ¦ ¦ +-------+----++++-------------------------+-----------------------------------¦ ¦ ¦4/ ¦¦¦¦ ¦ ¦ ¦PX-5225¦200 ¦¦¦¦Novart is Pharr Basle, ¦Zometa L aStory Study/ Report of ¦ ¦ ¦ ¦¦¦¦Switze rland ¦Results ¦ ¦ ¦0 ¦¦¦¦ ¦ ¦ +-------+----++++-------------------------+-----------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Zometa: ¦ ¦ ¦5/ ¦¦¦¦ ¦ ¦ ¦ ¦200 ¦¦¦¦ ¦Strategic ¦ ¦PX-5226¦ ¦¦¦¦ ¦ ¦ ¦ ¦0 ¦¦¦¦ ¦Plan ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Executive Summary ¦ +-------+----++++-------------------------+-----------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Zometa: ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦8/ ¦¦¦¦ ¦Global ¦ ¦ ¦200 ¦¦¦¦ ¦ ¦ ¦PX-5227¦ ¦¦¦¦ ¦Public ¦ ¦ ¦0 ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Relations ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Plan ¦ +-------+----++++-------------------------+-----------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Zometa GTL ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Aciton ¦ ¦ ¦8/27¦¦¦¦ ¦ ¦ ¦ ¦/ ¦¦¦¦ ¦Plan/ ¦ ¦PX-5228¦ ¦¦¦¦Held ¦ ¦ ¦ ¦2000¦¦¦¦ ¦Follow-up ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Action ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Items ¦ +-------+----++++-------------------------+-----------------------------------¦ ¦ ¦4/25¦¦¦¦ ¦ ¦ ¦PX-5229¦/ ¦¦¦¦ ¦Zometa in Oncology/ Zoledroni c ¦ ¦ ¦ ¦¦¦¦ ¦Acid in 'benign' ¦ ¦ ¦2001¦¦¦¦ ¦ ¦ +-------+----++++-------------------------+-----------------------------------¦ ¦PX-5230¦2000¦¦¦¦ ¦Joint IPT Marketing Presentat ion ¦ +-------+----++++-------------------------+-----------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Zoledronic Acid in ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Benign ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Bone- ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦4/ ¦¦¦¦ ¦related ¦ ¦ ¦200 ¦¦¦¦ ¦ ¦ ¦PX-5231¦ ¦¦¦¦ ¦Indications / ¦ ¦ ¦5 ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Target ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Product ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Profile/ ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Confidential ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Project: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ARD233B/ Bone Mets¦ ¦ ¦2/22¦ ¦ ¦ ¦Machal ¦ZOL446D/ H ¦ ¦PX-5232¦/ ¦ ¦ ¦ ¦aba ¦ ¦ ¦ ¦2001¦ ¦ ¦ ¦ ¦ZOL446E/ Treatment¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bone Mets ZOL446G/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Prev Bone Mets ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦12/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5233¦20 /¦ ¦ ¦ ¦ ¦Telecon Minutes ¦ ¦ ¦2000¦ ¦ ¦ ¦ ¦ ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦ ¦ ¦ ¦ ¦Arnold ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3/21¦ ¦ ¦ ¦Freund ¦Zometa IPT and ¦ ¦PX-5234¦/ ¦ ¦ ¦ ¦ ¦Zoledroni c Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦Machal ¦IPT ¦ ¦ ¦2001¦ ¦ ¦ ¦aba, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shepar ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦d ¦ ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦Machal ¦ ¦ ¦ ¦5/31¦ ¦ ¦ ¦ ¦Project ¦ ¦ ¦/ ¦ ¦ ¦ ¦aba, ¦ ¦ ¦PX-5235¦ ¦ ¦ ¦ ¦ ¦Team ¦ ¦ ¦2001¦ ¦ ¦ ¦Seaman,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦Kamal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Agenda ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦6/12¦ ¦ ¦ ¦ ¦Aredia/Zo meta ¦ ¦PX-5236¦/ ¦ ¦ ¦ ¦ ¦PIND Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Minutes of June ¦ ¦ ¦2001¦ ¦ ¦ ¦ ¦12, 2001 ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦9/2/¦ ¦ ¦ ¦ ¦Global Communica ¦ ¦PX-5237¦2 ¦ ¦ ¦ ¦ ¦tion Plan Brand ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Summary ¦ ¦ ¦001 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦11/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5238¦13 /¦ ¦ ¦ ¦ ¦Aredia Workshop ¦ ¦ ¦2001¦ ¦ ¦ ¦ ¦ ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦ ¦ ¦Reitsma ¦ ¦ ¦ ¦ ¦ ¦12/ ¦ ¦and ¦ ¦ ¦ ¦ ¦PX-5239¦11 /¦Hager ¦ ¦Email Subject: ODAC ¦ ¦ ¦ ¦ ¦2001¦ ¦Machalaba¦Key Messages ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦2/15¦ ¦ ¦Email Subject ¦ ¦ ¦ ¦PX-5240¦/ ¦Held ¦Machalaba¦Zoledronic Acid NEJM¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Proposal and Next ¦ ¦ ¦ ¦ ¦2002¦ ¦ ¦Steps ¦ ¦ ¦ +-------+----+------+---------+--------------------+-------+------------------¦ ¦ ¦ ¦ ¦ ¦URGENT/ PIB Meeting:¦ ¦ ¦ ¦ ¦3/15¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5241¦/ ¦Kappel¦ ¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2002¦ ¦ ¦labeling changes for¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia/ Zometa ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦3/18¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5242¦/ ¦Dunsire ¦Machalaba¦Zometa/ ¦ ¦ ¦ ¦ ¦2002¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Labels ¦ ¦ ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid ¦ ¦PX-5243¦2002¦ ¦ ¦ ¦Kamal ¦Launching the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Blockbuster ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Action Plan in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Response ¦ ¦ ¦7/2/¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5244¦2 ¦ ¦ ¦ ¦ ¦to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦ ¦Osteonecrosis SAEs ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Draft for Input and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Approval ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ASCO 2003 ¦ ¦ ¦7/ ¦ ¦ ¦ ¦Machalaba¦ ¦ ¦PX- ¦200 ¦ ¦ ¦ ¦ ¦Update ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦5245 ¦3 ¦ ¦ ¦ ¦ ¦Field ¦ ¦ ¦ ¦ ¦ ¦ ¦Tarassoff¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Communication ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ASCO 2003 ¦ ¦ ¦7/ ¦ ¦ ¦ ¦Machalaba¦ ¦ ¦PX- ¦200 ¦ ¦ ¦ ¦ ¦Update ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦5246 ¦3 ¦ ¦ ¦ ¦ ¦Field ¦ ¦ ¦ ¦ ¦ ¦ ¦Tarassoff¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Communication ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦9/20¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦Subject sNDA ¦ ¦ ¦ ¦PX-5247¦ ¦Machalaba¦Gotsche ¦PI fo ¦ ¦ ¦ ¦ ¦2002¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦discussion in¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the IPT ¦ ¦ ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa: ¦ ¦ ¦9/29¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5248¦/ ¦ ¦ ¦ ¦ ¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2001¦ ¦ ¦ ¦ ¦Communica tion Plan ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2002 ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦T3-2003 Implement ¦ ¦PX-5249¦2003¦ ¦ ¦ ¦ ¦ation Guide for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦1/7/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦Proposed ¦ ¦ ¦ ¦PX-5250¦ ¦Machalaba¦Konecne ¦ ¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦container ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦labeling ¦ ¦ ¦ +-------+----+---------+---------+-------------+---------+--------------------¦ ¦ ¦6/17¦ ¦ ¦Email ¦ ¦ ¦ ¦PX-5251¦/ ¦Dunsire ¦Linguri ¦Subject: ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦Issues ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Management ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/26¦ ¦ ¦Action ¦¦ ¦ ¦PX-5252¦/ ¦Mellor ¦Shepard ¦ ¦¦ ¦ ¦ ¦2003¦ ¦ ¦Requested: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Letter to ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Has ¦¦ ¦ +-------+----+---------+-----------------+------------------++----------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Revised ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/26¦ ¦ ¦Draft ¦¦ ¦ ¦PX-5253¦/ ¦Machalaba¦Dunsire ¦ ¦¦ ¦ ¦ ¦2003¦ ¦ ¦Osteonecrosis ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Communicatio ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ns/Standby ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Statement & Q & A ¦¦ ¦ +-------+----+---------+-----------------+------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Action Plan in ¦ ¦ ¦7/1/¦ ¦ ¦ ¦¦Response to ¦ ¦PX-5254¦2 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦Osteonecr osis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦SAEs Draft for ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Approval ¦ +-------+----+---------+-----------------+------------------++----------------¦ ¦ ¦7/2/¦ ¦ ¦Email Subject: ¦¦ ¦ ¦PX-5255¦2 ¦Machalaba¦Dunsire, Venditti¦Osteonecrosi s ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Action Plan ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+-----------------+------------------++----------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦7/3/¦ ¦ ¦ ¦¦ ¦ ¦ ¦2 ¦ ¦Fratarcang eli, ¦Subject: Dr. Marx-¦¦ ¦ ¦PX-5256¦ ¦Machablab¦Hei, Tarassoff ¦More background & ¦¦ ¦ ¦ ¦003 ¦ ¦and others ¦data ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦collection form ¦¦ ¦ +-------+----+---------+-----------------+------------------++----------------¦ ¦ ¦7/3/¦ ¦ ¦ ¦¦Osteonecrosis ¦ ¦PX-5257¦2 ¦ ¦ ¦ ¦¦Case Report Data¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦Collection ¦ +-------+----+---------+-----------------+------------------++----------------¦ ¦ ¦7/15¦ ¦ ¦Email Subject: ¦¦Osteonecrosis ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦Case Report Data¦ ¦PX-5258¦ ¦Machalaba¦Williams ¦Zometa ¦¦ ¦ ¦ ¦2003¦ ¦ ¦Osteonecrosis Data¦¦Collection ¦ ¦ ¦ ¦ ¦ ¦Collection Project¦¦ ¦ +-------+----+---------+-----------------+------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦7/15¦ ¦ ¦ ¦¦ ¦ ¦PX-5259¦/ ¦ ¦ ¦ ¦¦Mini-NEM ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Team ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦7/16¦ ¦ ¦ ¦¦Minutes from ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5260¦ ¦ ¦ ¦ ¦¦7/16/2003 NEM ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Teleconference ¦ +-------+----+---------+--------------+---------------++----------------------¦ ¦ ¦11/ ¦ ¦ ¦Email ¦¦ ¦ ¦PX-5261¦15 /¦Machalaba¦Lantwicki ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦Subject: ZOL ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ at next DPB¦¦ ¦ +-------+----+---------+--------------+---------------++----------------------¦ ¦ ¦3/ ¦ ¦ ¦ ¦¦Development ¦ ¦PX-5262¦200 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦4 ¦ ¦ ¦ ¦¦Project Board ¦ +-------+----+---------+--------------+---------------++----------------------¦ ¦ ¦1/10¦ ¦ ¦Email Subject: ¦¦ ¦ ¦PX-5263¦/ ¦Machalaba¦Hohneker ¦Draft DPB ¦¦ ¦ ¦ ¦2005¦ ¦ ¦Agenda ¦¦ ¦ +-------+----+---------+--------------+---------------++----------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: EPI ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Study of ¦¦ ¦ ¦PX- ¦7/25¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦Machalaba¦Sablinska ¦association ¦¦ ¦ ¦5264 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2003¦ ¦ ¦of ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis ¦¦ ¦ ¦ ¦ ¦ ¦ ¦of all sites ¦¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦¦ ¦ ¦ ¦ ¦ ¦ ¦bisphosphonates¦¦ ¦ +-------+----+---------+--------------+---------------++----------------------¦ ¦PX- ¦7/16¦ ¦ ¦ ¦¦Meeting # 4 (NEM) ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦Novartis Emergency ¦ ¦5265 ¦ ¦ ¦ ¦ ¦¦Managemen t Team July ¦ ¦ ¦2003¦ ¦ ¦ ¦¦16, 2003 ¦ +-------+----+---------+--------------+---------------++----------------------¦ ¦ ¦ ¦ ¦Fratarcangeli,¦ ¦¦ ¦ ¦ ¦7/22¦ ¦ ¦Email Subject: ¦¦ ¦ ¦PX- ¦/ ¦ ¦Dunsire, ¦Osteonecrosis -¦¦ ¦ ¦ ¦ ¦Hei ¦ ¦ ¦¦ ¦ ¦5266 ¦2003¦ ¦Tarassoff, ¦important! ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Machalaba ¦ ¦¦ ¦ +-------+----+---------+--------------+---------------++----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting # ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦9 (NEM) ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis Emergency ¦ ¦ ¦8/7/¦ ¦ ¦ ¦¦Managemen t Team ¦ ¦PX- ¦2 ¦ ¦ ¦ ¦¦August 7, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5267 ¦003 ¦ ¦ ¦ ¦¦2003 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦October ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦1, 2003 NEM ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting Minutes ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦11/ ¦ ¦ ¦Email ¦ ¦ ¦ ¦PX-5268¦18 /¦Machalaba¦Lantwicki¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦Subject: ZIM ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Proposal ¦ ¦ ¦ +-------+----+---------+---------+----------------+----------+----------------¦ ¦ ¦1/15¦ ¦ ¦ ¦ ¦Portfolio ¦ ¦PX-5269¦/ ¦ ¦ ¦ ¦ ¦Management Board¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(PMB) January ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦15, 2007 ¦ +-------+----+---------+---------+----------------+----------+----------------¦ ¦ ¦10/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5270¦23 /¦ ¦ ¦ ¦ ¦Zometa Workshops¦ ¦ ¦2000¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+---------+----------------+----------+----------------¦ ¦ ¦1/ ¦ ¦ ¦ ¦ ¦Joining Forces ¦ ¦PX- ¦200 ¦ ¦ ¦ ¦ ¦to Maximize ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledroni c Acid¦ ¦5271 ¦1 ¦ ¦ ¦ ¦ ¦Profitability to¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Novartis ¦ +-------+----+---------+---------+----------------+----------+----------------¦ ¦ ¦ ¦ ¦ ¦ ¦US ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Good ¦ ¦ ¦ ¦ ¦ ¦ ¦Health ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pharmacov ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦igilance ¦ ¦ ¦3/ ¦ ¦ ¦ ¦ ¦Practices and ¦ ¦PX- ¦200 ¦ ¦ ¦ ¦Human ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pharmacoe ¦ ¦5272 ¦5 ¦ ¦ ¦ ¦Services, ¦pidemiologic ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦FDA, ¦Assessmen ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CDER, ¦t ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CBER ¦ ¦ +-------+----+---------+---------+----------------+----------+----------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia, Clinical¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Expert Statement¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maladorno,¦Osteonecrosis of¦ ¦PX- ¦9/ ¦ ¦ ¦ ¦Lombar di,¦the ¦ ¦ ¦200 ¦ ¦ ¦ ¦ ¦ ¦ ¦5273 ¦ ¦ ¦ ¦ ¦Green, ¦Maxillofacial ¦ ¦ ¦3 ¦ ¦ ¦ ¦Spaet ¦Area-Spetember ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Overview ¦ +-------+----+---------+---------+----------------+----------+----------------¦ ¦ ¦ ¦ ¦ ¦:cases of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis of¦ ¦ ¦ ¦ ¦6/3/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦maxillofacial ¦ ¦ ¦ ¦ ¦ ¦Maladorno¦Close ¦area of ¦ ¦ ¦ ¦5274 ¦004 ¦ ¦ ¦novartisargus ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦database ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦excluding aredia¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and zometa ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Re ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦6/3/¦ ¦Csermak- ¦Osteonecrosis Treatment duration ¦ ¦¦ ¦PX-5275¦2 ¦Maladorno¦ ¦to ¦ ¦¦ ¦ ¦004 ¦ ¦Renner ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦AE for ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Aredia only: caculations ¦ ¦¦ +-------+----+---------+--------------+----------------------------------+---+¦ ¦ ¦7/2/¦ ¦ ¦Email ¦ ¦¦ ¦PX-5276¦2 ¦Tarassoff¦Green ¦ ¦ ¦¦ ¦ ¦002 ¦ ¦ ¦Subject: A request ¦ ¦¦ +-------+----+---------+--------------+----------------------------------+---+¦ ¦ ¦7/16¦ ¦ ¦Email ¦ ¦¦ ¦PX-5277¦/ ¦Green ¦Ruggiero ¦ ¦ ¦¦ ¦ ¦2002¦ ¦ ¦Subject: Re: Aredia ¦ ¦¦ +-------+----+---------+--------------+----------------------------------+---+¦ ¦ ¦ ¦ ¦ ¦Email Subject: Medical Inqui 3 ¦ ¦¦ ¦PX- ¦12/6¦ ¦ ¦females with ¦ ¦¦ ¦ ¦/ ¦Weiss ¦Abam ¦ ¦ry ¦¦ ¦5278 ¦ ¦ ¦ ¦necrotic bone- breast cancer, ¦ ¦¦ ¦ ¦2002¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦¦ +-------+----+---------+--------------+----------------------------------+---+¦ ¦ ¦ ¦ ¦ ¦E-mail ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦1/10¦ ¦ ¦Subject: ¦ ¦¦ ¦PX- ¦/ ¦ ¦Tarassoff, ¦ ¦ ¦¦ ¦ ¦ ¦Petrone ¦ ¦Spontaneous ¦ ¦¦ ¦5279 ¦2003¦ ¦Weiss, Lacerna¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦report? ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the jaw ¦ ¦¦ +-------+----+---------+--------------+----------------------------------+---+¦ ¦ ¦6/3/¦ ¦ ¦Email Subject: Osteonecrosis- ¦ ¦¦ ¦PX- ¦2 ¦ ¦ ¦Treatment duration to AE- Grand ¦ ¦¦ ¦ ¦ ¦Maladorno¦Csermak-Renner¦total: ¦ ¦¦ ¦5280 ¦004 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Calculations ¦ ¦¦ +-------+----+---------+--------------+----------------------------------+---+¦ ¦PX- ¦3/26¦Frata ¦ ¦Email Subject: Phone call to Dr. ¦ ¦¦ ¦ ¦/ ¦rcang ¦Hei ¦Schneider from FDA-Aredia and ¦ ¦¦ ¦5281 ¦ ¦ ¦ ¦Zometa osteonecrosis cases ¦ ¦¦ ¦ ¦2003¦eli ¦ ¦ ¦ ¦¦ +-------+----+---------+--------------+----------------------------------+---+¦ ¦ ¦ ¦ ¦ ¦Email Subject: ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦2/9/¦ ¦Bock, Hei, ¦Novartis Webc ¦ ¦¦ ¦PX- ¦2 ¦Kuriger- ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Altmeyer and ¦Adivsory ¦ast¦¦ ¦5282 ¦005 ¦Kara ¦others ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Board ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦members Feb 2005 ¦ ¦¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Labeling ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦July 7, ¦ ¦ ¦ ¦PX- ¦7/7/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2 ¦Stanten ¦Miranda ¦2004. FDA ¦ ¦ ¦ ¦5283 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦004 ¦ ¦ ¦submits it ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦proposed revision ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to NPC's ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦6/21/2004 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦labeling re: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosi s ¦ ¦ ¦ +-------+----+---------+-----------+------------------+---------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dear ¦ ¦ ¦9/24¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5284¦/ ¦ ¦ ¦ ¦Hohneker ¦Doctor ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Letter ¦ +-------+----+---------+-----------+------------------+---------+-------------¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦7/9/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦Petraglia¦FDA ¦ ¦ ¦ ¦ ¦5285 ¦004 ¦ ¦ ¦Labeling- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ +-------+----+---------+-----------+------------------+---------+-------------¦ ¦ ¦7/7/¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5286¦2 ¦Petraglia¦Dunsire ¦NEM Meeting 7-8-04¦ ¦ ¦ ¦ ¦004 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-----------+------------------+---------+-------------¦ ¦PX- ¦7/8/¦ ¦ ¦Re; FDA response ¦ ¦ ¦ ¦ ¦2 ¦Garaud ¦Hukkelhoven¦to osteonecrosi s ¦ ¦ ¦ ¦5287 ¦ ¦ ¦ ¦labeling-Zometa ¦ ¦ ¦ ¦ ¦004 ¦ ¦ ¦and Aredia ¦ ¦ ¦ +-------+----+---------+-----------+------------------+---------+-------------¦ ¦ ¦6/21¦ ¦ ¦ ¦ ¦NPC -briefing¦ ¦PX-5288¦/ ¦ ¦ ¦ ¦ ¦Book to FDA ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-----------+------------------+---------+-------------¦ ¦ ¦9/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5289¦200 ¦ ¦ ¦ ¦ ¦Zometa label ¦ ¦ ¦7 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-----------+------------------+---------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Development, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the Jaw ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(ONJ): ¦ ¦PX- ¦10/2¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦Maladorno¦Revision ¦ ¦5290 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2006¦ ¦ ¦ ¦ ¦of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Class- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Labeling ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Statement ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Expert ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Report ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Letter: ¦¦Updated ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Recommendatios for ¦ ¦ ¦ ¦ ¦ ¦Zometa: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦the ¦ ¦ ¦ ¦ ¦ ¦General ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Prevention, ¦ ¦ ¦9/22¦ ¦ ¦Correspondence, ¦¦ ¦ ¦PX-5291¦/ ¦McGrath ¦Justice ¦Zometa ¦¦Diagnosis , and ¦ ¦ ¦2006¦ ¦ ¦ ¦¦Treatment ¦ ¦ ¦ ¦ ¦ ¦Post-ODAC ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦of ¦ ¦ ¦ ¦ ¦ ¦Follow-up, ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis of ¦ ¦ ¦ ¦ ¦ ¦Serial No. ¦¦the Jaws in Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Patients: May 2 006¦ ¦ ¦ ¦ ¦ ¦357 ¦¦ ¦ +-------+----+--------+------------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Neuropathic Pain in¦ ¦ ¦2/26¦ ¦ ¦Email Subject: Zometa¦¦ ¦ ¦PX-5292¦/ ¦Herald ¦Miranda ¦PI (Osteonecros is) ¦¦Maxillofacial ¦ ¦ ¦2004¦ ¦ ¦Bouquet Manuscript ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Ostenecrosis ¦ +-------+----+--------+------------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Re: Aredia ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦and Zometa ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦9/4/¦ ¦ ¦Products ¦¦ ¦ ¦PX-5293¦2 ¦Johnston¦Germany ¦ ¦¦ ¦ ¦ ¦008 ¦ ¦ ¦Liability ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Litigation., ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦3:06-MD-1760 ¦¦ ¦ +-------+----+--------+------------+---------------------++-------------------¦ ¦ ¦ ¦ ¦Tarassoff, ¦Email ¦¦Osteonecrosis of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦the Jaw and use of ¦ ¦PX- ¦1/5/¦ ¦Dunsire, ¦Subject: ONJ ¦¦Bisphos; Dear ¦ ¦ ¦2 ¦Jansen ¦ ¦ ¦¦ ¦ ¦5294 ¦ ¦ ¦Hei, ¦HORIZON ¦¦HORIZON ¦ ¦ ¦004 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Mellor, ¦letter.doc ¦¦Investigator ¦ ¦ ¦ ¦ ¦Moran ¦ ¦¦ ¦ +-------+----+--------+------------+---------------------++-------------------¦ ¦ ¦1/28¦ ¦ ¦ ¦¦Osteonecrosis of ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦the Jaw and use of ¦ ¦ ¦ ¦Novartis¦Investigator¦ ¦¦Bisphos Dear ¦ ¦5295 ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Investigator ¦ +-------+----+--------+------------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦10/8¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦Krieg ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦man ¦Das ¦ ¦¦ ¦ ¦5296 ¦2006¦ ¦ ¦AAOMS ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting-ONJ Feedback ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦¦¦¦ ¦Once-Yearly Zoledroni c Acid 5 mg in ¦ ¦ ¦ ¦¦¦¦ ¦Postmenopausal Osteoporo sis: The ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦10/11¦¦¦¦ ¦HORIZON ¦ ¦PX-5297¦ ¦¦¦¦ ¦ ¦ ¦ ¦/2006¦¦¦¦ ¦Pivotal ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Fracture ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Trial ¦ +-------+-----++++--------------+---------------------------------------------¦ ¦ ¦11/3/¦¦¦¦Weitzm an and ¦ ¦ ¦PX-5298¦ ¦¦¦¦Erikse n ¦ONJ in oncology and non-oncology patients ¦ ¦ ¦2006 ¦¦¦¦ ¦ ¦ +-------+-----++++--------------+---------------------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Clinical ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Development & ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Medical ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Affairs, ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦6/8/ ¦¦¦¦ ¦Compound: ¦ ¦PX-5299¦2005 ¦¦¦¦Mesenb rink ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Zoledroni ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦c Acid ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Maxillofacial Complicat ion ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Adjudication ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Committee Sharter ¦ +-----------------------------------------------------------------------------+

+------------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Development ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aclasta/R eclast ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Injection ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CZOL446H-Postmenop¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ausal Oste Special¦ ¦ ¦1/3/¦ ¦ ¦Safety ¦ ¦Expert Evaluation ¦ ¦PX-5300¦2 ¦ ¦ ¦ ¦Grbic, ¦Report (SpEER) ¦ ¦ ¦007 ¦ ¦ ¦Update ¦Landesberg¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦maxillofa cial ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦adverse events of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5 mg ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦zoledronic acid ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦given once yearly ¦ +-------+----+---------+----------+--------------+----------+------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject:ZOL2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Altmeyer, ¦301 / ¦ ¦ ¦ ¦ ¦5/29¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5301¦/ ¦Lantwicki¦Maladorno,¦Aclasta: ONJ ¦ ¦ ¦ ¦ ¦2007¦ ¦Eriksen ¦Manuscript ¦ ¦ ¦ ¦ ¦ ¦ ¦and others¦-2nd Draft ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for ZIM ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Review ¦ ¦ ¦ +-------+----+---------+----------+--------------+----------+------------------¦ ¦ ¦ ¦ ¦ ¦Phone Call to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dr. ¦ ¦ ¦ ¦ ¦3/19¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦Schneider from¦ ¦ ¦ ¦PX-5302¦ ¦Miranda ¦Konecne ¦FDA-Aredia and¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosi s¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦cases ¦ ¦ ¦ +-------+----+---------+----------+--------------+----------+------------------¦ ¦PX- ¦6/11¦ ¦Shepard, ¦Urgent Zometa ¦ ¦ ¦ ¦ ¦/ ¦Konecne ¦Machalaba ¦ ¦ ¦ ¦ ¦5303 ¦ ¦ ¦and others¦Teleconference¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦Friday June 13¦ ¦ ¦ +-------+----+---------+----------+--------------+----------+------------------¦ ¦ ¦7/22¦ ¦ ¦ ¦ ¦NEM ¦ ¦PX-5304¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦Meeting #5 ¦ +-------+----+---------+----------+--------------+----------+------------------¦ ¦ ¦8/7/¦ ¦ ¦ ¦ ¦NEM ¦ ¦PX-5305¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦ ¦Meeting # 9 ¦ +-------+----+---------+----------+--------------+----------+------------------¦ ¦ ¦9/17¦ ¦Mellor and¦ ¦ ¦ ¦ ¦PX-5306¦/ ¦Sterner ¦Miranda ¦Re: zol CTIBL ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +------------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦11/27 ¦ ¦ ¦Re: Zometa New PI available (re: ¦¦¦ ¦PX-5307¦/2003 ¦Miranda ¦Robertone ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦osteonecrosis) ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦ ¦ ¦ ¦ ¦Important: Zometa PI-Revisions to ¦¦¦ ¦ ¦2/25/ ¦ ¦ ¦Post ¦¦¦ ¦PX-5308¦ ¦Miranda ¦Pease ¦ ¦¦¦ ¦ ¦2004 ¦ ¦ ¦Marketing ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦Experience ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦ ¦2/25/ ¦ ¦Bess, Close, ¦FDA wants to change the ¦¦¦ ¦PX-5309¦ ¦Maladorno¦Csermak Renner ¦Osteonecrosis USPI ¦¦¦ ¦ ¦2004 ¦ ¦ ¦statement-Zometa ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦PX- ¦2/25/ ¦ ¦ ¦RE: ¦¦¦ ¦ ¦ ¦Maladorno¦Miranda ¦ ¦¦¦ ¦5310 ¦2004 ¦ ¦ ¦Important: Zometa PI-Revisions to ¦¦¦ ¦ ¦ ¦ ¦ ¦Post-Marketing Experience ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦PX- ¦2/25/ ¦ ¦ ¦Zometa PI-Proposed Revised ¦¦¦ ¦ ¦ ¦Miranda ¦Dunsire ¦Osteonecrosis Labeling ¦¦¦ ¦5311 ¦2004 ¦ ¦ ¦ ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦ ¦ ¦ ¦ ¦Response ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦PX- ¦2/26/ ¦ ¦Dunsire, ¦Sent to FDA ¦¦¦ ¦ ¦ ¦Miranda ¦ ¦ ¦¦¦ ¦5312 ¦2004 ¦ ¦Petraglia and ¦re: Zometa PI- ¦¦¦ ¦ ¦ ¦ ¦others ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦Revisions to Osteonecrosis ¦¦¦ ¦ ¦ ¦ ¦ ¦labeling ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦PX-5313¦2/26/ ¦Herald ¦Pease ¦Zometa PI (Osteonecros is) Bouquet¦¦¦ ¦ ¦2004 ¦ ¦ ¦Manuscript ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦PX- ¦6/24/ ¦ ¦ ¦Subject: Zometa-Information ¦¦¦ ¦ ¦ ¦Miranda ¦Petraglia ¦request and meeting with FDA ¦¦¦ ¦5314 ¦2004 ¦ ¦ ¦ ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦PX-5315¦7/7/2 ¦Pease ¦Miranda ¦Zometa Labeling ¦¦¦ ¦ ¦004 ¦ ¦ ¦ ¦¦¦ +-------+------+---------+---------------+----------------------------------++¦ ¦PX-5316¦2/20/ ¦Miranda ¦Narang ¦Re; Latest version of Zometa ¦¦¦ ¦ ¦2004 ¦ ¦ ¦labeling ¦¦¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Yong, ¦ ¦¦¦ ¦PX-5317¦12/2/¦Lynch ¦ ¦ONJ Ad Board Outcomes ¦¦¦ ¦ ¦2005 ¦ ¦Lantwicki, Johnson ¦(very long email) ¦¦¦ ¦ ¦ ¦ ¦and others ¦ ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX-5318¦11/14¦Miranda ¦Cook ¦Re Action List from NEM ¦¦¦ ¦ ¦/2003¦ ¦ ¦Meeting 11/14/03 ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX- ¦2/25/¦ ¦ ¦Zometa PI-Proposed Revised¦¦¦ ¦ ¦ ¦Miranda ¦Dunsire ¦Osteonecrosi s Labeling ¦¦¦ ¦5319 ¦2004 ¦ ¦ ¦ ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦ ¦ ¦ ¦ ¦FDA ¦¦¦ ¦PX- ¦5/13/¦ ¦Dunsire, ¦ ¦¦¦ ¦ ¦ ¦Petraglia ¦ ¦discussion on reports of ¦¦¦ ¦5320 ¦2004 ¦ ¦Goessl and others ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦Osteonecrosi s with Zometa¦¦¦ ¦ ¦ ¦ ¦ ¦and Aredia ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX-5321¦6/23/¦Frararcangeli¦Petraglia, Goessl, ¦Call from Dr. Ruggiero ¦¦¦ ¦ ¦2004 ¦ ¦Maladorno and others¦ ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX-5322¦7/15/¦Narang ¦Reinhardt, Shannon, ¦Zometa: FDA Meeting ONJ ¦¦¦ ¦ ¦2004 ¦ ¦Garaud and others ¦[July 15, 04] ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX-5323¦7/16/¦Maladorno ¦Bess, Close ¦Zometa: FDA Meeting ONJ ¦¦¦ ¦ ¦2004 ¦ ¦ ¦[July 15, 04] ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX- ¦8/4/2¦ ¦Dunsire, Gorsky, ¦Re: NEM Update: FDA ¦¦¦ ¦ ¦ ¦Narang ¦Epstein and others ¦Labeling Outcome on ONJ ¦¦¦ ¦5324 ¦004 ¦ ¦ ¦ ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX- ¦12/23¦ ¦Burke, Hoppenot, ¦ ¦¦¦ ¦ ¦ ¦Narang ¦Hukkelhoven and ¦re: Zometa ¦¦¦ ¦5325 ¦/2004¦ ¦others ¦ ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦ ¦ ¦ ¦ ¦Updated Chronology of ¦¦¦ ¦PX- ¦1/5/2¦ ¦ ¦Zometa ¦¦¦ ¦ ¦ ¦Dunsire ¦Baerlocher ¦ ¦¦¦ ¦5326 ¦005 ¦ ¦ ¦label ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦changes ¦¦¦ +-------+-----+-------------+--------------------+--------------------------++¦ ¦PX- ¦2/10/¦ ¦ ¦Re; Status of searching ¦¦¦ ¦ ¦ ¦Zheng ¦Hei ¦for ONJ in Aredia trials ¦¦¦ ¦5327 ¦2005 ¦ ¦ ¦ ¦¦¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦3/1/¦ ¦Riva, ¦ ¦ ¦ ¦ ¦ ¦2 ¦ ¦Altmeyer, ¦Please ¦ ¦Proposed ¦ ¦PX-5328¦ ¦Hei ¦Narang, ¦ ¦ ¦Registry Study¦ ¦ ¦005 ¦ ¦Young ¦review- ONJ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Registry ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Study.ppt ¦ ¦ ¦ +-------+----+---------+------------+----------------+---------+--------------¦ ¦ ¦ ¦ ¦Hei, ¦ ¦ ¦ ¦ ¦ ¦3/31¦ ¦ ¦Teleconferen ce ¦ ¦ ¦ ¦PX-5329¦/ ¦Petraglia¦Maladorno, ¦next week-odac ¦ ¦ ¦ ¦ ¦2005¦ ¦Cook and ¦followup ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+---------+------------+----------------+---------+--------------¦ ¦ ¦4/25¦ ¦ ¦Email Subject: ¦ ¦Dear ¦ ¦ ¦/ ¦ ¦Dunsire, ¦Revised Dear ¦ ¦ ¦ ¦PX-5330¦ ¦Scott ¦Altmeyer and¦Dentist ¦ ¦Dentist ¦ ¦ ¦2005¦ ¦others ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Letter ¦ ¦Letter ¦ +-------+----+---------+------------+----------------+---------+--------------¦ ¦ ¦4/22¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5331¦/ ¦FDA ¦Petralgia ¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+------------+----------------+---------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Community ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Oncology ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦11/4¦ ¦ ¦ ¦ ¦Board ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦November ¦ ¦5332 ¦2005¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦4, 2005 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chicago, IL, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Exclusively ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Prepared for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Palio ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Communications¦ +-------+----+---------+------------+----------------+---------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Oncology ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Business ¦ ¦PX- ¦1/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦200 ¦ ¦ ¦ ¦Koukouras¦Analysis/ ¦ ¦5333 ¦6 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Qualitative ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Research ¦ +-------+----+---------+------------+----------------+---------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoldronic ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Issue ¦ ¦PX- ¦2/22¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦ ¦Management ¦ ¦5334 ¦2006¦ ¦ ¦ ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Core ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Notes ¦ +-------+----+---------+------------+----------------+---------+--------------¦ ¦ ¦3/27¦ ¦ ¦Email ¦ ¦ ¦ ¦PX-5335¦/ ¦Niebanck ¦Sauter ¦ ¦ ¦ ¦ ¦ ¦2006¦ ¦ ¦Subject: MM ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦4/21/¦ ¦ ¦ ¦¦Aclasta/ Z Osteonecrosis of ¦ ¦PX-5336¦ ¦ ¦ ¦ ¦¦the Jaw (ONJ) Update IMB April¦ ¦ ¦2006 ¦ ¦ ¦ ¦¦21, 2006 ¦ +-------+-----+--------+---------+------------++------------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zoldronic ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Issue ¦ ¦ ¦5/3/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5337¦2006 ¦ ¦ ¦ ¦¦Management Face to ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Face ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Notes ¦ +-------+-----+--------+---------+------------++------------------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/14/¦ ¦ ¦Subject: Sci¦¦ ¦ ¦PX-5338¦ ¦Niebanck¦Rao ¦Ops ¦¦ ¦ ¦ ¦2006 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Presentaions¦¦ ¦ ¦ ¦ ¦ ¦ ¦on ONJ ¦¦ ¦ +-------+-----+--------+---------+------------++------------------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦6/15/¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦Niebanck¦Hitchcock¦ ¦¦ ¦ ¦5339 ¦2006 ¦ ¦ ¦Dental ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Community ¦¦ ¦ ¦ ¦ ¦ ¦ ¦(Reclast) ¦¦ ¦ +-------+-----+--------+---------+------------++------------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Steering ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦11/20¦ ¦ ¦ ¦¦Committee ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5340 ¦/2005¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦November ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦20, 2005 ¦ +-------+-----+--------+---------+------------++------------------------------¦ ¦PX- ¦2/28/¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5341 ¦2007 ¦ ¦ ¦ ¦¦ ¦ +-------+-----+--------+---------+------------++------------------------------¦ ¦ ¦11/21¦ ¦ ¦ ¦¦FDA ¦ ¦PX-5342¦/2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Memorandum ¦ +-------+-----+--------+---------+------------++------------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa PI ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Proposal ¦ ¦ ¦2/25/¦ ¦ ¦ ¦¦ ¦ ¦PX-5343¦ ¦ ¦ ¦ ¦¦Post- ¦ ¦ ¦2004 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Marketing ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Experience ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email Subject: ¦¦ ¦ ¦ ¦2/25¦ ¦Miranda, ¦IMPORTANT-Zometa ¦¦ ¦ ¦PX-5344¦/ ¦Maladorno¦Petraglia, ¦PI-Revisions to ¦¦ ¦ ¦ ¦2004¦ ¦Csermak-Renner¦Post-Marketing ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Experience ¦¦ ¦ +-------+----+---------+--------------+----------------------++---------------¦ ¦ ¦ ¦ ¦ ¦E-mail Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Letter to ¦¦ ¦ ¦ ¦2/27¦ ¦Cook and ¦ ¦¦ ¦ ¦PX-5345¦/ ¦Petraglia¦ ¦non-US ¦¦ ¦ ¦ ¦2004¦ ¦others ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Investigators- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Informed ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Consent-Osteonecrosis ¦¦ ¦ +-------+----+---------+--------------+----------------------++---------------¦ ¦ ¦ ¦ ¦ ¦IND 55,831 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦5/11¦ ¦ ¦Zoledronate ¦¦ ¦ ¦PX-5346¦/ ¦FDA ¦Petraglia ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦for ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Injection ¦¦ ¦ +-------+----+---------+--------------+----------------------++---------------¦ ¦ ¦5/20¦ ¦Goessl, ¦Action ¦¦ ¦ ¦PX- ¦/ ¦ ¦Maladorno, ¦Plan-Preperation of ¦¦ ¦ ¦ ¦ ¦Petraglia¦Cook and ¦Briefing Package for ¦¦ ¦ ¦5347 ¦2004¦ ¦ ¦FDA meeting ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+---------+--------------+----------------------++---------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦5/27¦ ¦ ¦Zometa ¦¦ ¦ ¦PX- ¦/ ¦ ¦Goessl, ¦ ¦¦ ¦ ¦ ¦ ¦Petraglia¦Maladorno and ¦Briefing ¦¦ ¦ ¦5348 ¦2004¦ ¦others ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Package- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Additional ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Section ¦¦ ¦ +-------+----+---------+--------------+----------------------++---------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦of the ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Jaw-Prevention,¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Diagnosis and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Treatment ¦ ¦ ¦6/14¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦Informati ¦ ¦ ¦ ¦Germo ¦ ¦ ¦¦ ¦ ¦5349 ¦2004¦ ¦ ¦ ¦¦on for ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦People ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦living ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦with ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Cancer ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Petraglia, ¦Zometa ONJ FDA briefing workplan ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦6/25/¦ ¦Goessl, ¦V1.1 25-Jun- ¦¦¦ ¦PX-5350¦ ¦Jung ¦ ¦ ¦¦¦ ¦ ¦2004 ¦ ¦Dunsire ¦04.ppt- ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦and others ¦Updated Workplan & Key Action ¦¦¦ ¦ ¦ ¦ ¦ ¦Items ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦PX-5351¦6/30/¦Petraglia¦Tarassoff ¦Zometa Labeling-Osteonecrosis ¦¦¦ ¦ ¦2004 ¦ ¦ ¦ ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦ ¦7/8/2¦ ¦ ¦Re; FDA Response to Osteonecrosis ¦¦¦ ¦PX-5352¦ ¦Orloff ¦Dunsire ¦Labeling Zometa and Aredia ¦¦¦ ¦ ¦004 ¦ ¦ ¦ ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦PX-5353¦7/9/2¦Petraglia¦Pease ¦Zometa Labeling Osteonecrosis ¦¦¦ ¦ ¦004 ¦ ¦ ¦ ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦ ¦ ¦ ¦Goessl, ¦Zometa- PI and Dear Dr Letter ¦¦¦ ¦PX- ¦8/2/2¦ ¦Maladorno, Cook ¦reply- ¦¦¦ ¦ ¦ ¦Petraglia¦and ¦ ¦¦¦ ¦5354 ¦004 ¦ ¦ ¦Osteonecrosis ¦¦¦ ¦ ¦ ¦ ¦others ¦ ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦PX-5355¦8/4/2¦Staten ¦Petraglia ¦Action Items ¦¦¦ ¦ ¦004 ¦ ¦ ¦ ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦ ¦ ¦ ¦ ¦Re Draft letter for ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦FDA - ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦overview of ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦PX- ¦12/23¦ ¦ ¦MD Anderson ¦¦¦ ¦ ¦ ¦Maladorno¦Narang ¦ ¦¦¦ ¦5356 ¦/2004¦ ¦ ¦study ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦status- ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦feedbackon ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦comments ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦ ¦ ¦ ¦Hei, ¦ ¦¦¦ ¦PX-5357¦1/21/¦Petraglia¦ ¦Bisphosphona tes AERS database ¦¦¦ ¦ ¦2005 ¦ ¦Maladorno, Cook ¦search ¦¦¦ ¦ ¦ ¦ ¦and others ¦ ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦ ¦ ¦ ¦ ¦Re; Due ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦PX- ¦1/21/¦ ¦ ¦Diligence- ¦¦¦ ¦ ¦ ¦Mellor ¦Petraglia ¦ ¦¦¦ ¦5358 ¦2005 ¦ ¦ ¦Risk ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦Minimization Action Plan ¦¦¦ +-------+-----+---------+----------------+----------------------------------++¦ ¦PX-5359¦1/27/¦Petraglia¦Maladorno ¦Sent to FDA 1-26-05 ¦¦¦ ¦ ¦2005 ¦ ¦ ¦ ¦¦¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Hei, ¦ ¦ ¦ ¦ ¦ ¦1/31¦ ¦ ¦Follow-up to Telecon ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Maladorno,¦of 1-27-05 with the ¦ ¦ ¦ ¦ ¦ ¦ ¦Cook and ¦Office of Drug Safety ¦ ¦ ¦ ¦5360 ¦2005¦Petraglia¦others ¦Due ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦1/18¦Petraglia¦Hei, ¦Diligence-Risk ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦5361 ¦ ¦ ¦Maladorno,¦Minimization Action ¦ ¦ ¦ ¦ ¦2005¦ ¦Cook and ¦Plan ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Healthy ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦steps to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3/30¦ ¦Gallo, ¦ZOM-4039 ¦ ¦protect ¦ ¦PX-5362¦/ ¦McClellan¦ ¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦Laties ¦Patient tear Sheet ¦ ¦your ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦bones: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦brochure ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦Chart of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦5363 ¦ ¦ ¦ ¦ ¦ ¦Trials ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦PX- ¦7/3/¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦2 ¦ ¦ ¦ ¦ ¦Study 010 ¦ ¦5364 ¦001 ¦ ¦ ¦ ¦ ¦Volume 1 ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦PX- ¦7/30¦ ¦ ¦ ¦ ¦Study 010 ¦ ¦ ¦/ ¦ ¦ ¦ ¦ ¦Appendix ¦ ¦5365 ¦1998¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1 ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦ ¦7/30¦ ¦ ¦ ¦ ¦Clinical ¦ ¦PX-5366¦/ ¦ ¦ ¦ ¦ ¦Study 010 ¦ ¦ ¦1998¦ ¦ ¦ ¦ ¦Volume 2 ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦ ¦9/28¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5367¦ ¦ ¦ ¦ ¦ ¦Study ¦ ¦ ¦1999¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦IA03 ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Development ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman¦ ¦ ¦ ¦9/2/¦ ¦ ¦ ¦ ¦Zometa Study ¦ ¦PX-5368¦2 ¦ ¦ ¦ ¦, ¦No. ¦ ¦ ¦002 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chen, ¦42446-03010 ¦ ¦ ¦ ¦ ¦ ¦ ¦Dias ¦core and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦extension ¦ +-------+----+---------+----------+----------------------+------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Development ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa Study ¦ ¦ ¦9/30¦ ¦ ¦ ¦ ¦No. ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦42446-03010 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦core and ¦ ¦5369 ¦1999¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦extension ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Appendix ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦8/16¦ ¦ ¦ ¦ ¦Protective and ¦ ¦PX-5370¦/ ¦ ¦ ¦ ¦ ¦Confidentiality¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Order ¦ ¦ ¦2006¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5/9/¦ ¦ ¦Questions ¦ ¦ ¦ ¦ ¦2 ¦ ¦Petrone ¦ ¦ ¦ ¦ ¦PX-5371¦ ¦Kroger ¦and ¦for ZFAST- ¦ ¦ ¦ ¦ ¦005 ¦ ¦others ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Additional ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Information ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Requested ¦ ¦ ¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦7/9/¦ ¦Ambros ¦Email ¦ ¦ ¦ ¦PX-5372¦2 ¦Paramore ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: RSA Monthly ¦ ¦ ¦ ¦ ¦004 ¦ ¦others ¦Reports-June 2004 ¦ ¦ ¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦8/28¦Merlat- ¦ ¦Important-reporting ¦ ¦ ¦ ¦ ¦/ ¦ ¦Hei ¦of cases of ¦ ¦ ¦ ¦5373 ¦ ¦Guitard ¦ ¦osteonecrosis of the ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦jaw (ONJ) in clinical¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦trials involving ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦3/16¦ ¦Hohneker¦Email Subject: ¦ ¦ ¦ ¦PX-5374¦/ ¦Tarassoff¦and ¦Osteonecrosis: Zometa¦ ¦ ¦ ¦ ¦2004¦ ¦others ¦ ¦ ¦ ¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: ¦ ¦ ¦ ¦PX- ¦12/1¦ ¦Verma ¦**Zometa Issues: 15 ¦ ¦ ¦ ¦ ¦/ ¦Linguri ¦and ¦ ¦ ¦ ¦ ¦5375 ¦ ¦ ¦others ¦Nov 2003 ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦JCO** ¦ ¦ ¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Re: A ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Symposium in ¦ ¦5376 ¦ ¦ ¦ ¦ ¦ ¦San Antonio, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Texas ¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Overview: ¦ ¦ ¦6/10¦ ¦ ¦ ¦ ¦Zometa in ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Petrone¦the ¦ ¦5377 ¦2005¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Treatment of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bone Metastases¦ +-------+----+---------+--------+---------------------+-------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦US ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3/9/¦ ¦ ¦ ¦ ¦Business ¦ ¦PX-5378¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦006 ¦ ¦ ¦ ¦ ¦Review- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦2004 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5379¦2004¦ ¦ ¦ ¦¦CTIBL ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Strategy ¦ +-------+----+----------+-------------+------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Oncology Business ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Unit ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦National ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5380¦2006¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦US ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Developments and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Medical Affairs ¦ +-------+----+----------+-------------+------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Action ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Required- ¦¦ ¦ ¦ ¦2/23¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦Petrone and ¦Zometa ¦¦ ¦ ¦PX-5381¦ ¦Hei ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦Lacerna ¦Protocol ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Amendment ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦regarding ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ and Dose ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Adjustment ¦¦ ¦ +-------+----+----------+-------------+------------------++-------------------¦ ¦ ¦7/13¦ ¦Petrone and ¦Email ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Hei ¦Lacerna, ¦Subject ONJ in ¦¦ ¦ ¦5382 ¦2005¦ ¦Weiss and ¦ongoing clinical ¦¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦trials ¦¦ ¦ +-------+----+----------+-------------+------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Email Subject ¦¦ ¦ ¦ ¦1/12¦ ¦ ¦Osteonecrosis on ¦¦ ¦ ¦PX- ¦/ ¦ ¦McWhorter and¦the jaws- ¦¦ ¦ ¦ ¦ ¦Hei ¦others ¦ ¦¦ ¦ ¦5383 ¦2004¦ ¦ ¦inclusion in ¦¦ ¦ ¦ ¦ ¦ ¦ ¦patient informed ¦¦ ¦ ¦ ¦ ¦ ¦ ¦consent? ¦¦ ¦ +-------+----+----------+-------------+------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject ¦¦ ¦ ¦ ¦1/13¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦Spontaneous ¦¦ ¦ ¦ ¦ ¦Landesberg¦Petrone ¦ ¦¦ ¦ ¦5384 ¦2003¦ ¦ ¦report? ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosi ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦s of the jaw ¦¦ ¦ +-------+----+----------+-------------+------------------++-------------------¦ ¦ ¦3/3/¦ ¦Petrone and ¦Email ¦¦ ¦ ¦PX-5385¦2 ¦Weiss ¦ ¦ ¦¦ ¦ ¦ ¦005 ¦ ¦Tarassoff ¦Subject ONJ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦descriptive terms?¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Incidence ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Adverse ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Events ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Regardless of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Study ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5386¦ ¦ ¦ ¦ ¦¦Drug ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Relations hip ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Occuring in ¦ ¦ ¦ ¦ ¦ ¦ ¦¦more ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦than 10% of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Safety- ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Evaluable ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Patients ¦ +-------+----+-------+-----------------------+----------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Executive ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Summary/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa Bone ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦9/3/¦ ¦ ¦ ¦¦Endocrino logy¦ ¦PX-5387¦2 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦Advisory Board¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting August¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦14-16, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003 ¦ +-------+----+-------+-----------------------+----------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Draft: ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Executive ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Summary/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa Bone ¦ ¦ ¦9/8/¦ ¦ ¦ ¦¦ ¦ ¦PX-5388¦2 ¦ ¦ ¦ ¦¦Endocrino logy¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory Board¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting August¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦14-16, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2003 ¦ +-------+----+-------+-----------------------+----------------++--------------¦ ¦ ¦1/22¦ ¦Letter to All ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Csermak¦Investigators in ¦ ¦¦ ¦ ¦5389 ¦2002¦ ¦Zoledronic Acid ¦ ¦¦ ¦ ¦ ¦ ¦ ¦(ZOL446) Studies ¦ ¦¦ ¦ +-------+----+-------+-----------------------+----------------++--------------¦ ¦ ¦ ¦ ¦ ¦Re; Final Draft ¦¦ ¦ ¦ ¦1/20¦ ¦ ¦Report (Study ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦No. ¦¦ ¦ ¦ ¦ ¦Wang ¦Petrone ¦ ¦¦ ¦ ¦5390 ¦2003¦ ¦ ¦CZOL446 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦0705) ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦12/9¦ ¦ ¦Re: Amended Task Order for¦¦ ¦ ¦PX-5391¦/ ¦Landis¦Petrone ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦CZOL446EUS15 ¦¦ ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Email Subject URGENT: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Update of Urologic Clinics¦¦ ¦ ¦ ¦1/15¦ ¦Petrone ¦of ¦¦ ¦ ¦PX-5392¦/ ¦Hei ¦and ¦ ¦¦ ¦ ¦ ¦2004¦ ¦others ¦NA ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦manuscript ¦¦ ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Brant-e, ¦Subject ¦¦ ¦ ¦ ¦4/9/¦Vande ¦ ¦ ¦¦ ¦ ¦PX-5393¦2 ¦Pol ¦Kaminski,¦Poster ¦¦ ¦ ¦ ¦002 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Petrone ¦comments (My comments/cla ¦¦ ¦ ¦ ¦ ¦ ¦ ¦rifications on the Zometa ¦¦ ¦ ¦ ¦ ¦ ¦ ¦705 Poster) ¦¦ ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦PX-5394¦ ¦ ¦ ¦ ¦¦Follow Up Exam ¦ ¦ ¦ ¦ ¦ ¦ ¦¦-Week ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦ONJ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦9/26¦ ¦ ¦ ¦¦Chronology ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦5395 ¦ ¦ ¦ ¦ ¦¦September 26, 2005,¦ ¦ ¦2005¦ ¦ ¦ ¦¦For ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Internal Use Only ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦PX-5396¦2002¦ ¦ ¦ ¦¦Zometa Phase 4 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Summary ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2/15¦ ¦ ¦ ¦¦Trial ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Team ¦ ¦5397 ¦2005¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Minutes ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Summary ¦ ¦ ¦3/10¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5398 ¦2000¦ ¦ ¦ ¦¦Protocol: CZOL446 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦IA03I1 (Extension ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Study 1) ¦ +-------+----+------+---------+--------------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Medical ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Monitoring ¦ ¦PX- ¦12/1¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦Guidelines for ¦ ¦5399 ¦ ¦ ¦ ¦ ¦¦Protocol ¦ ¦ ¦2002¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦CZOL446E ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦US32 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Research ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦Overview: GCP, ¦ ¦ ¦ ¦ ¦ ¦ ¦Petrone ¦ ¦ ¦5400 ¦ ¦ ¦ ¦ ¦ ¦Regulatory ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Documents , ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Roles ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Oncology ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦US CD MA ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Trial ¦ ¦5401 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Contact ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦List ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦PX-5402¦ ¦ ¦ ¦ ¦ ¦Tracking ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦document ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦PX-5403¦ ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦Reitsm ¦Integrate d ¦ ¦ ¦7/30¦ ¦ ¦ ¦ ¦Summary of ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦a, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety/ ¦ ¦5404 ¦2001¦ ¦ ¦ ¦Chen, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman ¦ ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦ ¦ ¦ ¦ ¦A standard template¦ ¦ ¦ ¦ ¦10/8¦ ¦ ¦approval letter for¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦an ¦ ¦ ¦ ¦ ¦ ¦Petrone ¦Acrenas ¦ ¦ ¦ ¦ ¦5405 ¦2002¦ ¦ ¦Investigator ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Initiated Research ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Proposal ¦ ¦ ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Draft of ¦ ¦ ¦ ¦ ¦ ¦ ¦Wang ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(Medical ¦the ¦ ¦PX- ¦3/8/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦ ¦writer ¦Clinical Study ¦ ¦5406 ¦ ¦ ¦ ¦ ¦ ¦for The ¦ ¦ ¦002 ¦ ¦ ¦ ¦Kendle ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Intern ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦aitonal) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦705 Trial ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦ ¦2/11¦ ¦ ¦Email ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Ambros ¦ ¦ ¦ ¦ ¦ ¦ ¦Paramore¦and ¦Subject: RSA ¦ ¦ ¦ ¦5407 ¦2004¦ ¦others ¦January 2004 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Monthly Report ¦ ¦ ¦ +-------+----+--------+--------+-------------------+----------+---------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2/29¦ ¦ ¦Draft of ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Hei and ¦ ¦ ¦ ¦ ¦ ¦ ¦Dunsire ¦others ¦Ostenecrosis ¦ ¦ ¦ ¦5408 ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦protocal- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦please ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦clarify ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Appendix 2 Zometa/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Draft ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦summary ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Goessl ¦clinical ¦ ¦PX- ¦11/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦11 /¦ ¦ ¦ ¦, ¦study ¦ ¦5409 ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schran ¦protocal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CZOL446E2 430 in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦response ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to FDA ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦request ¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Expert ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Panel ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Recommend ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ations ¦ ¦ ¦6/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦200 ¦ ¦ ¦ ¦ ¦for the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5410 ¦4 ¦ ¦ ¦ ¦ ¦Prevention, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Diagnosis , And ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Treatment ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteoporo sis of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the Jaws: June 2004¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦PX- ¦4/ ¦ ¦ ¦ ¦ ¦Osteonecrosis of ¦ ¦ ¦200 ¦ ¦ ¦ ¦ ¦the Jaw (ONJ) and ¦ ¦5411 ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates ¦ ¦ ¦5 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦ ¦9/10¦ ¦ ¦FREQ ¦ ¦FREQ ¦ ¦PX-5412¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2009¦ ¦ ¦Procedure ¦ ¦Procedure ¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2/10¦ ¦ ¦Subject: Jaw ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Maladorno,¦osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦Sablinski¦Rodriquez ¦in cancer p ¦atients¦ ¦ ¦5413 ¦2003¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦26 ONJ- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦cluster ¦ ¦ ¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦ ¦ ¦ ¦ ¦FW: ¦ ¦ ¦ ¦PX- ¦6/14¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦Sablinski¦Cook ¦media.nejm.o ¦ ¦ ¦ ¦5414 ¦2005¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦rg Table of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Contents ¦ ¦ ¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦ ¦ ¦ ¦ ¦Re: FW: ¦ ¦ ¦ ¦PX- ¦6/15¦ ¦ ¦media.nejm.o ¦ ¦ ¦ ¦ ¦/ ¦Sablinski¦Cook ¦ ¦ ¦ ¦ ¦5415 ¦2005¦ ¦ ¦rg Table of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Contents ¦ ¦ ¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦PX- ¦6/20¦ ¦ ¦Re: US ¦ ¦ ¦ ¦ ¦/ ¦Eriksen ¦Lantwicki ¦ ¦ ¦ ¦ ¦5416 ¦2005¦ ¦ ¦Registry Study ¦ ¦ ¦ +-------+----+---------+----------+---------------+-------+-------------------¦ ¦PX-5417¦ ¦ ¦ ¦ ¦ ¦CV ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦12/ ¦ ¦ ¦Re: ¦Novart ¦ ¦ ¦PX- ¦10 ¦Curti¦ ¦ ¦is ¦ ¦ ¦ ¦ ¦s ¦Abam ¦Additional Cases of ¦ ¦ ¦ ¦5418¦/ ¦ ¦ ¦Osteonecrosis ¦Employee¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +----+----+-----+--------+---------------------------+--------+---------------¦ ¦PX- ¦2/21¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦Hei ¦Young ¦ODAC-Status Update on ONJ ¦Hei to ¦ ¦ ¦5419¦ ¦ ¦ ¦in clinical trials ¦Young ¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦ ¦ +----+----+-----+--------+---------------------------+--------+---------------¦ ¦ ¦6/ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦200 ¦ ¦ ¦ ¦ ¦Prescribing ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦9 ¦ ¦ ¦ ¦ ¦Informati on ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5420¦6/ ¦ ¦ ¦ ¦ ¦6/2009, ¦ ¦ ¦200 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦6/2003 ¦ ¦ ¦3 ¦ ¦ ¦ ¦ ¦ ¦ +----+----+-----+--------+---------------------------+--------+---------------¦ ¦PX- ¦8/ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦200 ¦ ¦ ¦ ¦ ¦Prescribi ¦ ¦5421¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦4 ¦ ¦ ¦ ¦ ¦Informati on ¦ +----+----+-----+--------+---------------------------+--------+---------------¦ ¦ ¦11/ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦PX- ¦20 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Prescribing ¦ ¦5422¦08 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Information ¦ +----+----+-----+--------+---------------------------+--------+---------------¦ ¦ ¦ ¦ ¦ ¦Medical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Officer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Review- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Efficacy ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/22¦ ¦ ¦Proposed ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hedin¦Macalush¦labeling for ¦ ¦ ¦ ¦5423¦1995¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Multiple ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Myeloma ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦indication & ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fax cover ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦sheet ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/16/1995 ¦ ¦ ¦ +----+----+-----+--------+---------------------------+--------+---------------¦ ¦PX- ¦12/ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦20 ¦ ¦ ¦ ¦ ¦Prescribi ¦ ¦5424¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦05 ¦ ¦ ¦ ¦ ¦Informati on ¦ +----+----+-----+--------+---------------------------+--------+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Highlights of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦9/ ¦ ¦ ¦ ¦ ¦Prescribing ¦ ¦ ¦200 ¦ ¦ ¦ ¦ ¦Informa Full ¦ ¦5425¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦7 ¦ ¦ ¦ ¦ ¦Prescribing ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Informati on ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦2/16¦ ¦ ¦NDA 21-386 S-002 FDA ¦ ¦ ¦ ¦PX-5426¦/ ¦Jamison¦McGrath¦T-Con Label Review ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Comments ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------+-------+-------------------------+-------+--------------¦ ¦ ¦9/9/¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5427¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦004 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------+-------+-------------------------+-------+--------------¦ ¦ ¦5/3/¦ ¦ ¦ ¦Michae ¦ ¦ ¦PX-5428¦2 ¦ ¦ ¦ ¦l ¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Scott ¦ ¦ +-------+----+-------+-------+-------------------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Preclinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Toxicolog ¦ ¦ ¦3/24¦ ¦ ¦ ¦Green, ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦Spaet, ¦y/Patholo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5429 ¦2004¦ ¦ ¦ ¦Choi ¦ZOL446K ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CV of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦experts- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦nonclinical ¦ +-------+----+-------+-------+-------------------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Profiling ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/8/¦ ¦ ¦ ¦ ¦and ¦ ¦PX- ¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Spaet ¦Assessment, ¦ ¦5430 ¦006 ¦ ¦ ¦ ¦ ¦Aredia 1.4.3 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CV ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦nonclinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦expert ¦ +-------+----+-------+-------+-------------------------+-------+--------------¦ ¦ ¦5/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5431¦198 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦7 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------+-------+-------------------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Preclinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ZOL446K, ¦ ¦PX- ¦3/31¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦Spaet ¦Zoledroni c ¦ ¦5432 ¦ ¦ ¦ ¦ ¦ ¦acid, ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2.6.6 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Toxicology ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Written ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Summary ¦ +-------+----+-------+-------+-------------------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Preclinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Green, ¦ZOL446K, ¦ ¦PX- ¦4/5/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦ ¦Choi, ¦Zoledroni c ¦ ¦5433 ¦ ¦ ¦ ¦ ¦ ¦acid, ¦ ¦ ¦004 ¦ ¦ ¦ ¦Spaet ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2.4 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nonclinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Overview ¦ +-----------------------------------------------------------------------------+

+---------------------------------------------------------------------+ ¦ ¦ ¦¦¦¦ ¦Aredia, Clincal Expert Statement¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦PX- ¦7/18/¦¦¦¦Malado rno, Lombar di,¦Osteonecrosis of ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦5434¦2003 ¦¦¦¦Green, Spaet ¦the ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Maxillofacial Area ¦ +----+-----++++----------------------+--------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Aredia, Clincal Expert Statement¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Osteonecrosis of the ¦ ¦PX- ¦10/17¦¦¦¦Malado rno, Lombar di,¦ ¦ ¦ ¦ ¦¦¦¦ ¦Maxillofacial Area-September ¦ ¦5435¦/2003¦¦¦¦Green, Spaet ¦ ¦ ¦ ¦ ¦¦¦¦ ¦2003 ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Overview ¦ +----+-----++++----------------------+--------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Aredia, Clincal Expert Statement¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Osteonecrosis of the ¦ ¦PX- ¦12/19¦¦¦¦Maladorno, Lombardi, ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Maxillofacial Area-October ¦ ¦5436¦/2003¦¦¦¦Green, Spaet ¦ ¦ ¦ ¦ ¦¦¦¦ ¦2003 ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Overview ¦ +----+-----++++----------------------+--------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Aredia, Clincal Expert Statement¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Osteonecrosis of ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦PX- ¦6/18/¦¦¦¦Maladorno, Csermak, ¦the ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦5437¦2004 ¦¦¦¦Green, Spaet ¦Maxillofacial ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Area- May 2004 ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Overview ¦ +---------------------------------------------------------------------+

+--------------------------------------------------------------------+ ¦ ¦ ¦¦¦¦ ¦Drug ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Regulatory ¦ ¦ ¦6/21/¦¦¦¦ ¦ ¦ ¦PX-5438¦ ¦¦¦¦ ¦Affairs, Zometa Injection , Aredia Injection¦ ¦ ¦2004 ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦, ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Briefing Package ¦ +-------+-----++++------+--------------------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Oncologic ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Drugs ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Advisory ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Committee ¦ ¦ ¦3/4/2¦¦¦¦ ¦ ¦ ¦PX-5439¦ ¦¦¦¦ ¦Meeting ¦ ¦ ¦005 ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦March 4, ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦2005 ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Zometa and ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Aredia ¦ +-------+-----++++------+--------------------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Preclinical ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Safety, ¦ ¦ ¦ ¦¦¦¦Green,¦ ¦ ¦PX- ¦8/25/¦¦¦¦ ¦ZOL446K, ¦ ¦ ¦ ¦¦¦¦Choi, ¦ ¦ ¦5440 ¦2004 ¦¦¦¦ ¦2.4 ¦ ¦ ¦ ¦¦¦¦Spaet ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Nonclinical ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Overview ¦ +-------+-----++++------+--------------------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Preclinical ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Safety, ¦ ¦PX- ¦8/25/¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦Spaet ¦ZOL446K, ¦ ¦5441 ¦2004 ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦2.6.6 ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Toxicology Written Summary ¦ +--------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦¦¦¦ ¦Safety ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Profiling ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦and ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦PX- ¦10/ ¦¦¦¦ ¦Assessment, ZOL446K ¦ ¦ ¦20 ¦¦¦¦Spaet¦ ¦ ¦5442¦ ¦¦¦¦ ¦CSE ¦ ¦ ¦05 ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Appendix-Nonclinical Overvie Zoledroni c acid preclinical ¦ ¦ ¦ ¦¦¦¦ ¦safety and ADME studies released between January ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦2000 and ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦September 2005 ¦ +----+----++++-----+----------------------------------------------------------¦ ¦ ¦ ¦¦¦¦ ¦Safety ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Profiling ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦and ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Assessment, ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦ZOL446K, ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦10/ ¦¦¦¦ ¦Zometa, ¦ ¦PX- ¦28 ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦Spaet¦Clinical ¦ ¦5443¦/ ¦¦¦¦ ¦ ¦ ¦ ¦2005¦¦¦¦ ¦Expert ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Statement ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦(Clinical ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Overview) ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦Appendix ¦ ¦ ¦ ¦¦¦¦ ¦ ¦ ¦ ¦ ¦¦¦¦ ¦1 ¦ +----+----++++-----+----------------------------------------------------------¦ ¦PX- ¦ ¦¦¦¦ ¦Zolendron ate, ¦ ¦ ¦ ¦¦¦¦Spaet¦ ¦ ¦5444¦ ¦¦¦¦ ¦Synopsis of Pre-clinical Data ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Safety ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Profiling ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Assessment, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia (15mg, 3 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦0mg, 60mg, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦90mg ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/17¦ ¦ ¦ ¦ ¦powder and ¦ ¦PX-5445¦/ ¦ ¦ ¦ ¦Spaet¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦solvent for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦solution for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦infusi ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CES ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Appendix ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1 : Non- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦overview ¦ +-------+----+-----+-------+---------------------------+-----+----------------¦ ¦ ¦7/18¦Dunsi¦Epstein¦Email Subject: Zometa NEM ¦ ¦ ¦ ¦PX-5446¦/ ¦re ¦and ¦Team Meeting Minutes-July ¦ ¦ ¦ ¦ ¦2003¦ ¦others ¦11 and July 14 ¦ ¦ ¦ +-------+----+-----+-------+---------------------------+-----+----------------¦ ¦ ¦11/ ¦ ¦ ¦Email Subject: Osteonecrosi¦ ¦ ¦ ¦PX-5447¦13 /¦Spaet¦Hei ¦s- beagle dog study ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-----+-------+---------------------------+-----+----------------¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦PX-5448¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦Advisory Board ¦ +-------+----+-----+-------+---------------------------+-----+----------------¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦PX-5449¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦Advisory Board ¦ +-------+----+-----+-------+---------------------------+-----+----------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5450 ¦2003¦ ¦ ¦ ¦ ¦Board ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Agenda ¦ +-------+----+-----+-------+---------------------------+-----+----------------¦ ¦ ¦3/24¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5451¦/ ¦Cook ¦Linguri¦Email Subject: Animal Study¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Oncologic ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Drugs ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Committee ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦3/4/¦ ¦ ¦ ¦¦ ¦ ¦PX-5452¦2 ¦ ¦ ¦ ¦¦March 4, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦¦2005 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Backgroun ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦d- ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Preclinical¦ ¦ ¦ ¦ ¦ ¦ ¦¦/MOA ¦ +-------+----+----------+-------------+--------------------------++-----------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦4/24¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦Hei and ¦Subject: Jpn ¦¦ ¦ ¦PX-5453¦ ¦Altmeyer ¦others ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ONJ Ad ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Boards-Highlights ¦¦ ¦ +-------+----+----------+-------------+--------------------------++-----------¦ ¦ ¦ ¦ ¦Seaman, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Scanned- ¦¦ ¦ ¦PX- ¦1/10¦ ¦Chen, ¦ ¦¦ ¦ ¦ ¦/ ¦Konecne ¦ ¦06Jan03_FDA Fax re NDA ¦¦ ¦ ¦5454 ¦ ¦ ¦Schran, ¦21-386 ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Hei and ¦Zometa ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+----------+-------------+--------------------------++-----------¦ ¦ ¦ ¦Jennifer ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Murphy, ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Consumer ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Promotion ¦ ¦Re: NDA 21386, Zometa ¦¦ ¦ ¦ ¦3/6/¦ ¦ ¦(zoledronic acid for ¦¦ ¦ ¦PX-5455¦2 ¦Analyst, ¦Konecne ¦injection) ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Regulatory¦ ¦MACMIS ID# 11456 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Review ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Officer ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦(FDA) ¦ ¦ ¦¦ ¦ +-------+----+----------+-------------+--------------------------++-----------¦ ¦ ¦ ¦ ¦ ¦Re: Dr. ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Ruggiero's ¦¦ ¦ ¦ ¦5/2/¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦2 ¦ ¦ ¦publication ¦¦ ¦ ¦ ¦ ¦Tarassoff ¦Frararcangeli¦ ¦¦ ¦ ¦5456 ¦003 ¦ ¦ ¦plans- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia and ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Project: ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ARD233B/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Bone Mets, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ZOL446D/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦HCM, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/5/¦ ¦ ¦ ¦¦ZOL446E/ ¦ ¦PX-5457¦2 ¦ ¦ ¦ ¦¦Treatment ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦Bone Mets, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ZOL446G/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Preventio ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦n, IPT ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Minutes ¦ +-------+----+-------+--------+---------------------------------++------------¦ ¦ ¦6/13¦ ¦Zometa ¦Action Plan in response to ¦¦ ¦ ¦PX-5458¦/ ¦Chi ¦and ¦reports of bone necrosis with the¦¦ ¦ ¦ ¦2003¦ ¦Aredia ¦use of Zometa and Aredia ¦¦ ¦ ¦ ¦ ¦ ¦IPT ¦ ¦¦ ¦ +-------+----+-------+--------+---------------------------------++------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Project: ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ARD233B/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Bone Mets, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ZOL446D/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦HCM, ¦ ¦ ¦7/14¦ ¦ ¦ ¦¦ ¦ ¦PX-5459¦/ ¦ ¦ ¦ ¦¦ZOL446E/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Treatment ¦ ¦ ¦2003¦ ¦ ¦ ¦¦Bone Mets, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ZOL446G/ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Prevention, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦IPT ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Minutes ¦ +-------+----+-------+--------+---------------------------------++------------¦ ¦ ¦7/8/¦ ¦ ¦ ¦¦NEM Kick-Off¦ ¦PX-5460¦2 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦Meeting ¦ +-------+----+-------+--------+---------------------------------++------------¦ ¦ ¦ ¦ ¦ ¦Aredia ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Vials, ¦¦ ¦ ¦ ¦7/18¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦Pazdur, ¦Zometa ¦¦ ¦ ¦ ¦ ¦Konecne¦FDA ¦ ¦¦ ¦ ¦5461 ¦2003¦ ¦ ¦Injection, ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Cases of ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis ¦¦ ¦ +-------+----+-------+--------+---------------------------------++------------¦ ¦ ¦8/6/¦ ¦ ¦Re: Summary of Zometa USPI FDA ¦¦ ¦ ¦PX-5462¦2 ¦Koerner¦Sterner ¦t-con ¦¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+--------+---------------------------------++------------¦ ¦ ¦8/25¦ ¦ ¦ ¦¦ ¦ ¦PX-5463¦/ ¦Shannon¦Dunsire ¦Re: Zometa and Aredia USPI change¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Re: ON ¦ ¦ ¦ ¦ ¦11/3¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5464¦/ ¦Porfido ¦Linguri ¦Aredia and ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦Zometa USPI ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦cost ¦ ¦ ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Injection, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦9/26¦ ¦ ¦Special ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sterner ¦Orloff ¦Supplement- ¦ ¦ ¦ ¦5465 ¦2003¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Changes ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Being ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Effected ¦ ¦ ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦11/3¦ ¦Linguri, ¦ON USPI change ¦ ¦ ¦ ¦PX-5466¦/ ¦Fratarcangeli¦Tarassoff ¦FDA ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦acknowledgement¦ ¦ ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦7/14¦ ¦ ¦Updated HA ¦ ¦ ¦ ¦PX-5467¦/ ¦Hakkelhoven ¦Konecne ¦Letter ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦3/29¦ ¦Weiss, ¦E-Mail Subject:¦ ¦ ¦ ¦PX-5468¦/ ¦Klein ¦Tarassoff ¦osteochemone ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦crosis ¦ ¦ ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦3/1/¦ ¦Dunsire, ¦Osteonecrosis ¦ ¦ ¦ ¦PX-5469¦2 ¦Malad orno ¦Goessl, ¦cases as of ¦ ¦ ¦ ¦ ¦004 ¦ ¦Cook and ¦Feb. 24, 2004 ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦ ¦Tarassoff, ¦To the ¦ ¦Tarass ¦ ¦ ¦PX-5470¦2003¦Csermak ¦Editor ¦ ¦off, ¦To the Editor ¦ ¦ ¦ ¦ ¦ ¦ ¦Csermak ¦ ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of the Jaws: ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1982¦ ¦ ¦ ¦Schwartz¦A ¦ ¦5471 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Complication ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chempther ¦ +-------+----+-------------+----------+---------------+--------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦Sung, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chan, ¦the ¦ ¦PX- ¦ ¦ ¦ ¦ ¦Sakura ¦ ¦ ¦ ¦2002¦ ¦ ¦ ¦ ¦maxilla as a ¦ ¦5472 ¦ ¦ ¦ ¦ ¦i, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦complication ¦ ¦ ¦ ¦ ¦ ¦ ¦Chung ¦to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦chemptherapy: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦a case report ¦ +-----------------------------------------------------------------------------+

+-------------------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦The ¦ ¦ ¦ ¦ ¦ ¦ ¦Chang,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Greens¦pathogenesis of¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis ¦ ¦PX-5473¦1999¦ ¦ ¦ ¦pan, ¦and the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gersbw¦relations hip ¦ ¦ ¦ ¦ ¦ ¦ ¦in ¦to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦corticosteroids¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5474¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5475¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦4/29¦ ¦ ¦Re: ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦Hei ¦Osteonecrosis with ¦ ¦ ¦ ¦5476 ¦2003¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦bisphosphonates ¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦7/2/¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5477¦2 ¦Tarassoff ¦Green ¦A Request ¦ ¦ ¦ ¦ ¦002 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦ ¦ ¦ ¦This letter is in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦response to your ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦request for ¦ ¦ ¦ ¦PX- ¦7/8/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2 ¦Tarassoff, ¦Ruggiero ¦information ¦ ¦ ¦ ¦5478 ¦ ¦Weiss ¦ ¦ ¦ ¦ ¦ ¦ ¦002 ¦ ¦ ¦regarding ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(pamidronatedisodium)¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦ ¦ ¦ ¦Re: Dr. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ruggieros's ¦ ¦ ¦ ¦ ¦5/2/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦publication ¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦Frararcangeli¦ ¦ ¦ ¦ ¦5479 ¦003 ¦ ¦ ¦plans- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦osteonecrosis ¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦6/9/¦ ¦Epstein, ¦ ¦ ¦ ¦ ¦PX-5480¦2 ¦Fratarcangeli¦Boehm, Burke ¦Issues Management ¦ ¦ ¦ ¦ ¦003 ¦ ¦and others ¦ ¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦PX- ¦8/25¦ ¦ ¦Re; ONJ munuscript ¦ ¦ ¦ ¦ ¦/ ¦Ruggiero ¦Brant-e ¦for your review ¦ ¦ ¦ ¦5481 ¦ ¦ ¦ ¦(NVR-242-6242) ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-------------+-------------+---------------------+------+---------------¦ ¦ ¦ ¦ ¦ ¦Re: ¦ ¦ ¦ ¦ ¦7/8/¦ ¦Petraglia, ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦Dunsire, ¦Osteonecrosis article¦ ¦ ¦ ¦ ¦ ¦Goessl ¦Maladorno and¦from Dr. Bouquot: A ¦ ¦ ¦ ¦5482 ¦004 ¦ ¦others ¦Multifactorial ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Etiology.pdf ¦ ¦ ¦ +-------------------------------------------------------------------------------------+

+-------------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Mayo Clinic ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Proceedings ¦ ¦ ¦ ¦ ¦ ¦ ¦Altmeyer, ¦ ¦ ¦ ¦ ¦ ¦8/ ¦ ¦Eriksen, ¦August 2006- ¦ ¦ ¦ ¦PX-5483¦200 ¦Lantwicki¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mounier and ¦FYI to ZIM ¦ ¦ ¦ ¦ ¦6 ¦ ¦others ¦Communication ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and KOL Team ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦please recommend¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦action ¦ ¦ ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦8/4/¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5484¦2 ¦Ruiz ¦Tarassoff ¦Re: Thank you!! ¦ ¦ ¦ ¦ ¦003 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦10/ ¦ ¦ ¦Re: project ¦ ¦ ¦ ¦ ¦10 ¦ ¦ ¦ZoDent in ¦ ¦ ¦ ¦PX-5485¦ ¦Eriksen ¦Lantwicki ¦Italy-Privileged¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦and ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Confidential ¦ ¦ ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦1/12¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5486¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2009¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦Osteonecrosis¦ ¦PX-5487¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Board ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦Novartis ¦ ¦PX-5488¦/ ¦ ¦ ¦ ¦ ¦Advisory ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Board ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦UT MD ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anderson ¦ ¦ ¦12/ ¦ ¦Dunsire, ¦E-Mail Subject: ¦ ¦ ¦ ¦PX- ¦18 ¦ ¦ ¦Toth ¦ ¦Cancer ¦ ¦ ¦ ¦Tarassoff¦Fratarcangeli ¦Letter-Dental Ad¦ ¦ ¦ ¦5489 ¦/ ¦ ¦and others ¦ ¦ ¦Center/ ¦ ¦ ¦2003¦ ¦ ¦Board ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dr. Toth ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Letter ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia, ¦ ¦ ¦ ¦ ¦ ¦ ¦Maladorno,¦Osteonecrosis¦ ¦PX- ¦12/5¦ ¦ ¦ ¦ ¦of the ¦ ¦ ¦/ ¦ ¦ ¦ ¦Close, ¦ ¦ ¦5490 ¦ ¦ ¦ ¦ ¦ ¦Maxillofa ¦ ¦ ¦2003¦ ¦ ¦ ¦Csermak ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦cial ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Region ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦12/5¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5491¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦2/5/¦ ¦Frararcangeli,¦E-Mail Subject: ¦ ¦ ¦ ¦PX-5492¦2 ¦Hlousek ¦ ¦ON ¦ ¦ ¦ ¦ ¦004 ¦ ¦Linguri ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ad Board ¦ ¦ ¦ +-------+----+---------+--------------+----------------+----------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Notice of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Importance ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Re: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦3/19¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦/ ¦ ¦ ¦ ¦Marx ¦ ¦ ¦5493 ¦ ¦ ¦ ¦ ¦ ¦Induced ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Avascular ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Necrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jaw ¦ +-------------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX-5494¦3/29/¦ ¦ ¦ ¦¦ ¦ ¦ ¦2004 ¦ ¦ ¦ ¦¦ ¦ +-------+-----+--------+-----------+---------------------++-------------------¦ ¦ ¦6/2/2¦ ¦ ¦E-Mail Subject: ¦¦ ¦ ¦PX-5495¦004 ¦Hei ¦Hlousek ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Urgent!. ¦¦ ¦ +-------+-----+--------+-----------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦copy of ¦¦ ¦ ¦ ¦ ¦ ¦Members of ¦ ¦¦ ¦ ¦PX- ¦ ¦ ¦ ¦notes taken ¦¦ ¦ ¦ ¦ ¦Hei ¦Advisory ¦ ¦¦ ¦ ¦5496 ¦ ¦ ¦ ¦during ¦¦ ¦ ¦ ¦ ¦ ¦Board ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Advisory ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Board ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦discussion ¦¦ ¦ +-------+-----+--------+-----------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Expert ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Panel ¦ ¦ ¦ ¦ ¦ ¦E-Mail ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Recommendations ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦for the ¦ ¦PX- ¦5/8/2¦ ¦ ¦Please ¦¦ ¦ ¦ ¦ ¦Schubert¦Hei ¦ ¦¦Prevention, ¦ ¦5497 ¦004 ¦ ¦ ¦Comment- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Diagnosis , and ¦ ¦ ¦ ¦ ¦ ¦short "white ¦¦Treatment ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦paper" ¦¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦the Jaw: May 2004 ¦ +-------+-----+--------+-----------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦E-Mail ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦aohoff, ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦5/12/¦ ¦Hei, ¦Please ¦¦ ¦ ¦ ¦ ¦Schubert¦ ¦ ¦¦ ¦ ¦5498 ¦2004 ¦ ¦Hauser and ¦comment: ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦short "white ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦paper" ¦¦ ¦ +-------+-----+--------+-----------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦E-Mail ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦5/12/¦ ¦Schubert ¦Please ¦¦ ¦ ¦ ¦ ¦Hoff ¦and others ¦ ¦¦ ¦ ¦5499 ¦2004 ¦ ¦ ¦comment- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦short 'white ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦paper' ¦¦ ¦ +-------+-----+--------+-----------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦E-Mail ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Urgent!- ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦5/28/¦ ¦ ¦revised ¦¦ ¦ ¦ ¦ ¦Schubert¦Hei ¦ ¦¦ ¦ ¦5500 ¦2004 ¦ ¦ ¦document for ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦your ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦approval-Action ¦¦ ¦ ¦ ¦ ¦ ¦ ¦needed by June 1, ¦¦ ¦ ¦ ¦ ¦ ¦ ¦2004 ¦¦ ¦ +-------+-----+--------+-----------+---------------------++-------------------¦ ¦ ¦ ¦ ¦ ¦E-Mail ¦¦ ¦ ¦PX-5501¦8/13/¦Houle ¦Hlousek ¦ ¦¦ ¦ ¦ ¦2004 ¦ ¦ ¦Subject: ONJ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Manuscript ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX- ¦9/8/¦ ¦ ¦E-mail Subject: ¦ ¦ ¦ ¦ ¦2 ¦Tarassoff¦Damato ¦Advisory Board ¦ ¦ ¦ ¦5502 ¦004 ¦ ¦ ¦Update ¦ ¦ ¦ +-------+----+---------+--------------+--------------------+----+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Revised ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Consensus ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Guidelines ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Prevention, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Diagnosis , ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and Treatment¦ ¦PX- ¦9/24¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/ ¦Brant ¦Tarassoff ¦E-Mail Subject: ¦ ¦of ¦ ¦5503 ¦ ¦ ¦ ¦Revised Manuscript ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦Osteonecrosis¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of the Jaws ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patients ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦with ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cancer ¦ +-------+----+---------+--------------+--------------------+----+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Revisions ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Consensus ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Guidelines ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Prevention, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/16¦ ¦ ¦E-Mail ¦ ¦Diagnosis , ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦and Treatment¦ ¦ ¦ ¦Schubert ¦Brant ¦Subject: ONJ ¦ ¦ ¦ ¦5504 ¦2004¦ ¦ ¦Manuscript for your ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦review ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of the Jaws ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patients ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦with ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cancer ¦ +-------+----+---------+--------------+--------------------+----+-------------¦ ¦ ¦ ¦ ¦Fratarcangeli,¦ ¦ ¦ ¦ ¦ ¦6/6/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦Maladorno, ¦Urgent-Osteonecrosis¦ ¦Medical ¦ ¦ ¦ ¦Hei ¦ ¦Situation ¦Marx¦ ¦ ¦5505 ¦003 ¦ ¦Csermak, ¦ ¦ ¦Alert ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦ ¦ ¦ ¦ +-------+----+---------+--------------+--------------------+----+-------------¦ ¦ ¦6/11¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5506¦/ ¦Tarassoff¦Ruiz ¦Thank you!! ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+--------------+--------------------+----+-------------¦ ¦PX- ¦7/22¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦/ ¦Tarassoff¦Ruiz ¦ ¦ ¦ ¦ ¦5507 ¦2003¦ ¦ ¦Subject: Re: Thank ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦you!! ¦ ¦ ¦ +-------+----+---------+--------------+--------------------+----+-------------¦ ¦PX- ¦7/23¦ ¦ ¦Meeting with Dr. ¦ ¦ ¦ ¦ ¦/ ¦Maladorno¦Close, Bess, ¦Marx-Miami- ¦ ¦ ¦ ¦5508 ¦ ¦ ¦Csermak Renner¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦Osteonecrosis cases ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX-5509¦6/28/ ¦ ¦ ¦ ¦ ¦2006 Zometa ¦ ¦ ¦2005 ¦ ¦ ¦ ¦ ¦KOL Plan ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦8/29/ ¦ ¦ ¦National KOLs ¦ ¦ ¦ ¦PX-5510¦ ¦Roelke ¦Timoney, ¦and Regional/ ¦ ¦ ¦ ¦ ¦2006 ¦ ¦Scott ¦Local Speakers ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for Zometa ¦ ¦ ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦List of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦KOLs ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦broken ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦out by ¦ ¦PX-5511¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦tumor ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦type ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦brought ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦by Mr. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Timoney ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦List of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦dental ¦ ¦5512 ¦ ¦ ¦ ¦ ¦ ¦physicians ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and dentists¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦ ¦ ¦ ¦ ¦Mike ¦2005-2006 ¦ ¦PX-5513¦20052006¦ ¦ ¦ ¦ ¦Lung Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦Barniger¦KOL Plan ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Winning ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Brands: The ¦ ¦PX- ¦3/200 ¦ ¦ ¦ ¦ ¦Power ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5514 ¦5 ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Influence ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marketing ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Primer/ ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2001 ¦ ¦ ¦ ¦ ¦Prostate ¦ ¦5515 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Update ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦11/22 / ¦ ¦ ¦Re: Urgent: ¦ ¦ ¦ ¦PX-5516¦2004 ¦Tarassoff¦Hukkelhoven¦Zometa ASH 2004 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ren-ONJ.doc ¦ ¦ ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦9/27/ ¦ ¦ ¦Broadcast Email ¦ ¦ ¦ ¦PX-5517¦2006 ¦Dorschner¦Scott ¦for New Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Slide Deck ¦ ¦ ¦ +-------+--------+---------+-----------+----------------+--------+------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦Speaker ¦ ¦ ¦5/9/2006¦ ¦ ¦ ¦ ¦ ¦ ¦5518 ¦ ¦ ¦ ¦ ¦ ¦Training ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Transcript ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jaw (ONJ): Prevention ¦ ¦5519 ¦ ¦ ¦ ¦ ¦ ¦and Management ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa in ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the ¦ ¦5520 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Treatment of Bone ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Metastases ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦1/27¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦Interventionz ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5521 ¦2006¦ ¦ ¦ ¦ ¦Certification ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Speaker ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦PX-5522¦8/ ¦ ¦ ¦Reclast Label¦ ¦Reclast Label ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦PX-5523¦9/ ¦ ¦ ¦Zometa Label ¦ ¦Zometa Label ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦PX-5524¦1991¦ ¦ ¦Aredia Label ¦ ¦Aredia Label ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦Tarass ¦ ¦ ¦ ¦10/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦20 ¦ ¦ ¦ ¦off ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5525 ¦03 ¦ ¦ ¦ ¦Csermak-¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Renner ¦ ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦PX-5526¦8/ ¦ ¦ ¦Zometa Label ¦ ¦Zometa Label ¦ ¦ ¦2001¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Population ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦12/3¦ ¦ ¦ ¦Honghui ¦Pharmacokinetic ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦Zhou ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Peiming ¦Analysis ¦ ¦5527 ¦1999¦ ¦ ¦ ¦Ma ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledronate ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦8/25¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5528¦/ ¦Shannon ¦Kappel¦ ¦ ¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦9/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5529¦200 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦5/7/¦ ¦ ¦Osteonecrosis¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦cases as ¦ ¦Maladorno count of ¦ ¦ ¦ ¦Maladorno ¦ ¦ ¦ ¦cases ¦ ¦5530 ¦004 ¦ ¦ ¦of May 4, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2004. ¦ ¦ ¦ +-------+----+-----------+------+-------------+--------+----------------------¦ ¦ ¦5/11¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5531¦/ ¦Hei,Hlousek¦ ¦ ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦For ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Review and Approv ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jaw in Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patients: Letters ¦ ¦ ¦6/14¦ ¦ ¦ ¦ ¦Published in the New ¦ ¦PX-5532¦/ ¦Sablinski ¦Cook ¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦England Journal of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Medicin ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Communications ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Document 6/10/2005 ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦PX-5533¦ ¦ ¦ ¦ ¦Tawfik¦Zometa Global ¦ ¦ ¦ ¦ ¦ ¦ ¦Kamal ¦Strategy ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦PX-5534¦2005¦ ¦ ¦Zometa Label ¦ ¦AAOMS Meeting ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦ ¦ ¦ ¦ASMs, ¦ ¦ ¦ ¦ ¦ ¦8/7/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦Machalaba,¦OSSs, ¦Program ¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦ ¦Schedule ¦ ¦ ¦ ¦5535 ¦003 ¦ ¦RSAs, ¦AAOMS Meeting¦ ¦ ¦ ¦ ¦ ¦ ¦RSDs, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦BRMs, RDs ¦ ¦ ¦ ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦ ¦ ¦ ¦ASMs, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/7/¦ ¦OSSs, ¦Topic ¦ ¦ ¦ ¦PX- ¦2 ¦Machalaba,¦ ¦Listings, ¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦RSAs, ¦2005 AAOMS ¦ ¦ ¦ ¦5536 ¦003 ¦ ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦RSDs, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦BRMs, RDs ¦ ¦ ¦ ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦ ¦ ¦ ¦ASMs, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/7/¦ ¦OSSs, ¦Osteonecrosis¦ ¦ ¦ ¦PX- ¦2 ¦Machalaba,¦ ¦of the Jaw in¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦RSAs, ¦Cancer ¦ ¦ ¦ ¦5537 ¦003 ¦ ¦ ¦Patients ¦ ¦ ¦ ¦ ¦ ¦ ¦RSDs, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦BRMs, RDs ¦ ¦ ¦ ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦ ¦ ¦ ¦ASMs, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8/7/¦ ¦OSSs, ¦Osteonecrosis¦ ¦ ¦ ¦PX- ¦2 ¦Machalaba,¦ ¦of the Jaw in¦ ¦ ¦ ¦ ¦ ¦Tarassoff ¦RSAs, ¦Cancer ¦ ¦ ¦ ¦5538 ¦003 ¦ ¦ ¦Patients ¦ ¦ ¦ ¦ ¦ ¦ ¦RSDs, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦BRMs, RDs ¦ ¦ ¦ ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦ ¦12/6¦ ¦ ¦Medical ¦ ¦ ¦ ¦PX-5539¦/ ¦Weiss ¦Abam ¦Inquiry ¦ ¦ ¦ ¦ ¦2002¦ ¦ ¦ ¦ ¦ ¦ +-------+----+----------+----------+-------------+------+---------------------¦ ¦ ¦2/11¦ ¦Goessl, ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Dunsire, ¦ ¦ ¦ ¦ ¦ ¦ ¦Hei ¦Maladorno,¦ON ICF ¦ ¦ ¦ ¦5540 ¦2004¦ ¦Cook and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX- ¦2/12¦ ¦ ¦Urgent: Zometa ¦¦ ¦ ¦ ¦/ ¦Petrone¦Baldari ¦ ¦¦ ¦ ¦5541 ¦2004¦ ¦ ¦osteonecrosis IC wording ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦3/12¦ ¦ ¦Re: Reported cases of ¦¦ ¦ ¦ ¦/ ¦Weiss ¦Arnbatlle ¦osteonecrosis ¦¦ ¦ ¦5542 ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory ¦ ¦PX- ¦3/29¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦Board ¦ ¦5543 ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦ ¦3/29¦ ¦ ¦Re: ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Weiss ¦Linguri ¦[Fwd:Bouquot : Novartis ¦¦ ¦ ¦5544 ¦2004¦ ¦ ¦Osteonecrosis Advisory ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Board] ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦ ¦6/5/¦ ¦ ¦ ¦¦ ¦ ¦PX-5545¦2 ¦Weiss ¦Rancourt, Abam ¦Medical Inquiry ¦¦ ¦ ¦ ¦004 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦6/25¦ ¦ ¦(No subject) I am at the ¦¦ ¦ ¦ ¦/ ¦Weiss ¦Petraglia, ¦MASCC ¦¦ ¦ ¦5546 ¦ ¦ ¦Gericke ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦meeting in Miami. ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦ ¦6/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5547¦200 ¦ ¦ ¦ ¦¦White Paper ¦ ¦ ¦4 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦4/6/¦ ¦ ¦ ¦¦Telecon ¦ ¦ ¦2 ¦ ¦ ¦ ¦¦Meeting ¦ ¦5548 ¦005 ¦ ¦ ¦ ¦¦Minutes ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦7/15¦ ¦ ¦ ¦¦NPC FDA ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦5549 ¦2004¦ ¦ ¦ ¦¦presentation¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦3/2/¦ ¦ ¦Re: FDA ¦¦ ¦ ¦ ¦2 ¦Hei ¦Maladorno ¦ ¦¦ ¦ ¦5550 ¦005 ¦ ¦ ¦Discussion Points for ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ODAC ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦3/4/¦ ¦Allan, Baba, ¦Todays FDA Advisory ¦¦ ¦ ¦ ¦2 ¦Hukke ¦Bible, Costa and¦Committee meeting on ¦¦ ¦ ¦5551 ¦ ¦lhoven ¦others ¦Zometa and Aredia ¦¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦3/4/¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦2 ¦ ¦ ¦ ¦¦ ¦ ¦5552 ¦005 ¦ ¦ ¦ ¦¦presentation¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦PX- ¦3/7/¦ ¦Riva, Narang, ¦ODAC ¦¦ ¦ ¦ ¦2 ¦Galen ¦Dunsire and ¦ ¦¦ ¦ ¦5553 ¦005 ¦ ¦others ¦Commentary FYI ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦ ¦3/16¦ ¦ ¦ ¦¦Meeting ¦ ¦PX-5554¦/ ¦ ¦ ¦ ¦¦Summary ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+----------------+-------------------------++------------¦ ¦ ¦ ¦ ¦ ¦IND 55,831 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦5/11¦ ¦ ¦Zoledronate ¦¦ ¦ ¦ ¦/ ¦Staten ¦Petraglia ¦ ¦¦ ¦ ¦5555 ¦2004¦ ¦ ¦for ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Injection ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦IND 55,831 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦5/25¦ ¦ ¦Zoledronate ¦¦ ¦ ¦PX-5556¦/ ¦Staten¦Petraglia ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦for ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Injection ¦¦ ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦FDA/Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦7/15¦ ¦ ¦ ¦¦ ¦ ¦PX-5557¦/ ¦ ¦ ¦ ¦¦Safety ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Update- ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecr ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦osis ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Slide ¦ ¦PX-5558¦8/6/¦Petra ¦Pazdur ¦General Corresponden ce 8/6/04¦¦Presentat ion ¦ ¦ ¦2004¦glia ¦ ¦Serial No. 288 ¦¦by Dr. Young -¦ ¦ ¦ ¦ ¦ ¦ ¦¦ONJ ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦ ¦ ¦ ¦Reinhardt,¦Email ¦¦ ¦ ¦ ¦12/ ¦Epste ¦ ¦ ¦¦ ¦ ¦PX-5559¦23 /¦in ¦Ebeling, ¦Subject: ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Dunsire ¦ODAC ¦¦ ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦ ¦12/ ¦ ¦ ¦Agenda for the upcoming ¦¦ ¦ ¦PX- ¦27 ¦Cliff ¦ ¦meeting Onocologic Drugs ¦¦ ¦ ¦ ¦ ¦ord ¦Petraglia ¦Advisory Committee ¦¦ ¦ ¦5560 ¦/ ¦ ¦ ¦-Disclosures ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦PX-5561¦3/ ¦ ¦ ¦ ¦¦Zometa ODAC ¦ ¦ ¦2005¦ ¦ ¦ ¦¦Team ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦PX- ¦1/24¦ ¦ ¦Email Subject: Some things ¦¦ ¦ ¦ ¦/ ¦Kimer ¦Hei ¦that I need for ¦¦ ¦ ¦5562 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦preperation for ODAC ¦¦ ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Potential ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦FDA Key ¦ ¦ ¦1/28¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦Questions and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5563 ¦2005¦ ¦ ¦ ¦¦Answers ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦for ONJ ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting Draft ¦ +-------+----+------+----------+------------------------------++--------------¦ ¦ ¦ ¦ ¦Altmeyer, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Mounier, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Hei, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦ ¦ ¦Tarassoff,¦Email Subject: ¦¦ ¦ ¦ ¦2/1/¦Scott ¦ ¦ ¦¦Availability ¦ ¦5564 ¦2005¦ ¦Narang ¦Advisor Update ¦¦of Advisors ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Petraglia,¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Carninis, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Lacerna ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Potential ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦FDA Key ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦1/28/¦ ¦ ¦ ¦¦Questions and ¦ ¦PX-5565¦2005 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Answers ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦for ONJ ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting Draft ¦ +-------+-----+-------+------------------+------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Proposal ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦29 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Question s- Feb ¦ ¦ ¦ ¦ ¦ ¦ ¦¦1st, 1:00 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦p.m. ¦ ¦PX-5566¦1/28/¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005 ¦ ¦ ¦ ¦¦Potential FDA ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Key Questions ¦ ¦ ¦ ¦ ¦ ¦ ¦¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Answers ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦for ONJ ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting Draft ¦ +-------+-----+-------+------------------+------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦2/200¦ ¦ ¦ ¦¦ ¦ ¦PX-5567¦ ¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦5 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Strategy PMB 02 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦February 2005 ¦ +-------+-----+-------+------------------+------------------++----------------¦ ¦PX-5568¦2/3/2¦Scott ¦Sledge ¦Subject: Advisor ¦¦ ¦ ¦ ¦005 ¦ ¦ ¦ ¦¦ ¦ +-------+-----+-------+------------------+------------------++----------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦PX-5569¦2/4/2¦Mounier¦Scott ¦ ¦¦ ¦ ¦ ¦005 ¦ ¦ ¦Subject: Feb 14 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Mock ODAC ¦¦ ¦ +-------+-----+-------+------------------+------------------++----------------¦ ¦ ¦ ¦ ¦Narang, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Goldfarb, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Cook, ¦ ¦¦ ¦ ¦PX- ¦2/5/2¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Scott ¦Dunsire, ¦ODAC open mic ¦¦ ¦ ¦5570 ¦005 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Mounier, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Petraglia, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Altmeyer,Tarassoff¦ ¦¦ ¦ +-------+-----+-------+------------------+------------------++----------------¦ ¦ ¦2/7/2¦ ¦ ¦Email Subject: ¦¦ ¦ ¦PX-5571¦005 ¦Young ¦Narang, Hei ¦Primary ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Presentation ¦¦ ¦ +-------+-----+-------+------------------+------------------++----------------¦ ¦ ¦3/4/2¦ ¦ ¦ ¦¦ODAC ¦ ¦PX-5572¦005 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Calendar ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Confidential ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Board ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2/11¦ ¦ ¦ ¦¦Meeting ¦ ¦PX-5573¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Recent ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Developments ¦ ¦ ¦ ¦ ¦ ¦ ¦¦in ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ONJ ¦ +-------+----+--------+-----------+----------------------------++-------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Confidential ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Board ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2/11¦ ¦ ¦ ¦¦Meeting ¦ ¦PX-5574¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Recent ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Developments ¦ ¦ ¦ ¦ ¦ ¦ ¦¦in ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ONJ ¦ +-------+----+--------+-----------+----------------------------++-------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Confident ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ial ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Board ¦ ¦ ¦2/11¦ ¦ ¦ ¦¦ ¦ ¦PX-5575¦/ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Recent ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Developments ¦ ¦ ¦ ¦ ¦ ¦ ¦¦in ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ONJ ¦ +-------+----+--------+-----------+----------------------------++-------------¦ ¦ ¦ ¦ ¦Young, ¦ ¦¦ ¦ ¦ ¦2/14¦ ¦ ¦Email Subject: Updated ODAC ¦¦ ¦ ¦PX-5576¦/ ¦Narang ¦Altmeyer, ¦Core Deck ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Hei ¦ ¦¦ ¦ +-------+----+--------+-----------+----------------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦2/16¦ ¦ ¦ ¦¦Team ¦ ¦PX- ¦/ ¦ ¦Bock, ¦Zometa Mock ¦¦ ¦ ¦ ¦ ¦Hei ¦ ¦ ¦¦Rehearsal and¦ ¦5577 ¦2005¦ ¦Romaine ¦Advisory ¦¦Mock Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Committee ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting ¦¦ ¦ +-------+----+--------+-----------+----------------------------++-------------¦ ¦PX- ¦2/15¦ ¦ ¦Email Subject: Outcome of ¦¦ ¦ ¦ ¦/ ¦Nalin ¦Altmeyer ¦today's mtg on core ODAC ¦¦ ¦ ¦5578 ¦ ¦ ¦ ¦slides ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ +-------+----+--------+-----------+----------------------------++-------------¦ ¦ ¦ ¦ ¦Dunsire, ¦ ¦¦ ¦ ¦ ¦2/15¦ ¦ ¦Email Subject: Last version ¦¦Draft ¦ ¦PX- ¦/ ¦ ¦Young, ¦ ¦¦ ¦ ¦ ¦ ¦Altmeyer¦ ¦of ODAC Core ¦¦ODAC Core ¦ ¦5579 ¦2005¦ ¦other ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Slides ¦¦Slides ¦ ¦ ¦ ¦ ¦individuals¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+--------------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Proposal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦29 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Questions-¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Feb 1st, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1:00 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦p.m. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Potential ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1/28¦ ¦ ¦ ¦ ¦FDA Key ¦ ¦ ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5580¦ ¦ ¦ ¦ ¦ ¦Questions ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Answers ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for ONJ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Draft ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦January ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦28, 2005 ¦ +-------+----+-----------+-----------+--------------------+-----------+----------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦2/16¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5581¦/ ¦Dunsire ¦Narang ¦Subject: NVS ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦Presentation : ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Closer ¦ ¦ ¦ +-------+----+-----------+-----------+--------------------+-----------+----------¦ ¦ ¦2/18¦ ¦ ¦Email Subject: ODAC ¦ ¦ ¦ ¦PX-5582¦/ ¦Altmeyer ¦Young and ¦Slides as Presented ¦ ¦ODAC Core ¦ ¦ ¦ ¦ ¦others ¦to mock ODAC ¦ ¦Slides ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+-----------+--------------------+-----------+----------¦ ¦ ¦ ¦Altmeyer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to ¦Altmeyer to¦ ¦ ¦ ¦ ¦PX- ¦2/18¦ ¦Narang, ¦Email Subject: ¦ ¦Feedback ¦ ¦ ¦/ ¦Naran ¦Young, ¦Outcome of ¦ ¦from Post ¦ ¦5583 ¦ ¦ ¦Lantwicki, ¦ ¦ ¦ ¦ ¦ ¦2005¦Young ¦Hei ¦Mock ODAC ¦ ¦Mock ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lantwicki, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hei ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+-----------+--------------------+-----------+----------¦ ¦ ¦ ¦Altmeyer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦2/18¦to ¦ ¦ ¦ ¦Feedback ¦ ¦PX- ¦/ ¦ ¦Altmeyer to¦Subject: 18 ¦ ¦from Post ¦ ¦ ¦ ¦Nalin ¦Nalin, ¦ ¦ ¦ ¦ ¦5584 ¦2005¦ ¦Lantwicki ¦Feb 05 Mock Zometa ¦ ¦Mock ODAC ¦ ¦ ¦ ¦, ¦ ¦Meeting Notes 2.doc ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lantwicki ¦ ¦ ¦ ¦ ¦ +-------+----+-----------+-----------+--------------------+-----------+----------¦ ¦ ¦ ¦Altmeyer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to ¦ ¦Email Subject: ¦Altmeyer to¦ ¦ ¦ ¦2/18¦ ¦Altmeyer to¦ ¦Zheng, ¦Feedback ¦ ¦PX- ¦/ ¦Zheng , Hei¦Zheng, Hei ¦Important-Additional¦ ¦from Post ¦ ¦ ¦ ¦ ¦and other ¦data/analyses ¦Hei ¦ ¦ ¦5585 ¦2005¦and ¦ ¦required ¦ ¦Mock ODAC ¦ ¦ ¦ ¦ ¦individuals¦ ¦and other ¦ ¦ ¦ ¦ ¦other ¦ ¦for ODAC ¦individuals¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦individuals¦ ¦ ¦ ¦ ¦ +--------------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Post Mock ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2/20/¦ ¦ ¦ ¦¦Feedback from ¦ ¦PX-5586¦2005 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisors updated ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦20 Feb ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ +-------+-----+-----+-------+---------------++--------------------------------¦ ¦PX-5587¦2/21/¦Young¦Zheng ¦Email Subject: ¦¦ ¦ ¦ ¦2005 ¦ ¦ ¦Zometa Slides ¦¦ ¦ +-------+-----+-----+-------+---------------++--------------------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦2/22/¦ ¦ ¦ ¦¦ ¦ ¦PX-5588¦2005 ¦Scott¦Lacerna¦Subject: FDA ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Mtg. Zometa ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ODAC ¦¦ ¦ +-------+-----+-----+-------+---------------++--------------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Post Mock ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦2/22/¦ ¦ ¦ ¦¦Feedback from ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5589 ¦2005 ¦ ¦ ¦ ¦¦Advisors Updated ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦22 Feb ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ +-------+-----+-----+-------+---------------++--------------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Post Mock ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦2/23/¦ ¦ ¦ ¦¦Feedback from ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5590 ¦2005 ¦ ¦ ¦ ¦¦Advisors Updated ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦23 Feb ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ +-------+-----+-----+-------+---------------++--------------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Post Mock ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦2/26/¦ ¦ ¦ ¦¦Feedback from ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5591 ¦2005 ¦ ¦ ¦ ¦¦Advisors Updated ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦26 Feb ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ +-------+-----+-----+-------+---------------++--------------------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Questions asked and feedback ¦ ¦ ¦ ¦ ¦ ¦ ¦¦from the Zometa Mock FDA Meeting¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦2/17/¦ ¦ ¦ ¦¦Hilton ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5592 ¦2005 ¦ ¦ ¦ ¦¦Short ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Hills ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Florham Park, NJ ¦ +-------+-----+-----+-------+---------------++--------------------------------¦ ¦ ¦2/17/¦ ¦ ¦ ¦¦Questions and ¦ ¦PX-5593¦2005 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦answers ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦July 2004 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦documents ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦reviewed ¦ ¦ ¦7/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5594¦2004¦ ¦ ¦ ¦¦by Dr. ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Young ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦before ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦the ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦deposition ¦ +-------+----+-------------+-----------+--------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦March ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦documents ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦3/ ¦ ¦ ¦ ¦¦reviewed ¦ ¦PX-5595¦2005¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦by Dr. ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Young ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦before ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦the ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦deposition ¦ +-------+----+-------------+-----------+--------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2/17¦ ¦ ¦ ¦¦Mock ¦ ¦ ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5596¦ ¦ ¦ ¦ ¦¦Meeting ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Feb 16-17 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ +-------+----+-------------+-----------+--------------------++----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Copy of CD ¦ ¦PX- ¦2/ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦2005¦ ¦ ¦ ¦¦Intelligence ¦ ¦5597 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Report Feb 2005 ¦ +-------+----+-------------+-----------+--------------------++----------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/17¦ ¦ ¦Subject: FDA ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦Briefing-Privileged ¦¦ ¦ ¦ ¦ ¦Goldfarb ¦Petraglia ¦and ¦¦ ¦ ¦5598 ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Confidential / ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Attorney Work ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Product ¦¦ ¦ +-------+----+-------------+-----------+--------------------++----------------¦ ¦ ¦ ¦ ¦Petraglia, ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦6/23¦ ¦Goessl, ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦Email Subject: Call ¦¦ ¦ ¦ ¦ ¦Fratarcangeli¦Maladorna ¦from Dr. Ruggiero ¦¦ ¦ ¦5599 ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦and other ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦individuals¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Taking Care of Yourself¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦While ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Living ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦with ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Cancer, ¦ ¦PX-5600¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Dental ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Health ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦the Jaw ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦12/23 ¦ ¦Burke, ¦ ¦¦ ¦ ¦PX-5601¦/2004 ¦Narang¦Hoppenot ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦¦ ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦PX-5602¦3/2003¦ ¦ ¦Zometa Label ¦¦Zometa label, Mar. 2003¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis ¦ ¦PX-5603¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Advisory Board ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦ONJ ¦ ¦PX-5604¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Chronology ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦PX-5605¦ ¦ ¦ ¦ ¦¦Q & As for ASH ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Program ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Schedule ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005 ¦ ¦ ¦Program Schedule ¦¦Symposia, ¦ ¦5606 ¦ ¦ ¦ ¦AAOMS Meeting ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦AAOMS Meeting, Hynes ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Conventio n Center ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Topic Listings, ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005 ¦ ¦ ¦Topic Listings, 2005¦¦2005 ¦ ¦5607 ¦ ¦ ¦ ¦AAOMS Meeting ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦AAOMS Meeting, Hynes ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Convention Center ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦PX-5608¦ ¦Petra ¦ ¦ ¦¦ ¦ ¦ ¦ ¦glia ¦ ¦ ¦¦ ¦ +-------+------+------+---------+--------------------++-----------------------¦ ¦PX-5609¦ ¦ ¦ ¦ ¦¦Untitled Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Transcript/Minutes ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Bisphosphonates¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦and ¦ ¦PX-5610¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Mandibular ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Necrosis ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦PX-5611¦ ¦ ¦ ¦ ¦¦Untitled table ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦PX-5612¦ ¦Dunsire ¦ ¦ ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦PX-5613¦ ¦ ¦ ¦ ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦PX-5614¦ ¦ ¦ ¦ ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5615¦ ¦ ¦ ¦ ¦¦Mock ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦ONJ and ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦Bisphosphonates¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5616 ¦ ¦ ¦ ¦ ¦¦Slide ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Deck ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦PX-5617¦ ¦Eriksen ¦ ¦ ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦PX-5618¦3/27/¦ ¦Maladorno ¦ ¦¦ ¦ ¦ ¦2003 ¦ ¦ ¦ ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦PX-5619¦ ¦ ¦ ¦Labeling Corresp. ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦ ¦ ¦ ¦ ¦NEM ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subcommittee ¦¦ ¦ ¦PX-5620¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Summary ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦ ¦06/23¦Csermak- ¦ ¦Osteonecrosis tcon ¦¦ ¦ ¦PX-5621¦/2003¦ ¦Konecne ¦minutes ¦¦ ¦ ¦ ¦ ¦Renner ¦ ¦ ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: Re: ¦¦ ¦ ¦PX- ¦7/08/¦John ¦Deborah ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Dunsire ¦FDA Response to ¦¦ ¦ ¦5622 ¦2004 ¦Orloff ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Labeling-Zometa and ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Aredia ¦¦ ¦ +-------+-----+-------------+----------+---------------------++---------------¦ ¦ ¦ ¦ ¦Maladorno,¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Stone, ¦Email Subject: ¦¦ ¦ ¦ ¦ ¦Stefa ¦ ¦Osteonecrosis: ¦¦ ¦ ¦PX- ¦5/02/¦ ¦Linguri, ¦Follow-up ¦¦ ¦ ¦ ¦ ¦no ¦ ¦ ¦¦ ¦ ¦5623 ¦2003 ¦ ¦Tarasoff, ¦to today's ¦¦ ¦ ¦ ¦ ¦Fratarcangeli¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Spaet, ¦teleconference ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Hei, Roth ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Important ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Drug ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Precaution ¦ ¦ ¦ ¦ ¦ ¦ ¦¦for Dental ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Health ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦5/05¦ ¦ ¦ ¦¦Professionals¦ ¦PX-5624¦/ ¦ ¦ ¦ ¦¦With ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦Patients ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Being ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Treated ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦For ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Cancer ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦9/28¦ ¦ ¦ ¦¦ ¦ ¦PX-5625¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦ ¦ ¦Deborah ¦ ¦¦ ¦ ¦ ¦11/ ¦ ¦ ¦Email Subject: ¦¦ ¦ ¦ ¦12 ¦Dionigi ¦Dunshire ¦Osteonecrosis cases as¦¦ ¦ ¦PX-5626¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦Maladorno¦and ¦of Nov. 4, ¦¦ ¦ ¦ ¦2003¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦Stefano ¦2003 ¦¦ ¦ ¦ ¦ ¦ ¦Fratarcangeli ¦ ¦¦ ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦2/12¦ ¦Dunshire, ¦ ¦¦ ¦ ¦ ¦/ ¦Dionigi ¦Goessl, Cook, ¦Email Subject: ¦¦ ¦ ¦PX-5627¦ ¦ ¦and other ¦Osteonecrosis cases as¦¦ ¦ ¦ ¦2004¦Maladorno¦ ¦of Feb. 6, 2004 ¦¦ ¦ ¦ ¦ ¦ ¦individual s ¦ ¦¦ ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦4/26¦ ¦Deborah ¦Email Subject: ¦¦ ¦ ¦PX-5628¦/ ¦Peter ¦Dunshire, ¦Teleconference with ¦¦ ¦ ¦ ¦ ¦Tarasoff ¦Stefano ¦Dr. Schwartz ¦¦ ¦ ¦ ¦2004¦ ¦Fratarcangeli ¦ ¦¦ ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦Units by ¦ ¦ ¦ ¦ ¦ ¦ ¦¦State ¦ ¦5629 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2002-2006 ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Clinical ¦¦Clinical ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Trial ¦¦Trial ¦ ¦5630 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Records ¦¦Records ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Clinical ¦¦Clinical ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Trial ¦¦Trial ¦ ¦5631 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Records ¦¦Records ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Clinical ¦¦Clinical ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Trial ¦¦Trial ¦ ¦5632 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Records ¦¦Records ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Clinical ¦¦Clinical ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Trial ¦¦Trial ¦ ¦5633 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Records ¦¦Records ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Clinical ¦¦Clinical ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Trial ¦¦Trial ¦ ¦5634 ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Records ¦¦Records ¦ +-------+----+---------+----------------+----------------------++-------------¦ ¦ ¦ ¦ ¦ ¦Clinical ¦¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5635¦ ¦ ¦ ¦Trial ¦¦Trial ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Records ¦¦Records ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦¦¦Clinical ¦ ¦Clinical ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦PX-5636¦ ¦¦¦Trial ¦ ¦Trial ¦ ¦ ¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦Records ¦ ¦Records ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦PX-5637¦ ¦¦¦ ¦Novartis¦ ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦PX-5638¦ ¦¦¦ ¦Novartis¦Amended DFS Fact Sheet ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦ ¦ ¦¦¦ ¦ ¦Photographs of Mr. ¦ ¦PX-5639¦ ¦¦¦ ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦White ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦PX- ¦12/ ¦¦¦ ¦ ¦Zoledroni c Acid ¦ ¦ ¦15 /¦¦¦ ¦ ¦Issue-Management [ZIM] Face to ¦ ¦5640 ¦2005¦¦¦ ¦ ¦Face Meeting Summary ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦PX- ¦12/ ¦¦¦ ¦ ¦Zoledroni c Acid ¦ ¦ ¦15 /¦¦¦ ¦ ¦Issue-Management [ZIM] Face to ¦ ¦5641 ¦2005¦¦¦ ¦ ¦Face Meeting Summary ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦ ¦5/21¦¦¦ ¦ ¦ ¦ ¦PX-5642¦/ ¦¦¦ ¦ ¦ ¦ ¦ ¦2008¦¦¦ ¦ ¦ ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦PX-5643¦ ¦¦¦ ¦ ¦ ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦PX- ¦8/19¦¦¦ ¦ ¦Notice of Videotape Deposition ¦ ¦ ¦/ ¦¦¦ ¦ ¦ ¦ ¦5644 ¦ ¦¦¦ ¦ ¦Pursuant to Rule 4: 14-2 ¦ ¦ ¦2009¦¦¦ ¦ ¦ ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦PX-5645¦ ¦¦¦ICD-9 Code Info ¦ ¦ICD-9 Code Info ¦ +-------+----+++---------------------+--------+-------------------------------¦ ¦ ¦ ¦¦¦Novartis Response to ¦ ¦Novartis Response ¦ ¦ ¦ ¦¦¦PSC's First ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦to PSC's First Requests for ¦ ¦PX- ¦ ¦¦¦Requests for ¦ ¦ ¦ ¦ ¦ ¦¦¦admission in MDL ¦ ¦admission ¦ ¦5646 ¦ ¦¦¦1760, dated June ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦in MDL 1760, ¦ ¦ ¦ ¦¦¦23, 2008 ¦ ¦ ¦ ¦ ¦ ¦¦¦ ¦ ¦dated June 23, 2008 ¦ +-----------------------------------------------------------------------------+

+-------------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Packaging / ¦ ¦PX-5647¦ ¦ ¦ ¦ ¦ ¦Labels/ package ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦inserts ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦Zometa 2003 MPH ¦ ¦PX-5648¦ ¦ ¦ ¦2003 MPH ¦ ¦Tactics ¦ ¦ ¦ ¦ ¦ ¦Tactics ¦ ¦ ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦ ¦Machalaba¦ ¦ ¦ ¦ ¦ ¦ ¦08/ ¦ ¦ ¦ONJ in ¦ ¦ONJ in Cancer ¦ ¦PX-5649¦07 /¦and ¦ ¦Cancer ¦ ¦Patients ¦ ¦ ¦2003¦ ¦ ¦Patients ¦ ¦ ¦ ¦ ¦ ¦Tarassoff¦ ¦ ¦ ¦ ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦ ¦US ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦US ¦ ¦ ¦ ¦ ¦Dept of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Good ¦ ¦Dept of ¦Good ¦ ¦ ¦ ¦Health ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦Pharmacovigilance¦ ¦Health ¦Pharmacovigilance¦ ¦PX- ¦3/22¦ ¦Practices and ¦ ¦ ¦Practices and ¦ ¦ ¦/ ¦Human ¦ ¦ ¦and Human¦ ¦ ¦5650 ¦ ¦ ¦Pharmacoep ¦ ¦Services,¦Pharmacoe ¦ ¦ ¦2005¦Services,¦idemiologic ¦ ¦ ¦pidemiologic ¦ ¦ ¦ ¦ ¦ ¦ ¦FDA, ¦ ¦ ¦ ¦ ¦FDA, ¦Assessment ¦ ¦CDER, ¦Assessment ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CDER, ¦ ¦ ¦CBER ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦CBER ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦3/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5651¦200 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦4 ¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦PX- ¦ ¦ ¦ ¦Curriculum¦ ¦Curriculum Vitae ¦ ¦ ¦ ¦ ¦ ¦Vitae of ¦ ¦of Dr. Robert ¦ ¦5652 ¦ ¦ ¦ ¦Dr. Robert¦ ¦Marx ¦ ¦ ¦ ¦ ¦ ¦Marx ¦ ¦ ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦ ¦ ¦ ¦Expert and¦ ¦Expert and ¦ ¦PX- ¦ ¦ ¦ ¦Rebuttal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reports of¦ ¦Rebuttal Reports ¦ ¦5653 ¦ ¦ ¦ ¦Dr. Robert¦ ¦of Dr. Robert ¦ ¦ ¦ ¦ ¦ ¦Marx ¦ ¦Marx ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦ ¦ ¦ ¦Curriculum¦ ¦ ¦ ¦PX-5654¦ ¦ ¦ ¦Vitae of ¦ ¦Curriculum Vitae ¦ ¦ ¦ ¦ ¦ ¦Dr. Wayne ¦ ¦of Dr. Wayne Ray ¦ ¦ ¦ ¦ ¦ ¦Ray ¦ ¦ ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦ ¦ ¦ ¦Expert and¦ ¦Expert and ¦ ¦PX- ¦ ¦ ¦ ¦Rebuttal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reports of¦ ¦Rebuttal Reports ¦ ¦5655 ¦ ¦ ¦ ¦Dr. Wayne ¦ ¦of Dr. ¦ ¦ ¦ ¦ ¦ ¦Ray ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wayne Ray ¦ +-------+----+---------+-----------------+----------+---------+-----------------¦ ¦ ¦ ¦ ¦ ¦Curriculum¦ ¦ ¦ ¦PX- ¦ ¦ ¦ ¦Vitae of ¦ ¦Curriculum Vitae ¦ ¦ ¦ ¦ ¦ ¦Dr. ¦ ¦of Dr. Suzanne ¦ ¦5656 ¦ ¦ ¦ ¦Suzanne ¦ ¦Parisian ¦ ¦ ¦ ¦ ¦ ¦Parisian ¦ ¦ ¦ +-------------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Expert, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rebuttal ¦ ¦ ¦ ¦ ¦ ¦Expert, Rebuttal¦ ¦Reports and ¦ ¦ ¦ ¦ ¦ ¦Reports and ¦ ¦ ¦ ¦PX-5657¦ ¦ ¦ ¦Supplemental ¦ ¦Supplemental ¦ ¦ ¦ ¦ ¦ ¦Reports of Dr. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Suzanne Parisian¦ ¦Reports of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dr. Suzanne ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Parisian ¦ +-------+----+-------------+-------------+----------------+-----+-------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: Re: ¦ ¦ ¦ ¦ ¦3/12¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5658¦/ ¦Kamal ¦Fratarcangeli¦Action ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦Required-Change ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of Informed ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦consent for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦trials ¦ ¦ ¦ +-------+----+-------------+-------------+----------------+-----+-------------¦ ¦ ¦4/23¦ ¦ ¦Email Subject: ¦ ¦ ¦ ¦PX-5659¦/ ¦Fratarcangeli¦Kamal ¦Important Zometa¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦BPI Change ¦ ¦ ¦ +-------+----+-------------+-------------+----------------+-----+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦OSO April ¦ ¦ ¦5/18¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5660¦/ ¦Kamal ¦ ¦ ¦Kamal¦monthly ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦reports ¦ +-------+----+-------------+-------------+----------------+-----+-------------¦ ¦ ¦ ¦ ¦ ¦Your tough ¦ ¦ ¦ ¦ ¦06/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5661¦25 /¦Dunsire ¦Burke et al. ¦questions ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦please ¦ ¦ ¦ +-------+----+-------------+-------------+----------------+-----+-------------¦ ¦PX-5662¦ ¦ ¦ ¦ ¦ ¦Agenda ¦ +-------+----+-------------+-------------+----------------+-----+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the Jaw ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦in Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patients: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Updated ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦9/24¦ ¦ ¦ ¦ ¦Situation ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Overview, ¦ ¦5663 ¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Key ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Messages, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Standby ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Statement and¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Q & As, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Version, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦24 Sept ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2004 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦10/ ¦ ¦ ¦Subject: Re: Novartis ¦¦ ¦ ¦PX-5664¦18 /¦Fratarcangeli¦Kamal ¦ASH ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦2004 Search ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Term Results ¦¦ ¦ +-------+----+-------------+----------+----------------------++---------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Zometa: ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis ¦ ¦ ¦ ¦ ¦ ¦ ¦¦of the Jaw in ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Patients: Q & ¦ ¦ ¦ ¦ ¦ ¦ ¦¦As ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦for ASH ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Abstracts 3151 ¦ ¦ ¦11/ ¦ ¦Petraglia,¦ ¦¦and ¦ ¦PX-5665¦24 /¦Cook ¦Goessl, ¦Update Renal and ONJ ¦¦ ¦ ¦ ¦2004¦ ¦Dunsire ¦Document ¦¦756, Global ¦ ¦ ¦ ¦ ¦and others¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Version, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦23 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦November ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2004, For ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Internal Use ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Only ¦ +-------+----+-------------+----------+----------------------++---------------¦ ¦ ¦ ¦ ¦ ¦(No Subject) We ¦¦ ¦ ¦ ¦ ¦ ¦ ¦believe ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦11/ ¦ ¦ ¦the ¦¦ ¦ ¦PX-5666¦24 /¦Epste in ¦Vasella ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦following factors ¦¦ ¦ ¦ ¦ ¦ ¦ ¦could result in ¦¦ ¦ ¦ ¦ ¦ ¦ ¦increased Zometa ¦¦ ¦ ¦ ¦ ¦ ¦ ¦attention. ¦¦ ¦ +-------+----+-------------+----------+----------------------++---------------¦ ¦ ¦12/2¦ ¦Cook and ¦Re:Zometa ¦¦ ¦ ¦PX-5667¦/ ¦Cook ¦others ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ASH update ¦¦ ¦ +-------+----+-------------+----------+----------------------++---------------¦ ¦ ¦ ¦ ¦Gorsky, ¦ ¦¦ ¦ ¦ ¦12/3¦ ¦Epstein, ¦Re; NEM Update on ONJ ¦¦ ¦ ¦PX-5668¦/ ¦Dunsi re ¦ ¦and ASH ¦¦ ¦ ¦ ¦2004¦ ¦Young and ¦ ¦¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ +-------+----+-------------+----------+----------------------++---------------¦ ¦ ¦12/6¦ ¦ ¦ ¦¦ ¦ ¦PX-5669¦/ ¦Maladorno ¦ ¦ ¦¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦¦ ¦ +-------+----+-------------+----------+----------------------++---------------¦ ¦ ¦ ¦ ¦ ¦WSJ.com- Jaw ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Ailment ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦12/8¦ ¦ ¦Shows ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Epstein ¦Vasella ¦Industry ¦¦ ¦ ¦5670 ¦2004¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Moves Slowly ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦on Drug ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Warnings ¦¦ ¦ +-------+----+-------------+----------+----------------------++---------------¦ ¦ ¦12/8¦ ¦ ¦oncology PR update: ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦Zometa and ¦¦ ¦ ¦ ¦ ¦Cook ¦ ¦Osteonecrosis of the ¦¦ ¦ ¦5671 ¦2004¦ ¦ ¦jaw- WSJ article; ASH ¦¦ ¦ ¦ ¦ ¦ ¦ ¦update *** ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦12/9¦ ¦ ¦the version that was ¦ ¦ ¦ ¦PX-5672¦/ ¦Epstein ¦Dunsire ¦presented ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦ ¦ ¦ ¦Re: ¦ ¦ ¦ ¦ ¦12/ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5673¦13 /¦Caminis ¦Sunsire ¦Discussion with Dr. ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦Van Poznak on MSKCC ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ cases ¦ ¦ ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦12/ ¦ ¦ ¦Email Subject: Zometa¦ ¦ ¦ ¦PX-5674¦22 /¦Kamal ¦Roth ¦PR PLAN 2005 ¦ ¦ ¦ ¦ ¦2004¦ ¦ ¦ ¦ ¦ ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦1/27¦ ¦ ¦Email ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kamal ¦Galen ¦Subject: PAM ONC Feb ¦ ¦ ¦ ¦5675 ¦2005¦ ¦ ¦17 Soundbites ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦exercises ¦ ¦ ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦2/5/¦ ¦ ¦ ¦ ¦ODAC Key ¦ ¦PX-5676¦2 ¦ ¦ ¦ ¦ ¦Messages, Draft¦ ¦ ¦005 ¦ ¦ ¦ ¦ ¦for Review ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ODAC ¦ ¦ ¦2/9/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦ ¦ ¦Position ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Statement , ¦ ¦5677 ¦005 ¦ ¦ ¦ ¦ ¦Draft for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Review ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦3/31¦ ¦Goldfarb, ¦Zometa ONC T2 ¦ ¦ ¦ ¦PX-5678¦/ ¦McClellan¦Petraglia,¦Handling ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦Objections-ZOM-8138 ¦ ¦ ¦ ¦ ¦ ¦ ¦Weiss ¦ ¦ ¦ ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦4/8/¦ ¦ ¦(no subject) It was ¦ ¦ ¦ ¦PX-5679¦2 ¦Filipovic¦Kamal ¦good talking to you ¦ ¦ ¦ ¦ ¦005 ¦ ¦ ¦today. ¦ ¦ ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦PX- ¦4/15¦ ¦ ¦Copy of 2005 ASCO ¦ ¦ ¦ ¦ ¦/ ¦Kamal ¦McCabe ¦search term list work¦ ¦ ¦ ¦5680 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦document.doc ¦ ¦ ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Global ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marketing ¦ ¦ ¦5/11¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦Amy ¦Spending ¦ ¦ ¦ ¦ ¦ ¦ ¦Doyle¦ ¦ ¦5681 ¦2005¦ ¦ ¦ ¦ ¦Results ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦April ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2005 ¦ +-------+----+---------+----------+---------------------+-----+---------------¦ ¦ ¦5/11¦ ¦ ¦ ¦ ¦5/11/2005 ¦ ¦PX-5682¦/ ¦ ¦ ¦ ¦ ¦Oncology Core ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦Team Agenda ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Jaw in Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Patients: Follow-Up ¦ ¦ ¦ ¦ ¦ ¦ ¦¦to FDA ODAC Meeting, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦5/19¦ ¦ ¦ ¦¦Global ¦ ¦PX-5683¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦Communications ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Documents ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦, 19 May ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ +-------+----+--------+---------+----------------------++---------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Jaw in Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Patients: Follow-Up ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦to FDA ODAC ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦5/19¦ ¦ ¦ ¦¦Global ¦ ¦PX-5684¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦Communications ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Documents ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦, 19 May ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2005 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Internal Use Only ¦ +-------+----+--------+---------+----------------------++---------------------¦ ¦ ¦5/23¦ ¦ ¦Re: Zometa News-Isn't ¦¦ ¦ ¦PX-5685¦/ ¦Cook ¦Lantwicki¦the ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦statement inaccurate ¦¦ ¦ +-------+----+--------+---------+----------------------++---------------------¦ ¦ ¦6/10¦ ¦ ¦Email Subject: Zometa ¦¦ ¦ ¦PX-5686¦/ ¦Ambatlie¦ ¦News #3 ¦¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦¦ ¦ +-------+----+--------+---------+----------------------++---------------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦7/1/¦ ¦ ¦Subject: PR Update: ¦¦ ¦ ¦PX- ¦2 ¦ ¦Cook, ¦Zometa ONJ Global ¦¦ ¦ ¦ ¦ ¦Roth ¦Mounier ¦ ¦¦ ¦ ¦5687 ¦005 ¦ ¦ ¦Communications ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Document re: 7 July ¦¦ ¦ ¦ ¦ ¦ ¦ ¦New England Journal of¦¦ ¦ ¦ ¦ ¦ ¦ ¦Medicine ONJ letters. ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦7/18¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5688¦/ ¦Kamal ¦Mounier ¦Subject: ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦Rep ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Survey ¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦7/18¦ ¦ ¦Email ¦ ¦ ¦ ¦PX-5689¦/ ¦Mounier ¦ ¦ ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rep survey¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦8/4/¦ ¦Mounier, ¦Dear ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦Dentist ¦ ¦ ¦ ¦PX-5690¦ ¦Lantwicki¦Cook, ¦Letter ¦ ¦ ¦ ¦ ¦005 ¦ ¦Csermak-Renner¦Market ¦ ¦ ¦ ¦ ¦ ¦ ¦and others ¦Research ¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦8/19¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5691¦/ ¦Conteras ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Survey ¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦9/8/¦ ¦ ¦Email ¦ ¦ ¦ ¦PX-5692¦2 ¦Conteras ¦ ¦Update on ¦ ¦ ¦ ¦ ¦005 ¦ ¦ ¦ONJ Survey¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦10/ ¦ ¦ ¦Re: ¦ ¦ ¦ ¦PX- ¦15 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kamal ¦Hei ¦ONJ ¦ ¦ ¦ ¦5693 ¦/ ¦ ¦ ¦Internal ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦training/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦discussion¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦during ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ECCO in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Paris ¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦ ¦ ¦Jacob, ¦Slides on ¦ ¦ ¦ ¦ ¦11/8¦ ¦ ¦ONJ from ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Hegazy, ¦ECCO ¦ ¦ ¦ ¦ ¦ ¦Hei ¦ ¦ ¦ ¦ ¦ ¦5694 ¦2005¦ ¦Chouycharo ¦internal ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦training ¦ ¦ ¦ ¦ ¦ ¦ ¦en and others ¦ ¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦11/ ¦ ¦ ¦Email: ¦ ¦ ¦ ¦PX- ¦14 ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦Cochrane ¦ ¦After Pam ¦ ¦ ¦ ¦5695 ¦/ ¦ ¦ ¦Onc Media ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦training ¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦11/ ¦ ¦ ¦Email ¦ ¦ ¦ ¦PX- ¦14 ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦Cochrane ¦ ¦After Pam ¦ ¦ ¦ ¦5696 ¦/ ¦ ¦ ¦Onc media ¦ ¦ ¦ ¦ ¦2005¦ ¦ ¦training ¦ ¦ ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledroni c ¦ ¦ ¦12/ ¦ ¦ ¦ ¦ ¦Acid Issue, ¦ ¦PX- ¦15 ¦ ¦ ¦ ¦ ¦Management ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦[ZIM], Face ¦ ¦5697 ¦/ ¦ ¦ ¦ ¦ ¦to Face ¦ ¦ ¦2005¦ ¦ ¦ ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Summary ¦ +-------+----+---------+--------------+----------+--------------+-------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦ONC ¦ ¦ ¦2006¦ ¦ ¦ ¦KathyKoukouras¦ ¦ ¦5698 ¦ ¦ ¦ ¦ ¦ ¦Detail ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Watch 2006 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦1/27¦ ¦ ¦ ¦¦Managing ONJ ¦ ¦PX-5699¦/ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦2006¦ ¦ ¦ ¦¦Communications ¦ +-------+----+---------+----------+--------------------++---------------------¦ ¦ ¦2/15¦ ¦Boehm, ¦Zometa Sales Rep ¦¦ ¦ ¦PX-5700¦/ ¦Koukouras¦Midwinter,¦Focus Groups-Market ¦¦ ¦ ¦ ¦ ¦ ¦Hohneker ¦Research Summary ¦¦ ¦ ¦ ¦2006¦ ¦and others¦ ¦¦ ¦ +-------+----+---------+----------+--------------------++---------------------¦ ¦ ¦3/15¦ ¦ ¦Email ¦¦ ¦ ¦PX-5701¦/ ¦Fazzaro ¦Jacob and ¦ ¦¦ ¦ ¦ ¦2006¦ ¦others ¦Subject: Per Capita:¦¦ ¦ ¦ ¦ ¦ ¦ ¦2005 December MAT ¦¦ ¦ +-------+----+---------+----------+--------------------++---------------------¦ ¦ ¦ ¦ ¦ ¦Worldwide Plans to ¦¦ ¦ ¦ ¦ ¦ ¦ ¦be placed in ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦5/24¦ ¦ ¦the ¦¦ ¦ ¦ ¦/ ¦Kamal ¦Snowden ¦ ¦¦ ¦ ¦5702 ¦ ¦ ¦ ¦respective brand ¦¦ ¦ ¦ ¦2006¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦section, in the open¦¦ ¦ ¦ ¦ ¦ ¦ ¦section of the ¦¦ ¦ ¦ ¦ ¦ ¦ ¦portal- ¦¦ ¦ +-------+----+---------+----------+--------------------++---------------------¦ ¦ ¦ ¦ ¦ ¦Re: For ¦¦ ¦ ¦PX- ¦8/15¦ ¦ ¦ ¦¦ ¦ ¦ ¦/ ¦Cook ¦Mounier ¦Immedicate Review: ¦¦ ¦ ¦5703 ¦ ¦ ¦ ¦Standby Statement ¦¦ ¦ ¦ ¦2006¦ ¦ ¦and Q & A Re: Mayo ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Consensus Statement ¦¦ ¦ +-------+----+---------+----------+--------------------++---------------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Standby/ Q & A ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Regarding ¦ ¦ ¦8/30¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦¦"Mayo ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5704 ¦2006¦ ¦ ¦ ¦¦Clinic Consensus ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Statement for the Use¦ ¦ ¦ ¦ ¦ ¦ ¦¦of Bisphosphonates in¦ ¦ ¦ ¦ ¦ ¦ ¦¦Multiple Myeloma" ¦ +-------+----+---------+----------+--------------------++---------------------¦ ¦PX- ¦10/4¦ ¦ ¦ ¦¦Zometa World Wide ¦ ¦ ¦/ ¦Mounier ¦Burrell ¦Email Subject: ¦¦Brand Plan-to-One ¦ ¦5705 ¦ ¦ ¦ ¦Zometa Background ¦¦20072011, C4 ¦ ¦ ¦2006¦ ¦ ¦ ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦10/9¦ ¦ ¦Email Subject: Draft Brief ¦¦ ¦ ¦PX-5706¦/ ¦Burre ¦ ¦ONJ ¦¦ ¦ ¦ ¦ ¦ll ¦ ¦ ¦¦ ¦ ¦ ¦2006¦ ¦ ¦Statement ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦10/ ¦ ¦ ¦RE: ONJ ¦¦ ¦ ¦PX-5707¦12 /¦Rao ¦Burrell ¦ ¦¦ ¦ ¦ ¦2006¦ ¦ ¦Business Reply Cards ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦10/ ¦ ¦ ¦Invitation to Attend Novartis¦¦ ¦ ¦ ¦18 ¦ ¦ ¦Advisory Board Meeting ¦¦ ¦ ¦PX-5708¦ ¦Scott ¦Burrell ¦(November 89, New York, NY)- ¦¦ ¦ ¦ ¦/ ¦ ¦ ¦Scott ¦¦ ¦ ¦ ¦2006¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦10/ ¦ ¦ ¦Email Subject: ¦¦ ¦ ¦PX-5709¦25 /¦Scott ¦Burrell ¦ ¦¦ ¦ ¦ ¦2006¦ ¦ ¦Forgiveness Items ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: FBST ¦¦ ¦ ¦ ¦10/ ¦ ¦ ¦Presentations Zometa ¦¦ ¦ ¦PX- ¦25 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦Burrell¦Blair ¦Tatical Plan Template, ¦¦Winning for The¦ ¦5710 ¦/ ¦ ¦ ¦ ¦¦Patient ¦ ¦ ¦2006¦ ¦ ¦Zometa 2006 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Overview ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦10/ ¦ ¦ ¦Email Subject: October Zometa¦¦ ¦ ¦PX-5711¦25 /¦Burrell¦Volante ¦ESR ¦¦ ¦ ¦ ¦2006¦ ¦ ¦ ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦10/ ¦ ¦ ¦Email ¦¦ ¦ ¦PX- ¦26 ¦ ¦Burrell ¦ ¦¦ ¦ ¦ ¦ ¦Cavuoto¦and ¦Subject:Zometa and General ¦¦ ¦ ¦5712 ¦/ ¦ ¦others ¦Oncology PRT Agenda-November ¦¦ ¦ ¦ ¦2006¦ ¦ ¦1, 2006 ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦ ¦ ¦ ¦Subject: Re: ¦¦ ¦ ¦ ¦11/9¦ ¦ ¦ ¦¦ ¦ ¦PX-5713¦/ ¦Kamal ¦Tarassoff¦Telecon ¦¦ ¦ ¦ ¦2006¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦tomorrow ¦¦ ¦ +-------+----+-------+---------+-----------------------------++---------------¦ ¦ ¦12/ ¦ ¦ ¦Email Subject: Safety ¦¦Putting ¦ ¦PX- ¦15 ¦ ¦ ¦Flashcard ¦¦Osteonecrosis ¦ ¦ ¦ ¦Burrell¦Timoney, ¦ ¦¦of the Jaw ¦ ¦5714 ¦/ ¦ ¦Blair ¦approved by ¦¦(ONJ) into ¦ ¦ ¦2006¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Global Core Team ¦¦Perspective ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦12/19 /¦Hoppe ¦Kamal, ¦Email Subject: Zometa in ¦¦ ¦ ¦PX-5715¦2006 ¦not ¦ ¦Multiple Myeloma ¦¦ ¦ ¦ ¦ ¦ ¦Mounier ¦ ¦¦ ¦ +-------+-------+-------+----------+--------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Palio ¦ ¦PX-5716¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Literature ¦ +-------+-------+-------+----------+--------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦2007 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Oncology ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Business ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Unit ¦ ¦PX-5717¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦National ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Meeting -Lead ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Investiga ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦tor's Guide ¦ +-------+-------+-------+----------+--------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: Status of ¦¦ ¦ ¦ ¦ ¦ ¦ ¦jaw ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦1/11/ ¦Lantw ¦ ¦osteonecrosis/ ¦¦ ¦ ¦ ¦ ¦icki ¦ ¦osteomyelitis ¦¦ ¦ ¦5718 ¦2007 ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦reports ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦(as of Dec. 2006) ¦¦ ¦ +-------+-------+-------+----------+--------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Novartis ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Oncology ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦1/19/ ¦ ¦ ¦COOP- Action ¦¦ ¦ ¦ ¦ ¦Kamal ¦Dortok ¦ ¦¦ ¦ ¦5719 ¦2007 ¦ ¦ ¦Items ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Summary: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦January 2007 ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦COOP ¦¦ ¦ +-------+-------+-------+----------+--------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: ¦¦ ¦ ¦PX- ¦1/24/ ¦ ¦Potter, ¦ ¦¦ ¦ ¦ ¦ ¦Kamal ¦ ¦Final ¦¦ ¦ ¦5720 ¦2007 ¦ ¦DiTrapani,¦ ¦¦ ¦ ¦ ¦ ¦ ¦Owen ¦Minutes-PMB Meeting ¦¦ ¦ ¦ ¦ ¦ ¦ ¦January 16, 2007 ¦¦ ¦ +-------+-------+-------+----------+--------------------------++--------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX- ¦2/8/2 ¦ ¦ ¦Hello ¦¦ ¦ ¦ ¦ ¦Burrell¦Naughton ¦ ¦¦ ¦ ¦5721 ¦007 ¦ ¦ ¦Regional ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Management ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Team ¦¦ ¦ +-------+-------+-------+----------+--------------------------++--------------¦ ¦PX- ¦2/19/ ¦ ¦ ¦Urgent: email ¦¦ ¦ ¦ ¦ ¦Boehm ¦Burrell ¦ ¦¦ ¦ ¦5722 ¦2007 ¦ ¦ ¦summary of ZOM turn around¦¦ ¦ ¦ ¦ ¦ ¦ ¦plan ¦¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦3/2/¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2 ¦ ¦Burrell and ¦Zometa ¦ ¦ ¦ ¦PX-5723¦ ¦Naughton ¦others ¦ ¦ ¦ ¦ ¦ ¦007 ¦ ¦ ¦Account ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Requiring ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦resources ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3/8/¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5724¦ ¦Tarassoff¦Burrell ¦Draft ¦ ¦ ¦ ¦ ¦007 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Version ECC ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Slides ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦ ¦3/14¦Zometa ¦ONC1, ONC3, ¦ ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦Dental Hotline for ¦ ¦ ¦ ¦PX-5725¦ ¦Brand ¦ASMs, RDs, ¦Helath Care ¦ ¦ ¦ ¦ ¦2007¦Team ¦ ¦Professional s ¦ ¦ ¦ ¦ ¦ ¦ ¦OMM ¦ ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3/29¦ ¦ ¦Suggested ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tarassoff¦Burrell ¦Revisions ¦ssion¦ ¦ ¦5726 ¦2007¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦for ONJ discu ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ideal ONJ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Message ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦PX- ¦3/30¦ ¦Naughton, ¦Email Subject: David ¦ ¦ ¦ ¦ ¦/ ¦Burrell ¦ ¦Epstein's ¦ ¦ ¦ ¦5727 ¦ ¦ ¦Engelhardt ¦ ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦Review ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦3/31¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦Naughton, ¦David ¦ ¦ ¦ ¦ ¦ ¦Burrell ¦Rao, and ¦ ¦ ¦ ¦ ¦5728 ¦2007¦ ¦others ¦Epstein's ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Business ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Review ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: C4 ¦ ¦ ¦ ¦ ¦4/1/¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦Sub-team ¦ ¦US ONJ Plan¦ ¦ ¦ ¦Burrell ¦Brandman ¦ ¦ ¦and Tatics ¦ ¦5729 ¦007 ¦ ¦ ¦meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦re:4th ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦strategic imperative ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦ ¦ ¦ ¦ ¦Email Subject: Dental ¦ ¦ ¦ ¦PX- ¦4/6/¦ ¦ ¦Hotline- ¦ ¦ ¦ ¦ ¦2 ¦Rao ¦Burrell and ¦ ¦ ¦ ¦ ¦5730 ¦ ¦ ¦others ¦First Call ¦ ¦ ¦ ¦ ¦007 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦received ¦ ¦ ¦ +-------+----+---------+-------------+----------------------+-----+-----------¦ ¦ ¦ ¦ ¦Rao, ¦Email Subject: Urgent ¦ ¦ ¦ ¦ ¦4/9/¦ ¦ ¦Request-Submit items ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦Timoney, ¦ ¦ ¦ ¦ ¦ ¦ ¦Burrell ¦ ¦for S2 ¦ ¦ ¦ ¦5731 ¦007 ¦ ¦Ellis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting Agenda ¦ ¦ ¦ ¦ ¦ ¦ ¦Blair ¦ ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Altmeyer, ¦Re: ¦ ¦ ¦ ¦ ¦4/12¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5732¦/ ¦Burrell ¦Volante, ¦Aclasta/Zometa ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦Dear HCP letter ¦ ¦ ¦ ¦ ¦ ¦ ¦McGrath ¦for your review ¦ ¦ ¦ +-------+----+---------+-------------+-----------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aclasta/Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dear HCP ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦4/12¦ ¦Altmeyer, ¦letter for your ¦ ¦ ¦ ¦PX-5733¦/ ¦Burrell ¦Volante, ¦review ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦(unintended ¦ ¦ ¦ ¦ ¦ ¦ ¦McGrath ¦damage due ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦misaligned ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦messages) ¦ ¦ ¦ +-------+----+---------+-------------+-----------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦4/13¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5734¦/ ¦Burrell ¦Volante ¦Subject: ECC ¦ ¦US BackUp Deck¦ ¦ ¦2007¦ ¦ ¦Meeting Slide ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Deck Pre-read ¦ ¦ ¦ +-------+----+---------+-------------+-----------------+-------+--------------¦ ¦ ¦4/14¦ ¦Epstein, ¦ ¦ ¦ ¦ ¦PX-5735¦/ ¦Mounier ¦Hoppenot, ¦ZOMETA Pre-read ¦ ¦ ¦ ¦ ¦2007¦ ¦Boehm and ¦for Monday ¦ ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ +-------+----+---------+-------------+-----------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦EIDETICS ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ONC ¦ ¦MD ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Behavior ¦ ¦Rationale for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Change ¦ ¦Changes in ¦ ¦PX- ¦4/16¦ ¦Burrell, ¦ ¦ ¦Zometa Use ¦ ¦ ¦/ ¦Koukouras¦Timoney, ¦Qualitative ¦ ¦ ¦ ¦5736 ¦ ¦ ¦Blair, Rao ¦ ¦ ¦Presented ¦ ¦ ¦2007¦ ¦ ¦Market ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦to ¦ ¦ ¦ ¦ ¦ ¦Research ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Novartis ¦ ¦ ¦ ¦ ¦ ¦Final Vendor ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦April 13, ¦ ¦ ¦ ¦ ¦ ¦Report ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2007 ¦ +-------+----+---------+-------------+-----------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa, ¦ ¦Reinvigorating¦ ¦PX- ¦4/25¦ ¦ ¦Reinvigorati ng ¦ ¦ ¦ ¦ ¦/ ¦ ¦ ¦Growth and ¦Burrell¦Growth ¦ ¦5737 ¦ ¦ ¦ ¦Patient ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦ ¦ ¦ ¦Freedom ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patient ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Freedom ¦ +-------+----+---------+-------------+-----------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦5/1/¦ ¦ ¦ ¦ ¦Usage ¦ ¦PX- ¦2 ¦ ¦Burrell, ¦intrinsiQ ¦ ¦ ¦ ¦ ¦ ¦Koukouras¦Timoney, ¦ ¦ ¦Review ¦ ¦5738 ¦007 ¦ ¦Blair, Rao ¦Monthly ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦March ¦ ¦ ¦ ¦ ¦ ¦Databook- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2007 ¦ ¦ ¦ ¦ ¦ ¦March 2007 ¦ ¦ ¦ +-------+----+---------+-------------+-----------------+-------+--------------¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5/5/¦ ¦ ¦Subject: ¦ ¦ ¦ ¦PX- ¦2 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Burrell ¦Blair ¦Investor ¦ ¦ ¦ ¦5739 ¦007 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Relations ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Questions ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Illumination ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5/7/¦ ¦ ¦Brief, ¦ ¦ ¦ ¦ ¦PX-5740¦2 ¦Burrell¦Rao ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Estimate, ¦ ¦ ¦ ¦ ¦ ¦007 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Task Order, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Timeline-Unbranded ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ONJ Reprint Center ¦ ¦ ¦ ¦ +-------+----+-------+---------+--------------------+-----+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦FDA ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Email Subject: ¦ ¦Teleconference¦ ¦ ¦ ¦5/16¦ ¦ ¦Urgent response ¦ ¦5/15 Zometa ¦ ¦ ¦PX-5741¦/ ¦Burrell¦Boehm, ¦needed: FDA revised ¦ ¦Japanese Study¦ ¦ ¦ ¦ ¦ ¦Volante ¦Plan label 21386 ¦ ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦Zometa P1-FDA ¦ ¦1501 (NDA ¦ ¦ ¦ ¦ ¦ ¦ ¦Version ¦ ¦21-386, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S-002) ¦ ¦ +-------+----+-------+---------+--------------------+-----+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦Email, ¦ ¦ ¦ ¦ ¦ ¦5/21¦ ¦Guidi, ¦ ¦ ¦ ¦ ¦ ¦PX-5742¦/ ¦Kamal ¦and ¦Scientific ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Communication Plan, ¦ ¦ ¦/ ¦ ¦ ¦2007¦ ¦others ¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ ¦ ¦ ¦ +-------+----+-------+---------+--------------------+-----+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ASCO 2007 ¦ ¦ ¦ ¦5/21¦ ¦ ¦ ¦Kyle,¦ ¦ ¦ ¦PX-5743¦/ ¦ ¦ ¦ ¦Yee ¦Clinical ¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Update ¦ ¦ +-------+----+-------+---------+--------------------+-----+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: Re: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Info:"Americ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5/22¦ ¦ ¦an Society of ¦ ¦ ¦ ¦ ¦PX- ¦/ ¦ ¦ ¦Clinical Oncology ¦ ¦ ¦ ¦ ¦ ¦ ¦Kamal ¦Boisclair¦ ¦ ¦ ¦ ¦ ¦5744 ¦2007¦ ¦ ¦2007 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical Practice ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Guideline Update on ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the Role of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Multiple Myeloma' ¦ ¦ ¦ ¦ +-------+----+-------+---------+--------------------+-----+--------------¦ ¦ ¦ ¦ ¦ ¦ ¦Email ¦ ¦Evidence on ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦6/7/¦ ¦Burrell ¦Subject: C2 Slides: ¦ ¦Display: ¦ ¦ ¦PX-5745¦2 ¦Becker ¦and ¦MyDoc and ¦ ¦Zometa ¦ ¦ ¦ ¦ ¦ ¦others ¦ ¦ ¦ ¦ ¦ ¦ ¦007 ¦ ¦ ¦ONJ ¦ ¦ONJ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Flashcard Slides ¦ ¦Flashcard ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦New ASCO ¦ ¦ ¦6/9/¦ ¦ ¦Fw: PUB ALERT: New ¦ ¦ ¦ ¦PX-5746¦2 ¦Kamal ¦Young ¦ ¦ ¦2007 ¦ ¦ ¦ ¦ ¦ ¦ASCO 2007 Guidelines in ¦ ¦ ¦ ¦ ¦007 ¦ ¦ ¦Multiple Myeloma + ¦ ¦Clinical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Update ¦ +-------+----+--------+--------+------------------------+--------+------------¦ ¦ ¦6/12¦ ¦ ¦ ¦ ¦Zoledroni c ¦ ¦PX-5747¦/ ¦ ¦ ¦ ¦Sabati ¦Acid Dental ¦ ¦ ¦ ¦ ¦ ¦ ¦no ¦Strategy ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦Update ¦ +-------+----+--------+--------+------------------------+--------+------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledroni ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦c Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦6/12¦ ¦ ¦Email Subject: Dental ¦ ¦Dental ¦ ¦ ¦/ ¦ ¦Timoney,¦Strategy ¦ ¦ ¦ ¦PX-5748¦ ¦Sabatino¦Burrell ¦ ¦ ¦Strategy ¦ ¦ ¦2007¦ ¦ ¦Update ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Update ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(June 6, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2007) ¦ +-------+----+--------+--------+------------------------+--------+------------¦ ¦PX- ¦6/13¦ ¦ ¦ ¦ ¦US Zometa ¦ ¦ ¦/ ¦Burrell ¦Loset ¦ ¦ ¦Turn-Around ¦ ¦5749 ¦ ¦ ¦ ¦ ¦ ¦07 Action ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦Plan ¦ +-------+----+--------+--------+------------------------+--------+------------¦ ¦ ¦ ¦ ¦ ¦Email Subject: Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Succes "This ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦7/24¦ ¦ ¦account had gone from ¦ ¦ ¦ ¦ ¦/ ¦Burrell ¦Volante ¦100% Zometa to !00% ¦s! ¦ ¦ ¦5750 ¦ ¦ ¦ ¦Pamidronate based on the¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦Mayo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦guidelines and ONJ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦concerns." ¦ ¦ ¦ +-------+----+--------+--------+------------------------+--------+------------¦ ¦ ¦8/22¦ ¦ ¦Email Subject: Request ¦ ¦ ¦ ¦PX- ¦/ ¦Burre ¦ ¦for M "thought we agreed¦ ¦ ¦ ¦ ¦ ¦ ¦McGinley¦to stress ONJ as a ¦aterials¦ ¦ ¦5751 ¦2007¦ll ¦ ¦disease rather than a ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦class effect." ¦ ¦ ¦ +-------+----+--------+--------+------------------------+--------+------------¦ ¦ ¦9/13¦ ¦ ¦Email Subject: Revised ¦ ¦Zometa Top ¦ ¦PX-5752¦/ ¦Scrudato¦Burrell ¦ZRT Deck ¦ ¦ ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦Institutions¦ +-------+----+--------+--------+------------------------+--------+------------¦ ¦ ¦9/22¦ ¦ ¦ ¦ ¦EGM/SAT ¦ ¦PX-5753¦/ ¦Kamal ¦ ¦ ¦ ¦meeting ¦ ¦ ¦2007¦ ¦ ¦ ¦ ¦actions ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦¦US ¦ ¦ ¦ ¦ ¦ ¦Email Subject: Zometa¦¦ ¦ ¦ ¦ ¦ ¦ ¦Tactical ¦¦Oncology- ¦ ¦ ¦10/8/¦ ¦McClung, ¦ ¦¦ ¦ ¦PX-5754¦2007 ¦Burrell ¦Volante and ¦Plan 2008 ¦¦Zometa ¦ ¦ ¦ ¦ ¦others ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Ver7.ppt ¦¦2008 ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Tactical Plan ¦ +-------+-----+---------+------------+---------------------++-----------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦PX-5755¦10/10¦Burrell ¦Manacek, ¦Subject:2006 ¦¦ ¦ ¦ ¦/2007¦ ¦Naughton ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦vs 2007 Data: Sloan ¦¦ ¦ ¦ ¦ ¦ ¦ ¦and Hopkins ¦¦ ¦ +-------+-----+---------+------------+---------------------++-----------------¦ ¦ ¦ ¦ ¦ ¦Email ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Subject: ON ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦1st ¦¦ ¦ ¦PX-5756¦11/2/¦DiTrapani¦Mantovani, ¦ ¦¦ ¦ ¦ ¦2007 ¦ ¦Kamal ¦Newsletter: please ¦¦ ¦ ¦ ¦ ¦ ¦ ¦review by ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦the 8th of ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦November ¦¦ ¦ +-------+-----+---------+------------+---------------------++-----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Novartis Response¦ ¦ ¦ ¦ ¦ ¦ ¦¦to PSC's ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Novartis Response to ¦¦First ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦PSC's First ¦¦Requests ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦Requests for ¦¦for ¦ ¦5757 ¦ ¦ ¦ ¦admission in MDL ¦¦ ¦ ¦ ¦ ¦ ¦ ¦1760, dated June ¦¦admission ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦23, 2008 ¦¦in MDL 1760, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦dated June 23, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2008 ¦ +-------+-----+---------+------------+---------------------++-----------------¦ ¦ ¦1/26/¦ ¦Dunsire and ¦Osteonecrosis Cases ¦¦ ¦ ¦PX-5758¦2004 ¦Maladorno¦Others ¦as of January 13, ¦¦ ¦ ¦ ¦ ¦ ¦ ¦2004 ¦¦ ¦ +-------+-----+---------+------------+---------------------++-----------------¦ ¦PX-5759¦ ¦ ¦ ¦ ¦¦ ¦ +-------+-----+---------+------------+---------------------++-----------------¦ ¦ ¦ ¦ ¦ ¦ ¦¦Expert ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Panel ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Recommendations ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦For the ¦ +-------+-----+---------+------------+---------------------+¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Prevention, ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Diagnosis , and ¦ ¦PX- ¦ ¦ ¦ ¦ ¦¦Treatment ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦5760 ¦ ¦ ¦ ¦ ¦¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦¦Osteonecrosis of ¦ ¦ ¦ ¦ ¦ ¦ ¦¦the Jaws: June ¦ ¦ ¦ ¦ ¦ ¦ ¦¦2004 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦¦¦¦¦ ¦Zoledronic Acid ONJ ¦ ¦PX-5761¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Executive Summary ¦ +-------+++++----------+------------------------------------------------------¦ ¦ ¦¦¦¦¦Marx ¦ ¦ ¦ ¦¦¦¦¦ ¦Oral ¦ ¦PX-5762¦¦¦¦¦and ¦ ¦ ¦ ¦¦¦¦¦ ¦Pathology Textbook ¦ ¦ ¦¦¦¦¦Stern ¦ ¦ +-------+++++----------+------------------------------------------------------¦ ¦ ¦¦¦¦¦ ¦Letter to ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦the ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Editor: Pamidronate ¦ ¦PX-5763¦¦¦¦¦Marx ¦ ¦ ¦ ¦¦¦¦¦ ¦(Aredia) and ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Zoledronate ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦(Zometa) Induced Avascular Necrosis of the Jaws: A ¦ ¦ ¦¦¦¦¦ ¦Growing Epidemic ¦ +-------+++++----------+------------------------------------------------------¦ ¦ ¦¦¦¦¦Ruggiero, ¦Bisphosphonate-related osteonecrosis of the jaw: ¦ ¦PX-5764¦¦¦¦¦ ¦backgroun d and guidelines for diagnosis , staging and¦ ¦ ¦¦¦¦¦Carlson ¦ ¦ ¦ ¦¦¦¦¦and others¦management ¦ +-------+++++----------+------------------------------------------------------¦ ¦ ¦¦¦¦¦ ¦Aredia: Clinical Expert Statement ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Osteonecrosis of ¦ ¦ ¦¦¦¦¦Maladorno,¦ ¦ ¦PX- ¦¦¦¦¦Lombardi, ¦the ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦5765 ¦¦¦¦¦Green, ¦Maxillofacial Area ¦ ¦ ¦¦¦¦¦Spaet ¦ ¦ ¦ ¦¦¦¦¦ ¦July 18, ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦2003 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦ ¦ ¦Neuropathic Pain in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-5766¦ ¦ ¦ ¦ ¦Bouquot¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ +-------+------+---------+-----+--------------+-------+-----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Medullary and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Odontogenic ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦disease in the painful ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦jaw: ¦ ¦ ¦ ¦ ¦ ¦ ¦Shankl ¦ ¦ ¦PX-5767¦ ¦ ¦ ¦ ¦and ¦clinicopathologic ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦review of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦500 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦consecutive ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦lesions ¦ +-------+------+---------+-----+--------------+-------+-----------------------¦ ¦ ¦ ¦ ¦ ¦Follow-up to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦the ¦ ¦ ¦ ¦PX-5768¦7/21/ ¦Tarassoff¦Dr. ¦ ¦ ¦ ¦ ¦ ¦2003 ¦ ¦Marx ¦Teleconference¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦discussion ¦ ¦ ¦ +-------+------+---------+-----+--------------+-------+-----------------------¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦AAOMS Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Transcript ¦ ¦5769 ¦ ¦ ¦ ¦ ¦ ¦ ¦ +-------+------+---------+-----+--------------+-------+-----------------------¦ ¦PX-5770¦ ¦ ¦ ¦ ¦ ¦ ¦ +-------+------+---------+-----+--------------+-------+-----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Strategic ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Advisory ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Board for ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦Zoledroni ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦5771 ¦ ¦ ¦ ¦ ¦ ¦c Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Report ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦15-17 April 2003 ¦ +-------+------+---------+-----+--------------+-------+-----------------------¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meeting of the Aclasta ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦International ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Strategic ¦ ¦PX- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Advisory ¦ ¦5772 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Board, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦19-20 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦September 2006 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦¦¦¦¦ ¦Executive ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Summary ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦PX- ¦¦¦¦¦ ¦of the ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦5773 ¦¦¦¦¦ ¦Aclasta/Reclast ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦International ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Strategic Roundtable held February 22, 2008 in¦ ¦ ¦¦¦¦¦ ¦Paris ¦ +-------+++++------------------+----------------------------------------------¦ ¦PX-5774¦¦¦¦¦Gotcher, Jee ¦ ¦ +-------+++++------------------+----------------------------------------------¦ ¦PX-5775¦¦¦¦¦Gotcher, Jee ¦ ¦ +-------+++++------------------+----------------------------------------------¦ ¦ ¦¦¦¦¦ ¦Executive Summary from the ONJ ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Advisory Board, ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦PX- ¦¦¦¦¦ ¦11-12 ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦5776 ¦¦¦¦¦ ¦February ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦2006, ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦London ¦ +-------+++++------------------+----------------------------------------------¦ ¦ ¦¦¦¦¦ ¦Aredia-Clinical Expert Statement ¦ ¦ ¦¦¦¦¦Maladorno, ¦ ¦ ¦PX- ¦¦¦¦¦Lombardi, ¦Osteonecrosis of ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦5777 ¦¦¦¦¦Green, Spaet ¦the ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Maxillofacial Area ¦ +-------+++++------------------+----------------------------------------------¦ ¦ ¦¦¦¦¦ ¦Novartis ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Pharmaceuticals ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Corporation's ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦PX- ¦¦¦¦¦ ¦Responses ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦5778 ¦¦¦¦¦ ¦to ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Plaintiffs' ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Steering Committee's First Request for ¦ ¦ ¦¦¦¦¦ ¦ ¦ ¦ ¦¦¦¦¦ ¦Admission ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------+ ¦ ¦¦ ¦ ¦¦ ¦DRAFT- ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Consensus ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Guidelines for the ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Prevention, ¦ ¦PX-5779¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Diagnosis , and Treatment of ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Osteonecrosis of the Jaws in ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Patients-with ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦notes/marginala by Novartis ¦ +-------++----+--------++----+------------------------------------------¦ ¦PX-5780¦¦Marx¦Schwartz¦¦Marx¦Serum CTX Testing ¦ +-------++----+--------++----+------------------------------------------¦ ¦ ¦¦ ¦ ¦¦ ¦Clinical Concerns of ¦ ¦PX-5781¦¦Marx¦ ¦¦Marx¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Aledronate Use ¦ +-------++----+--------++----+------------------------------------------¦ ¦ ¦¦ ¦ ¦¦ ¦Uncovering the Cause of "Phossy Jaw" Circa¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦1858 to ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦1906: ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Oral and ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Maxillofacial ¦ ¦PX- ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦Marx¦Surgery ¦ ¦5782 ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Closed ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Care ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Files- ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Case ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Closed ¦ +-------++----+--------++----+------------------------------------------¦ ¦ ¦¦ ¦ ¦¦ ¦Editorial ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Response- ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Editorial ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦PX- ¦¦ ¦ ¦¦ ¦Opinion ¦ ¦ ¦¦ ¦ ¦¦Marx¦ ¦ ¦5783 ¦¦ ¦ ¦¦ ¦Versus ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Real Data ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦and ¦ ¦ ¦¦ ¦ ¦¦ ¦ ¦ ¦ ¦¦ ¦ ¦¦ ¦Knowledge of the Literature ¦ +-----------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦¦¦¦¦¦AAOMS Position Paper on Bisphosphonate-Related Osteonecrosis of ¦ ¦ ¦¦¦¦¦¦the Jaws ¦ ¦PX-5784¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦-2009 ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Update ¦ +-------++++++----------------------------------------------------------------¦ ¦ ¦¦¦¦¦¦Executive ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Summary ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦From San ¦ ¦ ¦¦¦¦¦¦ ¦ ¦PX-5785¦¦¦¦¦¦Antonio ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Advisory ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Board ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Meeting ¦ +-------++++++----------------------------------------------------------------¦ ¦ ¦¦¦¦¦¦Executive ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Summary ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦From San ¦ ¦ ¦¦¦¦¦¦ ¦ ¦PX-5786¦¦¦¦¦¦Antonio ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Advisory ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Board ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Meeting ¦ +-------++++++----------------------------------------------------------------¦ ¦ ¦¦¦¦¦¦Executive ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Summary ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦From San ¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Antonio ¦ ¦5787 ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Advisory ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Board ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Meeting ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5788¦¦¦¦¦¦Slide Deck ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5789¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5790¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5791¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5792¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5793¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5794¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5795¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5796¦¦¦¦¦¦ ¦ +-------++++++----------------------------------------------------------------¦ ¦PX-5797¦¦¦¦¦¦ ¦ +-----------------------------------------------------------------------------+

+------------------------+ ¦ ¦¦¦¦¦¦ONJ ¦ ¦PX-5798¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Chronology ¦ +-------++++++-----------¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5799 ¦¦¦¦¦¦ ¦ +-------++++++-----------¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5800 ¦¦¦¦¦¦ ¦ +-------++++++-----------¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5801 ¦¦¦¦¦¦ ¦ +-------++++++-----------¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5802 ¦¦¦¦¦¦ ¦ +-------++++++-----------¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5803 ¦¦¦¦¦¦ ¦ +-------++++++-----------¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5804 ¦¦¦¦¦¦ ¦ +-------++++++-----------¦ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5805 ¦¦¦¦¦¦ ¦ +------------------------+

+----------------------------------------------+ ¦PX- ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5806¦¦¦¦¦¦ ¦ +----++++++------------------------------------¦ ¦ ¦¦¦¦¦¦Expert ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Panel* ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Recommendations ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦for the ¦ ¦ ¦¦¦¦¦¦ ¦ ¦PX- ¦¦¦¦¦¦Prevention, ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5807¦¦¦¦¦¦Diagnosis ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦, and ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Treatment ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦of ¦ ¦ ¦¦¦¦¦¦ ¦ ¦ ¦¦¦¦¦¦Osteonecrosis of the Jaws: June 2004¦ +----++++++------------------------------------¦ ¦PX- ¦¦¦¦¦¦All ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5808¦¦¦¦¦¦versions of the Aredia Label ¦ +----++++++------------------------------------¦ ¦PX- ¦¦¦¦¦¦All ¦ ¦ ¦¦¦¦¦¦ ¦ ¦5809¦¦¦¦¦¦versions of the Zometa label ¦ +----------------------------------------------+

Plaintiff's "Case Specific" Exhibits

+-----------------------------------------------------------------------------+ ¦Exhibit No. ¦ ¦ +-------------¦Title or Description ¦ ¦White ¦ ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1000 ¦William White Synopsis Presented in Acheson Deposition. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1001 ¦Affidavit of Custodian of Records, Medical Records of Dr. Guy ¦ ¦ ¦Acheson of William White Records. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1002 ¦Jackson, Richard F. to Guy Acheson, January 6, 2004, re: Bill ¦ ¦ ¦White. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1003 ¦Handwritten Notes, RE: Bill White, August 26, 1991. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1004 ¦July 28, 2003, Acheson slides of William White. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1005 ¦May, 2005, Acheson slides of William White. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1006 ¦Black and White Photo of Bill White Mouth Interior. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1007 ¦Black and White Photo of Bill White Mouth Interior. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1008 ¦Bill White X-ray, July 28, 2003 ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1009 ¦Bill White X-ray ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1010 ¦Bill White X-ray indicating Dr. Acheson ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1011 ¦Bill White X-ray, July 28, 2003 indicating Dr. Acheson ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1012 ¦Bill White X-ray, April 4, 2001 indicating Dr. Acheson ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1013 ¦Bill White X-Ray, March 3, 1999 indicating Dr. Acheson ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1014 ¦Bill White X-Ray, January 20, 1999 indicating Dr. Acheson ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1015 ¦Bill White X-Ray, March 5, 1999 indicating Dr. Acheson ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1016 ¦Bill White X-Ray, April 25, 1998 indicating Dr. Acheson ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1017 ¦Bill White Diagnostic Film ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1018 ¦Bill White Diagnostic Film ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1019 ¦January 5, 2004 Appointment Notes ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1020 ¦Plaintiff's Fact Sheet - William White ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1021 ¦State of William Knox White Supplement to Plaintiff's Fact ¦ ¦ ¦Sheet by Cheryl White ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1022 ¦William K. White, UCD Med Record with contact phone numbers. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1023 ¦Valad, Bart to Martin Calhoun, February 8, 2008, re: documents ¦ ¦ ¦WILWHI 00020-00158. ¦ +-------------+---------------------------------------------------------------¦ ¦PX-1024 ¦Certificate of Death for William Knox White issued October 12, ¦ ¦ ¦2006 and Zometa Product Information. ¦ +-------------+---------------------------------------------------------------¦ ¦ ¦Richman, Carol, MD to William K. White, April 29, 2004, Re: ¦ ¦PX-1025 ¦April 21, 2004 letter expressing dissatisfaction with oncology ¦ ¦ ¦care. ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦Letter, White, William and Cheryl to Carol Richman, March 31, 2004, ¦ ¦PX-1026¦cc: Michael Tanaka, John Macmillan and Jon Overholt, re: ¦ ¦ ¦dissatisfaction with oncology care ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1027¦Letter, Tanaka, Michael to Phillip Schneider, April 16, 2003, Re: ¦ ¦ ¦William White. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1028¦Hospital Records; UC Davis; William K. White, June 9, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1029¦Hospital Records; UC Davis; William K. White; Transcription of June ¦ ¦ ¦13, 204. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1030¦Hospital Records; UC Davis; William K. White; June 22, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1031¦Hospital Records; UC Davis; William K. White; August 18, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1032¦Hospital Records; UC Davis; William K. White; September 22, 2004 ¦ ¦ ¦Letter to Jon Overholt from Angela Davies. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1033¦Hospital Record; UC Davis; William K. White; October 20, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1034¦Hospital Records; UC Davis; William K. White; November 17, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1035¦Hospital Records; UC Davis; William K. White; November 17, 2004 ¦ ¦ ¦Transcription of letter to Jon Overholt from Angela Davies. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1036¦Hospital Records; UC Davis; William K. White; January 19, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1037¦Hospital Records; UC Davis; William K. White; Transcription of Letter¦ ¦ ¦to Jon Overholt from Angela Davis, January 21, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1038¦Hospital Record; UC Davis; Physicians Progress Record; William White;¦ ¦ ¦February 2, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1039¦Hospital Records; UC Davis; William K. White; Bone Imaging of Whole ¦ ¦ ¦Body; February 25, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1040¦Hospital Records; UC Davis; William K. White; March 9, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1041¦Hospital Records; UC Davis; William K. White; March 9, 2005 ¦ ¦ ¦Transcript of Letter to Jon Overholt from Angela Davies. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1042¦Hospital Records; UC Davis; William K. White; June 29, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1043¦Hospital Records; UC Davis; William K. White; July 27, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1044¦Hospital Records; UC Davis; William K. White; October 12, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1045¦Hospital Records; UC Davis; William K. White; October 20, 2005 ¦ ¦ ¦Transcript of letter to Jon Overholt from Angela Davies. ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX-1046¦Hospital Records; UC Davis; William K. White; November 9, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1047¦Letter Jacob, Rojymon, to Angela Davies, January 5, 2006. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1048¦Hospital Records; UC Davis; William K. White; January 12, 2006, Exam ¦ ¦ ¦by Cheryl Ho, MD. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1049¦Hospital Records; UC Davis; William K. White; March 3, 2006; Cheryl ¦ ¦ ¦Ho Exam. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1050¦Hospital Records; UC Davis; William K. White; June 23, 2006 ¦ ¦ ¦Transcript of letter to Jon Overholt from Angela Davies. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1051¦Hospital Records; UC Davis; William K. White; July 19, 2006 ¦ ¦ ¦Transcript of letter to Jon Overholt from Angela Davies. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1052¦Hospital Records; UC Davis; William K. White; July 20, 2006 ¦ ¦ ¦Transcript of Letter to Jon Overholt from Angela Davis. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1053¦Hospital Records; UC Davis; William K. White; August 22, 2006 ¦ ¦ ¦Transcript of letter to Jon Overholt from Angela Davies. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1054¦Email, Linnartz, Ronald to Lynne McGrath, March 30, 2006, re: FDA ¦ ¦ ¦Audit. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1055¦April 6-10, 2005, SWOG Executive Summary. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1056¦Hospital Record; UC Davis; William K. White; January 8, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1057¦Hospital Record; UC Davis; William K. White; Inpatient History and ¦ ¦ ¦Physical; January 6, 2004, John MacMillan. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1058¦UC Davis Admission Data Base; William K. White; January 6, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1059¦Hospital Records; UC Davis; William K. White; Handwritten notes; ¦ ¦ ¦January 6, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1060¦Hospital Records; UC Davis; Additional handwritten notes; January 6, ¦ ¦ ¦2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1061¦Hospital Records; UC Davis; William White; Handwritten Notes; January¦ ¦ ¦7, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1062¦Hospital Records; UC Davis; William White; Handwritten Notes of ¦ ¦ ¦January 7, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1063¦Hospital Records; UC Davis; William White; Handwritten Notes January ¦ ¦ ¦8, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1064¦Hospital Records; UC Davis; William White; Handwritten Notes January ¦ ¦ ¦8, 2004. ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX-1065¦Hospital Record; UC Davis; William White; Discharge Summary, January ¦ ¦ ¦16, 2004, Eric Boren. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1066¦Hospital Record; UC Davis; William White; January 7, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1067¦Fax, Acheson, Guy to Richard Jackson, DDS, October 22, 2003. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1068¦X-Ray; Bill White; November 6, 2003. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1069¦X-Ray; Bill White; Undated ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1070¦Surgical Treatment Report; April 27, 2004; William White. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1071¦Surgical Treatment; William White; December 4, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1072¦Black and White Photo of William K. White's Mouth Interior. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1073¦Fax, Acheson, Guy to Jon Overholt, October 3, 2000; re: Bill White. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1074¦Hospital Record; UC Davis; William White; Discharge Diagnosis; ¦ ¦ ¦January 16, 2004, Eric Boren. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1075¦Hospital Record; UC Davis; William White; Transcript of February 25, ¦ ¦ ¦2004 letter to Jon Overholt from Michael Tanaka. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1076¦Letter, Tanaka, Michael to Jon Overholt, February 25, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1077¦Hospital Record; UC Davis; William White; Carmichael Clinical Note, ¦ ¦ ¦June 11, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1078¦Hospital Record; UC Davis; William White; Carmichael Clinical Note; ¦ ¦ ¦January 24, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1079¦Hospital Record; UC Davis; William White; Carmichael Clinical Note, ¦ ¦ ¦May 25, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-108 ¦Hospital Record; UC Davis; William White; Carmichael Clinical Note, ¦ ¦0 ¦July 21, 2005. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1081¦Hospital Record; UC Davis; William White; Transcript Oncology ¦ ¦ ¦Clinical Note, January 12, 2006, Cheryl Ho. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1082¦Letter, Tanaka, Michael to James Goodnight, October 24, 2001; and ¦ ¦ ¦other Tanaka Correspondence. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1083¦Hospital Record; UC Davis; William K. White; April 1, 2002. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1084¦Hospital Record; UC Davis; William White; August 28, 2002. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1085¦Hospital Record; UC Davis; William White; Inpatient History and ¦ ¦ ¦Physical; January 6, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1086¦Radiology Report; UC Davis; January 7, 2004. ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX-1087¦Hospital Record; UC Davis; William White; Discharge Summary, January ¦ ¦ ¦16, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-108 ¦Hospital Record; UC Davis; William White; Transcript of letter from ¦ ¦8 ¦Lana Wania-Galicia to Jon Overholt, January 29, 2004. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-108 ¦Color Photographs of William K. White. ¦ ¦9 ¦ ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1090¦E-mail dated 8/21/06 to Elliot White, Alexis White and Lauren White ¦ ¦ ¦from William White, one page ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1091¦Copies of five color photographs ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1092¦Expert Report, Dec. 15, 2008, Jackson Rebuttal to Royse and ¦ ¦ ¦Felsenfeld ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1093¦"Osteonecrosis of the Jaws Associated with Cancer Chemotherapy," ¦ ¦ ¦Journal of Oral Maxillofacial Surgery, 2003. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1094¦X-Ray of William White. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1095¦Photocopy picture of William White's mouth. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1096¦Photocopy picture of William White's mouth. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1097¦Expert Report, Najjar in re White ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1098¦Rebuttal Report, Najjar in re White ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1099¦AAOMS Position Paper on BRONJ, 2007 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1100¦AAOMS Position Paper, Sept. 2006 ¦ +-------+---------------------------------------------------------------------¦ ¦ ¦Article, Ruggiero, et al., "Bisphosphonate-Related Osteonecrosis of ¦ ¦PX-1101¦the Jaw: Background and Guidelines for Diagnosis, Staging and ¦ ¦ ¦Managements" ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1102¦AAOMS Surgical Update, Vol. 20, Iss. 2, "Bisphosphonate-Related ¦ ¦ ¦Osteonecrosis of the Jaw" ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1103¦Marx, "Bisphosphonate-induced exposed bone osteonecrosis/ostepetrosis¦ ¦ ¦of the jaws: risk factors, recognition, prevention, and treatment." ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1104¦Table prepared by attorneys ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1105¦Najjar's Handwritten Notes ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1106¦Najjar Powerpoint re William White's ONJ. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1107¦Letter Dr. Jackson to Dr. Acheson, Jan. 6, 2004 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1108¦Dr. Acheson Record ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1109¦Dental Record ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1110¦Dr. Acheson Records ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1111¦Panoramic dated July 28, 2003. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1112¦White Medical Records ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1113¦NPC Internal Document, ZAEM-03603364, "Not for use with customers" ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1114¦Email from Weiss to Tarassoff, Rao, Boyer, Lantwicki re Ettinger ¦ ¦ ¦Report of AAOMS Sept. 2005 Symposium on BRONJ ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1115¦NPC Emails ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX-1116¦NPC Email re Ettinger is a KOL, NPC wants info re MDACC Study ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1117¦NPC Doc, "Protect, Prepare, Grow Zometa" ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1118¦NPC Doc, Lung Cancer Ad Board Meeting Notes ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1119¦Zometa label, 2004 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1120¦Zometa label, 2005 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1121¦Zometa label, Mar. 2008 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1122¦Picture of William White Mouth ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1123¦Picture of William White Mouth ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1124¦White, 7/14/2005 Clinic Note ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1125¦Novartis: Important Drug Precautions for Dental Health Professionals ¦ ¦ ¦with Patients being Treated for Cancer, May 5, 2005 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1126¦Letter from Jackson to Acheson, June 22, 2005 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1127¦White, Synopsis, 1994 to Dec. 19, 2005 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1128¦Letter from Davies to Jackson, Treatment Options Questions, Aug. 19, ¦ ¦ ¦2004 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1129¦Fax Overholt to Acheson, Oct. 3, 00 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1130¦Najjar White Powerpoint ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1131¦Color Photos ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1132¦Color Photos ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1133¦Letter Jackson Rebuttal Report ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1134¦Radiology Report ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1135¦Radiology Report ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1136¦Photograph ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1137¦Zometa Product Description, ZA-0553383 to 0553402 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1138¦Zometa Product Description, ZA-0704711 to 0704733 ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1139¦Records Produced by Plaintiff ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1140¦Records Produced by UC Davis Roseville ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1141¦Records Produced by Guy Acheson, D.D.S. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1142¦Records Produced by UC Davis Cancer Center ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1143¦Records Produced by UC San Francisco ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1144¦Records Produced by Oregon Health and Science University ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1145¦Records Produced by Mayo Clinic Scottsdale ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1146¦Records Produced by Walgreens ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1147¦Records Produced by Duke University Medical Center ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1148¦Records Produced by Delta Dental of California ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1149¦Records Produced by Richard Jackson, D.D.S. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1150¦Records Produced by MetLife ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1151¦Records Produced by Gordon L. Douglass, D.D.S. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1152¦Records Produced by Raley's ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦PX-1153¦Records Produced by James V. Jouret, D.D.S. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1154¦Records Produced by Beverly A. Kodama, D.D.S. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1155¦Records Produced by Health Net ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1156¦Records Produced by Dr. David Sox ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1157¦Records Produced by Mark H. Zablotsky, D.D.S. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1158¦Records Produced by Kennedy Wilson ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1159¦Records Produced by First Data Corporation ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1160¦Records Produced by Dr. Thomas O'Dorisio/University of Iowa Hospitals¦ +-------+---------------------------------------------------------------------¦ ¦PX-1161¦Records Produced by Assurant Health ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1162¦Records Produced by Dr. Richard Lockmiller ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1163¦Records Produced by Doctors Center Medical Group ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1164¦Records Produced by Unum ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1165¦Records Produced by Defendant as "ADE" File ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1166¦Plaintiff's Supplemental Response to Novartis Pharmaceutical's ¦ ¦ ¦Interrogatory No. 4. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1167¦All photographs of William White. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1168¦All x-rays/radiographic films of William White. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1169¦All medical imaging of William White. ¦ +-------+---------------------------------------------------------------------¦ ¦PX-1170¦All panorexes/dental imaging of William White. ¦ +-----------------------------------------------------------------------------+

Plaintiff's "Learned Treatise" Exhibits

+-----------------------------------------------------------------------------+ ¦Pl ¦ ¦ ¦ ¦ ¦ ¦ ¦DATE ¦AUTHOR(S) ¦TITLE ¦CITATION ¦ ¦Exhibit No.. ¦ ¦ ¦ ¦ ¦ +--------------+------+-----------+-----------------------------+-------------¦ ¦ ¦ ¦Ruggiero, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Salvatore ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.; Dodson,¦ ¦ ¦ ¦ ¦ ¦ ¦American Association of Oral ¦67 Journal of¦ ¦ ¦ ¦T.B.; ¦and Maxillofacial Surgeons ¦ ¦ ¦ ¦May-0 ¦ ¦Position Paper on ¦Oral ¦ ¦PX-3001 ¦9 ¦Assael, ¦Bisphosphonate-Related ¦ ¦ ¦ ¦ ¦ ¦ ¦Maxillofacial¦ ¦ ¦ ¦L.A.; ¦Osteonecrosis of the Jaws -- ¦Surgery 2 ¦ ¦ ¦ ¦ ¦2009 Update ¦(2009) ¦ ¦ ¦ ¦Landesberg,¦ ¦ ¦ ¦ ¦ ¦R.; Marx, ¦ ¦ ¦ ¦ ¦ ¦R.E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mehrotra B.¦ ¦ ¦ +--------------+------+-----------+-----------------------------+-------------¦ ¦PX-3002 ¦Jan-09¦Reid, Ian ¦Osteonecrosis of the Jaw Who ¦44 Bone 4 ¦ ¦ ¦ ¦ ¦Gets It, and Why? ¦(2009) ¦ +--------------+------+-----------+-----------------------------+-------------¦ ¦ ¦ ¦Brunello, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Antonella; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Saia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giorgia; ¦ ¦ ¦ ¦ ¦ ¦ ¦Worsening of Osteonecrosis of¦ ¦ ¦ ¦ ¦Bedogni, ¦the Jaw During Treatment with¦44 Bone 173 ¦ ¦PX-3003 ¦2009 ¦ ¦Sunitinib in a Patient with ¦ ¦ ¦ ¦ ¦Alberto; ¦Metastatic Renal Cell ¦(2009) ¦ ¦ ¦ ¦ ¦Carcinoma ¦ ¦ ¦ ¦ ¦Scaglione, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniela; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Basso, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Umberto ¦ ¦ ¦ +--------------+------+-----------+-----------------------------+-------------¦ ¦ ¦ ¦Edwards, ¦ ¦ ¦ ¦ ¦ ¦Beatrice ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gounder, ¦ ¦ ¦ ¦ ¦ ¦Mrinal; ¦ ¦ ¦ ¦ ¦ ¦McKoy, June¦ ¦ ¦ ¦ ¦ ¦M.; Boyd, ¦ ¦ ¦ ¦ ¦ ¦Ian; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Farrugia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mathew; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Migliorati,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cesar A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marx, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert; ¦Pharmacovigilance and ¦9 Lancet ¦ ¦ ¦ ¦ ¦Reporting Oversight in US FDA¦Oncology 1166¦ ¦PX-3004 ¦Dec-08¦Ruggiero, ¦Fasttrack Process: ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates and ¦(2008) ¦ ¦ ¦ ¦Salvatore; ¦Osteonecrosis of the Jw ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dimopoulos,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meletios; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Raisch, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dennis; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Singhal, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seema; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Carson, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ken; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Obadina, ¦ ¦ ¦ ¦ ¦ ¦Eniola; ¦ ¦ ¦ ¦ ¦ ¦Trifilio, ¦ ¦ ¦ ¦ ¦ ¦Steve ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Greuter, S.; ¦ ¦ ¦ ¦ ¦ ¦Schmid, F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦19 Annals of ¦ ¦PX-3005¦Dec-08 ¦Ruhstaller, ¦Bevacizumab-Associated ¦Oncology 2091 ¦ ¦ ¦ ¦T.; ¦Osteonecrosis of the Jaw ¦(2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Thuerlimann ,¦ ¦ ¦ ¦ ¦ ¦B. ¦ ¦ ¦ +-------+--------+-------------+-----------------------------+----------------¦ ¦ ¦ ¦Sarasquete, ¦ ¦ ¦ ¦ ¦ ¦Maria E.; ¦ ¦ ¦ ¦ ¦ ¦Garcia-Sanz, ¦ ¦ ¦ ¦ ¦ ¦R; Marin, L.;¦ ¦ ¦ ¦ ¦ ¦Alcoceba, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chillon, ¦ ¦ ¦ ¦ ¦ ¦M.C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Balanzategui,¦ ¦ ¦ ¦ ¦ ¦A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Santamaria, ¦ ¦ ¦ ¦ ¦ ¦C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate-Related ¦ ¦ ¦ ¦ ¦Rosinol, L.; ¦ ¦ ¦ ¦ ¦ ¦de la Rubia, ¦Osteonecrosis of the Jaw is ¦112 Blood 2709 ¦ ¦PX-3006¦1-Oct-08¦J.; ¦Associated with Polymorphisms¦ ¦ ¦ ¦ ¦ ¦of the Cytochrome P450 CYP2C8¦(2008) ¦ ¦ ¦ ¦Hernandez, ¦in Multiple Myeloma: A ¦ ¦ ¦ ¦ ¦ ¦Genome-Wide Single Nucleotide¦ ¦ ¦ ¦ ¦M.T.; ¦Analysis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Garcia- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Navarro, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦I.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lahuerta, ¦ ¦ ¦ ¦ ¦ ¦J.J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gonzalez, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.; San ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Miguel, Jesus¦ ¦ ¦ ¦ ¦ ¦F. ¦ ¦ ¦ +-------+--------+-------------+-----------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦US House of ¦ ¦ ¦ ¦ ¦ ¦Representative s¦ ¦ ¦ ¦ ¦ ¦Committee on ¦ ¦ ¦ ¦ ¦FDA Career Staff Objected to ¦Oversight and ¦ ¦PX-3007¦Oct-08 ¦ ¦Agency Preemption Policies ¦Government ¦ ¦ ¦ ¦ ¦ ¦Reform ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Majority Staff ¦ ¦ ¦ ¦ ¦ ¦Report, Oct 2008¦ +-------+--------+-------------+-----------------------------+----------------¦ ¦ ¦ ¦Hatoum, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hind T.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lin, Swu- ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid and ¦ ¦ ¦ ¦ ¦Jane; ¦ ¦ ¦ ¦ ¦ ¦ ¦Skeletal ¦ ¦ ¦ ¦15-Sep- ¦Smith, ¦ ¦113 Cancer ¦ ¦PX-3008¦ ¦ ¦Complications in Patients ¦ ¦ ¦ ¦08 ¦Mathew R.; ¦With Solid Tumors and Bone ¦1438 (2008) ¦ ¦ ¦ ¦ ¦Metastases -Analysis of a ¦ ¦ ¦ ¦ ¦Barghout, ¦National Medical Claims ¦ ¦ ¦ ¦ ¦ ¦Database ¦ ¦ ¦ ¦ ¦Victoria; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lipton, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Allan ¦ ¦ ¦ +-------+--------+-------------+-----------------------------+----------------¦ ¦ ¦ ¦Drake, ¦ ¦ ¦ ¦ ¦ ¦Matthew T.; ¦Bisphosphonates: Mechanism of¦83 Mayo Clinic ¦ ¦PX-3009¦Sep-08 ¦Clarke, Bart ¦Action and Role in Clinical ¦Proceedings 1032¦ ¦ ¦ ¦L.; Khosla, ¦Practice ¦(2008) ¦ ¦ ¦ ¦Sundeep ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Estilo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cherry L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fornier, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Monica; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Farooki, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦26 Journal of ¦ ¦ ¦2 ¦Azeez; ¦Osteonecrosis of the¦Clinical ¦ ¦PX-3010¦0-Aug-08 ¦ ¦Jaw Related to ¦ ¦ ¦ ¦ ¦Carlson, ¦Bevacizumab ¦Oncology 4037 ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ ¦ ¦ ¦Diane; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bohle, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦George III; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Huryn, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joseph M. ¦ ¦ ¦ +-------+---------+--------------------+--------------------+-----------------¦ ¦ ¦ ¦Visekruna, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maja; ¦ ¦ ¦ ¦ ¦ ¦ ¦Severely Suppressed ¦93 Journal of ¦ ¦ ¦ ¦Wilson, ¦Bone Turnover and ¦Clinical ¦ ¦PX-3011¦Aug-0 8 ¦ ¦Atypical Skeletal ¦Endocrinology and¦ ¦ ¦ ¦Deborah; ¦Fragililty ¦Metabolism 2948 ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ ¦ ¦ ¦McKiernan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fergus Eoin ¦ ¦ ¦ +-------+---------+--------------------+--------------------+-----------------¦ ¦ ¦ ¦LaVerde, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nicla; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bareggi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Claudia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Garassino, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marina; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Borgonova, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Karen; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sburlati, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Paola; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pedretti, ¦Osteonecrosis of the¦ ¦ ¦ ¦ ¦ ¦Jaw (ONJ) in Cancer ¦ ¦ ¦ ¦ ¦Donata; ¦Patients Treated ¦Support Care ¦ ¦ ¦ ¦ ¦ ¦Cancer __ ¦ ¦ ¦ ¦Bianchi, ¦With ¦ ¦ ¦PX-3012¦29-Jul-08¦ ¦ ¦(2008) (e- ¦ ¦ ¦ ¦Celso; ¦Bisphosphonates: How¦ ¦ ¦ ¦ ¦ ¦the Knowledge of a ¦publication ¦ ¦ ¦ ¦Perrone, ¦Phenomenon Can ¦pre-print) ¦ ¦ ¦ ¦ ¦Change Its Evolution¦ ¦ ¦ ¦ ¦Silvia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mihali, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dorian; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cobelli, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stefano; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mantica, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cristina; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rizzo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aurora; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Farina; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gabriella ¦ ¦ ¦ +-------+---------+--------------------+--------------------+-----------------¦ ¦ ¦ ¦Hess, Lisa M.; ¦Factors Associated ¦121 American ¦ ¦ ¦ ¦Jeter, Joanne M.; ¦with Osteonecrosis ¦Journal of ¦ ¦PX-3013¦Jun-0 8 ¦Benham-Hutchins, ¦of the Jaw Among ¦Medicine 475 ¦ ¦ ¦ ¦Marge; Alberts, ¦Bisphosphonate Users¦(2008) ¦ ¦ ¦ ¦David S. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Hoff, Ana O.;¦ ¦ ¦ ¦ ¦ ¦Toth, Bela ¦ ¦ ¦ ¦ ¦ ¦B.; Altundag,¦ ¦ ¦ ¦ ¦ ¦K.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Johnson, ¦ ¦ ¦ ¦ ¦ ¦Marcella ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Warneke, ¦ ¦ ¦ ¦ ¦ ¦Carla L.; Hu,¦ ¦ ¦ ¦ ¦ ¦Mimi; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nooka, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ajay; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sayegh, ¦ ¦23 Journal¦ ¦ ¦ ¦ ¦ ¦of Bone ¦ ¦ ¦ ¦Gilbert; ¦The Frequency and Risk Factors ¦and ¦ ¦ ¦ ¦ ¦Associated with Osteonecrosis of ¦Mineral ¦ ¦PX-3014¦Jun-0 8 ¦Guarneri, ¦the Jaw in Cancer Patients Treated ¦Research ¦ ¦ ¦ ¦ ¦with Intravenous Bisphosphonates ¦826 ¦ ¦ ¦ ¦Valentina; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ ¦ ¦ ¦Desrouleaux ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, Kimberly; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cui, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jeffrey; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Adamus, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Andrea; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gagel, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hortobagyi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gabriel N. ¦ ¦ ¦ +-------+--------+-------------+-----------------------------------+----------¦ ¦ ¦ ¦ ¦ ¦26 Journal¦ ¦ ¦ ¦Dickerson, ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.C.; ¦Osteonecrosis of the Jaw Incidence ¦Clinical ¦ ¦ ¦ ¦ ¦and Contributing Risk Factors in ¦ ¦ ¦ ¦2 ¦Desai, N.; ¦Cancer Patients Treated with IV ¦Oncology ¦ ¦PX-3015¦0-May-08¦Walden, E.; ¦ ¦ ¦ ¦ ¦ ¦Chang, M.; ¦Bisphosphonates: A Veterans ¦(Supp.) ¦ ¦ ¦ ¦Jiang, Y.; ¦Administration Healthcare Study ¦ ¦ ¦ ¦ ¦George, ¦(Abstract 20511) ¦Abstract ¦ ¦ ¦ ¦ ¦ ¦20511 ¦ ¦ ¦ ¦T.J. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ +-------+--------+-------------+-----------------------------------+----------¦ ¦ ¦ ¦Bamias, A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kastritis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦E.; ¦ ¦26 Journal¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦Melakopoulos,¦Osteonecrosis of the Jaw (ONJ) in ¦ ¦ ¦ ¦ ¦I.; Gika, D.;¦Patients with Prostate (PC) or ¦Clinical ¦ ¦ ¦ ¦Roussou, M.; ¦Breast (BC) Cancer Treated with ¦ ¦ ¦ ¦2 ¦Migkou, ¦Bisphosphonates: Study of the ¦Oncology ¦ ¦PX-3016¦0-May-08¦ ¦Effect of the Application of ¦ ¦ ¦ ¦ ¦M.; ¦Preventive Measures (Abstract ¦(Supp) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Elevtherakis,¦No. 16025) ¦Abstract ¦ ¦ ¦ ¦ ¦ ¦16025 ¦ ¦ ¦ ¦Papaiakovou ¦ ¦(2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dimopoulos, ¦ ¦ ¦ ¦ ¦ ¦M.A. ¦ ¦ ¦ +-------+--------+-------------+-----------------------------------+----------¦ ¦ ¦ ¦Sarin, J.; ¦ ¦ ¦ ¦ ¦ ¦Derossi, ¦ ¦14 Oral ¦ ¦ ¦ ¦ ¦Updates on Bisphosphonates and ¦Diseases ¦ ¦PX-3017¦May-0 8 ¦S.S.; ¦Potential Pathobiology of ¦277 ¦ ¦ ¦ ¦ ¦Bisphosphonate-Induced Jaw ¦ ¦ ¦ ¦ ¦Akintoye, ¦Osteonecrosis ¦(2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.O. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Brufsky, A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bundred, N.; ¦Integrated Analysis of ¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid for ¦ ¦ ¦ ¦ ¦Coleman, R.; ¦Prevention of Aromatase ¦13 Oncologist ¦ ¦PX-3018¦May-0¦ ¦Inhibitor-Associated Bone ¦ ¦ ¦ ¦8 ¦Lambert-Falls, R.;¦Loss in Postmenopausal Women ¦503 (2008) ¦ ¦ ¦ ¦Mena, R.; Hadji, ¦With Early Breast Cancer ¦ ¦ ¦ ¦ ¦P.; Jin, L.; ¦Receiving Adjuvant Letrozole ¦ ¦ ¦ ¦ ¦Schenk, N.; ¦ ¦ ¦ ¦ ¦ ¦Ericson, S.; ¦ ¦ ¦ ¦ ¦ ¦Perez, E. A. ¦ ¦ ¦ +-------+-----+------------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦ ¦26 Journal of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinicl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Oncology ¦ ¦ ¦ ¦ ¦ ¦(Supp.) Abst. ¦ ¦ ¦ ¦McArthur, ¦ ¦No. 9588 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦H.L.; ¦ ¦http://pediatr¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw ¦ ¦ ¦ ¦ ¦Estilo, C.; Huryn,¦(ONJ) Among Intravenous (IV) ¦icca.asco.org/¦ ¦ ¦ ¦J.; Williams, T.; ¦Bisphosphonate-and/or ¦ ¦ ¦ ¦ ¦ ¦Bevacizumab-Treated Patients ¦ASCO/Abstracts¦ ¦ ¦May-0¦Fornier, M.; ¦(pts) at Memorial ¦ ¦ ¦PX-3019¦8 ¦Traina, T. A.; ¦Sloan-Kettering Cancer Center¦+%26+Virtual+M¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Howard, J.; Hudis,¦(MSKCC) (Abstract ¦eeting/Abstrac¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.A.; ¦9588). ¦ts?&vmview=abs¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dickler, ¦ ¦t detail view&¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.N. ¦ ¦confID=55&abst¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ractID=32423 -¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦- Accessed ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦12/8/08 ¦ +-------+-----+------------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦Histomorphic evaluation of ¦J Oral ¦ ¦PX-3020¦May-0¦Pampu A.A.; ¦the effects of zoledronic ¦Maxillofac ¦ ¦ ¦8 ¦Dolanmaz D, H.H. ¦acid on mandibular ¦Surg 2008 May;¦ ¦ ¦ ¦ ¦distraction ¦66(5): 905-10 ¦ +-------+-----+------------------+-----------------------------+--------------¦ ¦ ¦ ¦Khan, Aliya ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sandor;Dore ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Morrison,;A ¦ ¦ ¦ ¦ ¦ ¦lsahli;Amin ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Peters;Hanl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ey;Chaudry; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dempster;Gl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦orieux;Nevi ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦35 Journal of ¦ ¦ ¦ ¦lle;Talwar; ¦Canadian Consensus Practice ¦Rheumatology ¦ ¦PX-3021¦Apr-0¦ ¦Guidelines for Bisphosphonate¦547 (2008) ¦ ¦ ¦8 ¦Clokie;Al ¦Associated Osteonecrosis of ¦(First Release¦ ¦ ¦ ¦ ¦the Jaw ¦ ¦ ¦ ¦ ¦Mardini;Pau ¦ ¦June 2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦l;Khosla;Jo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦sse;Sutherl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and;Lam;Car ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦michael;Bla ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦nas;Kendler ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦;Petak;St.- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marie;Brown ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦;Evans;Rios ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦; Compston, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.E. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw in ¦8 Clinical ¦ ¦ ¦ ¦Cafro, Anna ¦Patients with Multiple Myeloma ¦Lymphoma ¦ ¦PX-3022¦Apr-0 8 ¦ ¦Treated with Bisphosphonates: ¦Myeloma 111 ¦ ¦ ¦ ¦Maria ¦Definition and Management of the ¦(2008) ¦ ¦ ¦ ¦ ¦Risk Related to Zoledronic Acid ¦ ¦ +-------+---------+------------+---------------------------------+------------¦ ¦ ¦ ¦Dodson, ¦ ¦ ¦ ¦ ¦ ¦Thomas B.; ¦ ¦ ¦ ¦ ¦ ¦Raje, ¦ ¦358 New ¦ ¦ ¦ ¦ ¦Case 9-2008: A 65-Year-Old Woman ¦England ¦ ¦PX-3023¦20-Mar-08¦Noopur S.; ¦With a Nonhealing Ulcer of the ¦Journal of ¦ ¦ ¦ ¦Caruso, Paul¦Jaw ¦Medicine ¦ ¦ ¦ ¦A.; ¦ ¦1283 (2008) ¦ ¦ ¦ ¦Rosenberg, ¦ ¦ ¦ ¦ ¦ ¦Andrew E. ¦ ¦ ¦ +-------+---------+------------+---------------------------------+------------¦ ¦ ¦ ¦Pendrys, ¦ ¦6 Current ¦ ¦PX-3024¦Mar-08 ¦David G.; ¦Osteonecrosis of the Jaws and ¦Osteoporosis¦ ¦ ¦ ¦Silverman, ¦Bisphosphonates ¦Reports 31 ¦ ¦ ¦ ¦Stuart L. ¦ ¦(2008) ¦ +-------+---------+------------+---------------------------------+------------¦ ¦ ¦ ¦Burkinshaw, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Roger; ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw and ¦34 Cancer ¦ ¦ ¦ ¦Winter, ¦Dental Related Adverse Events ¦Treatment ¦ ¦ ¦ ¦ ¦During Adjuvant Therapy for Early¦Reviews S75 ¦ ¦PX-3025¦Mar-08 ¦Matt; ¦Breast Cancer: Initial Dental ¦ ¦ ¦ ¦ ¦ ¦Safety Findings from ¦(Supp.) ¦ ¦ ¦ ¦Thorpe, ¦ ¦(2008) ¦ ¦ ¦ ¦Helen; ¦the AZURE Study ¦ ¦ ¦ ¦ ¦Pedlar, Jon;¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Coleman, Rob¦ ¦ ¦ +-------+---------+------------+---------------------------------+------------¦ ¦ ¦ ¦ ¦ ¦358 New ¦ ¦ ¦ ¦ ¦ ¦England ¦ ¦ ¦21-Feb- ¦Ray, Wayne ¦Learning from Aprotinin ¦Journal of ¦ ¦PX-3026¦ ¦ ¦-Mandatory Trials of Comparative ¦ ¦ ¦ ¦08 ¦A. ¦Efficacy and Safety Needed ¦Medicine 840¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Hoff, Ana O.; ¦ ¦ ¦ ¦ ¦ ¦Toth, Bela B.; ¦ ¦ ¦ ¦ ¦ ¦Altundag, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦K.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Johnson, ¦ ¦ ¦ ¦ ¦ ¦Marcella ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Warneke, Carla ¦ ¦ ¦ ¦ ¦ ¦L.; Hu, Mimi; ¦ ¦ ¦ ¦ ¦ ¦Nooka, Ajay; ¦ ¦23 Journal of ¦ ¦ ¦ ¦Sayegh, ¦ ¦Bone and ¦ ¦ ¦ ¦ ¦ ¦Mineral ¦ ¦ ¦ ¦Gilbert; ¦The Frequency and Risk Factors¦Research 826 ¦ ¦ ¦4-Feb-¦ ¦Associated with Osteonecrosis ¦ ¦ ¦PX-3027¦ ¦Guarneri, ¦of the Jaw in Cancer Patients ¦(2008) (On ¦ ¦ ¦08 ¦Valentina; ¦Treated with Intravenous ¦ ¦ ¦ ¦ ¦Desrouleaux , ¦Bisphosphonates ¦Line ¦ ¦ ¦ ¦Kimberly; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Publication ¦ ¦ ¦ ¦Cui, ¦ ¦24-08) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jeffrey; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Adamus, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Andrea; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gagel, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hortobagyi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gabriel N. ¦ ¦ ¦ +-------+------+----------------+------------------------------+--------------¦ ¦ ¦ ¦Grant, Bao- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Thy; ¦ ¦66 Journal of ¦ ¦ ¦ ¦ ¦Outcomes of Placing Dental ¦Oral and ¦ ¦PX-3028¦Feb-08¦Amenedo, ¦Implants in Patients Taking ¦Maxillofacial ¦ ¦ ¦ ¦Christopher ; ¦Oral Bisphosphonates: A Review¦Surgery 223 ¦ ¦ ¦ ¦Freeman, ¦of 115 Cases ¦(2008) ¦ ¦ ¦ ¦Katherine; ¦ ¦ ¦ ¦ ¦ ¦Kraut, Richard ¦ ¦ ¦ ¦ ¦ ¦A. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Addeo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Raffaele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nocera, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Faiola, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bruno; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ferraro, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gabriella; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Montella, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Liliana; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Guarrasi, ¦ ¦ ¦ ¦ ¦ ¦ ¦Management of Pain in Elderly Patients¦16 Support ¦ ¦ ¦ ¦Rosario; ¦Receiving Infusion of Zoledronic Acid ¦Care Cancer¦ ¦PX-3029¦Feb-08¦ ¦for Bone Metastasis: A ¦ ¦ ¦ ¦ ¦Rossi, ¦Single-Institution Report ¦209 (2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eugenio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cennamo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gregorio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tonini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giuseppe; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Capasso, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Elena; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Santini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Caraglia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Michele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Del Prete, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Salvatore ¦ ¦ ¦ +-------+------+-----------+--------------------------------------+-----------¦ ¦ ¦ ¦Cartsos, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vassiliki ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦139 Journal¦ ¦ ¦ ¦M.; Zhu, ¦ ¦of the ¦ ¦ ¦ ¦ ¦Bisphosphonate Use and the Risk of ¦American ¦ ¦PX-3030¦Jan-08¦Shao; ¦Adverse Jaw Outcomes: A Medical Claims¦Dental ¦ ¦ ¦ ¦ ¦Study of 714,217 People ¦ ¦ ¦ ¦ ¦Zavras, ¦ ¦Association¦ ¦ ¦ ¦ ¦ ¦23 (2008) ¦ ¦ ¦ ¦Athanasios ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦I. ¦ ¦ ¦ +-------+------+-----------+--------------------------------------+-----------¦ ¦ ¦ ¦Grbic, John¦ ¦ ¦ ¦ ¦ ¦T.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Landesberg,¦ ¦ ¦ ¦ ¦ ¦R.; Lin, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.Q.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mesenbrink ¦ ¦ ¦ ¦ ¦ ¦P.; Reid, ¦ ¦139 Journal¦ ¦ ¦ ¦ ¦ ¦of the ¦ ¦ ¦ ¦I.R.; ¦Incidence of Osteonecrosis of the Jaw ¦American ¦ ¦ ¦ ¦ ¦in Women With Postmenopausal ¦Dental ¦ ¦PX-3031¦Jan-08¦Leung, ¦Osteoporosis in the Health Outcomes ¦ ¦ ¦ ¦ ¦ ¦and Reduced Incidence With Zoledronic ¦Association¦ ¦ ¦ ¦P.C.; ¦Acid Once Yearly Pivotal Fracture ¦32 ¦ ¦ ¦ ¦ ¦Trial ¦ ¦ ¦ ¦ ¦Casas, N.; ¦ ¦(2008) ¦ ¦ ¦ ¦Recknor, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.P.; Hua, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Y.; Delmas,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦P.D.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eriksen, ¦ ¦ ¦ ¦ ¦ ¦Erik F. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Vieillard, ¦ ¦ ¦ ¦ ¦ ¦Marie-Helene; Maes, ¦ ¦75 Joint Bone ¦ ¦ ¦ ¦Jean-Michel; Penel, ¦Thirteen Cases of Jaw ¦ ¦ ¦PX-3032¦Jan-08¦Guillaume; Facon, ¦Osteonecrosis in Patients¦Spine 34-40 ¦ ¦ ¦ ¦Thierry; Magro, ¦on Bisphosphonate Therapy¦ ¦ ¦ ¦ ¦Leonardo; Bonneterre,¦ ¦(2008) ¦ ¦ ¦ ¦Jacques; Cortet, ¦ ¦ ¦ ¦ ¦ ¦Bernard ¦ ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Abu-Id, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mario H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Warnke, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patrick H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gottschalk, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joachim; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Springer, ¦"Bis-Phossy Jaws" -High ¦36 Journal of ¦ ¦ ¦ ¦ ¦and Low Risk Factors for ¦Craniomaxillof¦ ¦PX-3033¦Jan-08¦Ingo; ¦Bisphosphonate-Induced ¦acial Surgery ¦ ¦ ¦ ¦ ¦ ¦95 (2008) ¦ ¦ ¦ ¦Wiltfang, ¦Osteonecrosis of the Jaw ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; Acil, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yahya; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦,Russo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Paul A. J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kreusch, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Thomas ¦ ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Khamaisi, M.; Elad, ¦ ¦100 Journal of¦ ¦ ¦ ¦ ¦Intravenous ¦the National ¦ ¦ ¦ ¦S.; ¦Bisphosphonate Therapy ¦Cancer ¦ ¦PX-3034¦Jan-08¦ ¦and Inflammatory ¦ ¦ ¦ ¦ ¦Wilkinson, Gregg S.; ¦Conditions or Surgery of ¦Institute 155 ¦ ¦ ¦ ¦Kuo, Yong-Fang; ¦the Jaw: A ¦ ¦ ¦ ¦ ¦Freeman, Jean L.; ¦Population-Based Analysis¦(2008) ¦ ¦ ¦ ¦Goodwin, James S. ¦ ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦ ¦Biophosphonate-Related ¦52 Dental ¦ ¦PX-3035¦Jan-08¦Ruggiero Salvatore ¦ ¦Clinics of ¦ ¦ ¦ ¦L.; Woo Sook-Bin ¦Osteonecrosis of the Jaws¦North America ¦ ¦ ¦ ¦ ¦ ¦111 (2008) ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦ ¦Bisphosphonate-Associated¦60 Reumatismo ¦ ¦PX-3036¦Jan-08¦Capsoni, F. ¦Osteonecrosis of the Jaw ¦ ¦ ¦ ¦ ¦ ¦in Rheumatology: A ¦6 (2008) ¦ ¦ ¦ ¦ ¦Sistematic [sic] Review ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Boonyapakorn, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Thacharot; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schirmer, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ingrid; ¦Bisphosphonate-Induced ¦ ¦ ¦ ¦ ¦ ¦ ¦20 Oral ¦ ¦ ¦ ¦Reichart, ¦Osteonecrosis of the ¦Oncology 1-15 ¦ ¦PX-3037¦2008 ¦ ¦Jaws: Prospective Study ¦ ¦ ¦ ¦ ¦Peter A.; ¦of 80 Patients With ¦(2008) ¦ ¦ ¦ ¦ ¦Multiple Myeloma and ¦ ¦ ¦ ¦ ¦Sturm, ¦Other Malignancies ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Isrid; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Massenkeil, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gero ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Wessel, John H.;¦Zoledronate, Smoking and ¦66 Journal of ¦ ¦ ¦ ¦Dodson, Thomas ¦Obesity are Strong Risk ¦Oral and ¦ ¦PX-3038¦2008¦B.; Zavras, ¦Factors for Osteonecrosis of ¦Maxillofacial ¦ ¦ ¦ ¦Athanasios ¦the Jaw: A Case-Control Study ¦Surgery 625 ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦66 Journal of ¦ ¦ ¦ ¦Allen, Matthew ¦Mandible Matrix Necrosis in ¦Oral and ¦ ¦PX-3039¦2008¦R.; Burr, David ¦Beagle Dogs After 3 Years of ¦Maxillofacial ¦ ¦ ¦ ¦B. ¦Daily Oral Bisphosphonate ¦Surgery 987 ¦ ¦ ¦ ¦ ¦Treatment ¦ ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦Ibrahim, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Toni; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Barbanti, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Francesca; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giorgio- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marrano, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gianluca; ¦Osteonecrosis of the Jaw in ¦ ¦ ¦ ¦ ¦ ¦Patients With Bone Metastases ¦13 Oncologist ¦ ¦PX-3040¦2008¦Mercatali, ¦Treated With Bisphosphonates: ¦ ¦ ¦ ¦ ¦ ¦A Retrospective Study ¦330 (2008) ¦ ¦ ¦ ¦Laura; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ronconi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sonia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vicini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Claudio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Amadori, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dino ¦ ¦ ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦Downloaded ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦4/7/2008 from ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A Critical Look at ¦http://www.qua ¦ ¦ ¦ ¦ ¦Cavitational Osteopathosis, ¦ckwatch.org/01 ¦ ¦PX-3041¦2008¦Barrett, Stephen¦NICO, and "Biological ¦ ¦ ¦ ¦ ¦ ¦Dentistry" ¦QuackeryRelate ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦d ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Topics/cavitat ¦ ¦ ¦ ¦ ¦ ¦ion.html ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦Adamo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Caristi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nicola; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sacca, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marcello ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maugeri; ¦ ¦ ¦ ¦ ¦ ¦ ¦Current Knowledge and Future ¦ ¦ ¦ ¦ ¦Ferraro, ¦Directions on ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate-Related ¦9 Expert Opinion¦ ¦PX-3042¦2008¦Giuseppa; ¦ ¦Pharmacotherap y¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw in ¦1351 (2008) ¦ ¦ ¦ ¦Arcana, ¦Cancer Patients ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Concetta; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maisano, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Roberto; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Santini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tonini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Biuseppe ¦ ¦ ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦Bauss, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Frieder; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦26 Journal of ¦ ¦ ¦ ¦Pfister, ¦Ibandronate Uptake in the Jaw ¦Bone Mineral ¦ ¦PX-3043¦2008¦ ¦is Similar to Long Bones and ¦Metabolism ¦ ¦ ¦ ¦Thomas; ¦Vertebrae in the Rat ¦406-408 (2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Papapoulos, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Socratets ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Walter, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Christian; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Al-Nawas, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bilal; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Grotz, Knut¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.; Thomas,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Christian; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Thuroff, ¦Prevalence and Risk Factors of ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate-Associated ¦European ¦ ¦PX-3044¦2008¦Joachim W.;¦Osteonecrosis of the Jaw in Prostate ¦Urology ¦ ¦ ¦ ¦ ¦Cancer Patients With Advanced Disease ¦(2008) ¦ ¦ ¦ ¦Zinser, ¦Treated with Zoledronate ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Viktoria; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gamm, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Heinold; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Beck, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joachim; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wagner, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wilfried ¦ ¦ ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦Dhillon, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sohita; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lyseng- ¦Zoledronic Acid -- A Review of Its Use¦68 Drugs 507 ¦ ¦PX-3045¦2008¦ ¦in the Management of Bone Metastases ¦ ¦ ¦ ¦ ¦Williamson,¦of Malignancy ¦(2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Katherine ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A. ¦ ¦ ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦ ¦Insight into Bisphosphonate-Associated¦7 Expert ¦ ¦PX-3046¦2008¦Wimalawansa¦Osteomyelitis of the Jaw: ¦Opinion Drug ¦ ¦ ¦ ¦, Sunil J. ¦Pathophysiology, Mechanisms and ¦Safety 491 ¦ ¦ ¦ ¦ ¦Clinical Management ¦(2008) ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦Santini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Martini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Federico; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fratto, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maria ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Elisabetta;¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Galluzzo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sara; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bruno; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦57 Cancer ¦ ¦ ¦ ¦Agrati, ¦ ¦Immunology ¦ ¦ ¦ ¦ ¦In Vivo Effects of Zoledronic Acid on ¦and ¦ ¦PX-3047¦2008¦Chiara; ¦Peripheral T Lymphocytes in Early ¦Immunotherapy¦ ¦ ¦ ¦ ¦Breast Cancer Patients ¦ ¦ ¦ ¦ ¦Turchi, ¦ ¦521 (2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Federica; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Piacentrini¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, Paola; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rocci, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Laura; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Manavalan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tonini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giuseppe; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Poccia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fabrizio ¦ ¦ ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦Pavlakis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦N.; ¦ ¦The Cochrane ¦ ¦ ¦ ¦ ¦Bisphosphonates for Breast Cancer ¦ ¦ ¦PX-3048¦2008¦Schmidt, ¦(Review) ¦Collaboration¦ ¦ ¦ ¦R.I.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ ¦ ¦ ¦Stockler, ¦ ¦ ¦ ¦ ¦ ¦M. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Bagan, Jose V.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jimenez, Yolanda; ¦ ¦ ¦ ¦ ¦ ¦Diaz, Jose M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Murillo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Judith; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sanchis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jose M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws in ¦Oral ¦ ¦PX-3049¦2008¦Poveda, ¦Intravenous Bisphosphonate Use:¦Oncology __ ¦ ¦ ¦ ¦ ¦Proposal for a Modification of ¦ ¦ ¦ ¦ ¦Rafael; ¦the Clinical Classification ¦(2008) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Carbonell, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Enrique; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gavalda, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Carmen; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Scully, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Crispian ¦ ¦ ¦ +-------+----+-------------------+-------------------------------+------------¦ ¦ ¦ ¦Dimopoulos, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kastritis, E.; ¦ ¦ ¦ ¦ ¦ ¦Barmia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Melakopoulo s, I.; ¦ ¦ ¦ ¦ ¦ ¦Gika, D.; Roussou, ¦Reduction of Osteonecrosis of ¦ ¦ ¦ ¦ ¦M.; Migkou, ¦the Jaw (ONJ) After ¦Annals of ¦ ¦ ¦ ¦ ¦Implementation of Preventive ¦Oncology __ ¦ ¦PX-3050¦2008¦M.; ¦Measures in Patients with ¦ ¦ ¦ ¦ ¦ ¦Multiple Myeloma Treated with ¦(2008) ¦ ¦ ¦ ¦Eleftheraki s- ¦Zoledronic Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Papaiakovou ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Christoulas ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, D.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Terpos, E.; Bamias,¦ ¦ ¦ ¦ ¦ ¦A. ¦ ¦ ¦ +-------+----+-------------------+-------------------------------+------------¦ ¦ ¦ ¦Kwek, ¦ ¦ ¦ ¦ ¦ ¦ ¦An Emerging Pattern of ¦39 Injury ¦ ¦ ¦ ¦Ernest Beng Kee; ¦Subtrochanteric Stress ¦224 ¦ ¦PX-3051¦2008¦Goh, Seo Kiat; Koh,¦Fractues: A Long-Term ¦ ¦ ¦ ¦ ¦Joyce Suang Bee; ¦Complication of Alendronate ¦(2008) ¦ ¦ ¦ ¦Png, Meng Ai; Howe,¦Therapy? ¦ ¦ ¦ ¦ ¦Tet Sen ¦ ¦ ¦ +-------+----+-------------------+-------------------------------+------------¦ ¦ ¦ ¦ ¦ ¦466 Clinical¦ ¦ ¦ ¦Chang, Jun-Dong; ¦Genetic Background of ¦Orthopedics ¦ ¦ ¦ ¦Hur, Mina; Lee, ¦Nontraumatic Osteonecrosis of ¦and Related ¦ ¦PX-3052¦2008¦Sang-Soo; Yoo, ¦the Femoral Head in the Korean ¦Research ¦ ¦ ¦ ¦Je-Hyun; Lee, Kyu ¦Population ¦1041 ¦ ¦ ¦ ¦Man ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ +-------+----+-------------------+-------------------------------+------------¦ ¦ ¦ ¦Dai, X.L.; Hong, ¦ ¦ ¦ ¦ ¦ ¦J.M.; Oh, B.; Cho, ¦Association Analysis of Tissue ¦ ¦ ¦ ¦ ¦Y.S.; ¦Factor Pathway Inhibitor ¦ ¦ ¦ ¦ ¦ ¦Polymorphisms and Haplotypes ¦26 Molecules¦ ¦PX-3053¦2008¦Lee, J.Y.; ¦with Osteonecrosis of the ¦and Cells - ¦ ¦ ¦ ¦ ¦Femoral Head in the Korean ¦(2008) ¦ ¦ ¦ ¦Park, E.K.; Kim, ¦Population ¦ ¦ ¦ ¦ ¦CY.; Kim, T.H.; ¦ ¦ ¦ ¦ ¦ ¦Kim, S.Y. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦466 Clinical ¦ ¦ ¦ ¦Glueck, ¦Heritable ¦Orthopedics and ¦ ¦ ¦ ¦Charles J.; ¦Thrombophilia-Hypofibrinolysis¦Related ¦ ¦PX-3054¦2008¦Freiberg, ¦and Osteonecrosis of the ¦ ¦ ¦ ¦ ¦Richard A.; ¦Femoral Head ¦Research 1034 ¦ ¦ ¦ ¦Wang, Ping ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ +-------+----+--------------+------------------------------+------------------¦ ¦ ¦ ¦Lehrer, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Steven; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Montazem, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Andre; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ramanathan, ¦ ¦106 Oral Surgery ¦ ¦ ¦ ¦ ¦Normal Serum Bone Markers in ¦Oral Medicine Oral¦ ¦ ¦ ¦Lakshmi; ¦Bisphosphonate-Induced ¦Pathology Oral ¦ ¦PX-3055¦2008¦ ¦ ¦Radiology and ¦ ¦ ¦ ¦Pessin- ¦Osteonecrosis of the Jaws ¦Endodontology 389 ¦ ¦ ¦ ¦ ¦ ¦(2008) ¦ ¦ ¦ ¦Minsley, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Melissa; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pfail, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John; Stock, ¦ ¦ ¦ ¦ ¦ ¦Richard G.; ¦ ¦ ¦ ¦ ¦ ¦Kogan, Rita ¦ ¦ ¦ +-------+----+--------------+------------------------------+------------------¦ ¦ ¦ ¦McArthur, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦H.L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Estilo, C.; ¦ ¦schweiz ¦ ¦ ¦ ¦Huryn, J.; ¦Slides Accompanying ¦ ¦ ¦ ¦ ¦Williams, T.; ¦Osteonecrosis of the Jaw (ONJ)¦Monatsschr ¦ ¦ ¦ ¦ ¦Among Intravenous (IV) ¦ ¦ ¦ ¦ ¦Fornier, M.; ¦Bisphosphonate-and/or ¦Zahnmed. ¦ ¦PX-3056¦2008¦Traina, ¦Bevacizumab-Treated Patients ¦ ¦ ¦ ¦ ¦ ¦(pts) at Memorial ¦2008;118(2):11 ¦ ¦ ¦ ¦T. A.; ¦Sloan-Kettering Cancer Center ¦ ¦ ¦ ¦ ¦ ¦ ¦3-23. French, ¦ ¦ ¦ ¦Howard, J.; ¦(MSKCC) (Abstract 9588). ¦German ¦ ¦ ¦ ¦Hudis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dickler, M.N. ¦ ¦ ¦ +-------+----+--------------+------------------------------+------------------¦ ¦ ¦ ¦Boonyapakor ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦n, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Thacharot; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schirmer, ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate-Induced ¦ ¦ ¦ ¦ ¦Ingrid; ¦ ¦44 Oral Oncology ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws: ¦857 ¦ ¦PX-3057¦2008¦Reichart, ¦Prospective Study of 80 ¦ ¦ ¦ ¦ ¦ ¦Patients With Multiple Myeloma¦(2008) ¦ ¦ ¦ ¦Peter A.; ¦and Other Malignancies ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sturm, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Isrid; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Massenkeil, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gero ¦ ¦ ¦ +-------+----+--------------+------------------------------+------------------¦ ¦ ¦ ¦Reade, Michael¦Bench-to-Bedside Review: ¦ ¦ ¦ ¦ ¦C.; Delaney, ¦Avoiding Pitfalls in Critical ¦ ¦ ¦ ¦ ¦Anthony; ¦Care Meta-Analysis -- Funnel ¦12 Critical ¦ ¦PX-3058¦2008¦Bailey, ¦Plots, Risk Estimates, Types ¦ ¦ ¦ ¦ ¦Michael J.; ¦of Heterogeneity, Baseline ¦Care 220 (2008) ¦ ¦ ¦ ¦Angus, Derek ¦Risk and the Ecologic Fallacy ¦ ¦ ¦ ¦ ¦C. ¦ ¦ ¦ +-------+----+--------------+------------------------------+------------------¦ ¦ ¦ ¦Karsdal MA et ¦Osteoclasts secrets non-bone ¦Biochem Biophys ¦ ¦PX-3059¦2008¦al ¦derived signals that induce ¦Res Commun. 2 008 ¦ ¦ ¦ ¦ ¦bone formation ¦ ¦ +-------+----+--------------+------------------------------+------------------¦ ¦ ¦ ¦ ¦ ¦Best Prac Res Clin¦ ¦ ¦ ¦De ¦ ¦Rheumatol 2008 ¦ ¦PX-3060¦2008¦ ¦Sclerosing Bone Disorders ¦Marc; 22 ¦ ¦ ¦ ¦Vernejoul MC ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(1): 71-83 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Dhillon S, ¦Zolendric acid: A review of ¦Auckland: ¦ ¦PX-3061¦2008 ¦Lyseng-Williamson¦its use in the management of ¦Wolters ¦ ¦ ¦ ¦KA ¦bone metastases of malignancy ¦Kluwer ¦ ¦ ¦ ¦ ¦ ¦Health; 2008 ¦ +-------+------+-----------------+------------------------------+-------------¦ ¦ ¦ ¦ ¦Osteonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jaw and ¦1 Clinical ¦ ¦PX-3062¦2007 ¦Vance, Michael A.¦ ¦Toxicology ¦ ¦ ¦ ¦ ¦Bisphosphonates: A Comparison ¦110 (2007) ¦ ¦ ¦ ¦ ¦with White Phosphorus, Radium,¦ ¦ ¦ ¦ ¦ ¦and Osteopetrosis ¦ ¦ +-------+------+-----------------+------------------------------+-------------¦ ¦ ¦ ¦Jadu, F.; Lee, ¦A Retrospective Study ¦ ¦ ¦ ¦ ¦L.; Pharoah, M.; ¦Assessing the Incidence, Risk ¦18 Annals of ¦ ¦PX-3063¦Dec-07¦Reece, D.; Wang, ¦Factors and Comorbidities of ¦Oncology 2015¦ ¦ ¦ ¦ ¦Pamidronate-Related Necrosis ¦ ¦ ¦ ¦ ¦L. ¦of the Jaws in Multiple ¦(2007) ¦ ¦ ¦ ¦ ¦Myeloma Patients ¦ ¦ +-------+------+-----------------+------------------------------+-------------¦ ¦ ¦ ¦Bertoldo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Francesco; ¦ ¦4 Nature ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦Santini, ¦Bisphosphonates and ¦Practice ¦ ¦PX-3064¦Dec-07¦ ¦Osteomyelitis of the Jaw: A ¦Oncology 711 ¦ ¦ ¦ ¦Daniele; Lo ¦Pathogenic Puzzle ¦ ¦ ¦ ¦ ¦ ¦ ¦(2007) ¦ ¦ ¦ ¦Cascio, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzo ¦ ¦ ¦ +-------+------+-----------------+------------------------------+-------------¦ ¦ ¦ ¦Marx , R.E.; ¦Oral Bisphosphonate-Induced ¦65 Journal of¦ ¦ ¦ ¦ ¦ ¦Oral and ¦ ¦PX-3065¦Dec-07¦Cillo, ¦Osteonecrosis: Risk Factors, ¦Maxillofacial¦ ¦ ¦ ¦ ¦Prediction of Risk Using Serum¦Surgery 2397 ¦ ¦ ¦ ¦J.E., Jr.; Ulloa,¦CTX Testing, Prevention, and ¦(2007) ¦ ¦ ¦ ¦J.J. ¦Treatment ¦ ¦ +-------+------+-----------------+------------------------------+-------------¦ ¦ ¦ ¦Diel, Ingo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fogelman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦I.; Al- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nawas; B.; ¦ ¦ ¦ ¦ ¦ ¦Hoffmeister ¦Pathophysiology, Risk Factors ¦ ¦ ¦ ¦ ¦ ¦and Management of ¦64 Critical ¦ ¦ ¦ ¦, B.; ¦Bisphosphonate-Associated ¦Reviews in ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw: ¦Oncology/ ¦ ¦PX-3066¦Dec-07¦Migliorati, C.; ¦ ¦Hemat ¦ ¦ ¦ ¦ ¦Is There a Diverse ¦ ¦ ¦ ¦ ¦Gligorov, ¦Relationship of Amino- and ¦ology 198 ¦ ¦ ¦ ¦ ¦Non-Aminobisphosphonates ¦(2007) ¦ ¦ ¦ ¦J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vaananen, K.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pylkkanen, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pecherstorfer, ¦ ¦ ¦ ¦ ¦ ¦M.; Aapro, M.S. ¦ ¦ ¦ +-------+------+-----------------+------------------------------+-------------¦ ¦ ¦ ¦Cheung, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦R.K.; ¦Sequential non-Traumatic ¦13 Hong Kong ¦ ¦ ¦ ¦ ¦Femoral Shaft Fractures in a ¦Medical ¦ ¦PX-3067¦Dec-07¦Leung, K.K.; Lee,¦Patient on Long-Term ¦Journal 485 ¦ ¦ ¦ ¦ ¦Alendronate ¦(2007) ¦ ¦ ¦ ¦K.C.; Chow, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦T.C. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦22 Journal ¦ ¦ ¦ ¦Khosla, ¦Editorial-Bisphosphonat-Associated¦of Bone and ¦ ¦ ¦ ¦Sundeep; ¦Osteonecrosis of the Jaw: Report ¦Mineral ¦ ¦PX-3068¦10-Nov-07¦Burr, D, ¦of a Task Force of the American ¦ ¦ ¦ ¦ ¦Demptster, ¦Society for Bone and Mineral ¦Research ¦ ¦ ¦ ¦DW, et al. ¦Research ¦1479 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2007) ¦ +-------+---------+-----------+----------------------------------+------------¦ ¦ ¦ ¦Edwards, ¦ ¦ ¦ ¦ ¦ ¦Beatrice ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gounder, ¦ ¦ ¦ ¦ ¦ ¦Mrinal; ¦ ¦ ¦ ¦ ¦ ¦McKoy, June¦ ¦ ¦ ¦ ¦ ¦M.; Boyd, ¦ ¦ ¦ ¦ ¦ ¦Ian; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Farrugia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mathew; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Migliorati,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cesar A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marx, ¦Bisphosphonate Use and ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw: A Review¦ ¦ ¦ ¦ ¦Robert; ¦of ¦ ¦ ¦ ¦2-Nov- ¦ ¦ ¦Lancet ¦ ¦PX-3069¦ ¦Ruggiero, ¦the ¦Oncology ¦ ¦ ¦07 ¦ ¦ ¦(Manuscript)¦ ¦ ¦ ¦Salvatore; ¦Pharmacovigilance and Reporting of¦ ¦ ¦ ¦ ¦ ¦this Serious Adverse Event ¦ ¦ ¦ ¦ ¦Dimopoulos,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meletios; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Raisch, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dennis; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Singhal, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seema; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Carson, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ken; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Obadina, ¦ ¦ ¦ ¦ ¦ ¦Eniola; ¦ ¦ ¦ ¦ ¦ ¦Trifilio, ¦ ¦ ¦ ¦ ¦ ¦Steve ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Lyles, Kenneth W.; ¦ ¦ ¦ ¦ ¦ ¦Colon-Emeric, CS; ¦ ¦ ¦ ¦ ¦ ¦Magaziner, JS; Adachi, ¦ ¦ ¦ ¦ ¦ ¦JD; Pieper, CF; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mautalen, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hyldstrup, L; Recknor, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C; ¦Zoledronic Acid ¦ ¦ ¦ ¦ ¦ ¦and Clinical ¦357 New England¦ ¦PX-3070¦1-Nov-07¦Nordsletter , L; Moore, ¦Fractures and ¦Journal of ¦ ¦ ¦ ¦ ¦Mortality After ¦Medicine 1799 ¦ ¦ ¦ ¦KA; ¦Hip Fracture ¦(2007) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lavecchia, C; Zhang, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mesenbrink, P; Hodgson, ¦ ¦ ¦ ¦ ¦ ¦PK; Abrams, K; Orloff, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦JJ; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Horowitz, Z; Eriksen, EF;¦ ¦ ¦ ¦ ¦ ¦Boonen,S ¦ ¦ ¦ +-------+--------+-------------------------+------------------+---------------¦ ¦ ¦ ¦ ¦Marble Bone ¦ ¦ ¦ ¦ ¦ ¦Disease: A Review ¦ ¦ ¦ ¦ ¦Lam, David K.; Sandor, ¦of Osteopetrosis ¦73 Journal of ¦ ¦ ¦ ¦George K. B.; Holmes, ¦and ¦the Canadian ¦ ¦PX-3071¦Nov-07 ¦Howard I.; Carmichael, ¦ ¦Dental ¦ ¦ ¦ ¦Robert P.; Clokie, ¦Its Oral Health ¦Association 839¦ ¦ ¦ ¦Cameron M. L. ¦ ¦(2007) ¦ ¦ ¦ ¦ ¦Implications for ¦ ¦ ¦ ¦ ¦ ¦Dentists ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Khosla,Sund ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦eep; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Burr,D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cauley,J;De ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦mpster,D;Eb ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦eling,P; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Felsenberg, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gagel,R;Gil ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦sanz,V; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦22 Journal ¦ ¦ ¦ ¦Guise,T;Kok ¦Bisphosphonate-Associated ¦of Bone and ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw: Report ¦Mineral ¦ ¦PX-3072¦Oct-07¦a,S; ¦of a Task Force of the American ¦ ¦ ¦ ¦ ¦ ¦Society for Bone and Mineral ¦Research ¦ ¦ ¦ ¦McCauley,L; ¦Research ¦14791491 ¦ ¦ ¦ ¦McGowan,J;M ¦ ¦(2007) ¦ ¦ ¦ ¦cKee,M;Mohl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦a,S; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pendrys, D; ¦ ¦ ¦ ¦ ¦ ¦Raisz, L; ¦ ¦ ¦ ¦ ¦ ¦Ruggiero, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S;Shafer,D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shum,L;Silv ¦ ¦ ¦ ¦ ¦ ¦erman,SL;Va n ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Poznak,CH; ¦ ¦ ¦ ¦ ¦ ¦Watts,N;Woo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦,S- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦B;Shane,Eli ¦ ¦ ¦ ¦ ¦ ¦zabeth ¦ ¦ ¦ +-------+------+---------------+---------------------------------+------------¦ ¦ ¦ ¦Glueck, Charles¦Detecting Thrombophilia, ¦18 Seminars ¦ ¦PX-3073¦Sep-07¦J.; Freiberg, ¦Hypofibrinolysis and Reduced ¦in ¦ ¦ ¦ ¦Richard A.; ¦Nitric Oxide Production in ¦Arthroplasty¦ ¦ ¦ ¦Wang, Ping ¦Osteonecrosis ¦184 (2007) ¦ +-------+------+---------------+---------------------------------+------------¦ ¦ ¦ ¦Reid, Ian R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Is Bisphosphonate-Associated ¦41 Bone 318 ¦ ¦PX-3074¦Sep-07¦Bolland, Mark ¦Osteonecrosis of the Jaw Caused ¦ ¦ ¦ ¦ ¦J.; Grey, ¦by Soft Tissue Toxicity? ¦(2007) ¦ ¦ ¦ ¦Andrew B. ¦ ¦ ¦ +-------+------+---------------+---------------------------------+------------¦ ¦ ¦ ¦Chen, Wei-Ming;¦Tracing the Genetic Origins of ¦18 Seminars ¦ ¦PX-3075¦Sep-07¦Liu, Yu-Fen; ¦ ¦in ¦ ¦ ¦ ¦Tsai, Shih-Feng¦Osteonecrosis of the Femoral Head¦Arthroplasty¦ ¦ ¦ ¦ ¦ ¦175 (2007) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Khosla,Sundeep; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Burr,D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cauley,J;De ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦mpster,D;Eb ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦eling,P; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Felsenberg, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gagel,R;Gil ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦sanz,V; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Guise,T;Kok ¦ ¦21 Journal of ¦ ¦ ¦ ¦ ¦Bisphosphonate-Associated¦Bone and Mineral ¦ ¦ ¦19-Jul-¦a,S; ¦Osteonecrosis of the Jaw:¦Research -- ¦ ¦PX-3076¦ ¦ ¦Report of a Task Force of¦e-publication ¦ ¦ ¦07 ¦McCauley,L; ¦the American Society for ¦prior to print ¦ ¦ ¦ ¦McGowan,J;M ¦Bone and Mineral Research¦publication ¦ ¦ ¦ ¦cKee,M;Mohl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦a,S; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pendrys, D;Raisz,¦ ¦ ¦ ¦ ¦ ¦L;Ruggiero, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S;Shafer,D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shum,L;Silv ¦ ¦ ¦ ¦ ¦ ¦erman,SL;Va n ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Poznak,CH; ¦ ¦ ¦ ¦ ¦ ¦Watts,N;Woo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦,S- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦B;Shane,Eli ¦ ¦ ¦ ¦ ¦ ¦zabeth ¦ ¦ ¦ +-------+-------+-----------------+-------------------------+-----------------¦ ¦ ¦ ¦Wilkinson, Gregg ¦Intravenous ¦99 Journal of the¦ ¦ ¦4-Jul- ¦S.; Kuo, ¦Bisphosphonate Therapy ¦National Cancer ¦ ¦PX-3077¦ ¦Yong-Fang; ¦and Inflammatory ¦ ¦ ¦ ¦07 ¦Freeman, Jean L.;¦Conditions or Surgery of ¦Institute 1016 ¦ ¦ ¦ ¦Goodwin, James S.¦the Jaw: A ¦(2007) ¦ ¦ ¦ ¦ ¦Population-Based Analysis¦ ¦ +-------+-------+-----------------+-------------------------+-----------------¦ ¦ ¦ ¦Woo, Sook-Bin; ¦Bisphosphonate Therapy ¦99 Journal of the¦ ¦ ¦4-Jul- ¦ ¦for Cancer and Prevalence¦National Cancer ¦ ¦PX-3078¦ ¦Solomon, Daniel ¦of Inflammatory Jaw ¦ ¦ ¦ ¦07 ¦H. ¦Conditions ¦Institute 986987 ¦ ¦ ¦ ¦ ¦ ¦(2007) ¦ +-------+-------+-----------------+-------------------------+-----------------¦ ¦ ¦ ¦Wang, Estee P.; ¦Incidence of ¦ ¦ ¦ ¦ ¦Kaban, Leonard ¦Osteonecrosis of the Jaw ¦65 Journal of ¦ ¦ ¦ ¦B.; Strewler, ¦in Patients With Multiple¦Oral and ¦ ¦PX-3079¦Jul-07 ¦Gordon J.; Raje, ¦Myeloma and Breast or ¦Maxillofacial ¦ ¦ ¦ ¦Noopur; Troulis, ¦Prostate Cancer on ¦Surgery 1328 ¦ ¦ ¦ ¦Maria J. ¦Intravenous ¦(2007) ¦ ¦ ¦ ¦ ¦Bisphosphonate Therapy ¦ ¦ +-------+-------+-----------------+-------------------------+-----------------¦ ¦ ¦ ¦Corso, A.; ¦ ¦ ¦ ¦ ¦ ¦Varettoni, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zappasodi, P.; ¦A Different Schedule of ¦ ¦ ¦ ¦ ¦Klersy, C.; ¦Zoledronic Acid Can ¦ ¦ ¦ ¦ ¦ ¦Reduce the Risk of ¦21 Leukemia ¦ ¦PX-3080¦Jul-07 ¦Mangiacaval ¦Osteonecrosis of the Jaw ¦ ¦ ¦ ¦ ¦ ¦in Patients With Multiple¦1545 (2007) ¦ ¦ ¦ ¦li, S.; ¦Myeloma ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pica, G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lazzarino, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Kyle, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert A.; Yee, Gary ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Somerfield, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mark R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Flynn, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patrick J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Halabi, ¦American Society of ¦ ¦ ¦ ¦ ¦ ¦Clinical Oncology ¦25 Journal ¦ ¦ ¦ ¦Susan; ¦ ¦of Clinical ¦ ¦ ¦10-Jun- ¦ ¦2007 Clinical ¦Oncology ¦ ¦PX-3081¦ ¦Jagannath, ¦ ¦2464 ¦ ¦ ¦07 ¦ ¦Practice Guideline Update¦ ¦ ¦ ¦ ¦Sundar; ¦on the Role of ¦(2007) ¦ ¦ ¦ ¦ ¦Bisphosphonates in ¦ ¦ ¦ ¦ ¦Orlowski, ¦Multiple Myeloma ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert Z.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Roodman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦David G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Twilde, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patricia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anderson, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kenneth ¦ ¦ ¦ +-------+--------+---------------------+-------------------------+------------¦ ¦ ¦ ¦Lam, David K.; ¦ ¦73 Journal ¦ ¦ ¦ ¦Sandor, George K. B.;¦A Review of ¦of the ¦ ¦PX-3082¦Jun-07 ¦Holmes, Howard I.; ¦Bisphosphonate-Associated¦Canadian ¦ ¦ ¦ ¦Evans, A. Wayne; ¦Osteonecrosis of the Jaws¦Dental ¦ ¦ ¦ ¦Clokie, Cameron M. L.¦and Its Management ¦Association ¦ ¦ ¦ ¦ ¦ ¦417 (2007) ¦ +-------+--------+---------------------+-------------------------+------------¦ ¦ ¦ ¦Black, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dennis M; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Delmas,PD; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eastell,R; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reid,IR; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Boonen,S; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cauley,JA; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cosman,F; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lakatos,P; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Leung,PC; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦356 New ¦ ¦ ¦ ¦Man,Z; ¦Once-Yearly Zoledronic ¦England ¦ ¦ ¦ ¦ ¦Acid for Treatment of ¦Journal of ¦ ¦PX-3083¦3-May-07¦Mautalen,C; ¦Postmenopausal ¦ ¦ ¦ ¦ ¦ ¦Osteoporosis ¦Medicine ¦ ¦ ¦ ¦Mesenbrink, ¦ ¦1809 (2007) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦P; Hu,H; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Caminis, J; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tong,K; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rosario- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jansen,T; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Krasnow,J; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hue,TF;Sell ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦meyer,D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eriksen,EF; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cummings,SR ¦ ¦ ¦ +-------+--------+---------------------+-------------------------+------------¦ ¦ ¦ ¦Murad, O.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Arora, S.; Farag, ¦Bisphosphonates and ¦13 Endocrine¦ ¦PX-3084¦May-07 ¦ ¦Osteonecrosis of the Jaw:¦Practice 232¦ ¦ ¦ ¦A.F.; ¦A Retrospective Study ¦(2007) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Guber, H.A. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Murad, Omar M.; ¦Bisphosphonates and ¦13 ¦ ¦PX-3085¦May-07¦Arora, Surender; ¦Osteonecrosis of the Jaw: A ¦Endocrine ¦ ¦ ¦ ¦Farag, Amal F.; ¦Retrospective Study ¦Practice ¦ ¦ ¦ ¦Guber, Helena A. ¦ ¦232 (2007) ¦ +-------+------+--------------------+-----------------------------+-----------¦ ¦ ¦ ¦Weitzman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Richard; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sauter, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nicholas; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eriksen, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Erik Fink; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tarassoff, ¦ ¦ ¦ ¦ ¦ ¦ ¦Critical Review: ¦ ¦ ¦ ¦ ¦Peter G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Updated ¦62 Critical¦ ¦ ¦ ¦Lacerna, ¦ ¦Reviews in ¦ ¦ ¦ ¦ ¦Recommendations for the ¦Oncology/ ¦ ¦PX-3086¦May-07¦Leo V.; ¦Prevention, Diagnosis, and ¦Hemat ¦ ¦ ¦ ¦ ¦Treatment of Osteonecrosis of¦ ¦ ¦ ¦ ¦Dias, Rosh; ¦the Jaw in Cancer ¦ology 148 ¦ ¦ ¦ ¦ ¦ ¦(2007) ¦ ¦ ¦ ¦Altmeyer, ¦Patients -- May 2006 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anne; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Csermak- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Renner, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Katalin; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦McGrath, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lynne; Lantwicki, ¦ ¦ ¦ ¦ ¦ ¦Linda; Hohneker, ¦ ¦ ¦ ¦ ¦ ¦John A. ¦ ¦ ¦ +-------+------+--------------------+-----------------------------+-----------¦ ¦ ¦ ¦Dannemann, C.; ¦ ¦ ¦ ¦ ¦ ¦Gratz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦K.W.; ¦Jaw Osteonecrosis Related to ¦40 Bone 828¦ ¦PX-3087¦Apr-07¦ ¦Bisphosphonate Therapy: A ¦ ¦ ¦ ¦ ¦Riener, ¦Severe Secondary Disorder ¦(2007) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.O.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zwahlen, R.A. ¦ ¦ ¦ +-------+------+--------------------+-----------------------------+-----------¦ ¦ ¦ ¦Tassinari, Davide; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Poggi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Barbara; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nicoletti, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stefania; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦10 Journal ¦ ¦ ¦ ¦Fantini, ¦Zoledronic Acid Treatment at ¦of ¦ ¦ ¦ ¦ ¦Home: Safety Data from an ¦Palliative ¦ ¦PX-3088¦Apr-07¦Manuela; ¦Observational Prospective ¦Medicine ¦ ¦ ¦ ¦ ¦Trial ¦352 ¦ ¦ ¦ ¦Tamburini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2007) ¦ ¦ ¦ ¦Emiliano; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Possenti, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cinzia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sartori, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sergio ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Shinohara, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Masahiro; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Koga, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Takako; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Okamoto, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kazuo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sakaguchi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shinya; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Arai, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kimiko; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yasuda, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hisataka; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Takai, ¦ ¦ ¦ ¦ ¦ ¦ ¦Tyrosine Kinases Btk and ¦ ¦ ¦ ¦ ¦Toshiyuki; ¦Tec Regulate Osteoclast ¦132 Cell 794 ¦ ¦PX-3089¦7-Mar-07¦ ¦Differentiation by Linking¦(2007) ¦ ¦ ¦ ¦Kodama, ¦RANK and ITAM Signals ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tatsuhiko; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Morio, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tomohiro; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Geha, Raif ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kitamura, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daisuke; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kurosaki, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tomohiro; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ellmeier, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wilfried; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Takayanagi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Horoshi ¦ ¦ ¦ +-------+--------+-------------------+--------------------------+-------------¦ ¦ ¦ ¦Khamaisi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mogher; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Regev, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eran; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yarom, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦92 Journal of¦ ¦ ¦ ¦Noam; Avni, ¦Possible Association ¦Clinical ¦ ¦ ¦ ¦ ¦Between Diabetes and ¦Endocrinology¦ ¦PX-3090¦1-Mar-07¦Batia; ¦Bisphosphonate-Related Jaw¦and ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦Metabolism ¦ ¦ ¦ ¦Leitersdorf ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1172 (2007) ¦ ¦ ¦ ¦, Eran; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Raz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Itamar; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Elad, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sharon ¦ ¦ ¦ +-------+--------+-------------------+--------------------------+-------------¦ ¦ ¦ ¦Bujanda, D Agular; ¦Assessment of Renal ¦18 Annals of ¦ ¦ ¦1-Mar- ¦Sarmiento, U. Bohn;¦Toxicity and Osteonecrosis¦Oncology 556 ¦ ¦PX-3091¦ ¦Suarex, M. Cabrera;¦of the Jaws in Patients ¦ ¦ ¦ ¦07 ¦Morales, J. Agular ¦Receiving Zoledronic Acid ¦(2007) ¦ ¦ ¦ ¦ ¦for Bone Metastasis ¦ ¦ +-------+--------+-------------------+--------------------------+-------------¦ ¦ ¦ ¦Mavrokokki, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tony; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cheng, ¦ ¦ ¦ ¦ ¦ ¦ ¦Nature and Frequency of ¦65 Journal of¦ ¦ ¦ ¦Andrew; ¦Bisphosphonate-Associated ¦Oral and ¦ ¦PX-3092¦Mar-07 ¦ ¦Osteonecrosis of the Jaws ¦Maxillofacial¦ ¦ ¦ ¦Stein, ¦in Australia ¦Surgery 415 ¦ ¦ ¦ ¦ ¦ ¦(2007) ¦ ¦ ¦ ¦Brien; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Goss, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Alastair ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦American Association of ¦65 Journal of ¦ ¦ ¦ ¦ ¦Oral and Maxillofacial ¦Oral and ¦ ¦PX-3093¦Mar-07¦Anonymous ¦Surgeons Position Paper ¦Maxillofacial ¦ ¦ ¦ ¦ ¦on Bisphosphonate-Related¦Surgery 369 ¦ ¦ ¦ ¦ ¦ ¦(2007) ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Krueger; C.D.; West, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦P.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate- ¦41 Annals of ¦ ¦ ¦ ¦Sargent, M.; ¦ ¦Pharmacotherap¦ ¦PX-3094¦Feb-07¦ ¦Induced ¦ ¦ ¦ ¦ ¦Lodolce, ¦ ¦y 276 (2007) ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw ¦ ¦ ¦ ¦ ¦A.E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pickard, A.S. ¦ ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦ ¦Therapy Insight: The ¦4 Nature ¦ ¦ ¦ ¦Dunstan, Colin R.; ¦Risks and Benefits of ¦Clinical ¦ ¦PX-3095¦Jan-07¦Felsenberg, Dieter; ¦Bisphosphonates for the ¦Practice ¦ ¦ ¦ ¦Seibel, Markus J. ¦Treatment of ¦Oncology 42 ¦ ¦ ¦ ¦ ¦Tumor-Induced Bone ¦(2007) ¦ ¦ ¦ ¦ ¦Disease ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Walter, Christian; ¦Prevalence of ¦15 Support ¦ ¦ ¦ ¦Groetz, Knut A; ¦Bisphosphonate Associated¦Care Cancer ¦ ¦PX-3096¦2007 ¦Kunkel, Martin; ¦Osteonecrosis of the Jaw ¦ ¦ ¦ ¦ ¦Al-Nawas, Bilal ¦Within the Field of ¦197 (2007) ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Pozzi,S;Mar ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦cheselli,R; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sacchi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S;Baldini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L;Angrilli, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦F;Pennese,E ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦;Quarta,G; ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate-Associated¦ ¦ ¦ ¦ ¦Stelitano,C ¦Osteonecrosis of the Jaw:¦4 8 Leukemia ¦ ¦ ¦ ¦ ¦A Review of 35 Cases and ¦and Lymphoma ¦ ¦PX-3097¦2007 ¦; ¦an Evaluation of Its ¦ ¦ ¦ ¦ ¦ ¦Frequency in Multiple ¦56 (2007) ¦ ¦ ¦ ¦Caparotti,G ; ¦Myeloma Patients ¦ ¦ ¦ ¦ ¦Luminari,S ;Musto,P; ¦ ¦ ¦ ¦ ¦ ¦Na tale,D;Brog lia,C;¦ ¦ ¦ ¦ ¦ ¦Cuogh ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦i, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A;Dini,D.;D ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦iTonno,P;Le onardi,G;¦ ¦ ¦ ¦ ¦ ¦Pi anezze,G;Pi ¦ ¦ ¦ ¦ ¦ ¦tini,V;Poli meno,G; ¦ ¦ ¦ ¦ ¦ ¦Ponc hi,L;Masini ,L; ¦ ¦ ¦ ¦ ¦ ¦Musso,M; Spriano,M;P ¦ ¦ ¦ ¦ ¦ ¦ollastri,G ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Oral & Intravenous ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate- ¦ ¦ ¦PX-3098¦2007¦Marx, ¦ ¦ ¦ ¦ ¦ ¦Robert E. ¦Induced ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws: History, ¦ ¦ ¦ ¦ ¦ ¦Etiology, Prevention, and Treatment ¦ ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦Van den ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wyngaert, ¦Osteonecrosis of the Jaw Related to ¦ ¦ ¦ ¦ ¦ ¦the ¦19 Current ¦ ¦PX-3099¦2007¦Tim; ¦ ¦Opinion in ¦ ¦ ¦ ¦ ¦Use of ¦Oncology 315 ¦ ¦ ¦ ¦Huizing, ¦ ¦(2007) ¦ ¦ ¦ ¦Manon T.; ¦Bisphosphonates ¦ ¦ ¦ ¦ ¦Vermorken, ¦ ¦ ¦ ¦ ¦ ¦Jan B. ¦ ¦ ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦Ortega, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cinzia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Montemurro,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Filippo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Faggiuolo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Roberto; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vormola, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦4 6 Acta ¦ ¦ ¦ ¦Roberto; ¦Osteonecrosis of the Jaw in Prostate ¦ ¦ ¦ ¦ ¦ ¦Cancer Patients With Bone Metastases ¦Oncologica ¦ ¦PX-3100¦2007¦Nanni, ¦Treated With Zoledronate: A ¦664 ¦ ¦ ¦ ¦ ¦Retrospective Analysis ¦ ¦ ¦ ¦ ¦Daniela; ¦ ¦(2007) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Goia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Franco; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gilardino; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Marco ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ottavio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aglietta, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Massimo ¦ ¦ ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦Garcia ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Saenz, Jose¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Angel; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tarruella, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sara Lopez;¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Paredes, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Beatriz ¦ ¦12 Medicina ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw as an Adverse¦Oral ¦ ¦ ¦ ¦Garcia; ¦Bisphosphonate Event: Three Cases of ¦Patalogia ¦ ¦PX-3101¦2007¦ ¦Bone Metastatic Prostate Cancer ¦Oral Cirugia ¦ ¦ ¦ ¦Lajusticia,¦Patients Treated With Zoledronic Acid ¦ ¦ ¦ ¦ ¦ ¦ ¦Bucal E351 ¦ ¦ ¦ ¦Laura ¦ ¦(2007) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rodriguez; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Villalobos,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Laura; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rubio, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eduardo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Diaz ¦ ¦ ¦ +-------+----+-----------+--------------------------------------+-------------¦ ¦ ¦ ¦Woo, ¦ ¦100 Alpha ¦ ¦PX-3102¦2007¦Sook-Bin; ¦Osteonecrosis of the Jaws and ¦Omegan ¦ ¦ ¦ ¦Kalmar, ¦Bisphosphonates ¦194-202 ¦ ¦ ¦ ¦John R. ¦ ¦(2007) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Santini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bruno; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Galluzzo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sara; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Battistoni,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fabrizio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rocci, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Laura; ¦ ¦ ¦ ¦ ¦ ¦ ¦Repeated ¦ ¦ ¦ ¦ ¦Venditti, ¦ ¦13 Clinical ¦ ¦ ¦ ¦ ¦Intermittent Low-Dose Therapy with ¦ ¦ ¦ ¦ ¦Olga; ¦Zoledronic Acid Induces an Early, ¦Cancer ¦ ¦PX-3103¦2007 ¦ ¦Sustained, and Long-Lasting ¦ ¦ ¦ ¦ ¦Schiavon, ¦Decrease of Peripheral Vascular ¦Research 4482¦ ¦ ¦ ¦ ¦Endothelial Growth Factor Levels in¦ ¦ ¦ ¦ ¦Gaia; ¦Cancer Patients ¦(2007) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Angeletti, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Silvia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Uzzalli, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Federica; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Caraglia, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Michele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dicuonzo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giordano; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tonini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giuseppe ¦ ¦ ¦ +-------+-------+-----------+-----------------------------------+-------------¦ ¦ ¦ ¦ ¦Farnesyl Pyrophosphate Synthase: ¦5 ASSAY and ¦ ¦ ¦ ¦Glickman, ¦Real-Time Kinetics and Inhibition ¦Drug ¦ ¦PX-3104¦2007 ¦J. Fraser; ¦by Nitrogen-Containing ¦ ¦ ¦ ¦ ¦Schmid, ¦Bisphosphonates in a Scintillation ¦Development ¦ ¦ ¦ ¦Andres ¦Assay ¦Technologies ¦ ¦ ¦ ¦ ¦ ¦205 (2007) ¦ +-------+-------+-----------+-----------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦3 ¦ ¦ ¦ ¦Seton, ¦ ¦Therapeutics ¦ ¦ ¦ ¦Margaret; ¦Uses of Zoledronic Acid in the ¦and Clinical ¦ ¦PX-3105¦2007 ¦Krane, ¦Treatment of Paget's Disease ¦Risk ¦ ¦ ¦ ¦Stephen M. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Management ¦ ¦ ¦ ¦ ¦ ¦913 (2007) ¦ +-------+-------+-----------+-----------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦12 Nature ¦ ¦ ¦ ¦Felsenberg,¦Osteonecrosis of the Jaw -- A ¦Clinical ¦ ¦PX-3106¦Dec-06 ¦ ¦Potential Adverse Effect of ¦Practice 662 ¦ ¦ ¦ ¦D. ¦Bisphosphonate Treatment ¦ ¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ +-------+-------+-----------+-----------------------------------+-------------¦ ¦ ¦ ¦Hadjidakis,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1092 Annals ¦ ¦ ¦ ¦Dimitrios ¦ ¦of the New ¦ ¦ ¦ ¦ ¦ ¦York Academy ¦ ¦PX-3107¦Dec-06 ¦J.; ¦Bone Remodeling ¦of Sciences ¦ ¦ ¦ ¦ ¦ ¦385 ¦ ¦ ¦ ¦Androulakis¦ ¦ ¦ ¦ ¦ ¦, Ioannis ¦ ¦(2006) ¦ ¦ ¦ ¦I. ¦ ¦ ¦ +-------+-------+-----------+-----------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦355 New ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw -- Do ¦England ¦ ¦ ¦30-Nov-¦Bilezikian,¦ ¦Journal of ¦ ¦PX-3108¦ ¦John P. ¦Bisphosphonates Pose ¦ ¦ ¦ ¦06 ¦ ¦ ¦Medicine 2278¦ ¦ ¦ ¦ ¦a Risk? ¦ ¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ +-------+-------+-----------+-----------------------------------+-------------¦ ¦ ¦25-Nov-¦ ¦Osteonecrosis of the Jaw and ¦333 British ¦ ¦PX-3109¦ ¦Waclawski, ¦ ¦Medical ¦ ¦ ¦06 ¦Eugene R. ¦Bisphosphonates: Historical Lesson ¦Journal 1123 ¦ ¦ ¦ ¦ ¦from Occupational Medicine ¦(2006) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Bisphosphonate-Related¦102 Oral Surgery, ¦ ¦ ¦ ¦Ruggiero, ¦ ¦Oral Medicine, Oral ¦ ¦ ¦ ¦Salvatore L.; ¦Osteonecrosis of the ¦Pathology, Oral ¦ ¦PX-3110¦Oct-06 ¦ ¦Jaw: Background and ¦Radiology and ¦ ¦ ¦ ¦Fantasia, John;¦Guidelines for ¦Edontology 433 ¦ ¦ ¦ ¦Carlson, Eric ¦Diagnosis, Staging and¦(2006) ¦ ¦ ¦ ¦ ¦Management ¦ ¦ +-------+---------+---------------+----------------------+--------------------¦ ¦ ¦ ¦Sanna, G.; ¦ ¦ ¦ ¦ ¦ ¦Preda, L.; ¦ ¦ ¦ ¦ ¦ ¦Bruschini, R.; ¦ ¦ ¦ ¦ ¦ ¦Rocca, M. ¦ ¦ ¦ ¦ ¦ ¦Cossu; ¦ ¦ ¦ ¦ ¦ ¦Ferretti, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates and ¦17 Annals of ¦ ¦PX-3111¦Oct-06 ¦Adamoli, L.; ¦Jaw Osteonecrosis in ¦Oncology 1512 ¦ ¦ ¦ ¦Verri, ¦Patients With Advanced¦ ¦ ¦ ¦ ¦ ¦Breast Cancer ¦(2006) ¦ ¦ ¦ ¦E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Franceschel ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦li, L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Goldhirsch, A.;¦ ¦ ¦ ¦ ¦ ¦Nole, F. ¦ ¦ ¦ +-------+---------+---------------+----------------------+--------------------¦ ¦ ¦ ¦ ¦Jaw Bone Necrosis and ¦3 ¦ ¦PX-3112¦Sep-06 ¦Boyde, Alan ¦Bisphosphonates: ¦BoneKEy-Osteovision ¦ ¦ ¦ ¦ ¦Microanatomical ¦19 (2006) ¦ ¦ ¦ ¦ ¦Questions ¦ ¦ +-------+---------+---------------+----------------------+--------------------¦ ¦ ¦ ¦Kraj, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maria; ¦ ¦ ¦ ¦ ¦ ¦ ¦The Incidence of Jaw ¦ ¦ ¦ ¦ ¦Poglod, ¦Osteonecrosis in ¦63 Acta Pol. ¦ ¦ ¦ ¦ ¦Multiple Myeloma ¦ ¦ ¦PX-3113¦Sep-06 ¦Ryszard; ¦Patients Treated With ¦Pharm. 450 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maj, ¦Bisphosphonates. ¦(2006) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stanislaw; ¦ ¦ ¦ ¦ ¦ ¦Owczarska, ¦ ¦ ¦ ¦ ¦ ¦Katarzyna ¦ ¦ ¦ +-------+---------+---------------+----------------------+--------------------¦ ¦ ¦ ¦Whyte, Michael ¦Paget's Disease of ¦355 New England ¦ ¦PX-3114¦10-Aug-06¦P. ¦Bone ¦Journal of Medicine ¦ ¦ ¦ ¦ ¦ ¦593 (2006) ¦ +-------+---------+---------------+----------------------+--------------------¦ ¦ ¦ ¦Anonymous (ADA ¦Dental Management of ¦137 Journal of the ¦ ¦ ¦ ¦ ¦Patients Receiving ¦American Dental ¦ ¦PX-3115¦Aug-0 6 ¦Council of ¦Oral Bisphosphonate ¦Association ¦ ¦ ¦ ¦Scientific ¦Therapy: Expert Panel ¦ ¦ ¦ ¦ ¦Affairs) ¦ ¦1144 (2006) ¦ ¦ ¦ ¦ ¦Recommendations ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Lacy,Martha ¦ ¦ ¦ ¦ ¦ ¦Q.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dispenzieri ¦ ¦ ¦ ¦ ¦ ¦,A;Gertz,MA ; ¦ ¦ ¦ ¦ ¦ ¦Greipp,PR; ¦ ¦ ¦ ¦ ¦ ¦Gollbach,KL ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hayman,SR; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kumar,S;Lus ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦t,JA;Rajkum ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ar,SV;Russe ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ll,SJ;Witzi ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦g,TE; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zeldenrust, ¦Mayo Clinic Consensus ¦ ¦ ¦ ¦Aug-0 ¦ ¦Statement for the Use of ¦81 Mayo Clinic ¦ ¦PX-3116¦6 ¦SR; ¦Bisphosphonates in ¦Proceedings 1047 ¦ ¦ ¦ ¦ ¦Multiple Myeloma ¦(2006) ¦ ¦ ¦ ¦Dingli,D; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bergsagel,P ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L;Fonseca,R ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦;Reeder,CB; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stewart,AK; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Roy,V; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dalton,RJ;C ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦arr,AB;Kade ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦mani,D;Kell ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦er,EE;Viozz ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦i,CF;Kyle,R ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A ¦ ¦ ¦ +-------+------+--------------+--------------------------+--------------------¦ ¦ ¦ ¦Kademani, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Deepak; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Koka, ¦Primary Surgical Therapy ¦81 Mayo Clinic ¦ ¦PX-3117¦Aug-0 ¦ ¦for Osteonecrosis of the ¦Proceedings ¦ ¦ ¦6 ¦Sreenivas; ¦Jaw Secondary to ¦ ¦ ¦ ¦ ¦Lacy, ¦Bisphosphonate Therapy ¦1100 (2006) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Martha Q.; ¦ ¦ ¦ ¦ ¦ ¦Rajkumar, S. ¦ ¦ ¦ ¦ ¦ ¦Vincent ¦ ¦ ¦ +-------+------+--------------+--------------------------+--------------------¦ ¦ ¦ ¦Van den ¦ ¦ ¦ ¦ ¦ ¦Wyngaert, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦T.; ¦Bisphosphonates and ¦17 Annals of ¦ ¦ ¦Aug-0 ¦ ¦Osteonecrosis of the Jaw: ¦Oncology 1197 ¦ ¦PX-3118¦6 ¦Huizing, ¦Cause and Effect or a Post¦ ¦ ¦ ¦ ¦ ¦Hoc Fallacy? ¦(2006) ¦ ¦ ¦ ¦M.T.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vermorken, ¦ ¦ ¦ ¦ ¦ ¦J.B. ¦ ¦ ¦ +-------+------+--------------+--------------------------+--------------------¦ ¦ ¦ ¦Dimitrakopo ¦ ¦ ¦ ¦ ¦ ¦ulos, I.; ¦ ¦35 ¦ ¦ ¦ ¦Magopoulos, ¦Bisphosphonate-Induced ¦ ¦ ¦PX-3119¦Jul-06¦C.; ¦Avascular Osteonecrosis of¦International ¦ ¦ ¦ ¦ ¦the Jaws: A Clinical ¦Journal of Oral and ¦ ¦ ¦ ¦Karakasis, ¦Report of 11 Cases ¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦Surgery 588 (2006) ¦ ¦ ¦ ¦D. ¦ ¦ ¦ +-------+------+--------------+--------------------------+--------------------¦ ¦ ¦ ¦ ¦Bisphosphonate- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Migliorati, ¦Associated ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.A.; ¦Osteonecrosis: A ¦7 Lancet Oncology ¦ ¦ ¦Jun-0 ¦ ¦ ¦508 ¦ ¦PX-3120¦6 ¦Siegal, M.A.; ¦Long-Term ¦ ¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ ¦ ¦ ¦Elting, ¦Complication of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.S. ¦Bisphosphonate ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Treatment ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Zavras, ¦Bisphosphonates Are ¦64 Journal of¦ ¦ ¦ ¦Athanasios I.; ¦Associated With Increased ¦Oral and ¦ ¦PX-3121¦Jun-0 6 ¦Zhu, ¦Risk for Jaw Surgery in ¦Maxillofacial¦ ¦ ¦ ¦ ¦Medical Claims Data: Is it ¦Surgery 917 ¦ ¦ ¦ ¦Shao ¦Osteonecrosis? ¦(2006) ¦ +-------+---------+-----------------+---------------------------+-------------¦ ¦ ¦ ¦Woo, S.B.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hellstein, ¦ ¦144 Annals of¦ ¦ ¦ ¦ ¦Systematic Review: ¦Internal ¦ ¦PX-3122¦16-May-06¦J.W.; ¦Bisphosphonates and ¦Medicine 753 ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws ¦ ¦ ¦ ¦ ¦Kalmar, ¦ ¦(2006) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.R. ¦ ¦ ¦ +-------+---------+-----------------+---------------------------+-------------¦ ¦ ¦ ¦Palmqvist, ¦Inhibition of Hormone and ¦ ¦ ¦ ¦ ¦ ¦Cytokine-Stimulated ¦ ¦ ¦ ¦ ¦Py; ¦Osteoclastogenesis and Bone¦ ¦ ¦ ¦ ¦ ¦Resorption by Interleukin-4¦ ¦ ¦ ¦ ¦Lundberg, ¦and Interleukin-13 Is ¦281 Journal ¦ ¦ ¦ ¦Pernilla; ¦Associated with Increased ¦of Biological¦ ¦PX-3123¦3-Feb-06 ¦Persson, Emma; ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteoprotegerin and ¦Chemistry ¦ ¦ ¦ ¦Johansson, ¦Decreased RANKL and ¦2414 (2006) ¦ ¦ ¦ ¦Anders; Lundgren,¦ ¦ ¦ ¦ ¦ ¦Inger; Lie, ¦RANK in a STAT6- ¦ ¦ ¦ ¦ ¦Anita; Conaway, ¦ ¦ ¦ ¦ ¦ ¦H. Herschel; ¦dependent Pathway ¦ ¦ ¦ ¦ ¦Lerner, Ulf H. ¦ ¦ ¦ +-------+---------+-----------------+---------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦354 New ¦ ¦ ¦12-Jan- ¦Ray, Wayne A.; ¦Reform of Drug Regulation ¦England ¦ ¦PX-3124¦ ¦Stein, C. Michael¦-- Beyond an Independent ¦Journal of ¦ ¦ ¦06 ¦ ¦Drug-Safety Board ¦Medicine 194 ¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ +-------+---------+-----------------+---------------------------+-------------¦ ¦ ¦ ¦Ruggiero, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Salvatore; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gralow, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Julie; ¦Practical Guidelines for ¦2 Journal of ¦ ¦ ¦ ¦ ¦the Prevention, Diagnosis, ¦Oncology ¦ ¦PX-3125¦Jan-06 ¦Marx, ¦and Treatment of ¦Practice 7 ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw in¦ ¦ ¦ ¦ ¦Robert E.; Hoff, ¦Patients With Cancer ¦(2006) ¦ ¦ ¦ ¦Ana ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schubert, Mark ¦ ¦ ¦ ¦ ¦ ¦M.; Huryn, Joseph¦ ¦ ¦ ¦ ¦ ¦M.; Toth, Bela; ¦ ¦ ¦ ¦ ¦ ¦Damato, Kathryn; ¦ ¦ ¦ ¦ ¦ ¦Valero, Vicente ¦ ¦ ¦ +-------+---------+-----------------+---------------------------+-------------¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw in¦ ¦ ¦ ¦ ¦ ¦Patients ¦73 Joint Bone¦ ¦PX-3126¦2006 ¦Naveau, Adrien; ¦ ¦Spine 7-9 ¦ ¦ ¦ ¦Naveau, Bertrand ¦Taking ¦(2006) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Dimopoulos, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meletios ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kastritis, E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw in ¦91 ¦ ¦ ¦ ¦Anagnostopo ¦Patients With Multiple Myeloma ¦ ¦ ¦PX-3127¦2006¦ulos, A.; ¦Treated With Bisphosphonates: ¦Haematologica¦ ¦ ¦ ¦Melakopoulo s, ¦Evidence of Increased Risk After ¦ ¦ ¦ ¦ ¦I.; Gika, D.; ¦Treatment With Zoledronic Acid ¦968 (2006) ¦ ¦ ¦ ¦Moulopoulos ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, L.A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bamia, C.; ¦ ¦ ¦ ¦ ¦ ¦Terpos, E.; ¦ ¦ ¦ ¦ ¦ ¦Tsionos, K.; ¦ ¦ ¦ ¦ ¦ ¦Bamias, A. ¦ ¦ ¦ +-------+----+----------------+---------------------------------+-------------¦ ¦ ¦ ¦Zervas, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kostas; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Verrou, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Evgenia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Teleloudis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zisis; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vahtsevanos ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, ¦Incidence, Risk Factors and ¦134 British ¦ ¦ ¦ ¦ ¦Management of Osteonecrosis of ¦Journal of ¦ ¦PX-3128¦2006¦Konstantino ¦the Jaw in Patients With Multiple¦Haematology ¦ ¦ ¦ ¦ ¦Myeloma: A Single-Centre ¦ ¦ ¦ ¦ ¦s; Banti, ¦Experience in 303 Patients ¦620 (2006) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anastasia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mihou, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dinutra; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Krikelis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dimitris; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Terpos, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Evangelos ¦ ¦ ¦ +-------+----+----------------+---------------------------------+-------------¦ ¦ ¦ ¦Zarychanski , ¦ ¦ ¦ ¦ ¦ ¦Ryan; Elphee, ¦ ¦ ¦ ¦ ¦ ¦Erin; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦81 American ¦ ¦ ¦ ¦Walton, ¦Osteonecrosis of the Jaw ¦Journal of ¦ ¦PX-3129¦2006¦ ¦Associated With Pamidronate ¦Hematology 73¦ ¦ ¦ ¦Paul; ¦Therapy ¦(2006) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Johnston, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦James ¦ ¦ ¦ +-------+----+----------------+---------------------------------+-------------¦ ¦ ¦ ¦Badros, Ashraf; ¦ ¦ ¦ ¦ ¦ ¦Weikel, D.; ¦ ¦ ¦ ¦ ¦ ¦Salama, A.: ¦ ¦ ¦ ¦ ¦ ¦Goloubeva, O.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schneider, A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw in ¦24 Journal of¦ ¦ ¦ ¦Rapoport, A.; ¦Multiple Myeloma Patients: ¦Clinical ¦ ¦PX-3130¦2006¦Fenton, R.; ¦Clinical Features and Risk ¦Oncology 945 ¦ ¦ ¦ ¦Gahres, N.; ¦Factors ¦ ¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ ¦ ¦ ¦Sausville, E.; ¦ ¦ ¦ ¦ ¦ ¦Ord, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Meiller, T. ¦ ¦ ¦ +-------+----+----------------+---------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦5 Expert ¦ ¦PX-3131¦2006¦Aspenberg, Per ¦Osteonecrosis of the Jaw: What Do¦Opinion Drug ¦ ¦ ¦ ¦ ¦Bisphosphonates Do? ¦Safety 743 ¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Dannemann, C.; ¦Clinical Experiences with ¦13 6 Swiss ¦ ¦PX-3132¦2006¦Gratz, K.W.; ¦Bisphosphonate-Induced ¦Medical Weekly ¦ ¦ ¦ ¦ ¦ ¦504 (2006) ¦ ¦ ¦ ¦Zwahlen, R. ¦Osteochemonecrosis of the Jaws¦ ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦Hellstein, ¦Bisphosphonate Induced ¦26 Special Care ¦ ¦ ¦ ¦ ¦ ¦Dentist 8 ¦ ¦PX-3133¦2006¦J.W.; ¦Osteochemonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦Jaws: An Ounce of Prevention ¦(2006) ¦ ¦ ¦ ¦Marek, C.L. ¦May Be Worth a Pound of Cure ¦ ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦Ortega, C.; ¦ ¦ ¦ ¦ ¦ ¦Faggiuolo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vormola, ¦ ¦ ¦ ¦ ¦ ¦ ¦Jaw Complications in Breast ¦45 Acta Oncol ¦ ¦PX-3134¦2006¦R.; ¦and Prostate Cancer Patients ¦ ¦ ¦ ¦ ¦ ¦Treated With Zoledronic Acid ¦216 (2006) ¦ ¦ ¦ ¦Montemurro, F.; ¦ ¦ ¦ ¦ ¦ ¦Nanni, D.; Goia,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aglietta, M. ¦ ¦ ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦Hoff, A.O.; ¦ ¦ ¦ ¦ ¦ ¦Toth, B.B.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Altundag, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦24 Journal of ¦ ¦ ¦ ¦K.; ¦Osteonecrosis of the ¦ ¦ ¦ ¦ ¦ ¦ ¦Clinical ¦ ¦ ¦ ¦Guarneri, V.; ¦Jaw in Patients ¦ ¦ ¦ ¦ ¦Adamus, A.; ¦ ¦Oncology ¦ ¦ ¦ ¦Nook, A.K.; ¦Receiving ¦ ¦ ¦ ¦ ¦Sayegn, ¦ ¦(Supp.) 8528 ¦ ¦PX-3135¦2006¦ ¦Intravenous ¦(2006) -- 2006 ¦ ¦ ¦ ¦G.G.; ¦ ¦ASCO Annual ¦ ¦ ¦ ¦ ¦Bisphosphonate ¦ ¦ ¦ ¦ ¦Johnson, ¦ ¦Meeting ¦ ¦ ¦ ¦ ¦Therapy (Abstract ¦Proceedings ¦ ¦ ¦ ¦M.M.; ¦ ¦(post meeting ¦ ¦ ¦ ¦ ¦8528) ¦edition) ¦ ¦ ¦ ¦Gagel, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦R.F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hortobagyi, G.N.¦ ¦ ¦ +-------+----+----------------+------------------------------+----------------¦ ¦ ¦ ¦Van Poznak, ¦ ¦17 Current ¦ ¦PX-3136¦2006¦Catherine; Ward,¦Osteonecrosis of the Jaw ¦Opinion in ¦ ¦ ¦ ¦Brent B. ¦ ¦Orthopaedics 462¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Tosi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Patrizia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zamagni, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦E. ; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cangini, D.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tacchetti, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦P.; Di ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Raimondo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦F. ; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Catalano, L.;¦Osteonecrosis of the Jaws in ¦ ¦ ¦ ¦ ¦D'Arco, A.; ¦Newly Diagnosed Multiple Myeloma ¦ ¦ ¦PX-3137¦2006¦ ¦Patients Treated With Zoledronic ¦108 Blood 3951 ¦ ¦ ¦ ¦Ronconi, S.; ¦Acid and ¦(2006) ¦ ¦ ¦ ¦ ¦Thalidomide-Dexamethasone ¦ ¦ ¦ ¦ ¦Cellini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Offidani, M.;¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Perrone, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦G. ; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ceccolini, ¦ ¦ ¦ ¦ ¦ ¦M.; Brioli, ¦ ¦ ¦ ¦ ¦ ¦A.; Tura, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Baccarani, ¦ ¦ ¦ ¦ ¦ ¦M.; Cavo, ¦ ¦ ¦ ¦ ¦ ¦Michele ¦ ¦ ¦ +-------+----+-------------+---------------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦64 Journal of ¦ ¦ ¦ ¦Schwartz, ¦Osteonecrosis: The Need for an ¦Oral and ¦ ¦PX-3138¦2006¦Harry C. ¦Evidence-Based Approach ¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦Surgery 1177 ¦ ¦ ¦ ¦ ¦ ¦(2006) ¦ +-------+----+-------------+---------------------------------+----------------¦ ¦ ¦ ¦Uhl, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kathleen; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cox, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Edward; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rogan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rose; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zeldis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jerome B.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hixson, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dena; ¦ ¦ ¦ ¦ ¦ ¦ ¦Thalidomide Use in the US -- ¦29 Drug Safety ¦ ¦PX-3139¦2006¦Furlong, ¦Experience With Pregnancy Testing¦ ¦ ¦ ¦ ¦ ¦in the S.T.E.P.S. Programme ¦321 (2006) ¦ ¦ ¦ ¦Lesley- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anne; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Singer, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sarah; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Holliman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tracy; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Beyer, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joanne; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Woolever, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦William ¦ ¦ ¦ +-------+----+-------------+---------------------------------+----------------¦ ¦ ¦ ¦Huja, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sarandeep ¦ ¦2 8 8A ¦ ¦ ¦ ¦ ¦Remodeling Dynamics in the ¦ ¦ ¦PX-3140¦2006¦S.; ¦Alveolar Process in Skeletally ¦Anatomical ¦ ¦ ¦ ¦ ¦Mature Dogs ¦Record Part A ¦ ¦ ¦ ¦Fernandez, ¦ ¦1243 (2006) ¦ ¦ ¦ ¦Soledad A.; ¦ ¦ ¦ ¦ ¦ ¦Hill, Kara ¦ ¦ ¦ ¦ ¦ ¦J.; Li, Yan ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦National ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Institute ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦PX-3141¦2006 ¦ ¦Brochure on Osteonecrosis¦ ¦ ¦ ¦ ¦Arthritis and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Musculoskel atal and¦ ¦ ¦ ¦ ¦ ¦Skin ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Diseases ¦ ¦ ¦ +-------+--------+--------------------+-------------------------+-------------¦ ¦ ¦ ¦Bamias A.; Kastritis¦ ¦ ¦ ¦ ¦ ¦E.; Bamia ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C. ; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Moulopoulos , L.A.; ¦ ¦ ¦ ¦ ¦ ¦Melakopoulo s, I.; ¦Osteonecrosis of the Jaw ¦23 Journal of¦ ¦ ¦ ¦Bozas G.; ¦in Cancer After Treatment¦Clinical ¦ ¦PX-3142¦1-Dec-05¦Koutsoukou, V.; ¦With Bisphophonates: ¦Oncology 8580¦ ¦ ¦ ¦Gika, ¦Incidence and Risk ¦ ¦ ¦ ¦ ¦ ¦Factors ¦(2005) ¦ ¦ ¦ ¦D. ; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anagnostopo ulos, ¦ ¦ ¦ ¦ ¦ ¦A.; Papadimitri ou, ¦ ¦ ¦ ¦ ¦ ¦C.; Terpos, E.; ¦ ¦ ¦ ¦ ¦ ¦Dimopoulos, M.A. ¦ ¦ ¦ +-------+--------+--------------------+-------------------------+-------------¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws¦136 Journal ¦ ¦ ¦ ¦ ¦in Patients With a ¦of the ¦ ¦ ¦ ¦Melo, Maico D.; ¦History of Receiving ¦American ¦ ¦PX-3143¦Dec-05 ¦Obeid, George ¦Bisphophonate Therapy: ¦Dental ¦ ¦ ¦ ¦ ¦Strategies for Prevention¦Association ¦ ¦ ¦ ¦ ¦and Early Recognition and¦1675 (2005) ¦ ¦ ¦ ¦ ¦Early Recognition ¦ ¦ +-------+--------+--------------------+-------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦136 Journal ¦ ¦ ¦ ¦Migliorati, Cesar ¦Managing the Care of ¦of the ¦ ¦ ¦ ¦A.; Casiglia, ¦Patients with ¦American ¦ ¦ ¦ ¦Jeffrey; Epstein, ¦Bisphosphonate-Associated¦Dental ¦ ¦PX-3144¦Dec-05 ¦Joel; Jacobsen, ¦Osteonecrosis: An ¦Association ¦ ¦ ¦ ¦Peter L.; Siegel, ¦American Academy of Oral ¦ ¦ ¦ ¦ ¦Michael A.; Woo, ¦Medicine Position Paper ¦1658-1668 ¦ ¦ ¦ ¦Sook-Bin ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+--------+--------------------+-------------------------+-------------¦ ¦ ¦ ¦Marx, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sawatari, ¦Bisphosphonate-Induced ¦ ¦ ¦ ¦ ¦ ¦Exposed Bone ¦63 Journal of¦ ¦ ¦ ¦Yoh; ¦(Osteonecrosis/Osteo ¦Oral and ¦ ¦PX-3145¦Nov-05 ¦ ¦petrosis) of the Jaws: ¦Maxillofacial¦ ¦ ¦ ¦Fortin, ¦Risk Factors, ¦Surgery 1567 ¦ ¦ ¦ ¦ ¦Recognition, Prevention, ¦(2005) ¦ ¦ ¦ ¦Michel; ¦and Treatment ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Broumand, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vishtash ¦ ¦ ¦ +-------+--------+--------------------+-------------------------+-------------¦ ¦ ¦ ¦Makani, S.; Mander, ¦ ¦199 British ¦ ¦PX-3146¦2 ¦C.; Cox, M.; Wragg, ¦Studies in Osteonecrosis ¦Dental ¦ ¦ ¦7-Aug-05¦K ¦ ¦Journal 212 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦353 New ¦ ¦ ¦11-Aug- ¦Rosen, ¦ ¦England ¦ ¦PX-3147¦ ¦Clifford J.¦Postmenopausal Osteoporosis ¦Journal of ¦ ¦ ¦05 ¦ ¦ ¦Medicine 595 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦183 Medical ¦ ¦PX-3148¦1-Aug-05¦Donoghue, ¦Bisphosphonates and Osteonecrosis:¦Journal of ¦ ¦ ¦ ¦A. Michael ¦Analogy to Phossy Jaw ¦Australia 163¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦Durie, B. ¦ ¦353 New ¦ ¦ ¦7-Jul- ¦G. M.; ¦Osteonecrosis of the Jaw and ¦England ¦ ¦PX-3149¦ ¦ ¦ ¦Journal of ¦ ¦ ¦05 ¦Katz, M.; ¦Bisphosphonates ¦Medicine 99 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ ¦ ¦ ¦Crowley, J.¦ ¦ ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦Maerevoet, ¦ ¦353 New ¦ ¦ ¦7-Jul- ¦M.; Martin,¦Osteonecrosis of the Jaw and ¦England ¦ ¦PX-3150¦ ¦C.; Duck, ¦ ¦Journal of ¦ ¦ ¦05 ¦L. ¦Bisphosphonates ¦Medicine 100 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦Woo, S.G.; ¦ ¦353 New ¦ ¦ ¦7-Jul- ¦Handle, K.;¦Osteonecrosis of the Jaw and ¦England ¦ ¦PX-3151¦ ¦Richardson,¦ ¦Journal of ¦ ¦ ¦05 ¦ ¦Bisphosphonates ¦Medicine 100 ¦ ¦ ¦ ¦P.G.; ¦ ¦(2005) ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦Hellstein, ¦ ¦63 Journal of¦ ¦ ¦ ¦John W.; ¦Bisphosphonate Osteochemonecrosis ¦Oral and ¦ ¦PX-3152¦May-05 ¦Marek, ¦(Bis-Phossy Jaw): Is This Phossy ¦Maxillofacial¦ ¦ ¦ ¦Cindy L. ¦Jaw of the 21st Century? ¦Surgery 682 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦Kohno, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Norio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aogi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kenjiro; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Minami, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hironobu; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nakamura, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seigo; ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid Significantly ¦ ¦ ¦ ¦ ¦Asaga, ¦Reduces Skeletal Complications ¦23 Journal of¦ ¦ ¦ ¦ ¦Compared With Placebo in Japanese ¦Clinical ¦ ¦PX-3153¦May-05 ¦Taro; Iino,¦Women With Bone Metastases From ¦Oncology 3314¦ ¦ ¦ ¦ ¦Breast Cancer: A Randomized, ¦ ¦ ¦ ¦ ¦Yuichi; ¦Placebo-Controlled Trial ¦(2005) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Watanabe, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Toru; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Goessl, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Carsten; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ohashi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yasuo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Takashima, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shigemitsu ¦ ¦ ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦Carter, ¦ ¦182 Medical ¦ ¦ ¦18-Apr- ¦Glen; Goss,¦Bisphosphonates and Avascular ¦Journal of ¦ ¦PX-3154¦ ¦Alastair ¦Necrosis of the Jaw: A Possible ¦Australia 413¦ ¦ ¦05 ¦N.; Doecke,¦Association ¦ ¦ ¦ ¦ ¦Chris ¦ ¦(2005) ¦ +-------+--------+-----------+----------------------------------+-------------¦ ¦ ¦ ¦Fantasia, ¦ ¦General ¦ ¦ ¦ ¦John E.; ¦Oral Diagnosis: Nonhealing ¦Dentistry 161¦ ¦PX-3155¦Mar-05 ¦Damm, ¦Extraction Site ¦(March- April¦ ¦ ¦ ¦ ¦ ¦2005) ¦ ¦ ¦ ¦Douglas D. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Agarwala, S.; ¦Efficacy of Alendronate, A ¦44 ¦ ¦ ¦ ¦Jain, D.; Joshi,¦Bisphosphonate, in the ¦ ¦ ¦PX-3156¦Mar-05 ¦V.R.; Sule, ¦Treatment of AVN of the Hip. ¦Rheumatology ¦ ¦ ¦ ¦ ¦A Prospective Open-Label ¦ ¦ ¦ ¦ ¦A. ¦Study ¦352 (2005) ¦ +-------+-------+----------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦Mechanistic Insight Into ¦83 Journal of ¦ ¦PX-3157¦Mar-05 ¦Takayanaqi, H. ¦Osteoclast Differentiation in¦Molecular ¦ ¦ ¦ ¦ ¦Osteoimmunology ¦Medicine 170 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+-------+----------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦ ¦352 New ¦ ¦ ¦ ¦ ¦ ¦England ¦ ¦ ¦24-Feb-¦Schneider, Hans ¦ ¦Journal of ¦ ¦PX-3158¦ ¦G.; Sentry, John¦Multiple Myeloma ¦ ¦ ¦ ¦05 ¦ ¦ ¦Medicine 840 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+-------+----------------+-----------------------------+--------------¦ ¦ ¦ ¦Kyle, ¦ ¦352 New ¦ ¦ ¦24-Feb-¦ ¦ ¦England ¦ ¦PX-3159¦ ¦Robert A.; ¦Multiple Myeloma ¦Journal of ¦ ¦ ¦05 ¦Rajkumar, S. ¦ ¦Medicine 841 ¦ ¦ ¦ ¦Vincent ¦ ¦(2005) ¦ +-------+-------+----------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦ ¦352 New ¦ ¦ ¦27-Jan-¦Stewart, Andrew ¦Hypercalcemia Associated With¦England ¦ ¦PX-3160¦ ¦F. ¦Cancer ¦Journal of ¦ ¦ ¦05 ¦ ¦ ¦Medicine 373 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+-------+----------------+-----------------------------+--------------¦ ¦ ¦ ¦Lenz, J.- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Steiner-Krammer,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦B. ; ¦ ¦ ¦ ¦ ¦ ¦ ¦Does Avascular Necrosis of ¦33 Journal of ¦ ¦ ¦ ¦Schmidt, W.; ¦the Jaws in Cancer Patients ¦CranioMaxillof¦ ¦PX-3161¦2005 ¦ ¦Only Occur Following ¦acial Surgery ¦ ¦ ¦ ¦Fietkau, ¦Treatment With ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates? ¦395 (2005) ¦ ¦ ¦ ¦R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mueller, P. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C. ; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gundlach, K. K. ¦ ¦ ¦ ¦ ¦ ¦H. ¦ ¦ ¦ +-------+-------+----------------+-----------------------------+--------------¦ ¦ ¦ ¦Bagan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.V.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Murillo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jimenez, Y.; ¦ ¦ ¦ ¦ ¦ ¦Poveda, R.; ¦Avascular Jaw Osteonecrosis ¦34 Journal of ¦ ¦ ¦ ¦Milian, ¦in Association With Cancer ¦Oral Pathology¦ ¦PX-3162¦2005 ¦ ¦Chemotherapy: Series of 10 ¦and Medicine ¦ ¦ ¦ ¦M.A.; ¦Cases ¦ ¦ ¦ ¦ ¦ ¦ ¦120 (2005) ¦ ¦ ¦ ¦Sanchis, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Silvestre, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦F.J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Scully, C. ¦ ¦ ¦ +-------+-------+----------------+-----------------------------+--------------¦ ¦ ¦ ¦Markiewicz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M. R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦136 Journal of¦ ¦ ¦ ¦Margarone, J.E. ¦Bisphosphonate-Associated ¦the American ¦ ¦PX-3163¦2005 ¦3rd; ¦Osteonecrosis of the Jaws: A ¦Dental ¦ ¦ ¦ ¦ ¦Review of Current Knowledge ¦Association ¦ ¦ ¦ ¦Campbell, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1669 (2005) ¦ ¦ ¦ ¦J.H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aguirre, A ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Sanna, G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zampino, ¦ ¦ ¦ ¦ ¦ ¦ ¦Jaw Avascular Bone Necrosis ¦16 Annals of ¦ ¦PX-3164¦2005¦M.G.; ¦Associated With Long-Term Use ¦Oncology 1207 ¦ ¦ ¦ ¦ ¦of Bisphosphonates ¦(2005) ¦ ¦ ¦ ¦Petosi, G.; ¦ ¦ ¦ ¦ ¦ ¦Nole, F.; ¦ ¦ ¦ ¦ ¦ ¦Goldhirsch, A. ¦ ¦ ¦ +-------+----+----------------+-------------------------------+---------------¦ ¦ ¦ ¦Pires, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦F.R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Miranda, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.M.M.A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cardoso, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦E.S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cardoso, ¦ ¦ ¦ ¦ ¦ ¦ ¦Oral Avascular Bone Necrosis ¦11 Oral ¦ ¦PX-3165¦2005¦A.S.; ¦Associated With Chemotherapy ¦Diseases 365 ¦ ¦ ¦ ¦ ¦and Bisphosphonate Therapy ¦ ¦ ¦ ¦ ¦Fregnani, E.R.; ¦ ¦(2005) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pereira, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Correa, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.E.P.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Almeida, J.P.; ¦ ¦ ¦ ¦ ¦ ¦de A. Alves, F.;¦ ¦ ¦ ¦ ¦ ¦Lopes, M.A.; de ¦ ¦ ¦ ¦ ¦ ¦Almeida, O.P. ¦ ¦ ¦ +-------+----+----------------+-------------------------------+---------------¦ ¦ ¦ ¦ ¦ ¦63 Journal of ¦ ¦ ¦ ¦ ¦ ¦Oral and ¦ ¦ ¦ ¦Schwartz, Harry ¦Osteonecrosis of the Jaws: A ¦Maxillofacial ¦ ¦PX-3166¦2005¦C. ¦Complex Group of Disorders ¦ ¦ ¦ ¦ ¦ ¦ ¦Surgery 1248 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+----+----------------+-------------------------------+---------------¦ ¦ ¦ ¦Migliorati, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C. A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schubert, ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate-Associated ¦ ¦ ¦ ¦ ¦M. M.; ¦Osteonecrosis of Mandibular and¦104 Cancer 83 ¦ ¦PX-3167¦2005¦ ¦Maxillary Bone: An Emerging ¦ ¦ ¦ ¦ ¦Peterson, ¦Oral Complication of Supportive¦(2005) ¦ ¦ ¦ ¦ ¦Cancer Therapy ¦ ¦ ¦ ¦ ¦D. E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seneda, L. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M. ¦ ¦ ¦ +-------+----+----------------+-------------------------------+---------------¦ ¦ ¦ ¦ ¦ ¦63 Journal of ¦ ¦ ¦ ¦Schwartz, ¦Bisphosphonate-Associated ¦Oral and ¦ ¦PX-3168¦2005¦ ¦Osteonecrosis of the Jaws ¦Maxillofacial ¦ ¦ ¦ ¦Harry C. ¦ ¦Surgery 1555 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+----+----------------+-------------------------------+---------------¦ ¦ ¦ ¦Guarneri, V.; ¦ ¦ ¦ ¦ ¦ ¦Donati, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Renal Safety and Efficacy of IV¦ ¦ ¦ ¦ ¦Nicolini, M.; ¦Bisphosphonates in Patients ¦10 Oncologist ¦ ¦PX-3169¦2005¦ ¦With Skeletal Metastases ¦ ¦ ¦ ¦ ¦Giovannelli ¦Treated for up to 10 Years ¦842 (2005) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D'Amico, R.; ¦ ¦ ¦ ¦ ¦ ¦Conte, P.F. ¦ ¦ ¦ +-------+----+----------------+-------------------------------+---------------¦ ¦ ¦ ¦Licata, Angelo ¦Discovery, Clinical ¦39 Annals of ¦ ¦PX-3170¦2005¦A. ¦Development, and Therapeutic ¦Pharmacotherap ¦ ¦ ¦ ¦ ¦Uses of Bisphosphonates ¦y 668 (2005) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Odvina, Clarita ¦ ¦ ¦ ¦ ¦ ¦V.; Zerwekh, ¦ ¦ ¦ ¦ ¦ ¦Joseph E.; Rao, ¦ ¦ ¦ ¦ ¦ ¦D. Sudhaker; ¦ ¦90 Journal of ¦ ¦ ¦ ¦Maalouf, Naim; ¦Severely Suppressed Bone ¦Clinical ¦ ¦PX-3171¦2005¦ ¦Turnover: A Potential ¦Endocrinology ¦ ¦ ¦ ¦Gottschalk, Frank¦Complication of Alendronate ¦and Metabolism¦ ¦ ¦ ¦A.; ¦Therapy ¦1294 (2005) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pak, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Charles Y.C. ¦ ¦ ¦ +-------+----+-----------------+-------------------------------+--------------¦ ¦ ¦ ¦Hozo, Stela ¦ ¦5 BMC [BioMed ¦ ¦ ¦ ¦Pudar; ¦Estimating the Mean and ¦Central] ¦ ¦PX-3172¦2005¦Djulbegovic , ¦Variance From the Median, ¦Medical ¦ ¦ ¦ ¦Benjamin; Hozo, ¦Range, and the Size of a Sample¦Research ¦ ¦ ¦ ¦Iztok ¦ ¦Methodology 1 ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ +-------+----+-----------------+-------------------------------+--------------¦ ¦ ¦ ¦Ferretti, ¦ ¦ ¦ ¦ ¦ ¦Gianluigi; Fabi, ¦ ¦ ¦ ¦ ¦ ¦A.; Carlini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦P.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Papaldo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦P.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cordiali Fei, P.;¦ ¦ ¦ ¦ ¦ ¦Di Cosimo, S.; ¦ ¦ ¦ ¦ ¦ ¦Sales, N.; ¦Zoledronic Acid-Induced ¦ ¦ ¦ ¦ ¦Giannarelli ¦Circulating Level Modifications¦ ¦ ¦ ¦ ¦ ¦of Angiogenic Factors, ¦69 Oncology ¦ ¦PX-3173¦2005¦, D.; ¦Metallo-Proteinases and ¦ ¦ ¦ ¦ ¦ ¦Proinflammatory Cytokines in ¦35-43 (2005) ¦ ¦ ¦ ¦Alimonti, ¦Metastatic Breast Cancer ¦ ¦ ¦ ¦ ¦ ¦Patients ¦ ¦ ¦ ¦ ¦A.; Di ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cocco, B.; ¦ ¦ ¦ ¦ ¦ ¦D'Agosto, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bordignon, V.; ¦ ¦ ¦ ¦ ¦ ¦Trento, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cognetti, F. ¦ ¦ ¦ +-------+----+-----------------+-------------------------------+--------------¦ ¦ ¦ ¦Doll, R.; Peto, ¦Mortality from Cancer in ¦92 British ¦ ¦PX-3174¦2005¦R.; Boreham, J.; ¦Relation to Smoking: 50 Years ¦Journal of ¦ ¦ ¦ ¦ ¦Observations on British Doctors¦Cancer 426 ¦ ¦ ¦ ¦Sutherland, I. ¦ ¦(2005) ¦ +-------+----+-----------------+-------------------------------+--------------¦ ¦ ¦ ¦La Grenade, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lois; Lee, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lauren; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Weaver, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joyce; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bonnel, ¦Comparison of Reporting of ¦ ¦ ¦ ¦ ¦ ¦Stevens-Johnson Syndrome and ¦28 Drug Safety¦ ¦PX-3175¦2005¦Renan; ¦Toxic Epidermal Necrolysis in ¦ ¦ ¦ ¦ ¦ ¦Association with Selective ¦917 (2005) ¦ ¦ ¦ ¦Karwoski, ¦COX-2 Inhibitors ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Claudia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Governale, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Laura; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Brinker, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Allen ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Junquera, ¦ ¦ ¦ ¦ ¦ ¦Luis; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rodriguez- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Recio, ¦ ¦26 American Journal¦ ¦ ¦ ¦ ¦ ¦of Otolaryngology ¦ ¦ ¦ ¦Cristian; ¦Autosomal Dominant ¦-- Head and Neck ¦ ¦PX-3176¦2005 ¦ ¦Osteopetrosis and ¦Medicine and ¦ ¦ ¦ ¦Villarreal, ¦Maxillomandibular ¦Surgery ¦ ¦ ¦ ¦ ¦Osteomyelitis ¦ ¦ ¦ ¦ ¦Pedro; ¦ ¦275 (2005) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Garcia- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Consuegra, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Luis ¦ ¦ ¦ +-------+---------+-------------+-------------------------+-------------------¦ ¦ ¦ ¦Vaananen, ¦Mechanism of Osteoclast ¦57 Advanced Drug ¦ ¦PX-3177¦2005 ¦ ¦Mediated Bone Resorption ¦Delivery Reviews ¦ ¦ ¦ ¦Kalervo ¦-Rationale for the Design¦959 (2005) ¦ ¦ ¦ ¦ ¦of new Therapeutics ¦ ¦ +-------+---------+-------------+-------------------------+-------------------¦ ¦ ¦ ¦ ¦ ¦Chapter in ¦ ¦ ¦ ¦ ¦ ¦Pharmacoepidem ¦ ¦ ¦ ¦ ¦ ¦iology (B.L. Strom,¦ ¦PX-3178¦2005 ¦Jones, J.K. ¦Determining Causation ¦Ed., ¦ ¦ ¦ ¦ ¦from Case Reports ¦ ¦ ¦ ¦ ¦ ¦ ¦4th ed. 2005) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦at 557 ¦ +-------+---------+-------------+-------------------------+-------------------¦ ¦ ¦ ¦Lasseter, ¦ ¦ ¦ ¦ ¦ ¦Kenneth C.; ¦ ¦ ¦ ¦ ¦ ¦Prras A.G.; ¦Pharmacokinetic ¦25 Clinical Drug ¦ ¦ ¦ ¦Denker A.; ¦Considerations in ¦ ¦ ¦PX-3179¦2005 ¦ ¦Determining the Terminal ¦Investigation 107 ¦ ¦ ¦ ¦Santhanagopal¦Elimination Half-Lives of¦(2005) ¦ ¦ ¦ ¦A.; ¦Bisphosphonates ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daifotis A. ¦ ¦ ¦ +-------+---------+-------------+-------------------------+-------------------¦ ¦ ¦ ¦Altundag, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kadri; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦352 New England ¦ ¦ ¦ ¦Altundag, ¦ ¦Journal of Medicine¦ ¦PX-3180¦2005 ¦ ¦Multiple Myeloma ¦840 ¦ ¦ ¦ ¦Ozden; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2005) ¦ ¦ ¦ ¦Gundesliogl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦u, Ozlem ¦ ¦ ¦ +-------+---------+-------------+-------------------------+-------------------¦ ¦ ¦ ¦ ¦ ¦http://www.fda ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦.gov/ohrms/doc kets¦ ¦ ¦ ¦ ¦ONJ Reported in ¦/ac/05/sli des/ ¦ ¦PX-3181¦2005 ¦Young, Dianne¦Bisphosphonate-Treated ¦2005- ¦ ¦ ¦ ¦ ¦Patients -An Overview ¦ ¦ ¦ ¦ ¦ ¦ ¦4095s2_index.h ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦tm ¦ +-------+---------+-------------+-------------------------+-------------------¦ ¦ ¦ ¦ ¦Oral Cavity Avascular ¦104 Blood 308b ¦ ¦ ¦ ¦ ¦Bone Necrosis: A Newly ¦ ¦ ¦ ¦ ¦ ¦Recognized Complication ¦(2004) ¦ ¦ ¦ ¦Schuster, ¦of Intravenous (IV) ¦ ¦ ¦PX-3182¦16-Nov-04¦M.W.; ¦Bisphosphonate ¦http://www.abs ¦ ¦ ¦ ¦ ¦ ¦tracts2view.co m/ ¦ ¦ ¦ ¦Dymek, J.M. ¦(Abstract 4905) ¦hem_sandiego 2004/ ¦ ¦ ¦ ¦ ¦ ¦view.php? nu=HEM4L1¦ ¦ ¦ ¦ ¦Therapy in Cancer ¦1071 ¦ ¦ ¦ ¦ ¦Patients (Abstract 4905).¦ ¦ +-------+---------+-------------+-------------------------+-------------------¦ ¦ ¦ ¦ ¦ ¦104 Blood 216a ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2004) ¦ ¦ ¦ ¦Durie, ¦Osteonecrosis of the Jaws¦ ¦ ¦ ¦ ¦B.G.M.; ¦in Myeloma: Time ¦http://www.abs ¦ ¦PX-3183¦16-Nov-04¦ ¦Dependent Correlation ¦tracts2view.co ¦ ¦ ¦ ¦Katz, M.; ¦With Aredia and Zometa ¦ ¦ ¦ ¦ ¦McCoy, J.; ¦ ¦m/hem_sandiego ¦ ¦ ¦ ¦Crowley, John¦Use (Abstract 756) ¦ ¦ ¦ ¦ ¦ ¦ ¦2004/view.php? ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦nu=HEM4L1 4010 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦104 Blood 315b¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaw in ¦(2004) ¦ ¦ ¦16 04¦Kut, V.; ¦Myeloma Patients Receiving ¦ ¦ ¦PX-3184¦ ¦Mehta, J; ¦Pamidronate or Zoledronate ¦://www.abstrac¦ ¦ ¦-Nov-¦Tariman, J. ¦(Abstract 4933) ¦ts2view.com/he¦ ¦ ¦ ¦ ¦ ¦m_sandiego2004¦ ¦ ¦ ¦ ¦ ¦/view.php?nu=H¦ ¦ ¦ ¦ ¦ ¦EM4L1 5029 ¦ +-------+-----+-------------+----------------------------------+--------------¦ ¦ ¦ ¦Kut, ¦Post-Marketing Assessments of Ser.¦ ¦ ¦ ¦ ¦ ¦Adv. Drug Reactions Reported by ¦104 Blood ¦ ¦ ¦ ¦Victoria; , ¦the Mfr. to the FDA Differ ¦http://www.abs¦ ¦ ¦16 04¦Mehta, J.; ¦Markedly With Those from an Ind. ¦tracts2view.co¦ ¦PX-3185¦ ¦Singhal, ¦Pharmacovigilance Prog.: Emp. ¦m/hem_sandiego¦ ¦ ¦-Nov-¦ ¦Findings Based on BP-Assoc. ON ¦ ¦ ¦ ¦ ¦S.; ¦Descripts. by the Res. on AE & ¦2004/view.php?¦ ¦ ¦ ¦ ¦Repts. Proj & the Prod. Mfr. ¦nu=HEM4L1_5234¦ ¦ ¦ ¦Bennett, C. ¦(3151) ¦ ¦ +-------+-----+-------------+----------------------------------+--------------¦ ¦ ¦ ¦Kyle, ¦ ¦351 New ¦ ¦ ¦28 04¦ ¦ ¦England ¦ ¦PX-3186¦ ¦Robert A.; ¦Multiple Myeloma ¦Journal of ¦ ¦ ¦-Oct-¦Rajkumar, S. ¦ ¦Medicine 1860 ¦ ¦ ¦ ¦Vincent ¦ ¦(2004) ¦ +-------+-----+-------------+----------------------------------+--------------¦ ¦ ¦ ¦Lugassy, G.; ¦ ¦117 American ¦ ¦ ¦15 04¦Shaham, R.; ¦Severe Osteomyelitis of the Jaw in¦Journal of ¦ ¦PX-3187¦ ¦Nemets, A.; ¦Long Term Survivors of Multiple ¦Medicine 440 ¦ ¦ ¦-Sep-¦Ben-Dor, D.; ¦Myeloma: A New Clinical Entity ¦(2004) ¦ ¦ ¦ ¦Nahlieli, O. ¦ ¦ ¦ +-------+-----+-------------+----------------------------------+--------------¦ ¦ ¦ ¦Rosen, Lee ¦ ¦ ¦ ¦ ¦ ¦S.; Gordon, ¦ ¦ ¦ ¦ ¦ ¦David; ¦ ¦ ¦ ¦ ¦ ¦Tchekmedyia ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦n, N. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Simon; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yanagihara, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ronald; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hirsh, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vera; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Krzakowski, ¦ ¦ ¦ ¦ ¦ ¦ ¦Long-Term Efficacy and Safety of ¦ ¦ ¦ ¦ ¦Maciej; ¦Zoledronic Acid in the Treatment ¦ ¦ ¦ ¦15 04¦ ¦of Skeletal Metastases in Patients¦100 Cancer ¦ ¦PX-3188¦ ¦Pawlicki, ¦With Nonsmall Cell Lung Carcinoma ¦ ¦ ¦ ¦-Jun-¦ ¦and Other Solid Tumors: A ¦2613 (2004) ¦ ¦ ¦ ¦Marek; de ¦Randomized, Phase II, ¦ ¦ ¦ ¦ ¦ ¦Double-Blind, Placebo-Controlled ¦ ¦ ¦ ¦ ¦Souza, ¦Trial ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Paul; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zheng, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ming; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Urbanowitz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gladys; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reitsma, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dirk; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Saad, Fred; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gleason, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Donald M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Murray, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robin; ¦ ¦ ¦ ¦ ¦ ¦ ¦Long-Term Efficacy of ¦ ¦ ¦ ¦ ¦Tchekmedyian, ¦Zoledronic Acid for the ¦ ¦ ¦ ¦ ¦Simon; ¦Prevention ¦96 Journal of ¦ ¦ ¦ ¦ ¦ ¦the National ¦ ¦PX-3189¦2-Jun-04 ¦Venner, ¦of Skeletal ¦Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Peter; ¦Complications in Patients ¦Institute 879 ¦ ¦ ¦ ¦ ¦With Metastatic ¦(2004) ¦ ¦ ¦ ¦Lacombe, ¦Hormone-Refractory ¦ ¦ ¦ ¦ ¦ ¦Prostate Cancer ¦ ¦ ¦ ¦ ¦Louis; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chin, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joseph L.; ¦ ¦ ¦ ¦ ¦ ¦Vinholes, ¦ ¦ ¦ ¦ ¦ ¦Jeferson J.; ¦ ¦ ¦ ¦ ¦ ¦Goas, J. Allen; ¦ ¦ ¦ ¦ ¦ ¦Zheng, Ming ¦ ¦ ¦ +-------+---------+----------------+--------------------------+---------------¦ ¦ ¦ ¦ ¦Osteonecrosis and ¦62 Journal of ¦ ¦ ¦ ¦Schwartz, Harry ¦Bisphosphonates: ¦Oral and ¦ ¦PX-3190¦Jun-04 ¦C. ¦Correlation Versus ¦Maxillofacial ¦ ¦ ¦ ¦ ¦Causation ¦Surgery 763 ¦ ¦ ¦ ¦ ¦ ¦(2004) ¦ +-------+---------+----------------+--------------------------+---------------¦ ¦ ¦ ¦Sweeting, ¦ ¦ ¦ ¦ ¦ ¦Michael J.; ¦What to Add to Nothing? ¦ ¦ ¦ ¦ ¦Sutton, ¦Use and Avoidance of ¦23 Statistics ¦ ¦PX-3191¦15-May-04¦Alexander ¦Continuity Corrections in ¦in Medicine ¦ ¦ ¦ ¦ ¦Meta-Analysis of Sparse ¦ ¦ ¦ ¦ ¦J.; ¦Data ¦1351 (2004) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lambert, Paul C.¦ ¦ ¦ +-------+---------+----------------+--------------------------+---------------¦ ¦ ¦ ¦Ruggiero, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Salvatore ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦62 Journal of ¦ ¦ ¦ ¦L.; ¦Osteonecrosis of the Jaws ¦Oral and ¦ ¦PX-3192¦May-04 ¦ ¦Associated With the Use of¦Maxillofacial ¦ ¦ ¦ ¦Mehrotra, ¦Bisphosphonates: A Review ¦Surgery 527 ¦ ¦ ¦ ¦Bhoomi; ¦of 63 Cases ¦(2004) ¦ ¦ ¦ ¦Rosenberg, ¦ ¦ ¦ ¦ ¦ ¦Tracey J.; ¦ ¦ ¦ ¦ ¦ ¦Engroff, Stephen¦ ¦ ¦ ¦ ¦ ¦L. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Schett, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Georg; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kiechl, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stefan; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Redlich, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kurt; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Oberhollenz¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦er, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Friedrich; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Weger, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Siegfried; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Egger, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦291 Journal of ¦ ¦ ¦ ¦Georg; ¦Soluble RANKL and ¦the American ¦ ¦PX-3193¦2-Mar-04¦ ¦ ¦Medical ¦ ¦ ¦ ¦Mayr, ¦Risk of Nontraumatic Fracture ¦Association ¦ ¦ ¦ ¦ ¦ ¦1108 (2004) ¦ ¦ ¦ ¦Agnes; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jocher, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Josef; Xu, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Qingbo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pietschmann¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, Peter; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Teitelbaum,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Steven; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Smolen, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Josef; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Willeit, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Johann ¦ ¦ ¦ +-------+--------+-----------+--------------------------------+---------------¦ ¦ ¦ ¦ ¦ ¦62 Journal of ¦ ¦ ¦ ¦Pogrel, ¦Bisphosphonates and Bone ¦Oral and ¦ ¦PX-3194¦Mar-04 ¦M.A. ¦Necrosis ¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦Surgery 391 ¦ ¦ ¦ ¦ ¦ ¦(2004) ¦ +-------+--------+-----------+--------------------------------+---------------¦ ¦ ¦ ¦Rosen, Lee ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; Gordon,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦David H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dugan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦William ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jr.; Major,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pierre; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Eisenberg, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Peter D.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid Is Superior to ¦ ¦ ¦ ¦ ¦Provencher,¦Pamidronate for the Treatment of¦100 Cancer 36 ¦ ¦PX-3195¦1-Jan-04¦ ¦Bone Metastases in Breast ¦ ¦ ¦ ¦ ¦Louise; ¦Carcinoma Patients with at Least¦(2004) ¦ ¦ ¦ ¦ ¦One Osteolytic Lesion ¦ ¦ ¦ ¦ ¦Kaminski, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mary; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Simeone, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joe; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John; Chen,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bee-Lian; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Coleman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert E. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Estilo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦22 Journal of Clinical¦ ¦ ¦ ¦C.S.; Van ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Oncology 8088 (Supp.) ¦ ¦ ¦ ¦Poznak, ¦ ¦S750 (2004) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.H.; ¦Osteonecrosis of the¦http://www.asc ¦ ¦ ¦ ¦ ¦Maxilla and Mandible¦ ¦ ¦ ¦ ¦Williams, ¦in Patients Treated ¦o.org/portal/s ite/ ¦ ¦ ¦ ¦ ¦ ¦ASCO/menui ¦ ¦PX-3196¦2004¦T.; ¦With ¦tem.34d60f5624 ¦ ¦ ¦ ¦ ¦ ¦ba07fd506fe310 ¦ ¦ ¦ ¦Evtimovska, E.; ¦Bisphosphonates: A ¦ee37a01d/?vgne xtoid= ¦ ¦ ¦ ¦Tkach, L; Halpern, ¦Retrospective Study ¦76f8201e ¦ ¦ ¦ ¦ ¦(Abstract 8088) ¦b61a7010VgnVCM ¦ ¦ ¦ ¦J.L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦100000ed730ad1 ¦ ¦ ¦ ¦Tunick, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦RCRD&vmview=ab ¦ ¦ ¦ ¦S.J.; ¦ ¦st_detail_view &confID¦ ¦ ¦ ¦ ¦ ¦=26&abs tractID=3684 ¦ ¦ ¦ ¦Huryn, J.M. ¦ ¦ ¦ +-------+----+--------------------+--------------------+----------------------¦ ¦ ¦ ¦Berthold, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦H. K.; Diel, ¦Phossy Jaw Revisited¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦I. J.; ¦-- Do ¦27 Drug Safety ¦ ¦PX-3197¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦Gouni- ¦Bisphosphonates ¦920 (2004) ¦ ¦ ¦ ¦ ¦Cause "Bisphossy ¦ ¦ ¦ ¦ ¦Berthold, ¦Jaws"? ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦I. ¦ ¦ ¦ +-------+----+--------------------+--------------------+----------------------¦ ¦ ¦ ¦Van Poznak, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Estilo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the¦88 Breast Cancer ¦ ¦ ¦ ¦Sauter, ¦Jaw in Patients With¦ ¦ ¦ ¦ ¦ ¦Metastatic Breast ¦Research and Treatment¦ ¦PX-3198¦2004¦N.P.; ¦Cancer (Abstract No.¦(Supp. 1) S131 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hudis, C.A.; ¦3057) ¦(2004) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Williams, T.; ¦ ¦ ¦ ¦ ¦ ¦Tunick, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Halpern, J.; Huyrn, ¦ ¦ ¦ ¦ ¦ ¦J.M. ¦ ¦ ¦ +-------+----+--------------------+--------------------+----------------------¦ ¦ ¦ ¦Carter, G.D.; Goss, ¦Bisphosphoonates and¦27 Australian ¦ ¦PX-3199¦2004¦A.N. ¦Avascular Mecrosis ¦Prescriber (Supp.) 32 ¦ ¦ ¦ ¦ ¦of the Jaws ¦(2004) ¦ +-------+----+--------------------+--------------------+----------------------¦ ¦ ¦ ¦ ¦Severe Osteomyelitis¦ ¦ ¦ ¦ ¦ ¦of the Jaws in Long ¦ ¦ ¦ ¦ ¦Lugassy, ¦Term Survivors ¦ ¦ ¦ ¦ ¦ ¦Multiple Myeloma ¦ ¦ ¦ ¦ ¦Gilles; ¦Patients Treated ¦104 Blood 307b ¦ ¦PX-3200¦2004¦ ¦ ¦ ¦ ¦ ¦ ¦Nemets, ¦With ¦(2004) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anatoly ¦Bisphosphonates: A ¦ ¦ ¦ ¦ ¦ ¦New Clinical Entity ¦ ¦ ¦ ¦ ¦ ¦(Abstract No. 4900) ¦ ¦ +-------+----+--------------------+--------------------+----------------------¦ ¦ ¦ ¦Balcewicz-Sablinska,¦ ¦ ¦ ¦ ¦ ¦ ¦Risk of ¦14 Annals of ¦ ¦ ¦ ¦M.K.; ¦ ¦Epidemiology ¦ ¦PX-3201¦2004¦ ¦Osteonecrosis in ¦ ¦ ¦ ¦ ¦Gonzales-Perez, A.; ¦Cancer Patients ¦593 (2004) ¦ ¦ ¦ ¦Garcia Rodriguez, ¦(Abstract P006) ¦ ¦ ¦ ¦ ¦L.A. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Estilo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.S.; Van ¦ ¦22 Journal of Clinical¦ ¦ ¦ ¦ ¦ ¦Ecology ¦ ¦ ¦ ¦Poznak, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(Supp.) S750 (2004) ¦ ¦ ¦ ¦C.H.; ¦Slides Accompanying ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Maxilla ¦http://www.asc o.org/ ¦ ¦ ¦ ¦Williams, ¦and Mandible in Patients ¦portal/s ite/ASCO/ ¦ ¦ ¦ ¦ ¦Treated ¦menui ¦ ¦ ¦ ¦T.; ¦ ¦ ¦ ¦PX-3202¦2004¦ ¦With ¦tem.34d60f5624 ¦ ¦ ¦ ¦Evtimovska,¦ ¦ ¦ ¦ ¦ ¦E.; Tkach, ¦Bisphosphonates: A ¦ba07fd506fe310 ¦ ¦ ¦ ¦L; Halpern,¦Retrospective Study (Abstract¦ee37a01d/?vgne xtoid= ¦ ¦ ¦ ¦ ¦8088) ¦76f8201e ¦ ¦ ¦ ¦J.L.; ¦ ¦b61a7010VgnVCM ¦ ¦ ¦ ¦ ¦ ¦100000ed730ad1 RCRD& ¦ ¦ ¦ ¦Tunick, ¦ ¦vmview=ab ¦ ¦ ¦ ¦ ¦ ¦st_detail_view &confID¦ ¦ ¦ ¦S.J.; ¦ ¦=26&abs tractID=3684 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Huryn, J.M.¦ ¦ ¦ +-------+----+-----------+-----------------------------+----------------------¦ ¦ ¦ ¦Cohen, ¦ ¦73 ¦ ¦ ¦ ¦Aaron ¦A Categorization and Analysis¦ ¦ ¦PX-3203¦2004¦Michael; ¦of the Criticisms of ¦International Journal ¦ ¦ ¦ ¦Stavri, P. ¦Evidence-Based Medicine ¦of Medical Informatics¦ ¦ ¦ ¦Zoe; Hersh,¦ ¦35 (2004) ¦ ¦ ¦ ¦William R. ¦ ¦ ¦ +-------+----+-----------+-----------------------------+----------------------¦ ¦ ¦ ¦Taranta, ¦ ¦ ¦ ¦ ¦ ¦Anna; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fortunati, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dario; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Longo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maurizio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rucci, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nadia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Iacomino, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Enzo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Aliberti, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ferdinando;¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Facciuto, ¦Imbalance of ¦19 Journal of Bone and¦ ¦ ¦ ¦ ¦Osteoclastogenesis-Regulating¦Mineral Research 1112 ¦ ¦PX-3204¦2004¦Enzo; ¦Factors in Patients With ¦ ¦ ¦ ¦ ¦ ¦Celiac Disease ¦(2004) ¦ ¦ ¦ ¦Migliaccio,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Silvia; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bardella, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maria ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Teresa; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dubini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Antonella; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Borghi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maria ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Orietta;Sar¦ ¦ ¦ ¦ ¦ ¦aifoger, ¦ ¦ ¦ ¦ ¦ ¦Silvia; ¦ ¦ ¦ ¦ ¦ ¦Teti, Anna;¦ ¦ ¦ ¦ ¦ ¦Bianchi, ¦ ¦ ¦ ¦ ¦ ¦Maria Luisa¦ ¦ ¦ +-------+----+-----------+-----------------------------+----------------------¦ ¦ ¦ ¦ ¦ ¦9 Oncologist (Supp. 4)¦ ¦PX-3205¦2004¦Green, ¦Bisphosphonates: Preclinical ¦3 ¦ ¦ ¦ ¦Jonathan R.¦Review ¦ ¦ ¦ ¦ ¦ ¦ ¦(2004) ¦ +-------+----+-----------+-----------------------------+----------------------¦ ¦ ¦ ¦Jewell, ¦Statistics for ¦ ¦ ¦PX-3206¦2004¦Nicholas P.¦Epidemiology-Attributable ¦2004 CRC Press ¦ ¦ ¦ ¦ ¦Risk ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦Bisphosphonates and Oral ¦21 Journal of ¦ ¦PX-3207¦15-Nov-03¦Migliorati, ¦Cavity Avascular Bone ¦Clinical ¦ ¦ ¦ ¦Cesar A. ¦Necrosis ¦Oncology 4253 ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ +-------+---------+--------------+-----------------------------+--------------¦ ¦ ¦ ¦Chang, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jennie T.; ¦ ¦349 New ¦ ¦ ¦ ¦ ¦ ¦England ¦ ¦ ¦23-Oct- ¦Green, ¦Renal Failure with the Use of¦Journal of ¦ ¦PX-3208¦ ¦ ¦Zoledronic Acid ¦Medicine 1676 ¦ ¦ ¦03 ¦Lanh; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ ¦ ¦ ¦Beitz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Julie ¦ ¦ ¦ +-------+---------+--------------+-----------------------------+--------------¦ ¦ ¦ ¦Tarassoff, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦61 Journal of ¦ ¦ ¦ ¦Peter; ¦Avascular Necrosis of the ¦Oral and ¦ ¦PX-3209¦Oct-03 ¦ ¦Jaws: Risk Factors in ¦Maxillofacial ¦ ¦ ¦ ¦Csermak, ¦Metastatic Cancer Patients ¦Surgery 1238 ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ ¦ ¦ ¦Katalin ¦ ¦ ¦ +-------+---------+--------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦ ¦61 Journal of ¦ ¦ ¦ ¦Wang, J.; ¦ ¦Oral and ¦ ¦ ¦ ¦Goodger, N. ¦Osteonecrosis of the Jaw ¦Maxillofacial ¦ ¦PX-3210¦Sep-03 ¦M.; Pogrel, ¦Associated With Cancer ¦ ¦ ¦ ¦ ¦ ¦Chemotherapy ¦Surgery ¦ ¦ ¦ ¦M. A. ¦ ¦11041107 ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ +-------+---------+--------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦ ¦61 Journal of ¦ ¦ ¦ ¦ ¦Pamidronate (Aredia) and ¦Oral and ¦ ¦PX-3211¦Sep-03 ¦Marx, Robert ¦Zoledronate (Zometa) Induced ¦Maxillofacial ¦ ¦ ¦ ¦E. ¦Avascular Necrosis of the ¦Surgery 1115 ¦ ¦ ¦ ¦ ¦Jaws: A Growing Epidemic ¦ ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ +-------+---------+--------------+-----------------------------+--------------¦ ¦ ¦ ¦ ¦A Histopathological ¦ ¦ ¦ ¦ ¦Kaynak, Deniz;¦Investigation on the Effect ¦ ¦ ¦ ¦ ¦Meffert, R; ¦of Systemic Administration of¦ ¦ ¦ ¦ ¦Bostanci, H; ¦the Bisphosphonate ¦74 Periodontal¦ ¦PX-3212¦Sep-03 ¦Gunhan, O; ¦Alendronate on Resorptive ¦ ¦ ¦ ¦ ¦Ozkaya, ¦Phase Following ¦2003 No. 9 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦OG ¦Mucoperiosteal Flap Surgery ¦ ¦ ¦ ¦ ¦ ¦in the Rat Mandible ¦ ¦ +-------+---------+--------------+-----------------------------+--------------¦ ¦ ¦ ¦Million Women ¦Breast Cancer and ¦362 Lancet 419¦ ¦PX-3213¦19-Aug-03¦Study ¦Hormone-Replacement Therapy ¦(2003) ¦ ¦ ¦ ¦Collaborato rs¦in the Million Women Study ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Rosen, Lee ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; Gordon,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦David; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tchekmedyia¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦n, Simon; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yanagihara,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ronald; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hirsh, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vera; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Krzakowski,¦ ¦ ¦ ¦ ¦ ¦ ¦Zoledronic Acid Versus Placebo in ¦21 Journal¦ ¦ ¦ ¦M.; ¦the Treatment of Skeletal Metastases¦of ¦ ¦ ¦15-Aug- ¦ ¦in Patients With Lung Cancer and ¦Clinical ¦ ¦PX-3214¦ ¦Pawlicki, ¦Other Solid Tumors: A Phase III, ¦Oncology ¦ ¦ ¦03 ¦ ¦Double-Blind, Randomized Trial -- ¦3150 ¦ ¦ ¦ ¦M.; de ¦The Zoledronic Acid Lung Cancer and ¦ ¦ ¦ ¦ ¦ ¦Other Solid Tumors Study Group ¦(2003) ¦ ¦ ¦ ¦Souza, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Paul; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zheng, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ming; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Urbanowitz,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gladys; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reitsma, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dirk; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John J. ¦ ¦ ¦ +-------+---------+-----------+------------------------------------+----------¦ ¦ ¦ ¦Santini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bruno; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dicuonzo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giordano; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Avvisati, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giuseppe; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Massacesi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cristian; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Battistoni,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fabrizio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦9 Clinical¦ ¦ ¦ ¦Gavasci, ¦Zoledronic Acid Induces Significant ¦ ¦ ¦ ¦ ¦ ¦and Long-Lasting Modifications of ¦Cancer ¦ ¦PX-3215¦1-Aug-03 ¦Michele; ¦Circulating Angiogenic Factors in ¦ ¦ ¦ ¦ ¦ ¦Cancer Patients ¦Research ¦ ¦ ¦ ¦Rocci, ¦ ¦2893 ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ ¦ ¦ ¦Laura; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tirindelli,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maria ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cristina; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Altomare, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vittorio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tocchini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Massimo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bonsignori,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maurizio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tonini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giuseppe ¦ ¦ ¦ +-------+---------+-----------+------------------------------------+----------¦ ¦ ¦ ¦Whyte, M. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦P.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wenkert, ¦ ¦349 New ¦ ¦ ¦ ¦ ¦Bisphosphonate ¦ ¦ ¦ ¦ ¦D.; ¦ ¦England ¦ ¦PX-3216¦31-Jul-03¦ ¦Induced ¦Journal of¦ ¦ ¦ ¦Clements, ¦ ¦Medicine ¦ ¦ ¦ ¦ ¦Osteopetrosis ¦457-463 ¦ ¦ ¦ ¦K.L.; ¦ ¦(2003) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦McAlister, ¦ ¦ ¦ ¦ ¦ ¦W.H.; Mumm,¦ ¦ ¦ ¦ ¦ ¦S. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦48 Australian¦ ¦PX-3217¦2003¦Carter, G.D.; Goss,¦Bisphosphonates and Avascular ¦Dental ¦ ¦ ¦ ¦A.N. ¦Necrosis of the Jaws ¦Journal 268 ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ +-------+----+-------------------+------------------------------+-------------¦ ¦ ¦ ¦Rosen, Lee S.; ¦ ¦ ¦ ¦ ¦ ¦Gordon, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kaminski, M.; ¦ ¦ ¦ ¦ ¦ ¦Howell, A.; Belch, ¦Long-Term Efficacy and Safety ¦ ¦ ¦ ¦ ¦ ¦of Zoledronic Acid Compared ¦ ¦ ¦ ¦ ¦A. ; Mackey, J.; ¦With Pamidronate Disodium in ¦ ¦ ¦ ¦ ¦ ¦the Treatment of ¦ ¦ ¦ ¦ ¦Apffelstaedt, J.; ¦ ¦98 Cancer ¦ ¦ ¦ ¦ ¦Skeletal ¦1735 ¦ ¦PX-3218¦2003¦Hussein, ¦ ¦ ¦ ¦ ¦ ¦ ¦Complications in Patients With¦(2003) ¦ ¦ ¦ ¦M.A.; ¦Advanced Multiple Myeloma or ¦ ¦ ¦ ¦ ¦ ¦Breast Carcinoma: A ¦ ¦ ¦ ¦ ¦Coleman, ¦Randomized, Double-Blind, ¦ ¦ ¦ ¦ ¦ ¦Multicenter, Comparative Trial¦ ¦ ¦ ¦ ¦R.E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reitsma, DJ.; Chen,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦B. -L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman, J.J. ¦ ¦ ¦ +-------+----+-------------------+------------------------------+-------------¦ ¦ ¦ ¦Pogrel, ¦ ¦61 Journal of¦ ¦ ¦ ¦ ¦ ¦Oral and ¦ ¦PX-3219¦2003¦M.A.; ¦A Case of Maxillary Necrosis ¦Maxillofacial¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Miller, C.E. ¦ ¦Surgery ¦ ¦ ¦ ¦ ¦ ¦489493 (2003)¦ +-------+----+-------------------+------------------------------+-------------¦ ¦ ¦ ¦Marx, ¦Oral and Maxillo-Facial ¦ ¦ ¦PX-3220¦2003¦ ¦Pathology: A Rationale for ¦ ¦ ¦ ¦ ¦Robert E.; Stern D.¦Diagnosis and Treatment ¦ ¦ +-------+----+-------------------+------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦32 ¦ ¦ ¦ ¦Reuther, T.; ¦Osteoradionecrosis of the Jaws¦ ¦ ¦ ¦ ¦ ¦As a Side Effect of ¦International¦ ¦ ¦ ¦Schuster, T.; ¦Radiotherapy of Head and Neck ¦Journal of ¦ ¦PX-3221¦2003¦Mende, U.; Kubler, ¦Tumour Patients -- A Report of¦Oral and ¦ ¦ ¦ ¦ ¦a Thirty Year Retrospective ¦Maxillofacial¦ ¦ ¦ ¦A. ¦Review ¦ ¦ ¦ ¦ ¦ ¦ ¦Surgery 289 ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ +-------+----+-------------------+------------------------------+-------------¦ ¦ ¦ ¦Hillner, Bruce E.; ¦ ¦ ¦ ¦ ¦ ¦Ingle, James N.; ¦ ¦ ¦ ¦ ¦ ¦Chlebowski, Rowan ¦ ¦ ¦ ¦ ¦ ¦T.; Gralow, Julie; ¦ ¦ ¦ ¦ ¦ ¦Yee, ¦ ¦ ¦ ¦ ¦ ¦ ¦American Society of Clinical ¦ ¦ ¦ ¦ ¦Gary C.; ¦Oncology 2003 Update on the ¦21 Journal of¦ ¦ ¦ ¦ ¦Role of ¦Clinical ¦ ¦PX-3222¦2003¦Janjan, Nora A.; ¦ ¦ ¦ ¦ ¦ ¦Cauley, Jane A.; ¦Bisphosphonates and Bone ¦Oncology 4042¦ ¦ ¦ ¦Blumenstein , Brent¦Health Issues in Women With ¦(2003) ¦ ¦ ¦ ¦A.; Albain, ¦Breast Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kathy S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lipton, Allan; ¦ ¦ ¦ ¦ ¦ ¦Brown, Susan ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Alberg, Anthony ¦ ¦123 Chest ¦ ¦PX-3223¦2003 ¦J.; Samet, ¦Epidemiology of Lung Cancer ¦21S (2003)¦ ¦ ¦ ¦Jonathan M. ¦ ¦ ¦ +-------+---------+----------------+-------------------------------+----------¦ ¦ ¦ ¦Kashiwagi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maki; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chaoui, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rabih; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦67 Birth ¦ ¦ ¦ ¦Stallmach, ¦Fetal Bilateral Renal Agenesis,¦Defects ¦ ¦ ¦ ¦ ¦Phocomelia, and Single ¦Research ¦ ¦PX-3224¦2003 ¦Thomas; ¦Umbilical Artery Associated ¦(PartA) ¦ ¦ ¦ ¦ ¦with Cocaine Abuse in Early ¦951 ¦ ¦ ¦ ¦Hurlimann, ¦Pregnancy ¦ ¦ ¦ ¦ ¦ ¦ ¦(2003) ¦ ¦ ¦ ¦Sandra; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lauper, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Urs; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hebisch, Gundula¦ ¦ ¦ +-------+---------+----------------+-------------------------------+----------¦ ¦ ¦ ¦Fournier, ¦ ¦ ¦ ¦ ¦ ¦Pierrick; ¦ ¦ ¦ ¦ ¦ ¦Boissier, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Filleur, ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates Inhibit ¦62 Cancer ¦ ¦ ¦ ¦S.; ¦Angiogenesis in Vitro and ¦Research ¦ ¦PX-3225¦15-Nov-02¦ ¦Testosterone-Stimulated ¦6538 ¦ ¦ ¦ ¦Guglielmi, J.; ¦Vascular Regrowth in the ¦ ¦ ¦ ¦ ¦Cabon, ¦Ventral Prostate in Castrated ¦(2002) ¦ ¦ ¦ ¦ ¦Rats ¦ ¦ ¦ ¦ ¦F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Colombel, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Clezardin, P. ¦ ¦ ¦ +-------+---------+----------------+-------------------------------+----------¦ ¦ ¦ ¦Saad, Fred; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Murray, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Donald M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Murray, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robin; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tchekmedyian, ¦ ¦94 Journal¦ ¦ ¦ ¦Simon; ¦A Randomized, ¦of the ¦ ¦ ¦2-Oct- ¦ ¦Placebo-Controlled Trial of ¦National ¦ ¦PX-3226¦ ¦Venner, ¦Zoledronic Acid in Patients ¦Cancer ¦ ¦ ¦02 ¦ ¦With Hormone-Refractory ¦ ¦ ¦ ¦ ¦Peter; ¦Metastatic Prostate Carcinoma ¦Institute ¦ ¦ ¦ ¦ ¦ ¦1458 ¦ ¦ ¦ ¦Lacombe, ¦ ¦(2002) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Louis; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chin, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joseph L.; ¦ ¦ ¦ ¦ ¦ ¦Vinholes, ¦ ¦ ¦ ¦ ¦ ¦Jeferson J.; ¦ ¦ ¦ ¦ ¦ ¦Goas, J. Allen; ¦ ¦ ¦ ¦ ¦ ¦Chen, Bee ¦ ¦ ¦ +-------+---------+----------------+-------------------------------+----------¦ ¦ ¦ ¦Berenson, James ¦ ¦ ¦ ¦ ¦ ¦R.; Hillner, ¦ ¦ ¦ ¦ ¦ ¦Bruce E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kyle, ¦ ¦20 Journal¦ ¦ ¦ ¦ ¦American Society of Clinical ¦of ¦ ¦ ¦ ¦Robert A.; ¦Oncology Clinical Practice ¦Clinical ¦ ¦PX-3227¦Sep-02 ¦Anderson, Ken; ¦Guidelines: The Role of ¦Oncology ¦ ¦ ¦ ¦Lipton, Allan; ¦Bisphosphonates in Multiple ¦3719 ¦ ¦ ¦ ¦Yee, ¦Myeloma ¦ ¦ ¦ ¦ ¦ ¦ ¦(2002) ¦ ¦ ¦ ¦Gary C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Biermann, J. ¦ ¦ ¦ ¦ ¦ ¦Sybil ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Sung, Eric ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.; Chan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stephen M.;¦ ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Maxilla as a ¦22 Special ¦ ¦PX-3228¦Jul-02¦Sakurai, ¦Complication to Chemotherapy: A Case ¦Care Dentist¦ ¦ ¦ ¦ ¦Report ¦142 (2002) ¦ ¦ ¦ ¦Kari; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chung, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Evelyn ¦ ¦ ¦ +-------+------+-----------+-------------------------------------+------------¦ ¦ ¦ ¦Santini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bruno; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Avvisati, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giuseppe; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dicuonzo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giordano; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦8 Clinical ¦ ¦ ¦ ¦Battistoni,¦Pamidronate Induces Modifications of ¦Cancer ¦ ¦PX-3229¦May-02¦ ¦Circulating Angiogenic Factors in ¦ ¦ ¦ ¦ ¦Fabrizio; ¦Cancer Patients ¦Research ¦ ¦ ¦ ¦ ¦ ¦1080 (2002) ¦ ¦ ¦ ¦Gavasci, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Michele; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Salerno, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Alfredo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Denaro, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vincenzo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tonini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Giuseppe ¦ ¦ ¦ +-------+------+-----------+-------------------------------------+------------¦ ¦ ¦ ¦Agarwala, ¦ ¦ ¦ ¦ ¦ ¦A.; Sule, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦41 ¦ ¦PX-3230¦Mar-02¦A. ; Pai, ¦Alendronate in the Treatment of ¦ ¦ ¦ ¦ ¦ ¦Avascular Necrosis of the Hip ¦Rheumatology¦ ¦ ¦ ¦B. U.; ¦ ¦346 (2002) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Joshi, V.R.¦ ¦ ¦ +-------+------+-----------+-------------------------------------+------------¦ ¦ ¦ ¦van Beek, ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates Suppress Bone ¦ ¦ ¦ ¦ ¦E.R.; ¦Resorption by a Dir. Eff. On Early ¦ ¦ ¦ ¦ ¦ ¦Osteoclast Precursors w/o Affecting ¦ ¦ ¦ ¦ ¦Lowik, ¦the Osteoclastogenic Capac. Of ¦30 Bone 64 ¦ ¦PX-3231¦Jan-02¦ ¦Osteogenic Cells: The Role of Protein¦ ¦ ¦ ¦ ¦C.W.G.M.; ¦ ¦(2002) ¦ ¦ ¦ ¦ ¦Geranylgeranylation in the Action of ¦ ¦ ¦ ¦ ¦Papapoulos,¦Nitrogen-Containing Bisphosphoates on¦ ¦ ¦ ¦ ¦ ¦Osteoclast ¦ ¦ ¦ ¦ ¦S.E. ¦ ¦ ¦ +-------+------+-----------+-------------------------------------+------------¦ ¦ ¦ ¦Wood, ¦ ¦ ¦ ¦ ¦ ¦Jeanette; ¦ ¦ ¦ ¦ ¦ ¦Bonjean, ¦ ¦ ¦ ¦ ¦ ¦K.; Ruetz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦302 Journal ¦ ¦ ¦ ¦S.; ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bellheene, ¦Novel Antiangiogenic Effects of the ¦Pharmacology¦ ¦PX-3232¦2002 ¦A.; Devy, ¦Bisphosphonate Compound Zoledronic ¦ ¦ ¦ ¦ ¦L.; ¦Acid ¦and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Foidart, ¦ ¦Experimental¦ ¦ ¦ ¦ ¦ ¦Therapeutics¦ ¦ ¦ ¦J.M.; ¦ ¦1055 (2002) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Castronovo,¦ ¦ ¦ ¦ ¦ ¦V.; Green, ¦ ¦ ¦ ¦ ¦ ¦Jonathan R.¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Marx, ¦Oral and Maxillofacial ¦ ¦ ¦PX-3233¦2003 ¦ ¦Pathology - A Rationale ¦ ¦ ¦ ¦ ¦Robert E.; Stern, ¦for Diagnosis and ¦ ¦ ¦ ¦ ¦D. ¦Treatment ¦ ¦ +-------+---------+-------------------+-------------------------+-------------¦ ¦ ¦ ¦Graham, David J.; ¦ ¦286 Journal ¦ ¦ ¦ ¦Drinkard, Carol R.;¦Liver Enzyme Monitoring ¦of the ¦ ¦PX-3234¦15-Aug-01¦Shatin, Deborah, ¦in Patients Treated with ¦American ¦ ¦ ¦ ¦Tsong, Yi; Burgess,¦Troglitazone ¦Medical ¦ ¦ ¦ ¦Margaret J. ¦ ¦Association ¦ ¦ ¦ ¦ ¦ ¦831 (2001) ¦ +-------+---------+-------------------+-------------------------+-------------¦ ¦ ¦ ¦Motyckova, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Linking ¦ ¦ ¦ ¦ ¦Weilbaecher , K.N.;¦ ¦98 ¦ ¦ ¦ ¦Horstmann, M.; ¦Osteopetrosis and ¦Proceedings ¦ ¦ ¦ ¦Rieman, ¦Pycnodysostosis: ¦of the ¦ ¦PX-3235¦8-May-01 ¦ ¦Regulation of Cathepsin K¦National ¦ ¦ ¦ ¦D.J.; ¦Expression by the ¦Academy of ¦ ¦ ¦ ¦ ¦Microphthalmia ¦Sciences 5798¦ ¦ ¦ ¦Fisher, ¦Transcription Factor ¦(2001) ¦ ¦ ¦ ¦ ¦Family ¦ ¦ ¦ ¦ ¦D.Z.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fisher, D.E. ¦ ¦ ¦ +-------+---------+-------------------+-------------------------+-------------¦ ¦ ¦ ¦Berenson, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦James R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Rosen, Lee ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.; Howell, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Anthony; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Porter, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lester; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Coleman, ¦Zoledronic Acid Reduces ¦ ¦ ¦ ¦ ¦ ¦Skeletal-Related Events ¦ ¦ ¦ ¦ ¦Robert E.; ¦in Patients with ¦91 Cancer ¦ ¦ ¦1-Apr- ¦ ¦Osteolytic ¦1191 ¦ ¦PX-3236¦ ¦Morley, ¦ ¦ ¦ ¦ ¦01 ¦ ¦Metastases A ¦(2001) ¦ ¦ ¦ ¦Walter; ¦Double-Blind, Randomized ¦ ¦ ¦ ¦ ¦ ¦Dose-Response Study ¦ ¦ ¦ ¦ ¦Drelcer, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kuross, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Steven A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Lipton, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Allan; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John J. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Murphy, Trudy V.; ¦ ¦ ¦ ¦ ¦ ¦Gargiullo, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Paul M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Massoudi, Mehran S.; ¦ ¦ ¦ ¦ ¦ ¦Nelson, David B.; ¦ ¦ ¦ ¦ ¦ ¦Jumaan, Aisha O.; ¦ ¦ ¦ ¦ ¦ ¦Okoro, Catherine A.; ¦ ¦344 New ¦ ¦ ¦ ¦Znardi, Lynn R.; ¦ ¦ ¦ ¦ ¦ ¦Setia, Sabeena; Fair, ¦ ¦England ¦ ¦ ¦ ¦ ¦Intussusception Among ¦Journal of¦ ¦PX-3237¦22-Feb-01¦Elizabeth; ¦Infants Given an Oral ¦Medicine ¦ ¦ ¦ ¦ ¦Rotavirus Vaccine ¦564 ¦ ¦ ¦ ¦LeBaron, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2001) ¦ ¦ ¦ ¦Charles W.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wharton, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Melinda; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Livingood, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John R. ¦ ¦ ¦ +-------+---------+----------------------+-------------------------+----------¦ ¦ ¦ ¦Seaman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J;Abdi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦E;Andrew ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Love Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Centre;Bell ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦, R;Bendigo ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hospital;Body, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J;Boston ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Group;Quebe ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fehling, ¦Zoledronic Acid is ¦ ¦ ¦ ¦ ¦ ¦Superior to Pamidronate ¦19 Journal¦ ¦ ¦ ¦E;Yunus, ¦in the Treatment of ¦of ¦ ¦ ¦15-Jan- ¦ ¦Hypercalcemia of ¦Clinical ¦ ¦PX-3238¦ ¦F;Journal ¦Malignancy A Pooled ¦Oncology ¦ ¦ ¦01 ¦ ¦Analysis of Two ¦558 ¦ ¦ ¦ ¦of Clinical ¦Randomized Controlled ¦ ¦ ¦ ¦ ¦ ¦Clinical Trials ¦(2000) ¦ ¦ ¦ ¦Oncology;Co ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦mprehensive ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Institute;I ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦nstitut ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jules ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bordet;Hon, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J;Novartis ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pharma;Feist Weiller ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Center; ¦ ¦ ¦ +-------+---------+----------------------+-------------------------+----------¦ ¦ ¦ ¦ ¦Nontraumatic ¦24 ¦ ¦ ¦ ¦Winquist, Eric W.; ¦Osteonecrosis After ¦American ¦ ¦PX-3239¦2001 ¦Bauman, Glenn S.; ¦Chemotherapy for ¦Journal of¦ ¦ ¦ ¦Balogh, Judith ¦Testicular Cancer: A ¦Clinical ¦ ¦ ¦ ¦ ¦Systematic Review ¦Oncology ¦ ¦ ¦ ¦ ¦ ¦603 (2001)¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Shibutani, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Toshiaki; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Inuduka, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Akihiro; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦12 Clinical ¦ ¦ ¦ ¦Horiki, ¦Bisphosphonate Inhibits Alveolar Bone¦Oral Implants ¦ ¦PX-3240¦2001¦ ¦Resorption in Experimentally-Induced ¦Research 109 ¦ ¦ ¦ ¦Itaru; ¦Peri-Implantitis in Dogs ¦(2001) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Luan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Qingxing; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Iwayama, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yukio ¦ ¦ ¦ +-------+----+-----------+-------------------------------------+--------------¦ ¦ ¦ ¦Evans, S. ¦ ¦10 ¦ ¦ ¦ ¦J. W.; ¦Use of Proportional Reporting Ratios ¦ ¦ ¦ ¦ ¦ ¦(PRRs) for Signal Generation from ¦Pharmacoepidem¦ ¦PX-3241¦2001¦Waller, P. ¦Spontaneous Adverse Drug Reaction ¦iology and ¦ ¦ ¦ ¦C.; Davis, ¦Reports ¦Drug Safety ¦ ¦ ¦ ¦ ¦ ¦483 (2001) ¦ ¦ ¦ ¦S. ¦ ¦ ¦ +-------+----+-----------+-------------------------------------+--------------¦ ¦ ¦ ¦de ¦ ¦69 Calcified ¦ ¦ ¦ ¦ ¦Human Osteopetrosis and Other ¦Tissue ¦ ¦PX-3242¦2001¦Vernejoul, ¦Sclerosing Disorders: Recent Genetic ¦ ¦ ¦ ¦ ¦M. C.; ¦Developments ¦International ¦ ¦ ¦ ¦Benichou, ¦ ¦ ¦ ¦ ¦ ¦O. ¦ ¦1 (2001) ¦ +-------+----+-----------+-------------------------------------+--------------¦ ¦ ¦ ¦Rosen, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gordon, D.;¦ ¦ ¦ ¦ ¦ ¦Kaminski, ¦ ¦ ¦ ¦ ¦ ¦M.; Howell,¦ ¦ ¦ ¦ ¦ ¦A.; Belch, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A. ; ¦ ¦ ¦ ¦ ¦ ¦Mackey, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Apffelstaed¦Zoledronic Acid Versus Pamidronate in¦ ¦ ¦ ¦ ¦t, J.; ¦the Treatment of Skeletal Metastases ¦7 Cancer ¦ ¦PX-3243¦2001¦Hussein, ¦in Patients with Breast Cancer or ¦Journal 377 ¦ ¦ ¦ ¦ ¦Osteolytic Lesions of Multiple ¦ ¦ ¦ ¦ ¦M.; ¦Myeloma: A Phase III, Double-Blind, ¦(2001) ¦ ¦ ¦ ¦ ¦Comparative Trial ¦ ¦ ¦ ¦ ¦Coleman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦R.E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reitsma, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D.J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman, ¦ ¦ ¦ ¦ ¦ ¦J.J.; Chen,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦B. L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ambros, Y. ¦ ¦ ¦ +-------+----+-----------+-------------------------------------+--------------¦ ¦ ¦ ¦Mashiba, ¦ ¦ ¦ ¦ ¦ ¦T.; Turner,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hirano, T.;¦ ¦ ¦ ¦ ¦ ¦ ¦Effects of Suppressed Bone Turnover ¦ ¦ ¦ ¦ ¦Forwood, ¦by Bisphosphnates on Microdamage ¦28 Bone 524 ¦ ¦PX-3244¦2001¦ ¦Accumulation and Biomechanical ¦ ¦ ¦ ¦ ¦M.R.; ¦Properties in Clinically Relevant ¦(2001) ¦ ¦ ¦ ¦ ¦Skeletal Sites in Beagles ¦ ¦ ¦ ¦ ¦Johnston, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C. C.; ¦ ¦ ¦ ¦ ¦ ¦Burr, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D. B. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Mashiba, T.;¦ ¦ ¦ ¦ ¦ ¦Turner, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C. H.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hirano, T.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Forwood, ¦Effects of High-Dose Etidronate ¦ ¦ ¦ ¦ ¦ ¦Treatment on Microdamage ¦29 Bone 271 ¦ ¦PX-3245¦2001 ¦M.R.; ¦Accumulation and Biomechanical ¦ ¦ ¦ ¦ ¦ ¦Properties in Beagle Bone Before ¦(2001) ¦ ¦ ¦ ¦Jacob, ¦Occurrence of Spontaneous ¦ ¦ ¦ ¦ ¦ ¦Fractures ¦ ¦ ¦ ¦ ¦D. S.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Johnston, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C. C.; Burr,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D. B. ¦ ¦ ¦ +-------+-------+------------+----------------------------------+-------------¦ ¦ ¦ ¦Jagdev, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.P.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Purohit, ¦ ¦ ¦ ¦ ¦ ¦ ¦Comparison of the Effects of ¦ ¦ ¦ ¦ ¦O.P.; ¦Intravenous Pamidronate and Oral ¦12 Annals of ¦ ¦PX-3246¦2001 ¦ ¦Clodronate on Symptoms and Bone ¦Oncology 1433¦ ¦ ¦ ¦Heatley, S.;¦Resorption in Patients with ¦ ¦ ¦ ¦ ¦ ¦Metastatic Bone Disease ¦(2001) ¦ ¦ ¦ ¦Herling, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Coleman, ¦ ¦ ¦ ¦ ¦ ¦R.E. ¦ ¦ ¦ +-------+-------+------------+----------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦J Nucl Med ¦ ¦ ¦ ¦Carrasquill ¦Alendronate Does Not Interfere ¦ ¦ ¦PX-3247¦2001 ¦o, Jjorge A;¦with 99m Tc-Methylene ¦2001; 42: ¦ ¦ ¦ ¦Whatley ¦Disphosphonate Bone Scanning ¦ ¦ ¦ ¦ ¦ ¦ ¦1359-1363 ¦ +-------+-------+------------+----------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦J ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Musculoskelet¦ ¦ ¦ ¦ ¦Osteonecrosis and Osteonecrosis of¦Neuronal ¦ ¦PX-3248¦2001 ¦H K W Kim ¦the jaw (ONJ) ¦ ¦ ¦ ¦ ¦ ¦ ¦Interact ¦ ¦ ¦ ¦ ¦ ¦2007; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦7(4):348-349 ¦ +-------+-------+------------+----------------------------------+-------------¦ ¦ ¦ ¦Smalley, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Walter; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shatin, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Deborah; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Wysowski, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Diane K.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gurwitz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jerry; ¦ ¦284 Journal ¦ ¦ ¦ ¦ ¦ ¦of the ¦ ¦ ¦20-Dec-¦Andrade, ¦Contraindicated Use of Cisapride: ¦American ¦ ¦PX-3249¦ ¦ ¦Impact of Food and Drug ¦Medical ¦ ¦ ¦00 ¦Susan E.; ¦Administration Regulatory Action ¦Association ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Goodman, ¦ ¦3036 (2000) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Michael; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Chan, K. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Arnold; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Platt, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Richard; ¦ ¦ ¦ ¦ ¦ ¦Schech, ¦ ¦ ¦ ¦ ¦ ¦Stephanie ¦ ¦ ¦ ¦ ¦ ¦D.; Ray, ¦ ¦ ¦ ¦ ¦ ¦Wayne A. ¦ ¦ ¦ +-------+-------+------------+----------------------------------+-------------¦ ¦ ¦ ¦Vaananen, H.¦ ¦ ¦ ¦ ¦ ¦Kalervo; ¦ ¦ ¦ ¦ ¦ ¦Zhao, Haibo;¦ ¦113 Journal ¦ ¦ ¦ ¦Mulari, ¦The Cell Biology of Osteoclast ¦of Cell ¦ ¦PX-3250¦Feb-00 ¦ ¦Function ¦Science ¦ ¦ ¦ ¦Mika; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦377 (2000) ¦ ¦ ¦ ¦Halleen, ¦ ¦ ¦ ¦ ¦ ¦Jussi M. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Mashiba, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tasuku; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hirano, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Toru; ¦Suppressed Bone ¦ ¦ ¦ ¦ ¦ ¦Turnover By ¦ ¦ ¦ ¦ ¦Turner, ¦Bisphosphonates ¦ ¦ ¦ ¦ ¦ ¦Increases Microdamage ¦15 Journal of¦ ¦ ¦ ¦Charles H.; ¦Accumulation and ¦Bone Mineral ¦ ¦PX-3251¦2000 ¦ ¦Reduces Some ¦Research 613 ¦ ¦ ¦ ¦Forwood, ¦Biomechanical ¦(2000) ¦ ¦ ¦ ¦ ¦Properties in Dog ¦ ¦ ¦ ¦ ¦Mark R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Rib ¦ ¦ ¦ ¦ ¦Johnston, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.Conrad; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Burr, David ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦B. ¦ ¦ ¦ +-------+------+------------------------+-----------------------+-------------¦ ¦ ¦ ¦Hillner, Bruce E.; ¦ ¦ ¦ ¦ ¦ ¦Ingle, James N.; ¦ ¦ ¦ ¦ ¦ ¦Berenson, James R.; ¦American Society of ¦ ¦ ¦ ¦ ¦Janjan, Nora A.; Albain,¦Clinical Oncology ¦18 Journal of¦ ¦ ¦ ¦Kathy S.; Lipton, Allan;¦Guideline on the Role ¦Clinical ¦ ¦PX-3252¦2000 ¦Yee, Gary; Biermann, ¦of ¦Oncology 1378¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J. Sybil; ¦Bisphosphonates in ¦(2000) ¦ ¦ ¦ ¦ ¦Breast Cancer ¦ ¦ ¦ ¦ ¦Chelbowski, Rowan T.; ¦ ¦ ¦ ¦ ¦ ¦Pfister, David G. ¦ ¦ ¦ +-------+------+------------------------+-----------------------+-------------¦ ¦ ¦ ¦ ¦Quinolone-Induced QT ¦45 Journal of¦ ¦ ¦ ¦ ¦Interval ¦Antimicrobial¦ ¦PX-3253¦2000 ¦Ball, Peter ¦ ¦Chemotherapy ¦ ¦ ¦ ¦ ¦Prolongation: A ¦ ¦ ¦ ¦ ¦ ¦Not-So-Unexpected Class¦557 (2000) ¦ ¦ ¦ ¦ ¦Effect ¦ ¦ +-------+------+------------------------+-----------------------+-------------¦ ¦ ¦ ¦Sutton, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.J., ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦New York, NY:¦ ¦ ¦ ¦Abrams, ¦ ¦ ¦ ¦ ¦ ¦ ¦Methods for ¦John Wiley ¦ ¦PX-3254¦2000 ¦K.R., ¦meta-analysis in ¦and ¦ ¦ ¦ ¦ ¦medical research ¦ ¦ ¦ ¦ ¦Jones, ¦ ¦Sons (2000) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D.R., ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sheldon, T.A., Song, F. ¦ ¦ ¦ +-------+------+------------------------+-----------------------+-------------¦ ¦ ¦ ¦ ¦Physiology and ¦45 Clinical ¦ ¦PX-3255¦1999 ¦Raisz, Lawrence G. ¦Pathophysiology of Bone¦Chemistry ¦ ¦ ¦ ¦ ¦Remodeling ¦1353 (1999) ¦ +-------+------+------------------------+-----------------------+-------------¦ ¦ ¦ ¦ ¦ ¦8 Cancer ¦ ¦ ¦ ¦ ¦The Surveillance, ¦Epidemiology,¦ ¦ ¦ ¦Hankey, Benjamin F.; ¦Epidemiology, and End ¦Biomarkers ¦ ¦PX-3256¦Dec-99¦Ries, Lynn A.; Edwards, ¦Results Program: A ¦and ¦ ¦ ¦ ¦Brenda K. ¦National Resource ¦Prevention ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1117 (1999) ¦ +-------+------+------------------------+-----------------------+-------------¦ ¦ ¦ ¦Russell, R.G.G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates: From ¦25 Bone 97 ¦ ¦PX-3257¦Jul-99¦Rogers, ¦the Laboratory to the ¦(1999) ¦ ¦ ¦ ¦ ¦Clinic and Back Again ¦ ¦ ¦ ¦ ¦M.J. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Theriault, Richard¦ ¦ ¦ ¦ ¦ ¦L.; Lipton, Allan;¦ ¦ ¦ ¦ ¦ ¦Hortobagyi, ¦ ¦ ¦ ¦ ¦ ¦Gabriel N.; Leff, ¦ ¦ ¦ ¦ ¦ ¦Richard; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Gluck, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stefan; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Steward, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Costello, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sean; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kennedy, ¦Pamidronate Reduces Skeletal¦ ¦ ¦ ¦ ¦ ¦Morbidity in Women With ¦17 Journal ¦ ¦ ¦ ¦Ian; ¦Advanced Breast Cancer and ¦of Clinical¦ ¦PX-3258¦1999 ¦ ¦Lytic Bone Lesions: A ¦Oncology ¦ ¦ ¦ ¦Simeone, ¦Randomized, ¦846 (1999) ¦ ¦ ¦ ¦ ¦Placebo-Controlled Trial ¦ ¦ ¦ ¦ ¦Joseph; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seman, John ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; Knight, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert D.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Mellars, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kathleen; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Heffernan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maika; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Reitsma, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Dirk ¦ ¦ ¦ +-------+---------+------------------+----------------------------+-----------¦ ¦ ¦ ¦Beek, ¦ ¦Biochem. ¦ ¦ ¦ ¦ ¦Farnesyl Pyrophosphate ¦And Bioph ¦ ¦ ¦ ¦Ermond Van, ¦Synthase is the Molecular ¦Re. Comm. ¦ ¦PX-3259¦1999 ¦ ¦Target of ¦264, ¦ ¦ ¦ ¦Pieterman, ¦Nitrogen-Containing ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonates ¦108-111 ¦ ¦ ¦ ¦E ¦ ¦(1999) ¦ +-------+---------+------------------+----------------------------+-----------¦ ¦ ¦ ¦Weissman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Neil J.; ¦An Assessment of Heart-Valve¦ ¦ ¦ ¦ ¦ ¦Abnormalities in Obese ¦339 New ¦ ¦ ¦10-Sep- ¦Tighe, John ¦Patients Taking ¦England ¦ ¦PX-3260¦ ¦ ¦ ¦Journal of ¦ ¦ ¦98 ¦F.; ¦Dexfenfluramine, ¦Medicine ¦ ¦ ¦ ¦ ¦Sustained-Release ¦725 (1998) ¦ ¦ ¦ ¦Gottdiener, John ¦Dexfenfluramine, or Placebo ¦ ¦ ¦ ¦ ¦S.; Gwynne, John ¦ ¦ ¦ ¦ ¦ ¦T. ¦ ¦ ¦ +-------+---------+------------------+----------------------------+-----------¦ ¦PX-3261¦18-Apr-98¦Dally, Ann ¦Thalidomide: Was the Tragedy¦351 Lancet ¦ ¦ ¦ ¦ ¦Preventable? ¦1197 (1998)¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦O'Brien, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Katherine ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Selanikio, J. ¦ ¦ ¦ ¦ ¦ ¦D.; Hecdivert, ¦ ¦ ¦ ¦ ¦ ¦C.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Placide, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦M,-F.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Louis, M.; ¦ ¦ ¦ ¦ ¦ ¦Barr, D.B.; ¦ ¦279 Journal of¦ ¦ ¦ ¦Barr, J.R.; ¦Epidemic of Pediatric Deaths¦the American ¦ ¦ ¦ ¦Hospedales, J.;¦from Acute Renal Failure ¦Medical ¦ ¦PX-3262¦15-Apr-98¦Lewis, ¦Caused by Diethylene Glycol ¦Association ¦ ¦ ¦ ¦ ¦Poisoning ¦ ¦ ¦ ¦ ¦M.J.; ¦ ¦1175 (1998) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schwartz, B.; ¦ ¦ ¦ ¦ ¦ ¦Philen, R.M.; ¦ ¦ ¦ ¦ ¦ ¦St. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Victor, S.; ¦ ¦ ¦ ¦ ¦ ¦Espindola, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Needham, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.L.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Denerville, ¦ ¦ ¦ ¦ ¦ ¦Karl ¦ ¦ ¦ +-------+---------+---------------+----------------------------+--------------¦ ¦ ¦ ¦Barbaglio, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Alberto; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cortelazzi, ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteopetrosis Complicated by¦ ¦ ¦ ¦ ¦Roberto; ¦Osteomyelitis of the ¦56 Journal of ¦ ¦ ¦ ¦ ¦Mandible: A Case Report ¦Oral and ¦ ¦PX-3263¦Mar-98 ¦Martignoni, ¦Including Gross and ¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦Surgery 393 ¦ ¦ ¦ ¦Guido; ¦Microscopic Findings ¦(1998) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nocini, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pier ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Francesco ¦ ¦ ¦ +-------+---------+---------------+----------------------------+--------------¦ ¦ ¦ ¦Fleisch, ¦Bisphosphonates: Mechanisms ¦19 Endocrine ¦ ¦PX-3264¦1998 ¦Herbert ¦of Action ¦Reviews 8 0 ¦ ¦ ¦ ¦ ¦ ¦(1998) ¦ +-------+---------+---------------+----------------------------+--------------¦ ¦ ¦ ¦O'uchi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Naoto; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nishikawa, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Haruko; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Yoshino, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Taiji; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kanoh, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hiroyuki; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Motoie, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hiroyuki; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Nishimori, ¦ ¦ ¦ ¦ ¦ ¦ ¦Inhibitory Effects of YM175,¦33 Journal of ¦ ¦ ¦ ¦Emi; ¦a Bisphosphonate, on the ¦Periodontal ¦ ¦PX-3265¦1998 ¦ ¦Progression of Experimental ¦Research 196 ¦ ¦ ¦ ¦Shimaoka, ¦Periodontitis in Beagle Dogs¦ ¦ ¦ ¦ ¦ ¦ ¦(1998) ¦ ¦ ¦ ¦Toshio; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Abe, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tetsushi; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shikama, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hisataka; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fujikura, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Takashi; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Matsue, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Miyoko; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Matsue, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Ichiro ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Berenson, James R.; ¦ ¦ ¦ ¦ ¦ ¦Lichtenstei n, Alan; ¦ ¦ ¦ ¦ ¦ ¦Porter, Lester; ¦ ¦ ¦ ¦ ¦ ¦Dimopoulos, Meletios ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bordoni, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Roldolfo; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Simeone, ¦ ¦ ¦ ¦ ¦ ¦ ¦Long-Term Pamindronate ¦16 Journal of ¦ ¦ ¦ ¦Joseph F.; ¦Treatment of Advanced ¦Clinical ¦ ¦PX-3266¦1998 ¦ ¦Multiple Myeloma ¦Oncology 593 ¦ ¦ ¦ ¦Reitsma, ¦Patients Reduces ¦ ¦ ¦ ¦ ¦ ¦Skeletal Events ¦(1998) ¦ ¦ ¦ ¦Dirk J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Heffernan, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maika; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seaman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Knight, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Robert D. ¦ ¦ ¦ +-------+------+---------------------+------------------------+---------------¦ ¦ ¦ ¦ ¦Long Term Prevention ¦ ¦ ¦ ¦ ¦Hortobagyi, G. N.; ¦ ¦16 Journal of ¦ ¦ ¦ ¦Theriault, R.L.; ¦of Skeletal ¦Clinical ¦ ¦PX-3267¦1998 ¦ ¦ ¦Oncology 2038 ¦ ¦ ¦ ¦Lipton, A. ¦Complication of ¦(1998) ¦ ¦ ¦ ¦ ¦Metastatic Breast Cancer¦ ¦ ¦ ¦ ¦ ¦with Pamidronate ¦ ¦ +-------+------+---------------------+------------------------+---------------¦ ¦ ¦ ¦ ¦Effect of ¦ ¦ ¦ ¦ ¦ ¦ ¦47 Physiology ¦ ¦PX-3268¦1998 ¦Kapitola, J.; Zak, J.¦Pamidronate on Bone ¦Research 237 ¦ ¦ ¦ ¦ ¦Blood Flow in ¦(1998) ¦ ¦ ¦ ¦ ¦Oophorectomized Rats ¦ ¦ +-------+------+---------------------+------------------------+---------------¦ ¦ ¦ ¦Friedman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Fundamentals of Clinical¦New York, ¦ ¦PX-3269¦1998 ¦Furberg, ¦Trials (3rd Ed.) ¦ ¦ ¦ ¦ ¦ ¦ ¦Springer-Verlag¦ ¦ ¦ ¦C. D.; DeMets, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D. L. ¦ ¦ ¦ +-------+------+---------------------+------------------------+---------------¦ ¦ ¦ ¦Egger, ¦ ¦315 British ¦ ¦ ¦ ¦ ¦ ¦Medical Journal¦ ¦ ¦ ¦Matthias; ¦ ¦1533 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Smith, ¦ ¦(1997) --http:/¦ ¦ ¦6-Dec-¦ ¦Meta-Analysis: ¦/www.bmj ¦ ¦PX-3270¦ ¦George ¦Principles and ¦ ¦ ¦ ¦97 ¦ ¦Procedures ¦.com/cgi/conte ¦ ¦ ¦ ¦Davey; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦nt/full/315/71 ¦ ¦ ¦ ¦Phillips, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦21/1533 ¦ ¦ ¦ ¦Andrew N. ¦ ¦ ¦ +-------+------+---------------------+------------------------+---------------¦ ¦ ¦ ¦Connolly, Heidi M.; ¦ ¦ ¦ ¦ ¦ ¦Crary, Jack L.; ¦ ¦ ¦ ¦ ¦2 ¦McGoon, Michael D.; ¦Valvular Heart Disease ¦337 New England¦ ¦PX-3271¦8-Aug-¦Hensrud, Donald D.; ¦Associated with ¦Journal of ¦ ¦ ¦ ¦Edwards, Brooks S.; ¦Fenfluramine-Phentermine¦Medicine 581 ¦ ¦ ¦97 ¦Edwards, William D.; ¦ ¦(1997) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schaff, Hartzell V. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Ozmen, Y.; ¦Osteomyelitis of the Facial¦1 Mund Kiefer ¦ ¦PX-3272¦1997 ¦Klesper, B.; ¦Skull in Albers-Schonberg ¦Gesichtschirur¦ ¦ ¦ ¦Lenzen, J. ¦Osteopetrosis ¦gie 121 (1997)¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦ ¦The Clinical Impact of ¦MEDWATCH, ¦ ¦PX-3273¦Oct-96 ¦Goldman, S. ¦Adverse Event Reporting ¦October 1996 ¦ ¦ ¦ ¦ ¦ ¦at 1-12 ¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦Gelb, Bruce D.; ¦ ¦ ¦ ¦ ¦ ¦Shi, ¦ ¦ ¦ ¦ ¦3 ¦ ¦Pycnodysostosis, a ¦273 Science ¦ ¦PX-3274¦0-Aug-96¦Guo-Ping; ¦Lysosomal Disease Caused by¦ ¦ ¦ ¦ ¦Chapman, Harold ¦Cathepsin K Deficiency ¦1236 (1996) ¦ ¦ ¦ ¦A.; Desnick, ¦ ¦ ¦ ¦ ¦ ¦Robert J. ¦ ¦ ¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦Felix, R.; ¦Recent Developments in the ¦134 European ¦ ¦ ¦ ¦ ¦Understanding of the ¦Journal of ¦ ¦PX-3275¦Feb-96 ¦Hofstetter, W.; ¦ ¦Endocrinology ¦ ¦ ¦ ¦ ¦Pathophysiology of ¦ ¦ ¦ ¦ ¦Cecchini, M.G. ¦Osteopetrosis ¦143 (1996) ¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦Hanada, T.; ¦ ¦ ¦ ¦ ¦ ¦Furuta, S.; ¦ ¦ ¦ ¦ ¦ ¦Moriyama, I.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦34 Rhinology ¦ ¦PX-3276¦1996 ¦Hanamure, ¦Maxillary Osteomyelitis ¦ ¦ ¦ ¦ ¦ ¦Secondary to Osteopetrosis ¦242 (1996) ¦ ¦ ¦ ¦Y.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Miyanohara, T.; ¦ ¦ ¦ ¦ ¦ ¦Ohyama, M. ¦ ¦ ¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦Tyrrell, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C.T.; ¦Pamidronate Infusions as ¦31A European ¦ ¦ ¦ ¦ ¦Single-Agent Therapy for ¦Journal of ¦ ¦PX-3277¦Nov-95 ¦Bruning, P.F.; ¦Bone Metastases: A Phase II¦ ¦ ¦ ¦ ¦May-Levin, F.; ¦Trial in Patients with ¦Cancer 1976 ¦ ¦ ¦ ¦Rose, C.; ¦Breast Cancer ¦(1995) ¦ ¦ ¦ ¦Mauriac, L.; ¦ ¦ ¦ ¦ ¦ ¦Soukop, M.; Ford,¦ ¦ ¦ ¦ ¦ ¦J.M. ¦ ¦ ¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦ ¦ ¦10 ¦ ¦ ¦ ¦Starck, ¦ ¦ ¦ ¦ ¦ ¦ ¦Failure of Osseointegrated ¦International ¦ ¦PX-3278¦1995 ¦W.J.; ¦Dental Implants After ¦Journal of ¦ ¦ ¦ ¦ ¦Diphosphonate Therapy for ¦Oral and ¦ ¦ ¦ ¦Epker, B.N. ¦Osteoporosis: A Case Report¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦Implants 74 ¦ ¦ ¦ ¦ ¦ ¦(1995) ¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦Marx, R.E.; ¦ ¦ ¦ ¦ ¦ ¦Carlson, ¦Isolation of Actinomyces ¦52 Journal of ¦ ¦ ¦ ¦ ¦Species and Eikenella ¦Oral and ¦ ¦PX-3279¦Jan-94 ¦E.R.; ¦Corrodens From Patients ¦Maxillofacial ¦ ¦ ¦ ¦ ¦With Chronic Diffuse ¦Surgery 26 ¦ ¦ ¦ ¦Smith, B.R.; ¦Sclerosing Osteomyelitis ¦(1994) ¦ ¦ ¦ ¦ ¦(with discussion) ¦ ¦ ¦ ¦ ¦Toraya, N. ¦ ¦ ¦ +-------+--------+-----------------+---------------------------+--------------¦ ¦ ¦ ¦Ray, Wayne ¦ ¦329 New ¦ ¦ ¦30-Dec- ¦ ¦Evaluating Drugs After ¦England ¦ ¦PX-3280¦ ¦A.; ¦Their Approval for Clinical¦Journal of ¦ ¦ ¦93 ¦ ¦Use ¦Medicine 2029 ¦ ¦ ¦ ¦Griffin, Marie ¦ ¦ ¦ ¦ ¦ ¦R..; Avorn, Jerry¦ ¦(1993) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦van ¦ ¦ ¦ ¦ ¦ ¦Holten-Verzantvoort, ¦ ¦ ¦ ¦ ¦ ¦A.T.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kroon, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦H.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bijvoet, O.L.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cleton, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦F. J.; Beex, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.V.A.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Blijham, ¦Palliative Pamidronate ¦11 Journal of ¦ ¦ ¦ ¦ ¦Treatment in Patients ¦Clinical ¦ ¦PX-3281¦Mar-93¦G. ; ¦With Bone Metastases From¦Oncology 491 ¦ ¦ ¦ ¦ ¦Breast Cancer ¦ ¦ ¦ ¦ ¦Hermans, J.; Neijt, ¦ ¦(1993) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.P.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Papapoulos, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦S.E.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sleeboom, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦H. P.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vermey, P. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zwinderman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.H. ¦ ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Brunsvold, Michael ¦Effects of a ¦63 Journal of ¦ ¦ ¦ ¦A.; Chaves, Eros S.; ¦Bisphosphonate on ¦Periodontology¦ ¦PX-3282¦1992 ¦Kornman, Kenneth S.; ¦Experimental ¦ ¦ ¦ ¦ ¦Aufdemorte, Thomas ¦Periodontitis in Monkeys ¦825 (1992) ¦ ¦ ¦ ¦B.; Wood, Robert ¦ ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦Bouquot, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J.E.; ¦Neuralgia-Inducing ¦73 Oral ¦ ¦ ¦ ¦ ¦Cavitational ¦Surgery Oral ¦ ¦ ¦ ¦Roberts, A.M.; ¦Osteonecrosis (NICO) -- ¦Medicine Oral ¦ ¦PX-3283¦1992 ¦ ¦Osteomyelitis in 224 ¦Pathology 307 ¦ ¦ ¦ ¦Person, P.; ¦Jawbone Samples from ¦ ¦ ¦ ¦ ¦ ¦Patients With Facial ¦(1992) ¦ ¦ ¦ ¦Christian, ¦Neuralgia ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦J. ¦ ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦ ¦ ¦12 Journal of ¦ ¦ ¦ ¦Ray, Wayne ¦Psychotropic Drugs and ¦Clinical ¦ ¦PX-3284¦1992 ¦ ¦Injuries Among the ¦Psychopharmaco¦ ¦ ¦ ¦A. ¦Elderly: A Review ¦logy 386 ¦ ¦ ¦ ¦ ¦ ¦(1992) ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦ ¦Skeletal ¦ ¦ ¦ ¦ ¦Hommeyer, Steven H.; ¦ ¦33 Journal of ¦ ¦PX-3285¦1992 ¦Varney, Dawn M.; ¦Nonvisualization in a ¦Nuclear ¦ ¦ ¦ ¦Eary, Janet F. ¦Bone Scan Secondary to ¦Medicine 748 ¦ ¦ ¦ ¦ ¦Intravenous Etidronate ¦(1992) ¦ ¦ ¦ ¦ ¦Therapy ¦ ¦ +-------+------+---------------------+-------------------------+--------------¦ ¦ ¦ ¦ ¦Analysis and ¦266 Journal of¦ ¦ ¦3-Jul-¦Yusuf, Salim; Wittes,¦Interpretation of ¦the American ¦ ¦PX-3286¦ ¦Janet; Probstfield , ¦Treatment Effects in ¦Medical ¦ ¦ ¦91 ¦Jeffrey; Tyroler, ¦Subgroups of Patients in ¦ ¦ ¦ ¦ ¦Herman A. ¦Randomized Clinical ¦Association 93¦ ¦ ¦ ¦ ¦Trials ¦(1991) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Thiebaud, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Daniel; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Leyvraz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Serge; von ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fliedner, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Vladimir; ¦ ¦ ¦ ¦ ¦ ¦ ¦Treatment of Bone ¦27 European Journal ¦ ¦ ¦ ¦Perey, ¦Metastases from Breast ¦of Cancer 37 ¦ ¦PX-3287¦1991 ¦ ¦Cancer and Myeloma With ¦ ¦ ¦ ¦ ¦Lucien; ¦Pamidronate ¦(1991) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cornu, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pierre; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Thiebaud, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sylviane; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Burckhardt, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Peter ¦ ¦ ¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦Sackett, ¦ ¦ ¦ ¦ ¦ ¦D.L.; Haynes,¦Clinical Epidemiology: A ¦ ¦ ¦PX-3288¦1991 ¦R.B.; ¦Basic Science for Clinical¦ ¦ ¦ ¦ ¦ ¦Medicine (2nd ed.) ¦ ¦ ¦ ¦ ¦Tugwell, P. ¦ ¦ ¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦Khochtali, ¦ ¦92 Rev ¦ ¦PX-3289¦1991 ¦H.; ¦Osteomyelitis of the Jaw ¦ ¦ ¦ ¦ ¦Abassi-Bakir,¦and Osteopetrosis ¦Stomatol Chir ¦ ¦ ¦ ¦D. ¦ ¦Maxillofac 273 (1991)¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦Sandler, E. ¦ ¦ ¦ ¦ ¦ ¦Dayan; ¦ ¦ ¦ ¦ ¦ ¦Parisi, ¦ ¦32 Journal of Nuclear¦ ¦ ¦ ¦Marguerite ¦Duration of Etidronate ¦ ¦ ¦PX-3290¦1991 ¦ ¦Effect Demonstrated by ¦Medicine 1782 ¦ ¦ ¦ ¦T.; ¦Serial Bone Scintigraphy ¦ ¦ ¦ ¦ ¦ ¦ ¦(1991) ¦ ¦ ¦ ¦Hattner, ¦ ¦ ¦ ¦ ¦ ¦Robert S. ¦ ¦ ¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦Nandakumar, ¦ ¦ ¦ ¦ ¦ ¦ ¦Massive ¦28 British Journal of¦ ¦PX-3291¦1990 ¦H.; ¦ ¦Oral and ¦ ¦ ¦ ¦ ¦Sequestration of the Upper¦Maxillofacial Surgery¦ ¦ ¦ ¦Shankaramba ,¦Jaw: A Case Report ¦55 (1990) ¦ ¦ ¦ ¦K.B. ¦ ¦ ¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦Eidson, M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Philen, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦R.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦L-Tryptophan and ¦335 Lancet 645 ¦ ¦PX-3292¦1990 ¦Sewell, C.M.;¦Eosinopiliamyalgia ¦ ¦ ¦ ¦ ¦ ¦Syndrome in New Mexico ¦(1990) ¦ ¦ ¦ ¦Vorrhees, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦R.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Kilbourne, ¦ ¦ ¦ ¦ ¦ ¦E.M. ¦ ¦ ¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦Myers, R.A., ¦Use of Hyperbaric Oxygen ¦NCI ¦ ¦PX-3293¦1990 ¦R.E. ¦in Post Radiation Head and¦ ¦ ¦ ¦ ¦ ¦Neck Surgery ¦Monographs, Number ¦ ¦ ¦ ¦Marx ¦ ¦9:151-7 ¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦ ¦Osteoclast Biology: ¦34 American Journal ¦ ¦PX-3294¦Sep-89¦Marks, S.C. ¦Lessons from Mammalian ¦of Medical Genetics ¦ ¦ ¦ ¦ ¦Mutations ¦43 (1989) ¦ +-------+------+-------------+--------------------------+---------------------¦ ¦ ¦ ¦Fouda, N.; ¦ ¦3 Advances in Dental ¦ ¦ ¦ ¦ ¦Developmental Disturbances¦ ¦ ¦PX-3295¦Sep-89¦Caracatsanis,¦of the Rat Molar Induced ¦Research 234 ¦ ¦ ¦ ¦M.; ¦by Two Diphosphonates ¦ ¦ ¦ ¦ ¦Hammarstrom ,¦ ¦(1989) ¦ ¦ ¦ ¦L. ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Balogh, Judith ¦Osteoradionecrosis of the ¦18 Journal of ¦ ¦PX-3296¦1989 ¦M.; Sutherland, ¦Mandible: A Review ¦Otolaryngology ¦ ¦ ¦ ¦Susan E. ¦ ¦245 (1989) ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦Griffin, Marie ¦ ¦ ¦ ¦ ¦ ¦R.; Ray, Wayne ¦Risk of Sudden Death ¦319 New England ¦ ¦ ¦ ¦A.; ¦Syndrome After Immunization ¦Journal of ¦ ¦PX-3297¦Sep-88¦ ¦with the ¦Medicine 618 ¦ ¦ ¦ ¦Livengood, John ¦Diphtheria-Tetanus-Pertussis¦(1988) ¦ ¦ ¦ ¦R.; Schaffner, ¦Vaccine ¦ ¦ ¦ ¦ ¦William ¦ ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦ ¦A Short History of ¦ ¦ ¦ ¦ ¦ ¦ ¦38 Teratology ¦ ¦PX-3298¦1988 ¦Lenz, W. ¦Thalidomide ¦203 (1988) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Embryopathy ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦Rossi, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.C.; ¦ ¦259 Journal of ¦ ¦ ¦ ¦ ¦ ¦the American ¦ ¦ ¦ ¦Bosco, L.; ¦The Importance of Adverse ¦Medical ¦ ¦PX-3299¦1988 ¦Faich, ¦Reaction Reporting by ¦Association ¦ ¦ ¦ ¦ ¦Physicians ¦ ¦ ¦ ¦ ¦G.A.; ¦ ¦1203 (1988) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Tanner, A.; ¦ ¦ ¦ ¦ ¦ ¦Temple, R. ¦ ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦Epstein, Joel ¦ ¦ ¦ ¦ ¦ ¦B.; Wong, ¦ ¦45 Journal of ¦ ¦ ¦ ¦ ¦ ¦Oral and ¦ ¦ ¦ ¦Frances L. ¦Osteoradionecrosis: Clinical¦Maxillofacial ¦ ¦PX-3300¦1987 ¦ ¦Experience and a Proposal ¦Surgery 104 ¦ ¦ ¦ ¦W.; ¦for Classification ¦ ¦ ¦ ¦ ¦ ¦ ¦(1987) ¦ ¦ ¦ ¦Stevenson-Moore,¦ ¦ ¦ ¦ ¦ ¦P. ¦ ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦van ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦16 ¦ ¦ ¦ ¦Merkesteyne ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦International ¦ ¦ ¦ ¦, J.P.; ¦Osteomyelitis of the Jaws in¦Journal of Oral ¦ ¦PX-3301¦1987 ¦ ¦ ¦and ¦ ¦ ¦ ¦Bras, J.; ¦Pycnocysostosis ¦Maxillofacial ¦ ¦ ¦ ¦Vermeeren, J.I.;¦ ¦Surgery 615 ¦ ¦ ¦ ¦van der Sar, A.;¦ ¦(1987) ¦ ¦ ¦ ¦Statius van Eps,¦ ¦ ¦ ¦ ¦ ¦L.W. ¦ ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦Hurwitz, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦E.S.; ¦ ¦257 Journal of ¦ ¦ ¦ ¦ ¦Public Health Service Study ¦the American ¦ ¦PX-3302¦1987 ¦Barrett, ¦of Reye's Syndrome and ¦Medical ¦ ¦ ¦ ¦ ¦Medications ¦Association 1905¦ ¦ ¦ ¦M.J.; ¦ ¦(1987) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bregman, D. ¦ ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦ ¦Osteopetrosis -Multiple ¦5 Applied ¦ ¦PX-3303¦1987 ¦Marks, S.C. ¦Pathways for the ¦Pathology 172 ¦ ¦ ¦ ¦ ¦Interception of Osteoclast ¦(1987) ¦ ¦ ¦ ¦ ¦Function ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦ ¦ ¦Kelsey, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jennifer ¦ ¦ ¦ ¦ ¦ ¦ ¦Methods in ¦ ¦ ¦ ¦ ¦L.; ¦ ¦ ¦ ¦PX-3304¦1986 ¦ ¦Observational ¦ ¦ ¦ ¦ ¦Thompson, ¦ ¦ ¦ ¦ ¦ ¦ ¦Epidemiology ¦ ¦ ¦ ¦ ¦W.D.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Evans, A.S. ¦ ¦ ¦ +-------+------+----------------+----------------------------+----------------¦ ¦PX-3305¦1986 ¦Rothman, Kenneth¦Modern Epidemiology, 1st ¦ ¦ ¦ ¦ ¦J. ¦Ed.. Chapter 12 ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦ ¦95 ¦ ¦ ¦ ¦ ¦Osteomyelitis of the Maxilla ¦ ¦ ¦PX-3306¦1986 ¦Crocket, D.M,;¦in a Patient with ¦Otolaryngology ¦ ¦ ¦ ¦Stanley, R.B. ¦Osteopetrosis ¦Head & Neck ¦ ¦ ¦ ¦ ¦(Albers-Schonberg Disease) ¦Surgery 117 ¦ ¦ ¦ ¦ ¦ ¦(1986) ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦15 ¦ ¦ ¦ ¦Gupta, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦International ¦ ¦PX-3307¦1986 ¦D.S.; ¦Osteomyelitis of the Mandible¦Journal of Oral ¦ ¦ ¦ ¦ ¦in Marble Bone Disease ¦and ¦ ¦ ¦ ¦Gupta, M.K. ¦ ¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦Surgery 201 ¦ ¦ ¦ ¦ ¦ ¦(1986) ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦Gardner, Lytt ¦ ¦ ¦ ¦ ¦16-Mar-¦I.; ¦Phocomelia in Infant Whose ¦337 Lancet 636 ¦ ¦PX-3308¦ ¦Welsh-Sloan, ¦Mother Took Large Doses of ¦ ¦ ¦ ¦85 ¦Jannell; Cacy,¦Pyridoxine During Pregnancy ¦(1985) ¦ ¦ ¦ ¦Robert B. ¦ ¦ ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦Osborn, ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteomyelitis of the Mandible¦40 Journal of ¦ ¦PX-3309¦1985 ¦C.V.; ¦in a Patient with Malignant ¦Oral Medicine 76¦ ¦ ¦ ¦ ¦Osteopetrosis ¦(1985) ¦ ¦ ¦ ¦Boland, T. ¦ ¦ ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦ ¦In Vitro Stability of 99Tcm ¦ ¦ ¦ ¦ ¦ ¦Bone Scan Preparations from ¦5 Nuclear ¦ ¦PX-3310¦Jul-84 ¦Pauwels, E.K.;¦Different Manufacturers ¦Medicine ¦ ¦ ¦ ¦Feitsma, R.I. ¦Measured by Various ¦Communications ¦ ¦ ¦ ¦ ¦Radiopharmaceutical ¦467 (1984) ¦ ¦ ¦ ¦ ¦Parameters ¦ ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦41 Journal of ¦ ¦ ¦ ¦Marx, Robert ¦A New Concept in the ¦Oral and ¦ ¦PX-3311¦1983 ¦E. ¦Treatment of ¦Maxillofacial ¦ ¦ ¦ ¦ ¦Osteoradionecrosis ¦Surgery 283 ¦ ¦ ¦ ¦ ¦ ¦(1983) ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦PX-3312¦1983 ¦Pocock, S.J. ¦Clinical Trials: A Practical ¦New York, John ¦ ¦ ¦ ¦ ¦Approach ¦Wiley and Sons ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦Friedman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦L.M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Fundamentals of Clinical ¦Boston: John ¦ ¦PX-3313¦1983 ¦Furberg, ¦Trials ¦Wright & Sons ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦C. D.; DeMets,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦D. L. ¦ ¦ ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦41 Journal of ¦ ¦ ¦ ¦Marx, Robert ¦Osteoradionecrosis: A New ¦Oral and ¦ ¦PX-3314¦1983 ¦E. ¦Concept of Its ¦Maxillofacial ¦ ¦ ¦ ¦ ¦Pathophysiology ¦Surgery 351 ¦ ¦ ¦ ¦ ¦ ¦(1983) ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦ ¦ ¦108 Archives ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Shaff, Max I.;¦Osteomyelitis of the Mandible¦of ¦ ¦PX-3315¦Feb-82 ¦Mathis, John ¦-- An Initial Feature in ¦ ¦ ¦ ¦ ¦M. ¦Late-Onset Osteopetrosis ¦Otolaryngology ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦120 (1982) ¦ +-------+-------+--------------+-----------------------------+----------------¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws: A ¦4 Head and Neck ¦ ¦PX-3316¦1982 ¦Schwartz, H.C.¦Complication of Cancer ¦Surgery 251 ¦ ¦ ¦ ¦ ¦Chemotherapy ¦(1982) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦ ¦The Progress of the ¦16 Journal of ¦ ¦ ¦ ¦Gotcher, ¦Periodontal Syndrome in the ¦Periodontal ¦ ¦PX-3317¦1981 ¦J.E.; Jee,¦Rice Rat -II. The Effects of a¦Research 441455 ¦ ¦ ¦ ¦W.S.S. ¦Diphosphonate on the ¦(1981) ¦ ¦ ¦ ¦ ¦Periodontium ¦ ¦ +-------+---------+----------+------------------------------+-----------------¦ ¦ ¦ ¦ ¦ ¦4 & 5 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-3318¦1981 ¦Fleisch, ¦Diphosphonates: History and ¦Metabolic Bone ¦ ¦ ¦ ¦H. ¦Mechanisms of Action ¦Disease and ¦ ¦ ¦ ¦ ¦ ¦Related Research ¦ ¦ ¦ ¦ ¦ ¦279288 (1981) ¦ +-------+---------+----------+------------------------------+-----------------¦ ¦ ¦ ¦ ¦Guillain-Barre Syndrome: The ¦ ¦ ¦ ¦ ¦ ¦Swine Influenza Virus Vaccine ¦ ¦ ¦ ¦ ¦Langmuir, ¦Incident in the United States ¦72 Journal of the¦ ¦PX-3319¦Sep-79 ¦Alexander ¦of ¦Royal Society of ¦ ¦ ¦ ¦D. ¦ ¦Medicine 660 ¦ ¦ ¦ ¦ ¦America, 1976-77: ¦(1979) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Preliminary Communication ¦ ¦ +-------+---------+----------+------------------------------+-----------------¦ ¦ ¦ ¦ ¦Mortality in Relation to ¦2 British Medical¦ ¦ ¦ ¦Doll, R.; ¦Smoking: 20 Years' ¦Journal 1525 ¦ ¦PX-3320¦1976 ¦Peto, R. ¦ ¦ ¦ ¦ ¦ ¦ ¦Observations on Male British ¦(1976) ¦ ¦ ¦ ¦ ¦Doctors ¦ ¦ +-------+---------+----------+------------------------------+-----------------¦ ¦ ¦ ¦Bok, P.; ¦ ¦32 Journal of ¦ ¦PX-3321¦1974 ¦ ¦Osteomyelitis Secondary to ¦Oral Surgery 769 ¦ ¦ ¦ ¦van der ¦Osteopetrosis: Report of Case ¦(1974) ¦ ¦ ¦ ¦Waal, I. ¦ ¦ ¦ +-------+---------+----------+------------------------------+-----------------¦ ¦ ¦ ¦Winer, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦H.J.; ¦ ¦ ¦ ¦ ¦ ¦ ¦Palatal Necrosis Secondary to ¦84 Journal of the¦ ¦PX-3322¦Apr-72 ¦McMahon, ¦Cytotoxin Therapy: Report of ¦American Dental ¦ ¦ ¦ ¦ ¦Case ¦Association 862 ¦ ¦ ¦ ¦R.E.; ¦ ¦(1972) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Olson, ¦ ¦ ¦ ¦ ¦ ¦R.E. ¦ ¦ ¦ +-------+---------+----------+------------------------------+-----------------¦ ¦ ¦ ¦Herbst, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦A.L.; ¦Adenocarcinoma of the Vagina: ¦2 84 New England ¦ ¦ ¦ ¦ ¦Association of Maternal ¦Journal of ¦ ¦PX-3323¦1971 ¦Ulfelder, ¦Stilbestrol Therapy with Tumor¦Medicine 878 ¦ ¦ ¦ ¦H.; ¦Appearance in Young Females ¦ ¦ ¦ ¦ ¦ ¦ ¦(1971) ¦ ¦ ¦ ¦Poskanzer,¦ ¦ ¦ ¦ ¦ ¦D.C. ¦ ¦ ¦ +-------+---------+----------+------------------------------+-----------------¦ ¦ ¦ ¦Hill, ¦ ¦58 Proceedings of¦ ¦PX-3324¦14-Jan-65¦ ¦The Environment and Disease: ¦the Royal Society¦ ¦ ¦ ¦Austin ¦Association or Causation? ¦of Medicine 295 ¦ ¦ ¦ ¦Bradford ¦ ¦(1965) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦Bayne- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jones, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Stanhope; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Burdette, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Walter J.;¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Cochran, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦William ¦ ¦ ¦ ¦ ¦ ¦G.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Farber, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Emmanuel; ¦ ¦Public Health ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fieser, ¦Smoking and Health: Report¦Service ¦ ¦ ¦ ¦ ¦of the Advisory Committee ¦ ¦ ¦PX-3325¦1964 ¦Louis; ¦to the Surgeon General of ¦Publication ¦ ¦ ¦ ¦ ¦the Public Health Service ¦ ¦ ¦ ¦ ¦Furth, ¦ ¦No. 1103 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Jacob; ¦ ¦(1964) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Hickam, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦John B.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦LeMaistre,¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Charles; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Schuman, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Leonard ¦ ¦ ¦ ¦ ¦ ¦M.; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Seevers, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maurice H.¦ ¦ ¦ +-------+-----------+----------+--------------------------+-------------------¦ ¦PX-3326¦17-Aug-01 ¦Dearden, ¦The Causation of ¦2 British Medical ¦ ¦ ¦ ¦W.F. ¦Phosphorus Necrosis ¦Journal 408 (1901) ¦ +-------+-----------+----------+--------------------------+-------------------¦ ¦ ¦ ¦Dearden, ¦Fragilitas Ossium Amonst ¦2 British Medical ¦ ¦PX-3327¦29-Jul-1899¦W. F. ¦Workers in Lucifer Match ¦Journal 270271 ¦ ¦ ¦ ¦ ¦Factories ¦(1899) ¦ +-------+-----------+----------+--------------------------+-------------------¦ ¦ ¦ ¦ ¦ ¦J ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Musculoskelet ¦ ¦PX-3328¦ ¦M. R. ¦Animal models of ¦Neuronal ¦ ¦ ¦ ¦Allen ¦osteonecrosis of the jaw ¦ ¦ ¦ ¦ ¦ ¦ ¦Interact 2007; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦7(4):358-360 ¦ +-------+-----------+----------+--------------------------+-------------------¦ ¦ ¦ ¦M. C. de ¦Human Osteopetrosis and ¦ ¦ ¦ ¦ ¦ ¦Other Sclerosing ¦Calcif Tissue Int ¦ ¦PX-3329¦ ¦Vernejoul,¦Disorders: Recent Genetic ¦(2001) 69:1-6 ¦ ¦ ¦ ¦O. ¦Developments ¦ ¦ ¦ ¦ ¦Benichou ¦ ¦ ¦ +-------+-----------+----------+--------------------------+-------------------¦ ¦ ¦ ¦J. ¦ ¦ ¦ ¦ ¦ ¦ ¦Effect of Growth Hormone ¦Physiol. Res. ¦ ¦ ¦ ¦Kapitola, ¦and Pamidronate on Bone ¦ ¦ ¦PX-3330¦ ¦J. Zak, Z.¦Blood Flow, Bone Mineral ¦49 (Suppl. 1): ¦ ¦ ¦ ¦ ¦and IGF-I Levels in the ¦ ¦ ¦ ¦ ¦Lacinova, ¦Rat ¦S101-S106, 2000 ¦ ¦ ¦ ¦V. Justova¦ ¦ ¦ +-------+-----------+----------+--------------------------+-------------------¦ ¦ ¦ ¦ ¦Abstract, Allen et al., ¦ ¦ ¦ ¦ ¦ ¦Exposed bone and oral ¦ ¦ ¦ ¦ ¦Allen et ¦seqeustra following ¦ ¦ ¦PX-3334¦ ¦ ¦high-dose zoledronate ¦ ¦ ¦ ¦ ¦al. ¦treatment and dental ¦ ¦ ¦ ¦ ¦ ¦extraction in a beagle dog¦ ¦ ¦ ¦ ¦ ¦model ¦ ¦ +-------+-----------+----------+--------------------------+-------------------¦ ¦ ¦ ¦ ¦ ¦AAOMS Position ¦ ¦ ¦ ¦ ¦AAOMS Position Paper on ¦Paper on ¦ ¦ ¦ ¦ ¦Bisphosphonate-Related ¦Bisphosphonat ¦ ¦ ¦9/25/20 ¦ ¦ ¦e-Related ¦ ¦PX-3335¦ ¦AAOMS ¦Osteonecrosis of the Jaw ¦Osteonecrosis of ¦ ¦ ¦06 ¦ ¦Approved Sept. ¦the Jaw Approved ¦ ¦ ¦ ¦ ¦ ¦Sept. ¦ ¦ ¦ ¦ ¦25, 2006 ¦ ¦ ¦ ¦ ¦ ¦ ¦25, 2006 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦ ¦ ¦American ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Winter¦Association¦Bisphosphonate Associated ¦ ¦ ¦PX-3336¦2007 ¦ ¦Osteonecrosis of the Jaw ¦ ¦ ¦ ¦ ¦of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Endodontics¦ ¦ ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦ ¦ ¦ ¦ ¦Amer. J. of ¦ ¦ ¦July, ¦Bi, Y., ¦Bisphosphonates Cause Osteonecrosis ¦Pathology, ¦ ¦PX-3337¦ ¦Gao, Y. et ¦of the Jaw-Like Disease in Mice ¦Vol. 177, No.¦ ¦ ¦2010 ¦al. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1 ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦ ¦ ¦ ¦Inhibition by Diphosphonates of Bone¦ ¦ ¦PX-3338¦ ¦ ¦Resorption in Mice and Comparison ¦ ¦ ¦ ¦ ¦ ¦with Grey-Lethal Osteopetrosis ¦ ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦PX-3339¦ ¦Robert Marx¦Clincal Concerns of Alendronate Use ¦ ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦ ¦ ¦ ¦Oral Bisphosphonate-Induced ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦PX-3340¦ ¦Khosla ¦Osteonecrosis: Risk Factors: ¦ ¦ ¦ ¦ ¦ ¦Prediction of Risk Using Serum CTX ¦ ¦ ¦ ¦ ¦ ¦Testing, Prevention, and Treatment ¦ ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦ ¦ ¦ ¦Paget's Disease and ¦ ¦ ¦PX-3341¦ ¦Schwartz ¦Bisphosphonate-Associated ¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis of the Jaws ¦ ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦ ¦ ¦ ¦Temporomandibular Disorders in ¦ ¦ ¦PX-3342¦ ¦Assael ¦Surgical Practice: Does Science ¦ ¦ ¦ ¦ ¦ ¦Support Treatment Decisions? ¦ ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦ ¦ ¦ ¦Consensus Development Conference on ¦ ¦ ¦ ¦ ¦ ¦Oral Complications of Cancer ¦ ¦ ¦ ¦ ¦ ¦Therapies: Diagnosis, ¦ ¦ ¦PX-3343¦ ¦Myers, Marx¦ ¦ent ¦ ¦ ¦ ¦ ¦Prevention and Treatm Use of ¦ ¦ ¦ ¦ ¦ ¦Hyperbaric Oxygen in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Postradiation Head and Neck Surgery ¦ ¦ +-------+------+-----------+------------------------------------+-------------¦ ¦PX-3344¦12/9/ ¦MARCHIONE, ¦Promising bone drug flops in breast ¦Associated ¦ ¦ ¦20 10 ¦MARILYNN ¦cancer study ¦Press ¦ +-----------------------------------------------------------------------------+

Exhibit "D": Defendant's Exhibits

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦University of California, San Francisco, Medical Records ¦ ¦DX-0001¦ ¦ ¦ ¦ ¦ ¦for William White ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Oregon Health and Science University, Medical Records for ¦ ¦ ¦ ¦William White ¦ ¦0002 ¦ ¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Records ¦ ¦DX-0003¦ ¦ ¦ ¦ ¦ ¦Produced to NPC by Plaintiff for William White ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Walgreen Company, Pharmacy Records for William White ¦ ¦0004 ¦ ¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Duke ¦ ¦ ¦ ¦ ¦ ¦0005 ¦ ¦University, Medical Records for William White ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0006¦ ¦Delta Dental, Insurance Records for William White ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Guy Acheson, ¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦D.D.S., ¦ ¦0007 ¦ ¦ ¦ ¦ ¦ ¦American River Dental, Medical Records for William White ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦University of California, Davis, Medical Records for William ¦ ¦ ¦ ¦White ¦ ¦0008 ¦ ¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Drs. Jackson, ¦ ¦ ¦ ¦ ¦ ¦0009 ¦ ¦Heise & Alpha Oral and Maxillofacial Surgery, Medical Records ¦ ¦ ¦ ¦for William White ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0010¦ ¦MetLife, Insurance Records for William White ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0011¦ ¦Gordon L. Douglass, D.D.S., Medical Records for William ¦ ¦ ¦ ¦White ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦Raley's, Bel ¦ ¦DX-0012¦ ¦ ¦ ¦ ¦ ¦Air Pharmacy, Pharmacy Records for William White ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Bevery A. Kodama, D.D.S., Medical Records for William White ¦ ¦0013 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0014¦ ¦HealthNet, Insurance Records for William White ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Mark H. Zablotsky, D.D.S., Medical Records for William White¦ ¦0015 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Steven L. Brown, D.D.S., Medical Records for William White ¦ ¦0016 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦The Doctors Center Medical Group, Medical Records for ¦ ¦ ¦ ¦William White ¦ ¦0017 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦Photographs of William White Produced by Health Care ¦ ¦ ¦ ¦Providers ¦ ¦0018 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦All x- ¦ ¦ ¦ ¦ ¦ ¦DX- ¦ ¦rays/radiologic ¦ ¦ ¦ ¦ ¦ ¦0019 ¦ ¦al ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦films/medical imaging/dental imaging taken of William White ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0020¦9/30/ ¦Certificate of Death of William White ¦ ¦ ¦2006 ¦ ¦ +-----------------------------------------------------------------------------+

+--------------------------------+ ¦Ex. ¦ ¦ ¦ ¦ ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +----+----------+----------------¦ ¦ ¦ ¦A randomized, ¦ +----+----------+----------------¦ ¦ ¦ ¦double blind, ¦ +----+----------+----------------¦ ¦ ¦ ¦multi-center, ¦ +----+----------+----------------¦ ¦ ¦ ¦comparative ¦ +----+----------+----------------¦ ¦ ¦ ¦trial of i.v. ¦ +----+----------+----------------¦ ¦ ¦ ¦zoledronate (4 ¦ +----+----------+----------------¦ ¦ ¦ ¦or 8) mg versus ¦ +----+----------+----------------¦ ¦ ¦ ¦i.v. Aredia (90 ¦ +----+----------+----------------¦ ¦ ¦ ¦mg), as an ¦ +----+----------+----------------¦ ¦ ¦ ¦adjunct to ¦ +----+----------+----------------¦ ¦ ¦ ¦standard ¦ +----+----------+----------------¦ ¦ ¦ ¦therapies, in ¦ +----+----------+----------------¦ ¦ ¦ ¦the treatment ¦ +----+----------+----------------¦ ¦ ¦ ¦of multiple ¦ +----+----------+----------------¦ ¦ ¦ ¦myeloma and ¦ +----+----------+----------------¦ ¦ ¦ ¦breast cancer ¦ +----+----------+----------------¦ ¦ ¦ ¦patients with ¦ +----+----------+----------------¦ ¦ ¦ ¦cancer-related ¦ +----+----------+----------------¦ ¦ ¦ ¦bone lesions ¦ +----+----------+----------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦10/16/1998¦ ¦ ¦0021¦ ¦ ¦ +----+----------+----------------¦ ¦ ¦ ¦A randomized, ¦ +----+----------+----------------¦ ¦ ¦ ¦double blind, ¦ +----+----------+----------------¦ ¦ ¦ ¦multi-center, ¦ +----+----------+----------------¦ ¦ ¦ ¦comparative ¦ +----+----------+----------------¦ ¦ ¦ ¦trial of i.v. ¦ +----+----------+----------------¦ ¦ ¦ ¦zoledronate (4 ¦ +----+----------+----------------¦ ¦ ¦ ¦or 8) mg versus ¦ +----+----------+----------------¦ ¦ ¦ ¦i.v. Aredia (90 ¦ +----+----------+----------------¦ ¦ ¦ ¦mg), as an ¦ +----+----------+----------------¦ ¦ ¦ ¦adjunct to ¦ +----+----------+----------------¦ ¦ ¦ ¦standard ¦ +----+----------+----------------¦ ¦ ¦ ¦therapies, in ¦ +----+----------+----------------¦ ¦ ¦ ¦the treatment ¦ +----+----------+----------------¦ ¦ ¦ ¦of multiple ¦ +----+----------+----------------¦ ¦ ¦ ¦myeloma and ¦ +----+----------+----------------¦ ¦ ¦ ¦breast cancer ¦ +----+----------+----------------¦ ¦ ¦ ¦patients with ¦ +----+----------+----------------¦ ¦DX- ¦ ¦cancer-related ¦ ¦ ¦7/30/1998 ¦ ¦ ¦0022¦ ¦bone lesions ¦ +--------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦A randomized, double blind, multi-center, trial to evaluate the ¦ ¦ ¦ ¦safety and efficacy of zoledronate (4 ¦ ¦DX- ¦6/26¦ ¦ ¦ ¦/ ¦or 8) ¦ ¦0023 ¦1998¦ ¦ ¦ ¦ ¦administered intravenously as an adjuvant to anticancer therapy ¦ ¦ ¦ ¦to patients with any cancer with bone metastases other than ¦ ¦ ¦ ¦breast cancer multiple myeloma or prostate cancer ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Agarwala S, et al. Alendronate in the ¦ ¦DX- ¦00/ ¦ ¦ ¦ ¦00/ ¦Treatment of Avascular Necrosis of the Hip, Rheumatol ¦ ¦0024 ¦2002¦ ¦ ¦ ¦ ¦2002; 41: 346347. ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Assouline-Dayan, et al. Pathogenesis and Natural History of ¦ ¦DX- ¦00/ ¦Osteonecrosis, Semin Arthritis ¦ ¦ ¦00/ ¦ ¦ ¦0025 ¦2002¦Rheum 2002; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦32(2): 94-124 ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Bouquot JE, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦McMahon RE. Neuropathic Pain in Maxillofacial Osteonecrosis, ¦ ¦ ¦00/ ¦ ¦ ¦DX-0026¦00/ ¦J Oral ¦ ¦ ¦2000¦ ¦ ¦ ¦ ¦Maxillofac Surg ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2000; 58: 10031020 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Fleisch H, Russell RG, et ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦al. ¦ ¦ ¦ ¦ ¦ ¦DX-0027¦00/00¦Diphosphonates inhibit ¦ ¦ ¦/1969¦ ¦ ¦ ¦ ¦hydroxyapatite dissolution in vitro and bone resorption in ¦ ¦ ¦ ¦tissue culture and in vivo, Science 1969; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦165(899): 1262-64. ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Glueck CJ, et ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦al. ¦ ¦DX- ¦00/00¦ ¦ ¦ ¦/1996¦Thrombophilia, hypofibrinolysi s, and alveolar osteonecrosis of¦ ¦0028 ¦ ¦the jaws, Oral Surg Oral Med Oral Pathol Oral Radiol Endod ¦ ¦ ¦ ¦1996; 81: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦557-566. ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Little DG, Peat RA, McEvoy A, et al. ¦ ¦ ¦ ¦ ¦ ¦DX- ¦00/00¦Zoledronic acid treatment results in retention of femoral head ¦ ¦ ¦/2003¦structure after traumatic osteonecrosis in young Wistar rats. J¦ ¦0029 ¦ ¦Bone Miner Res ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(2003) 18:2016-22. ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Machalaba Field ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Communication ¦ ¦ ¦8/7/ ¦ ¦ ¦DX-0030¦2003 ¦to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ASM/OSS/RSA/RSD ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦/BRM/RD (Aug. 7, 2003) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Mirzai R, Chang C, Greenspan A, Gershwin ME. The ¦ ¦ ¦ ¦ ¦ ¦DX- ¦00/00¦pathogenesis of osteonecrosis and the relationships ¦ ¦ ¦/1999¦ ¦ ¦0031 ¦ ¦to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦corticosteroids , J Asthma 1999; 36(1): 77-95. ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦8/25/¦Open-label, extention trial intravenous infusion of zoledronate¦ ¦ ¦1999 ¦vs. Aredia in cancer patients with osteolytic bone metastases ¦ ¦0032 ¦ ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Pogrel MA, ¦ ¦ ¦ ¦ ¦ ¦ ¦00/00¦Miller CE. A ¦ ¦DX-0033¦/2003¦ ¦ ¦ ¦ ¦Case of Maxillary Necrosis, J Oral Maxillofac Surg 2003; 61: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦489-493. ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Rosenberg TJ, Ruggiero S. Osteonecrosis of the jaws associated ¦ ¦ ¦08/00¦with the use of bisphosphonates [abstract], J Oral Maxillofac ¦ ¦DX-0034¦/2003¦Surg 2003 Aug.; 61(8 Suppl ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1):60 ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Schwartz HC. Osteonecrosis of the Jaws: A Complication of ¦ ¦ ¦ ¦Cancer ¦ ¦DX-0035¦00/00¦ ¦ ¦ ¦/1982¦Chemotherapy, Head Neck Surg ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1982; 4: 251253. ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Shankland WE. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Medullary and Odontogenic Disease in the Painful Jaw: ¦ ¦ ¦00/00¦Clinicopathologic Review of 500 Consecutive Lesions, J ¦ ¦DX-0036¦/2002¦Craniomandibular Practice ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2002; 20(4): ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦295-303. ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Sung EC, et al. Osteonecrosis of the Maxilla as a ¦ ¦ ¦ ¦ ¦ ¦ ¦00/00¦Complication to Chemotherapy: A Case Report, Spec Care ¦ ¦DX-0037¦/2002¦ ¦ ¦ ¦ ¦Dentist 2002; ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦22(4): 142-146. ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦00/00¦Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk ¦ ¦ ¦/2003¦factors in metastatic cancer patients, J Oral Maxillofac Surg ¦ ¦0038 ¦ ¦2003, 61(10): 12381239 ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Winer HJ, et al. Palatal Necrosis Secondary to Cytotoxin ¦ ¦DX-0039¦00/00¦Therapy: Report of Case, J Amer Dent Assoc ¦ ¦ ¦/1972¦ ¦ ¦ ¦ ¦1972; 84: 862866. ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Napoli et al., Aspergeilosis and necrosis of the maxilla: A case¦ ¦ ¦ ¦report, J ¦ ¦ ¦ ¦ ¦ ¦DX-0040¦1991¦Oral ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Maxillofacial ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Surg, 49:532534, 1991. ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Gruppo et al., ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦The ¦ ¦ ¦ ¦ ¦ ¦DX-0041¦1996¦pathophysiology of alveolar osteonecrosis of the jaw: ¦ ¦ ¦ ¦anticardiolipin antibodies, thrombophilia, and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦hypofibrinolysi s. J Lab Clin Med ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1996;127:481-489 ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Glueck et al., Heterozygosity for the Leiden mutation of the ¦ ¦ ¦ ¦factor V gene, a common pathoetiology for ¦ ¦ ¦ ¦ ¦ ¦DX- ¦ ¦osteonecrisis of the jaw, with ¦ ¦ ¦1997¦ ¦ ¦0042 ¦ ¦thrombophilia augmented by exogenous estrogens. J Lab Clin Med ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1997;130:540- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦543 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Glueck et al., A preliminary pilot study of treatment of ¦ ¦ ¦ ¦thrombophilia and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦hypofibrinolysi s and ¦ ¦DX-0043¦1998¦ ¦ ¦ ¦ ¦amelioration of the pain of osteonecrosis of the jaws. Oral Surg¦ ¦ ¦ ¦Oral Med Oral Pathol Oral Radiol Endod ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1998;85:64-73 ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Glueck et al., Exogenous estrogen therapy may exacerbate ¦ ¦DX-0044¦1998¦thrombophilia, impair bone healing, and contribute to ¦ ¦ ¦ ¦development of chronic facial pain. Cranio, The Jounral of ¦ ¦ ¦ ¦Craniomandibular Practice 1998;16:143-153 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Glueck, Neuralgia-inducing cavitational osteonecrosis-In Reply, ¦ ¦ ¦1998¦Letter. Oral Surg O 1998;86:5-7 ¦ ¦0045 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +-----+-----+-----------------------------------------------------------------¦ ¦ ¦ ¦Astrand et al., ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Systemic ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦alendronate ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦prevents ¦ ¦ ¦ ¦ ¦ ¦DX- ¦ ¦resorption of ¦ ¦ ¦2002 ¦ ¦ ¦0046 ¦ ¦necrotic bone ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦during ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦revascularizati on. A bone chamber study in rates. BMC ¦ ¦ ¦ ¦Musculoskeletal Disorders, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦3:1471-1474, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2002. ¦ +-----+-----+-----------------------------------------------------------------¦ ¦ ¦ ¦Arico et al., Osteonecrosis: An emerging complication of ¦ ¦ ¦ ¦intensive chemotherapy for childhood acute ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦lymphoblastic ¦ ¦DX- ¦ ¦ ¦ ¦ ¦2003 ¦leukemia. ¦ ¦0047 ¦ ¦ ¦ ¦ ¦ ¦Haematologica, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦88:747-753, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦2003. ¦ +-----+-----+-----------------------------------------------------------------¦ ¦ ¦ ¦Bouquot et al., ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Neuralgia- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦inducing ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦cavitational ¦ ¦DX- ¦3/1/ ¦ ¦ ¦ ¦1992 ¦osteonecrosis ¦ ¦0048 ¦ ¦ ¦ ¦ ¦ ¦(NICO. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Osteomyelitis in 224 jawbone samples from patients with facial ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦neuralgia, Oral Surg. Oral Med. Oral Pathol, 73(3): 307-319 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(1992) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Bouquot et al., More about neuralgia-inducing cavitation ¦ ¦DX- ¦9/1/ ¦osteonecrosis (NICO), Oral Surg. Oral Med. Oral Pathol, 74(3): ¦ ¦ ¦1992 ¦348-350 ¦ ¦0049 ¦ ¦ ¦ ¦ ¦ ¦(1992) ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦IND 30145 (May ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦28, 1987) ¦ ¦ ¦ ¦ ¦ ¦DX- ¦5/28/¦Notice of Claimed ¦ ¦ ¦1987 ¦ ¦ ¦0050 ¦ ¦Investigational Exemption for a ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦New Drug [CGP 23339A Disodium APD ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Pentahydrate] ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Aredia NDA ¦ ¦DX- ¦12/20¦ ¦ ¦ ¦/1989¦20036 (Dec 20, ¦ ¦0051 ¦ ¦ ¦ ¦ ¦ ¦1989) Original New Drug Application ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0052¦12/20¦Aredia Integrated Summary of Safety ¦ ¦ ¦/1989¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0053¦10/31¦Bilstad Ltr. to Hanagan, Aredia Approval Letter ¦ ¦ ¦/1991¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0054¦1/1/ ¦1992 Case Files ¦ ¦ ¦1992 ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦1/31/¦ ¦ ¦ ¦1992 ¦01-SEP-1991 to ¦ ¦0055 ¦ ¦ ¦ ¦ ¦ ¦30-NOV-1991 ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦4/28/¦ ¦ ¦ ¦1992 ¦01-DEC-1991 to ¦ ¦0056 ¦ ¦ ¦ ¦ ¦ ¦29-FEB-1992 ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦7/30/¦ ¦ ¦ ¦1992 ¦01-MAR-1992 to ¦ ¦0057 ¦ ¦ ¦ ¦ ¦ ¦31-MAY-1992 ¦ +-----------------------------------------------------------------------------+

+-------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦9/23/1992 ¦Aredia Integrated Summary of Safety ¦ ¦0058 ¦ ¦ ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX-0059¦10/28/1992¦ ¦ ¦ ¦ ¦01-JUN-1992 to 31-AUG-1992 ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX-0060¦1/28/1993 ¦ ¦ ¦ ¦ ¦01-SEP-1992 to 30-NOV-1992 ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX-0061¦4/22/1993 ¦ ¦ ¦ ¦ ¦01-DEC-1992 to 28-FEB-1993 ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/3/1993 ¦01-MAR-1993 to ¦ ¦0062 ¦ ¦ ¦ ¦ ¦ ¦31-MAY-1993 ¦ +-------+----------+------------------------------------------------¦ ¦DX- ¦ ¦IND 43240 (Aug 12 1993) ¦ ¦ ¦8/12/1993 ¦ ¦ ¦0063 ¦ ¦Investigational New Drug Application [CGP 42446]¦ +-------+----------+------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦10/8/1993 ¦Aredia Integrated Summary of Safety ¦ ¦0064 ¦ ¦ ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX-0065¦12/7/1993 ¦ ¦ ¦ ¦ ¦01-JUN-1993 to 31-AUG-1993 ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX-0066¦2/14/1994 ¦ ¦ ¦ ¦ ¦01-SEP-1993 to 30-NOV-1993 ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX-0067¦4/14/1994 ¦ ¦ ¦ ¦ ¦01-DEC-1993 to 28-FEB-1994 ¦ +-------+----------+------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX-0068¦8/10/1994 ¦ ¦ ¦ ¦ ¦01-MAR-1994 to 30-APR-1994 ¦ +-------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX-0069¦9/21/1994¦Sobel Ltr to Califre ¦ +-------+---------+-----------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦ ¦11/29/ ¦ ¦ ¦DX-0070¦1994 ¦01-MAY-1994 to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦31-JUL-1994 ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX-0071¦2/3/1995 ¦Preclinical Report: 3-month intravenous toxicity study in ¦ ¦ ¦ ¦rats ¦ +-------+---------+-----------------------------------------------------------¦ ¦ ¦ ¦CGP 42446: 3- ¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/3/1995 ¦month ¦ ¦0072 ¦ ¦ ¦ ¦ ¦ ¦subcutaneous toxicity study in rats ¦ +-------+---------+-----------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/8/1995 ¦01-AUG-1994 to ¦ ¦0073 ¦ ¦ ¦ ¦ ¦ ¦31-OCT-1994 ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX-0074¦2/28/1995¦Aredia NDA 20036 (Feb 28, 1995) SNDA: Myeloma ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX-0075¦2/28/1995¦Aredia Integrated Summary of Safety ¦ +-------+---------+-----------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦4/28/1995¦01-NOV-1994 to ¦ ¦0076 ¦ ¦ ¦ ¦ ¦ ¦31-JAN-1995 ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX-0077¦7/1/1995 ¦ODAC meeting minutes ¦ +-------+---------+-----------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/4/1995 ¦01-FEB-1995 to ¦ ¦0078 ¦ ¦ ¦ ¦ ¦ ¦30-APR-1995 ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦Medical Officer Review: Aredia Efficacy Supplement for ¦ ¦ ¦8/15/1995¦Myeloma ¦ ¦0079 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦9/1/1995 ¦Sobel Ltr. to Birch, Aredia Multiple Myeloma Approval ¦ ¦0080 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+---------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+----------+--------------------------------------------------------¦ ¦ ¦ ¦CGP 42446: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦26/52 Week ¦ ¦ ¦ ¦ ¦ ¦DX-0081¦9/19/1995 ¦Intravenous Toxicity Study ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦in Mature Dogs (MIN 944045), ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦26-Week Interim Report ¦ +-------+----------+--------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦ ¦ ¦ ¦ ¦DX-0082¦10/9/1995 ¦01-MAY-1995 to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦31-JUL-1995 ¦ +-------+----------+--------------------------------------------------------¦ ¦ ¦ ¦Plasma ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦concentrations ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦of CGP 42 446 ¦ ¦ ¦ ¦ ¦ ¦DX-0083¦10/27/1995¦during a 3-month ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦subcutaneous toxicity study in rats. Report No.: BPK(CH)¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1995/046. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Protocol No.: 92-6259 ¦ +-------+----------+--------------------------------------------------------¦ ¦ ¦ ¦CGP 42446: ¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/12/1996 ¦6/12-Month ¦ ¦0084 ¦ ¦ ¦ ¦ ¦ ¦Subcutaneous Toxicity Study in Rats ¦ +-------+----------+--------------------------------------------------------¦ ¦DX-0085¦1/12/1996 ¦Aredia NDA 20036 (Jan 12, 1996) SNDA: Bone Metastases ¦ +-------+----------+--------------------------------------------------------¦ ¦DX-0086¦1/12/1996 ¦Aredia Integrated Summary of Safety ¦ +-------+----------+--------------------------------------------------------¦ ¦ ¦ ¦Preclinical ¦ ¦ ¦ ¦ ¦ ¦DX- ¦ ¦Report CGP 42446: 26/52- ¦ ¦ ¦11/13/1996¦ ¦ ¦0087 ¦ ¦week ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦intravenous toxicity study in mature dogs, final report ¦ +-------+----------+--------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦11/20/1996¦01-AUG-1995 to ¦ ¦0088 ¦ ¦ ¦ ¦ ¦ ¦31-JUL-1996 ¦ +---------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Letter from FDA to Merck Research Laboratories, Attn. Michelle ¦ ¦ ¦4/25¦Kloss, Ph.D, ¦ ¦DX-0089¦/ ¦ ¦ ¦ ¦1997¦NDA 20-560/S- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦003, S-006 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0090¦July¦Aredia ISS ¦ ¦ ¦1997¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦7/21¦Preclinical Report: effects on tibial cancellous bone in a 6/12 ¦ ¦DX-0091¦/ ¦month subcutaneous toxicity study in rats. Bone histomorphometr ¦ ¦ ¦1997¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Clinical Trial Report. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Protocol 18- ¦ ¦ ¦ ¦ ¦ ¦DX- ¦8/29¦Phase I and II. ¦ ¦ ¦/ ¦ ¦ ¦0092 ¦1997¦Title: A ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦comparative trial of Aredia versus placebo for the preventionof ¦ ¦ ¦ ¦skeletal-related complications in patients with breast cancer ¦ ¦ ¦ ¦and lytic bone lesions treated with hormonal therapy. Clinical ¦ ¦ ¦ ¦trial phase III ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Clinical Trial Report. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Protocol 19- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Phase I and II. ¦ ¦ ¦8/29/¦ ¦ ¦DX-0093¦1997 ¦Title: ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Comparative trial of Aredia versus placebo for the preventionof¦ ¦ ¦ ¦skeletal-related complications in patients with breast cancer ¦ ¦ ¦ ¦and lytic bone lesions treated with ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦chemotherapy. Clinical trial phase III ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦9/22/¦Aredia Integrated Summary of ¦ ¦DX-0094¦1997 ¦ ¦ ¦ ¦ ¦Safety ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦ ¦10/30¦ ¦ ¦DX-0095¦/1997¦01AUG-1996 to ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦31-JUL-1997 ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0096¦1/26/¦Summary of Expert Report Author's Meeting ¦ ¦ ¦1998 ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0097¦3/5/ ¦Clinical Study protocol 039 ¦ ¦ ¦1998 ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0098¦8/21/¦Aredia Safety Periodic Report ¦ ¦ ¦1998 ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦9/22/¦Justice Ltr. to Cutler, Aredia osteolytic Bone Metastases ¦ ¦ ¦1998 ¦Approval Letter ¦ ¦0099 ¦ ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦11/4/¦Investigators Brochure -Edition 6, replacing Edition 5 ¦ ¦ ¦1998 ¦-Zoledronate -CGP 42446 (aka ZOL446) ¦ ¦0100 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦12/24/ ¦ ¦ ¦ ¦1998 ¦01-AUG-1997 to ¦ ¦0101 ¦ ¦ ¦ ¦ ¦ ¦30-OCT-1998 ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0102¦7/1/ ¦Nonclinical Summary of Toxicology Studies, ¦ ¦ ¦1999 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦ ¦Clinical Trial Serious (Expedited) Adverse Event Experience ¦ ¦ ¦8/9/99 ¦Report (Patient No. 1303) ¦ ¦0103 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0104¦9/18/ ¦Clinical trial doc, patient 1303 ¦ ¦ ¦1999 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0105¦10/4/ ¦Clinical trial doc, patient ¦ ¦ ¦1999 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦11/11/ ¦ ¦ ¦ ¦1999 ¦Summary of nonclinical pharmacology, toxicology and ADME, ¦ ¦0106 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0107¦11/11/ ¦Comprehensive Study of Toxicology Studies ¦ ¦ ¦1999 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0108¦12/21/ ¦Zometa NDA 21-223 ¦ ¦ ¦1999 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0109¦12/21/ ¦Zometa Integrated Summary of Safety ¦ ¦ ¦1999 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Investigators Brochure -Amendment 1 to Edition 6 - CGP ¦ ¦DX- ¦12/23/ ¦ ¦ ¦ ¦1999 ¦42446 (aka ¦ ¦0110 ¦ ¦ ¦ ¦ ¦ ¦ZOL446) ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦12/28/ ¦ ¦ ¦ ¦1999 ¦30- OCT-1998 to ¦ ¦0111 ¦ ¦ ¦ ¦ ¦ ¦31- OCT-1999 ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦5/18/ ¦Email ¦ ¦ ¦2000 ¦ ¦ ¦0112 ¦ ¦communication with FDA re: Data Monitoring Board ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦5/31/¦Record of Telephone Conversation ¦ ¦ ¦2000 ¦ ¦ ¦0113 ¦ ¦with FDA re: DSMB ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0114¦6/9/ ¦Correspondence with FDA ¦ ¦ ¦2000 ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0115¦9/18/¦Medical Officer Review of NDA 21-223 ¦ ¦ ¦2000 ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0116¦9/18/¦Correspondence with FDA ¦ ¦ ¦2000 ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦10/11¦Novartis letter enclosing Novartis minutes of September 25, ¦ ¦ ¦/2000¦2000 meeting of the Data Safety Monitoring Board and Renal ¦ ¦0117 ¦ ¦Advisory Board ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦10/11¦Minutes of the joint meeting of Data Safety Monitoring Board ¦ ¦ ¦/2000¦and Renal Advisory Board for Zometa (zoledronic acid) held on ¦ ¦0118 ¦ ¦25 September 2000 ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦10/24¦Submission to FDA of ¦ ¦DX-0119¦/2000¦ ¦ ¦ ¦ ¦recommendations of DSMB and RAB ¦ +-------+-----+---------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦12/28¦ ¦ ¦ ¦/2000¦31-OCT-1999 to ¦ ¦0120 ¦ ¦ ¦ ¦ ¦ ¦30-OCT-2000 ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX- ¦4/25/¦Medical Officer Review of a Complete Response to an Approvable ¦ ¦ ¦2001 ¦Letter ¦ ¦0121 ¦ ¦ ¦ +-------+-----+---------------------------------------------------------------¦ ¦DX-0122¦6/27/¦Patient: 2382 ¦ ¦ ¦2001 ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/1/2001 ¦Zometa Safety Summary 7/01 ¦ ¦0123 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/31/2001¦Type 6 NDA Supplement Index ¦ ¦0124 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/1/2001 ¦Zometa Package Insert. T2001-42 ¦ ¦0125 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/13/2001¦Medical Officer Review of NDA 20-036 ¦ ¦0126 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦ ¦ ¦FDA Zometa Drug ¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/20/2001¦Approval ¦ ¦0127 ¦ ¦ ¦ ¦ ¦ ¦Package ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/20/2001¦FDA Approval Letter from John Jenkins ¦ ¦0128 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/20/2001¦Jenkins letter to Ryan ¦ ¦0129 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦Zometa NDA 21386 (Aug 21, 2001) Type 6 NDA Supplement (bone ¦ ¦ ¦8/21/2001¦ ¦ ¦0130 ¦ ¦metastases) ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦8/21/2001¦Zometa Integrated Summary of Safety ¦ ¦0131 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦10/4/2001¦CGP4244603 Zoledronate; Clinical trial doc, patient 02023 ¦ ¦0132 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/6/2001¦Correspondence with FDA re: Data Monitoring Board ¦ ¦0133 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦12/17/ ¦Zometa Periodic Safety Report for the period 20-AUG-2001 to ¦ ¦ ¦2001 ¦19-NOV-2001 ¦ ¦0134 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦12/21/ ¦ ¦ ¦ ¦2001 ¦31-OCT-2000 to ¦ ¦0135 ¦ ¦ ¦ ¦ ¦ ¦30-OCT-2001 ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/3/2002 ¦ODAC Briefing Package ¦ ¦0136 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0137¦1/31/ ¦ODAC Draft minutes ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0138¦1/31/ ¦ODAC Agenda ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0139¦1/31/ ¦ODAC Tentative Agenda ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0140¦1/31/ ¦ODAC Questions to the Committee ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0141¦1/31/ ¦ODAC Member List ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX- ¦1/31/ ¦ODAC Other Voting Participant List: Remote locations, ¦ ¦ ¦2002 ¦Consultant, Guest Speakers, Patient Rep ¦ ¦0142 ¦ ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0143¦1/31/ ¦ODAC Briefing Information Document Index ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0144¦1/31/ ¦FDA Clinical Briefing Document for ODAC ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0145¦1/31/ ¦ODAC Meeting Transcript ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0146¦1/31/ ¦ODAC Draft Minutes ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0147¦2/14/ ¦FDA Medical Officer Review of a NDA 21-386 ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0148¦2/22/ ¦Pazdur letter to Rinaldi ¦ ¦ ¦2002 ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Investigators Brochure -Edition 8, replacing Edition 7 ¦ ¦ ¦ ¦-Zoledronate -Zometa ¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/28/ ¦(Zoldedronic acid) (aka zoledronate, ¦ ¦0149 ¦2002 ¦ ¦ ¦ ¦ ¦CGP 42446, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ZOL446) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+---------+-----------------------------------------------------¦ ¦DX-0150¦3/1/2002 ¦Zometa Trial Summary ¦ +-------+---------+-----------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/20/2002¦20-NOV-2001 to ¦ ¦0151 ¦ ¦ ¦ ¦ ¦ ¦19-FEB-2002 ¦ +-------+---------+-----------------------------------------------------¦ ¦ ¦ ¦13-week intravenous infusion (once tri-weekly dosing)¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦toxicity study in dogs. Study ¦ ¦DX- ¦ ¦ ¦ ¦ ¦4/4/2002 ¦No. ¦ ¦0152 ¦ ¦ ¦ ¦ ¦ ¦0170102. Final. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦(from PREDI database) ¦ +-------+---------+-----------------------------------------------------¦ ¦DX-0153¦5/17/2002¦Clinical Study Protocol ZOL3446E US32 ¦ +-------+---------+-----------------------------------------------------¦ ¦DX-0154¦5/17/2002¦Clinical Study Protocol ZOL3446E US32 Am. 1 ¦ +-------+---------+-----------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/17/2002¦20 Feb 2002 to ¦ ¦0155 ¦ ¦ ¦ ¦ ¦ ¦19 May 2002 ¦ +-------+---------+-----------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/19/2002¦22-Feb-2002 to ¦ ¦0156 ¦ ¦ ¦ ¦ ¦ ¦21-May-2002 ¦ +-------+---------+-----------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/19/2002¦20 Feb 2002 to ¦ ¦0157 ¦ ¦ ¦ ¦ ¦ ¦19 May 2002 ¦ +-----------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+----------+----------------------------------------------------------¦ ¦ ¦ ¦ZOL446: 6-month intravenous infusion (once triweekly ¦ ¦ ¦ ¦dosing) ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦toxicity study in dogs with a 3-week recovery. Covance ¦ ¦DX- ¦ ¦Study ¦ ¦ ¦6/28/2002 ¦ ¦ ¦0158 ¦ ¦No. 6135-206. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Sponsor Reference No. ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦018037. Final (from PREDI database) ¦ +-------+----------+----------------------------------------------------------¦ ¦DX-0159¦7/2/2002 ¦Tarassoff email to Green ¦ +-------+----------+----------------------------------------------------------¦ ¦DX-0160¦7/3/2002 ¦Tarassoff EMail to Weiss ¦ +-------+----------+----------------------------------------------------------¦ ¦DX-0161¦7/8/2002 ¦Weiss letter to Ruggiero ¦ +-------+----------+----------------------------------------------------------¦ ¦DX-0162¦7/16/2002 ¦Green E-mail to Ruggiero ¦ +-------+----------+----------------------------------------------------------¦ ¦DX-0163¦8/1/2002 ¦ARGUS Case # PHEH2002US07199 ¦ +-------+----------+----------------------------------------------------------¦ ¦DX-0164¦8/27/2002 ¦Clinical Study Protocol ZOL3446E US32 (Abbrev.) Am. 1 ¦ +-------+----------+----------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦9/1/2002 ¦22 May 2002 to ¦ ¦0165 ¦ ¦ ¦ ¦ ¦ ¦21 Aug 2 0 02 ¦ +-------+----------+----------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦9/17/2002 ¦20 May 2002 to ¦ ¦0166 ¦ ¦ ¦ ¦ ¦ ¦19 Aug 2002 ¦ +-------+----------+----------------------------------------------------------¦ ¦DX-0167¦10/16/2002¦Zometa Integrated Summary of Safety ¦ +-----------------------------------------------------------------------------+

+---------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦DSMB Closed Session Minutes DSMB ¦ ¦ ¦11/20/2002¦ ¦ ¦0168 ¦ ¦Teleconference 20 November 2002 ¦ +-------+----------+--------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/1/2002 ¦22 Aug 2002 to ¦ ¦0169 ¦ ¦ ¦ ¦ ¦ ¦21 Nov 2002 ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/6/2002 ¦Weiss E-mail to Abam ¦ ¦0170 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦DCT Adverse Event Summary Form (Dec. 6, ¦ ¦ ¦12/6/2002 ¦ ¦ ¦0171 ¦ ¦2002) ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/9/2002 ¦Abam Ltr. to Migliorati ¦ ¦0172 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/12/2002¦MedWatch Report ¦ ¦0173 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/16/2002¦Migliorati Letter to Abam ¦ ¦0174 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/17/2002¦20 Aug 2002 to ¦ ¦0175 ¦ ¦ ¦ ¦ ¦ ¦19 Nov 2002 ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/18/2002¦CZOL46/0704 ¦ ¦0176 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/20/2002¦31-OCT-2001 to ¦ ¦0177 ¦ ¦ ¦ ¦ ¦ ¦30-OCT-2002 ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/10/2003 ¦Petrone E-mail to Tarassoff (Jan. 10, 2003) ¦ ¦0178 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/13/2003 ¦Weiss eml to Petrone ¦ ¦0179 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/13/2003 ¦Abam Ltr. to Ruggiero ¦ ¦0180 ¦ ¦ ¦ +-------+----------+--------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/13/2003 ¦Weiss e-mail to Maladorno ¦ ¦0181 ¦ ¦ ¦ +---------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/14/2003¦Abam E-mail to Renner ¦ ¦0182 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/15/2003¦Abam eml to Brown ¦ ¦0183 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/16/2003¦CS&E DCT Adverse Event Summary ¦ ¦0184 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/22/2003¦MedWatch Report ¦ ¦0185 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/30/2003¦Abam eml to Ross ¦ ¦0186 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/4/2003 ¦Abam eml to Ruggiero ¦ ¦0187 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/6/2003 ¦Abam eml to Renner ¦ ¦0188 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/10/2003¦Sablinska eml to Maladorno ¦ ¦0189 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/12/2003¦Abam eml to Ruggiero ¦ ¦0190 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/12/2003¦Abam eml to Ruggiero ¦ ¦0191 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦ ¦ ¦Annual Report covering period August 20, 2001 through ¦ ¦DX- ¦ ¦August ¦ ¦ ¦2/20/2003¦ ¦ ¦0192 ¦ ¦19, 2002. NDA No. 21-223 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Zometa ¦ +-------+---------+-----------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the period ¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/1/2003 ¦20 Nov 2002 to ¦ ¦0193 ¦ ¦ ¦ ¦ ¦ ¦19 Feb 2003 ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/6/2003 ¦Abam eml to Ruggiero ¦ ¦0194 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/14/2003¦Ruggiero E-Mail to Abam ¦ ¦0195 ¦ ¦ ¦ +-------+---------+-----------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/17/2003¦Maladorno Email to Mellor ¦ ¦0196 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0197¦3/19/ ¦Miranda eml to Konecne ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0198¦3/19/ ¦Abam E-mail to Ruggiero ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0199¦3/21/ ¦Zometa Safety Periodic Report ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦3/25/ ¦ ¦ ¦ ¦2003 ¦Fratarcangeli eml to Hei ¦ ¦0200 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦3/27/ ¦ ¦ ¦ ¦2003 ¦Maladorno Email to Renner, et al ¦ ¦0201 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦4/2/2003¦Ruggiero E-Mail to Abam ¦ ¦0202 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦4/3/2003¦Abam eml to Ruggiero ¦ ¦0203 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦4/8/2003¦Labeling History NDA 21-386/S-001 ¦ ¦0204 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦DSMB Closed Session Minutes and Action Items DSMB ¦ ¦DX- ¦4/28/ ¦ ¦ ¦ ¦2003 ¦Meeting 28 ¦ ¦0205 ¦ ¦ ¦ ¦ ¦ ¦April 2003 ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦4/30/ ¦ ¦ ¦ ¦2003 ¦Maladorno email to Renner ¦ ¦0206 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦5/1/2003¦Abam E-mail to Maladorno ¦ ¦0207 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦5/5/2003¦E-mail string re: ON Follow-Up ¦ ¦0208 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦5/8/2003¦Maladorno eml to Csernak-Renner ¦ ¦0209 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦5/14/ ¦ ¦ ¦ ¦2003 ¦Abam eml to Ruggiero ¦ ¦0210 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦5/15/ ¦ ¦ ¦ ¦2003 ¦Abam eml to Curtis ¦ ¦0211 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦5/16/ ¦Letter from FDA to Hoffmann-La Roche Inc. Attn. Mark Hope ¦ ¦ ¦2003 ¦NDA 21-455 ¦ ¦0212 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0213¦5/20/ ¦Abam eml to Maladorno ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0214¦5/20/ ¦Abam eml to Ruggiero ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦5/20/ ¦ ¦ ¦ ¦2003 ¦Ruggiero E-Mail to Abam ¦ ¦0215 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦5/20/ ¦ ¦ ¦ ¦2003 ¦Abam E-mail to Ruggiero ¦ ¦0216 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/1/ ¦Zometa Periodic Safety Report for the Period 20 Feb 2003 ¦ ¦ ¦2003 ¦through 19 May 2003 ¦ ¦0217 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the Period ¦ ¦DX- ¦6/1/ ¦ ¦ ¦ ¦2003 ¦22 Feb 2003 - ¦ ¦0218 ¦ ¦ ¦ ¦ ¦ ¦21 May 2003 ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/3/ ¦ ¦ ¦ ¦2003 ¦Abam E-mail to Maladorno ¦ ¦0219 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/3/ ¦ ¦ ¦ ¦2003 ¦Abam E-mail to Marx ¦ ¦0220 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/4/ ¦ ¦ ¦ ¦2003 ¦Maladorno Email to Fratarcangeli ¦ ¦0221 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/6/ ¦ ¦ ¦ ¦2003 ¦Marx, et al. EMail to Abam ¦ ¦0222 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/6/ ¦ ¦ ¦ ¦2003 ¦Ruiz E-mail to Hei ¦ ¦0223 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/6/ ¦ ¦ ¦ ¦2003 ¦Ruiz to Abam ¦ ¦0224 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/6/ ¦ ¦ ¦ ¦2003 ¦Hei E-mail to Fratarcangeli, et al ¦ ¦0225 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/9/ ¦ ¦ ¦ ¦2003 ¦Ruiz E-mail to Hei ¦ ¦0226 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/9/ ¦ ¦ ¦ ¦2003 ¦Spaet E-Mail to Hei ¦ ¦0227 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/9/ ¦ ¦ ¦ ¦2003 ¦Tarassoff Email to Ruiz ¦ ¦0228 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/10/2003¦Tarassoff Email to Hei ¦ ¦0229 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/10/2003¦Tarassoff Email to Ruiz ¦ ¦0230 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/11/2003¦Tarassoff Email to Ruiz ¦ ¦0231 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦6/11/03 Konecne e-mail re Zometa ¦ ¦ ¦6/11/2003¦ ¦ ¦0232 ¦ ¦teleconference ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/13/2003¦6/13/03 Memo re Action Plan ¦ ¦0233 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/18/2003¦Ruggiero eml to Tarrassoff ¦ ¦0234 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/18/2003¦Maladorno memo. Re discussion with Bouquot¦ ¦0235 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/20/2003¦Summary points from meeting with Ruggiero ¦ ¦0236 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦O'Meyer to Abam, ¦ ¦ ¦6/20/2003¦ ¦ ¦0237 ¦ ¦Maladorno, Renner et al ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/20/2003¦Goessl to Hei ¦ ¦0238 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/23/2003¦IPT Minutes, 6/23/03 ¦ ¦0239 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/23/2003¦Ruiz e-mail to Tarassoff ¦ ¦0240 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/24/2003¦Abam e-mail to Marx ¦ ¦0241 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦6/26/2003¦Hei E-mail to Keller, et al ¦ ¦0242 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/1/2003 ¦Osteonecrosis Action Plan dated 7/1/03 ¦ ¦0243 ¦ ¦ ¦ +-------+---------+------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/3/2003 ¦Machalaba Email to Fratarcangeli, et al ¦ ¦0244 ¦ ¦ ¦ +------------------------------------------------------------+

+------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/8/2003 ¦NPC Kickoff Meeting: Emergency Management Team Minutes¦ ¦0245 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/10/2003¦Renner E-mail to Dunsire, et al. ¦ ¦0246 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/11/2003¦Novartis Emergency Management Team Minutes ¦ ¦0247 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/14/2003¦Novartis Emergency Management Team Minutes ¦ ¦0248 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/15/2003¦Tarassoff email to Ruiz ¦ ¦0249 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/16/2003¦Novartis Emergency Management Team Minutes ¦ ¦0250 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦ ¦ ¦Sablinska ¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/18/2003¦epidemiological ¦ ¦0251 ¦ ¦ ¦ ¦ ¦ ¦report ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/18/2003¦E-mail string re: Team Meeting Minutes ¦ ¦0252 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦Aredia Clinical Expert Statement: Osteonecrosis of the¦ ¦ ¦7/18/2003¦ ¦ ¦0253 ¦ ¦Maxillofacial Area ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/18/2003¦Letter to Pazdur from Koneckne ¦ ¦0254 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/21/2003¦Tarassoff Ltr. to Marx ¦ ¦0255 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/22/2003¦Tarassoff Email to Maria Ruiz and Dr. Marx ¦ ¦0256 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/22/2003¦Novartis Emergency Management Team Minutes ¦ ¦0257 ¦ ¦ ¦ +-------+---------+------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦7/23/2003¦Maladorno Email to Close ¦ ¦0258 ¦ ¦ ¦ +------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0259¦7/24/ ¦Novartis Emergency Management Team Minutes ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0260¦7/25/ ¦Maladorno Email to Abam ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0261¦7/29/ ¦E-mail string re: case report on Aredia in July 31 issue of ¦ ¦ ¦2003 ¦NEJM ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦7/29/ ¦ ¦ ¦ ¦2003 ¦Novartis Emergency Management Team Minutes ¦ ¦0262 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦7/31/ ¦ ¦ ¦ ¦2003 ¦Novartis Emergency Management Team Minutes ¦ ¦0263 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦8/4/ ¦ ¦ ¦ ¦2003 ¦Ruiz e-mail to Tarassoff ¦ ¦0264 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦8/4/ ¦ ¦ ¦ ¦2003 ¦Williams E-mail to Dr. Marx ¦ ¦0265 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦8/7/ ¦ ¦ ¦ ¦2003 ¦Novartis Emergency Management Team Minutes ¦ ¦0266 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦8/14/ ¦ ¦ ¦ ¦2003 ¦Novartis Emergency Management Team Minutes ¦ ¦0267 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦8/18/ ¦ ¦ ¦ ¦2003 ¦Goldfarb letter to Marx ¦ ¦0268 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦8/18/ ¦ ¦ ¦ ¦2003 ¦Pazdur letter to Sterner ¦ ¦0269 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦8/21/ ¦ ¦ ¦ ¦2003 ¦Novartis Emergency Management Team Minutes ¦ ¦0270 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the Period ¦ ¦DX- ¦9/1/ ¦ ¦ ¦ ¦2003 ¦20 May 2003 - ¦ ¦0271 ¦ ¦ ¦ ¦ ¦ ¦19 Aug 2003 ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦9/1/ ¦Zometa Periodic Safety Report for the Period 22 May 2003 ¦ ¦ ¦2003 ¦through 21 Aug 2003 ¦ ¦0272 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0273¦9/2/2003¦9/2/03 Dunsire e-mail with Marx Medical Alert ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0274¦9/12/ ¦Maxillary Osteonecrosis: Summary of Related Literature ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0275¦9/15/ ¦NEM Meeting Minutes ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the Period ¦ ¦DX- ¦9/17/ ¦ ¦ ¦ ¦2003 ¦20 May 2003 - ¦ ¦0276 ¦ ¦ ¦ ¦ ¦ ¦19 Aug 2003 ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦ARGUS ID: ¦ ¦ ¦ ¦ ¦ ¦DX- ¦9/19/ ¦PHEH2006US11546 ¦ ¦ ¦2003 ¦ ¦ ¦0277 ¦ ¦, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Bisphosphonate & Osteonecrosis of the Jaw, Version 4 ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0278¦9/23/ ¦NPC ON Site Report ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦Special ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Supplment CBE-0 and Application dated Sept. 23, 2003 re: ¦ ¦DX- ¦ ¦Zometa with ¦ ¦ ¦9/23/ ¦ ¦ ¦0279 ¦2003 ¦attachments, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ZSupp 1 - 49 ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦and ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0280¦9/26/ ¦Havrilla E-mail to Williams, et al ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0281¦9/26/ ¦NDA Labeling Supplement ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0282¦9/26/ ¦Sterner Letter to Orloff ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0283¦9/30/ ¦Williams E-Mail to Abam ¦ ¦ ¦2003 ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0284¦10/1/ ¦Novartis Emergency Management Team Minutes ¦ ¦ ¦2003 ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦ ¦E-mail from Steven Williams to Robert Marx re: ¦ ¦ ¦10/2/03¦ ¦ ¦0285 ¦ ¦Osteonecrosis cases ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0286¦10/2/ ¦Williams e-mail to Marx ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0287¦10/8/ ¦Goessl eml to Maladorno ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0288¦10/10/ ¦Maladorno Email to Goessl, et al ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0289¦10/10/ ¦Novartis Emergency Management Team Minutes ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦10/17/ ¦Aredia Clinical Expert Statement: Osteonecrosis of the ¦ ¦ ¦2003 ¦ ¦ ¦0290 ¦ ¦Maxillofacial Area- September 2003 Overview ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0291¦10/27/ ¦Hedin Ltr. to Sterner, Aredia ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0292¦10/27/ ¦Hedin Ltr. to Sterner, Zometa ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Email from Stefano Fratarcangeli to Margaret Linguri Dean and¦ ¦DX- ¦ ¦Peter Tarassoff re: ¦ ¦ ¦11/4/ ¦ ¦ ¦0293 ¦2003 ¦FDA ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Acknowledgement ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0294¦11/6/ ¦Novartis Emergency Management Team Minutes ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0295¦11/11/ ¦E-mail from Deborah Dunsire re: Zometa NEM Update ¦ ¦ ¦2003 ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦11/13/ ¦ ¦ ¦ ¦2003 ¦Novartis Emergency Management Team Minutes ¦ ¦0296 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦11/14/ ¦E-mail from Robert Miranda to Geoffrey Cook re Action List ¦ ¦ ¦2003 ¦from NEM Meeting 11/14/03 ¦ ¦0297 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦11/18/ ¦Email from Margaret Linguri re: Osteonecrosis letter to ¦ ¦ ¦2003 ¦Editor JCO with attachments ¦ ¦0298 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦11/21/ ¦Chang to Pazdur re: ¦ ¦DX-0299¦2003 ¦ ¦ ¦ ¦ ¦Osteonecrosis ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦11/24/ ¦E-mail from Robert Miranda to Carsten Goessl re Zometa New PI¦ ¦ ¦2003 ¦available (re: osteonecrosis) ¦ ¦0300 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the Period ¦ ¦DX- ¦12/1/ ¦ ¦ ¦ ¦2003 ¦(20 Aug 2003 - ¦ ¦0301 ¦ ¦ ¦ ¦ ¦ ¦19 Nov 2003) ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the Period ¦ ¦DX- ¦12/1/ ¦ ¦ ¦ ¦2003 ¦(20 Aug 2003 - ¦ ¦0302 ¦ ¦ ¦ ¦ ¦ ¦19 Nov 2003) ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0303¦12/5/ ¦NPC Ad. Bd. Exec. Summary ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0304¦12/5/ ¦Osteonecrosis Advisory Board Dec. 5, 2003 Agenda ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0305¦12/5/ ¦Novartis Advisory Board Slide Deck ¦ ¦ ¦2003 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦12/8/ ¦E-mail string re: Update on Zometa ¦ ¦ ¦2003 ¦ ¦ ¦0306 ¦ ¦Osteonecrosis Advisory Board ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦12/10/ ¦ ¦ ¦ ¦2003 ¦Abam E-mail to Tarassoff ¦ ¦0307 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦12/10/ ¦ ¦ ¦ ¦2003 ¦Tarassoff Email to Abam ¦ ¦0308 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦ ¦ ¦DSMB Closed Session Minutes and Action Items DSMB ¦ ¦DX- ¦12/11/ ¦ ¦ ¦ ¦2003 ¦Meeting 11-12 ¦ ¦0309 ¦ ¦ ¦ ¦ ¦ ¦December 2003 ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦12/16/ ¦ ¦ ¦ ¦2003 ¦E-mail from Katarzyna Sablinska with attachment ¦ ¦0310 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦12/18/ ¦Zometa Periodic Safety Report for the Period (20 Aug 2003 ¦ ¦ ¦2003 ¦-19 Nov 2003) ¦ ¦0311 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦12/19/ ¦ ¦ ¦ ¦2003 ¦Aredia Clinical Expert Statement, 10/03 Overview, ¦ ¦0312 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦12/23/ ¦ ¦ ¦ ¦2003 ¦Abam E-mail to Tarassoff ¦ ¦0313 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦12/23/ ¦ ¦ ¦ ¦2003 ¦31-OCT-2002 to ¦ ¦0314 ¦ ¦ ¦ ¦ ¦ ¦30-OCT-2003 ¦ +------+---------+------------------------------------------------------------¦ ¦ ¦ ¦Aredia Periodic Safety Report for the period ¦ ¦DX- ¦12/23/ ¦ ¦ ¦ ¦2003 ¦31-OCT-2002 to ¦ ¦0315 ¦ ¦ ¦ ¦ ¦ ¦30-OCT-2003 ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/6/2004 ¦Fratarcangeli E-mail to Goessl ¦ ¦0316 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/16/2004¦Cook E-Mail to Goessl, et al. ¦ ¦0317 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦1/29/2004¦Sablinska Email to Maladorno ¦ ¦0318 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/13/2004¦Novartis Advisory Board ¦ ¦0319 ¦ ¦ ¦ +------+---------+------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/20/2004¦Miranda E-mail to Narang ¦ ¦0320 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦ ¦E-mail ¦ ¦ ¦2/20/ ¦ ¦ ¦0321¦2004 ¦correspondence between Miranda and Petraglia re: changes to the ¦ ¦ ¦ ¦Zometa PI received from Dotti Pease of FDA ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/23/ ¦ ¦ ¦ ¦2004 ¦Miranda E-mail to Sterner ¦ ¦0322¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/24/ ¦ ¦ ¦ ¦2004 ¦Miranda e-mail to Pease ¦ ¦0323¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/24/ ¦ ¦ ¦ ¦2004 ¦Miranda e-mail to Pease ¦ ¦0324¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Pease E-mail to Miranda, et al ¦ ¦0325¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Miranda to Pease ¦ ¦0326¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Miranda E-Mail to Pease ¦ ¦0327¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Miranda E-Mail to Maladorno ¦ ¦0328¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Maladorno to Miranda ¦ ¦0329¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Miranda to Dunsire ¦ ¦0330¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Pease E-mail to Miranda, et al ¦ ¦0331¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/25/ ¦ ¦ ¦ ¦2004 ¦Miranda to Pease ¦ ¦0332¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/26/ ¦ ¦ ¦ ¦2004 ¦Miranda e-mail to Pease ¦ ¦0333¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/26/ ¦ ¦ ¦ ¦2004 ¦Miranda e-mail, forwarding Pease to Petraglia ¦ ¦0334¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/26/ ¦ ¦ ¦ ¦2004 ¦Miranda e-mail to Pease ¦ ¦0335¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0336¦2/26/ ¦Miranda e-mail to Pease ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0337¦2/26/ ¦Miranda e-mail to Pease ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0338¦2/26/ ¦Miranda e-mail to Dunsire et al ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Zometa ¦ ¦DX- ¦ ¦ ¦ ¦ ¦2/26/ ¦Zoledronic Acid Injection Concentrate for Intravenous ¦ ¦0339 ¦2004 ¦Infusion Rx Only ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Prescribing Information ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0340¦2/27/ ¦Miranda e-mail to Narang ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0341¦2/27/ ¦Pease e-mail to Miranda ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦2/27/ ¦ ¦ ¦ ¦2004 ¦Pazdur letter to Miranda: Revised labeling approval ¦ ¦0342 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0343¦3/1/ ¦Zometa Package Insert. T2004-27 ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦3/1/ ¦Zometa Periodic Safety Report for the Period 20 Nov 2003 ¦ ¦ ¦2004 ¦through 19 Feb 2004 ¦ ¦0344 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0345¦3/19/ ¦Marx fax to Tarassoff ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0346¦3/19/ ¦Abam letter to Marx ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Zometa Periodic Safety Report for the Period 20 Nov 2003 ¦ ¦DX- ¦3/19/ ¦ ¦ ¦ ¦2004 ¦through 19 Feb ¦ ¦0347 ¦ ¦ ¦ ¦ ¦ ¦2004 ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0348¦3/23/ ¦3/23/04 Dunsire e-mail forwarding MDACC info ¦ ¦ ¦2004 ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0349¦3/24/ ¦Supplement Approved ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0350¦3/24/ ¦Letter from FDA to Sterner re: Aredia label ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0351¦3/29/ ¦Novartis Advisory Board Meeting -Advisors ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0352¦3/29/ ¦Novartis Advisory Board Meeting Slides ¦ ¦ ¦2004 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Investigators Brochure -Edition 9, replacing Edition 8 ¦ ¦ ¦ ¦-Zoledronate -Zometa ¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/29/ ¦(Zoldedronic acid) (aka zoledronate, ¦ ¦0353 ¦2004 ¦ ¦ ¦ ¦ ¦CGP 42446, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ZOL446) ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Investigators Brochure -Edition 9, replacing Edition 8 ¦ ¦ ¦ ¦-Zoledronate -Zometa ¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/29/ ¦(Zoldedronic acid) (aka zoledronate, ¦ ¦0354 ¦2004 ¦ ¦ ¦ ¦ ¦CGP 42446, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦ZOL446) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Clinical Study Report. Stufy ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦NO. ¦ ¦ ¦ ¦ ¦ ¦DX- ¦4/15¦IT01[ZOL446EIT0 1]. Title: An ¦ ¦ ¦/ ¦ ¦ ¦0355 ¦2004¦open-label clinical study to evaluate the efficacy and ¦ ¦ ¦ ¦tolerability on intravenous Zometa® (zoledronic add) 4 mg in ¦ ¦ ¦ ¦metastatic breat cancer patients in whom treatment with a ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦bisphosphonate is indicated. Development phase: IIIb ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦4/30¦ ¦ ¦DX-0356¦/ ¦Abam fax to Marx ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0357¦5/1/¦Ruggiero E-Mail to Abam ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0358¦5/5/¦Novartis Emergency Management Team Minutes ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0359¦5/6/¦Chang 'ODS Postmarketing Safety Review' to Pazdur ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦5/11¦ ¦ ¦DX-0360¦/ ¦Staten to Petraglia NPC re FDA meeting ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦5/16¦ ¦ ¦DX-0361¦/ ¦Linguri E-mail to Stone, et al ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦5/17¦ ¦ ¦DX-0362¦/ ¦Goessl E-mail to Zheng ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦5/21¦ ¦ ¦DX-0363¦/ ¦Urbanowitz Email to Goessl ¦ ¦ ¦2004¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦5/24¦Cancer Care Patient ¦ ¦DX-0364¦/ ¦ ¦ ¦ ¦2004¦Advocacy Summit - Attendance List ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦5/25/ ¦ ¦ ¦ ¦2004 ¦Staten fax to Petraglia ¦ ¦0365¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦5/26/ ¦ ¦ ¦ ¦2004 ¦Novartis Emergency Management Team Minutes ¦ ¦0366¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦6/1/ ¦Expert Panel Recommendations for the Prevention, Diagnosis, and ¦ ¦ ¦2004 ¦Treatment of Osteonecrosis of the Jaws ¦ ¦0367¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦6/1/ ¦Zometa Periodic Safety Report for the Period 20 Feb 2004 through ¦ ¦ ¦2004 ¦19 May 2004 ¦ ¦0368¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦6/21/ ¦ ¦ ¦ ¦2004 ¦Briefing Package: Safety Update ¦ ¦0369¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦1/21/ ¦Dougherty Email ¦ ¦ ¦2005 ¦ ¦ ¦0370¦ ¦to Hei ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦1/24/ ¦Letter from FDA to Merck & Co., Inc., Attn: Michele Flicker NDA ¦ ¦ ¦2005 ¦21-575 ¦ ¦0371¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦1/26/ ¦ ¦ ¦ ¦2005 ¦Petraglia EMail to FDA ¦ ¦0372¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦1/28/ ¦ ¦ ¦ ¦2005 ¦Dougherty Email to Hei ¦ ¦0373¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/10/ ¦ ¦ ¦ ¦2005 ¦Dougherty Email to Zheng ¦ ¦0374¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/15/ ¦Hei Email to ¦ ¦ ¦2005 ¦ ¦ ¦0375¦ ¦Young ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/22/ ¦ ¦ ¦ ¦2005 ¦Hei Email to Dougherty ¦ ¦0376¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/24/ ¦ ¦ ¦ ¦2005 ¦Hei Email to Macerata ¦ ¦0377¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦2/24/ ¦ ¦ ¦ ¦2005 ¦Hei Email to Dougherty ¦ ¦0378¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0379¦3/1/¦Macerata Email to Lantwicki ¦ ¦ ¦2005¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0380¦3/2/¦Petraglia EMail to Clifford ¦ ¦ ¦2005¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦www.fda.gov/ohr ¦ ¦ ¦3/4/¦ ¦ ¦0381 ¦2005¦ms/dockets/ac/0 5/transcripts/2 005-4095T2.htm, ODAC Transcript ¦ ¦ ¦ ¦Volume 2 ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦3/4/¦Core ¦ ¦DX-0382¦2005¦ ¦ ¦ ¦ ¦Presentation -Zometa ODAC ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0383¦3/4/¦ODAC complete package ¦ ¦ ¦2005¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0384¦3/4/¦ODAC Slide Deck ¦ ¦ ¦2005¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Food and Drug Administration. Questions to the Committee, ¦ ¦ ¦ ¦Oncologic Drug Advisory Committee 2005 Mar. 5. available at ¦ ¦ ¦ ¦http://www.fda. gov/ohrms/docke ts/AC/05/questi ¦ ¦ ¦ ¦ ¦ ¦DX- ¦3/5/¦ons/2005- ¦ ¦ ¦2005¦ ¦ ¦0385 ¦ ¦4095Q2 02 Zomet ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦a-Aredia- ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Questions.pdf ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦An Open-label, Randomized, Multicenter Study to Evaluate the ¦ ¦ ¦ ¦Use of ¦ ¦ ¦ ¦ ¦ ¦DX- ¦11/22/ ¦Zoledronic Acid in the ¦ ¦ ¦2006 ¦ ¦ ¦0386 ¦ ¦Prevention of Cancer Treatment-Related Bone Loss in ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Postmenopausalk Women with ER+ and/or PR+ Breast Cancer ¦ ¦ ¦ ¦Receiving Letrozole as Adjuvant Therapy ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦12/1/ ¦Guidline for Industry FDA Approval of New Cancer ¦ ¦ ¦998 ¦ ¦ ¦0387 ¦ ¦Treatment Uses for Marketed Drug and biological Products ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0388¦ ¦Clinical trial record (Patient Number 006-102) ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0389¦ ¦Clinical trial record (Patient Number 22640.11160) ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0390¦ ¦Clinical trial record (Patient Number 2346-20593) ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0391¦ ¦Clinical trial record (Patient Number 609-2023) ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0392¦ ¦Clinical trial record (Patient Number 627-2382) ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0393¦ ¦Clinical trial record (Patient Number 1694E-1303) ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0394¦ ¦Clinical trial record (Patient Number 521-002) ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0395¦ ¦ARGUS Case # PHEH2002US07199 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0396¦ ¦CZOL446EUS32 ID 0026-00007 ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Ruggiero ¦ ¦ ¦ ¦ ¦ ¦DX-0397¦ ¦Medical ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Advisory ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0398¦ ¦Protocol 010 Slide Deck, ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0399¦ ¦Adverse Event Report Form ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0400¦ ¦Summary of Preclinical Oral Safety Studies, draft ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0401¦ ¦Integrated Safety Systems Proposal of Services ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0402¦ ¦CZOL446E U532 App. 6 ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Draft ¦ ¦DX-0403¦ ¦ ¦ ¦ ¦ ¦Osteonecrosis Study ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Patient ¦ ¦ ¦ ¦ ¦ ¦DX-0404¦ ¦information ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦form ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0405¦ ¦Appendix 7 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Compilation of Aredia Clinical Trials ¦ ¦ ¦ ¦ ¦ ¦0406 ¦ ¦submitted in support of labeling instructions ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Compilation of NPC sponsored medical affairs post-marketing ¦ ¦ ¦ ¦trials in the US ¦ ¦0407 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Compilation of Zometa Clinical Trials ¦ ¦ ¦ ¦ ¦ ¦0408 ¦ ¦submitted in support of labeling instructions ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦American Board of Oral and Maxillofacial Pathology Bylaws, ¦ ¦ ¦ ¦Article XIV - ¦ ¦ ¦ ¦ ¦ ¦DX- ¦ ¦Examinations. ¦ ¦ ¦ ¦ ¦ ¦0409 ¦ ¦http://www.abom ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦p.org/aboutus.h ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦tm#exams2 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦Roff Memo to Spaet re Osteonecrosis resulting from the use of ¦ ¦ ¦ ¦bisphosphonates in animals ¦ ¦0410 ¦ ¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0411¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0412¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0413¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0414¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0415¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0416¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0417¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0418¦ ¦Regulatory Correspondence ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦Email ¦ ¦DX-0419¦ ¦ ¦ ¦ ¦ ¦correspondences to Dr. Marx (various dates) ¦ +-----------------------------------------------------------------------------+

+---------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+----------+--------------------------¦ ¦DX-0420¦ ¦Regulatory Correspondence ¦ +-------+----------+--------------------------¦ ¦DX-0421¦ ¦Regulatory Correspondence ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦May 1993 ¦Aredia Drug Package Insert¦ ¦0422 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Jun. 1994 ¦Aredia Drug Package Insert¦ ¦0423 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Oct. 1994 ¦Aredia Drug Package Insert¦ ¦0424 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Oct. 1995 ¦Aredia Drug Package Insert¦ ¦0425 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Oct. 1996 ¦Aredia Drug Package Insert¦ ¦0426 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Jul. 1998 ¦Aredia Drug Package Insert¦ ¦0427 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Dec. 1998 ¦Aredia Drug Package Insert¦ ¦0428 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Jul. 1999 ¦Aredia Drug Package Insert¦ ¦0429 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Sept. 2001¦Aredia Drug Package Insert¦ ¦0430 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Jul. 2002 ¦Aredia Drug Package Insert¦ ¦0431 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Jul. 2003 ¦Aredia Drug Package Insert¦ ¦0432 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Nov. 2003 ¦Aredia Drug Package Insert¦ ¦0433 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Oct. 2004 ¦Aredia Drug Package Insert¦ ¦0434 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Apt. 2005 ¦Aredia Drug Package Insert¦ ¦0435 ¦ ¦ ¦ +-------+----------+--------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Mar. 2006 ¦Aredia Drug Package Insert¦ ¦0436 ¦ ¦ ¦ +---------------------------------------------+

+----------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Mar. 2002 ¦Zometa Drug Package Insert ¦ ¦0437 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Mar. 2003 ¦Zometa Drug Package Insert ¦ ¦0438 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Nov. 2003 ¦Zometa Drug Package Insert ¦ ¦0439 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Apr. 2004 ¦Zometa Drug Package Insert ¦ ¦0440 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Oct. 2004 ¦Zometa Drug Package Insert ¦ ¦0441 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Dec. 2004 ¦Zometa Drug Package Insert ¦ ¦0442 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦May 2005 ¦Zometa Drug Package Insert ¦ ¦0443 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Jan. 2 006¦Zometa Drug Package Insert ¦ ¦0444 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2002 ¦Carboplatin Drug Package Inserts ¦ ¦0445 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Current ¦Carboplatin Drug Package Inserts ¦ ¦0446 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2002 ¦CPT-11 / Camptosar Drug Package Inserts ¦ ¦0447 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Current ¦CPT-11 / Camptosar Drug Package Inserts ¦ ¦0448 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2003 ¦Cisplatin Drug Package Inserts ¦ ¦0449 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦Current ¦Cisplatin Drug Package Insert ¦ ¦0450 ¦ ¦ ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦VP-16 / ¦ ¦ ¦2003 ¦ ¦ ¦0451 ¦ ¦Etoposide Drug Package Inserts ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦VP-16 / ¦ ¦ ¦Current ¦ ¦ ¦0452 ¦ ¦Etoposide Drug Package Insert ¦ +-------+----------+---------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦2005 ¦Strontium 89 / Metastron Drug Package Inserts¦ ¦0453 ¦ ¦ ¦ +----------------------------------------------------------------+

+--------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+------------+-----------------------------------------------------¦ ¦DX-0454¦Current ¦Strontium 89 / Metastron Drug Package Inserts ¦ +-------+------------+-----------------------------------------------------¦ ¦DX-0455¦Current ¦triamcinolone / Trivaris Drug Package Inserts ¦ +-------+------------+-----------------------------------------------------¦ ¦DX-0456¦2000-present¦Physicians' Desk Reference ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/2/2008 ¦Expert Report of Dr. Janet Arrowsmith ¦ ¦0457 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Current CV of Dr. Janet Arrowsmith ¦ ¦0458 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/3/2008 ¦Expert Report of Dr. Graham Russell ¦ ¦0459 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Current CV of Dr. Graham Russell ¦ ¦0460 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦12/3/2008 ¦Expert Report of Dr. Warren Browner ¦ ¦0461 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Current CV of Dr. Warren Browner ¦ ¦0462 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦All rebuttal reports of NPC's Experts ¦ ¦0463 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦All updates and supplements to NPC's Experts' Reports¦ ¦0464 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦ ¦ ¦Adverse Event ¦ ¦ ¦ ¦ ¦ ¦DX- ¦ ¦Reporting ¦ ¦ ¦ ¦ ¦ ¦0465 ¦ ¦System, ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦http://www.hous e.gove/stupak/a ccutane/p1 46.p df ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/15/2010 ¦PubMed search results of articles re bisphosphonates ¦ ¦0466 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦3/29/2006 ¦Complaint and Jury Demand in White v. NPC ¦ ¦0467 ¦ ¦ ¦ +-------+------------+-----------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦9/17/2006 ¦Plaintiff's Fact Sheet -William White ¦ ¦0468 ¦ ¦ ¦ +--------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦ ¦ ¦Estate of William Knox ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦White ¦ ¦DX- ¦5/16/ ¦ ¦ ¦ ¦2007 ¦Supplement to ¦ ¦0469¦ ¦ ¦ ¦ ¦ ¦Plaintiff's ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Fact Sheet by Cheryl White ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦12/7/ ¦Novartis Pharmaceuticals Corporation's First Set of MDL Requests ¦ ¦ ¦2007 ¦for the Production of Documents to Cheryl J. White ¦ ¦0470¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦12/7/ ¦Novartis Pharmaceuticals Corporation's First Set of MDL ¦ ¦ ¦2007 ¦ ¦ ¦0471¦ ¦Interrogatories to Cheryl J. White ¦ +----+------+-----------------------------------------------------------------¦ ¦ ¦ ¦Plaintiff's Response to NPC's First Set ¦ ¦DX- ¦1/30/ ¦ ¦ ¦ ¦2008 ¦of MDL ¦ ¦0472¦ ¦ ¦ ¦ ¦ ¦Interrogatories ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦1/30/ ¦Plaintiff's Response to NPC's First MDL Requests for Production ¦ ¦ ¦2008 ¦of Documents ¦ ¦0473¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦DX- ¦9/12/ ¦Plaintiff's Supplemental Response to NPC's MDL Interrogatory No. ¦ ¦ ¦2008 ¦4 ¦ ¦0474¦ ¦ ¦ +----+------+-----------------------------------------------------------------¦ ¦ ¦ ¦Plaintiff's Second ¦ ¦ ¦ ¦ ¦ ¦DX- ¦12/19/¦Supplemental Response to ¦ ¦ ¦2008 ¦ ¦ ¦0475¦ ¦NPC's MDL ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Interrogatory No. 4 ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0476¦5/4/ ¦Plaintiff's Supplemental Response to NPC's Request for ¦ ¦ ¦2009 ¦Production of Documents No. 5 ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦2/9/ ¦Plaintiff's Rule ¦ ¦DX-0477¦2009 ¦ ¦ ¦ ¦ ¦26(a)(2)(a) Statement ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0478¦ ¦Stedman's Medical Dictionary. 28th Ed. 2005 ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Depositions referenced in ¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦NPC's ¦ ¦0479 ¦ ¦ ¦ ¦ ¦ ¦deposition designations and exhibits thereto ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Deposition of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦James Vogel in In re Aredia & Zometa ¦ ¦DX- ¦4/2/ ¦ ¦ ¦ ¦2009 ¦Litigation and ¦ ¦0480 ¦ ¦ ¦ ¦ ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Deposition of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦James Vogel in In re Aredia & Zometa ¦ ¦DX- ¦1/7/ ¦ ¦ ¦ ¦2010 ¦Litigation and ¦ ¦0481 ¦ ¦ ¦ ¦ ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Deposition of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Talib Najjar in In re Aredia & Zometa ¦ ¦DX- ¦3/17/ ¦ ¦ ¦ ¦2009 ¦Litigation and ¦ ¦0482 ¦ ¦ ¦ ¦ ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Deposition of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Talib Najjar in In re Aredia & Zometa ¦ ¦DX- ¦3/18/ ¦ ¦ ¦ ¦2009 ¦Litigation and ¦ ¦0483 ¦ ¦ ¦ ¦ ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +------+-------+--------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Talib Najjar in In re Aredia & Zometa ¦ ¦ ¦ ¦ ¦ ¦DX- ¦3/19/ ¦Litigation and ¦ ¦ ¦2009 ¦ ¦ ¦0484 ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +------+-------+--------------------------------------------------------------¦ ¦DX- ¦2/12/ ¦Deposition of Michael Tanaka in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0485 ¦ ¦ ¦ +------+-------+--------------------------------------------------------------¦ ¦DX- ¦2/13/ ¦Deposition of Cheryl White in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0486 ¦ ¦ ¦ +------+-------+--------------------------------------------------------------¦ ¦DX- ¦2/13/ ¦Deposition of Richard Jackson in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0487 ¦ ¦ ¦ +------+-------+--------------------------------------------------------------¦ ¦DX- ¦6/3/ ¦Deposition of Guy Acheson in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0488 ¦ ¦ ¦ +------+-------+--------------------------------------------------------------¦ ¦DX- ¦6/3/ ¦Deposition of Jon Overholt in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0489 ¦ ¦ ¦ +------+-------+--------------------------------------------------------------¦ ¦DX- ¦7/18/ ¦Deposition of Angela Davies in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0490 ¦ ¦ ¦ +------+-------+--------------------------------------------------------------¦ ¦DX- ¦7/30/ ¦Deposition of Carol Richman in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0491 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦7/30/ ¦Deposition of Gordon Douglass in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0492 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦7/31/ ¦Deposition of John MacMillan in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0493 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦9/24/ ¦Deposition of Cheryl White in White v. NPC and all ¦ ¦ ¦2008 ¦accompanying exhibits ¦ ¦0494 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦4/22/ ¦Deposition of Richard Jackson in White v. NPC and all ¦ ¦ ¦2009 ¦accompanying exhibits ¦ ¦0495 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦4/19/ ¦Deposition of Robin Robillard in White v. NPC and all ¦ ¦ ¦2010 ¦accompanying exhibits ¦ ¦0496 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦4/20/ ¦Deposition of Catherine Alexis Friedman in White v. NPC and ¦ ¦ ¦2010 ¦all accompanying exhibits ¦ ¦0497 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦4/20/ ¦Deposition of Elliot White in White v.NPC and all ¦ ¦ ¦2010 ¦ ¦ ¦0498 ¦ ¦accompanying exhibits ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦6/2/ ¦Deposition of Jagdish Lallian in White v. NPC and all ¦ ¦ ¦2010 ¦accompanying exhibits ¦ ¦0499 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Keith Skubitz in In re Aredia & Zometa ¦ ¦ ¦ ¦Litigation and ¦ ¦DX-0500¦2/16/ ¦ ¦ ¦ ¦2009 ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Deposition of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Keith Skubitz ¦ ¦ ¦4/27/ ¦ ¦ ¦DX-0501¦2009 ¦in In re Aredia & Zometa Litigation and ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Deposition of ¦ ¦ ¦8/31/ ¦ ¦ ¦DX-0502¦2009 ¦Keith Skubitz ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦in Stevens v. NPC and all accompanying exhibits ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Deposition of ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Keith Skubitz ¦ ¦DX- ¦11/23/¦ ¦ ¦ ¦2009 ¦in In re Aredia & Zometa Litigation and ¦ ¦0503 ¦ ¦ ¦ ¦ ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+------+--------------------------------------------------------------¦ ¦DX- ¦5/15/ ¦Deposition of Robert Marx in In re Aredia and Zometa ¦ ¦ ¦2007 ¦Litigation, Vol I & II and all accompanying exhibits ¦ ¦0504 ¦ ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Robert Marx in In re Aredia & Zometa ¦ ¦ ¦ ¦ ¦ ¦DX- ¦5/18/ ¦Litigation, Vol ¦ ¦ ¦2007 ¦ ¦ ¦0505 ¦ ¦III & IV and all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Robert Marx in In re Aredia & Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Litigation, Vol ¦ ¦ ¦ ¦ ¦ ¦DX-0506¦3/5/2009¦V and all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦exhibits ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Robert Marx in In re Aredia & Zometa ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Litigation, Vol ¦ ¦DX-0507¦3/6/2009¦ ¦ ¦ ¦ ¦VI and all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Robert Marx in In re Aredia & Zometa ¦ ¦ ¦ ¦ ¦ ¦DX- ¦5/26/ ¦Litigation, Vol ¦ ¦ ¦2009 ¦ ¦ ¦0508 ¦ ¦VII and all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦7/23/ ¦Deposition of Robert Marx in Stevens v. NPC and all ¦ ¦ ¦2009 ¦accompanying exhibits ¦ ¦0509 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦10/14/ ¦Transcript of Trial Testimony of Robert Marx in Stevens v. ¦ ¦ ¦2009 ¦NPC ¦ ¦0510 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Robert Marx in In re Aredia & Zometa ¦ ¦ ¦ ¦ ¦ ¦DX- ¦12/8/ ¦Litigation and ¦ ¦ ¦2009 ¦ ¦ ¦0511 ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0512¦5/18/ ¦Transcript of Trial Testimony of Robert Marx in Hogan v. NPC¦ ¦ ¦2011 ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. ¦Date ¦Description ¦ ¦No. ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Robert Marx in In re Aredia & Zometa ¦ ¦ ¦ ¦ ¦ ¦DX- ¦5/13/ ¦Litigation and ¦ ¦ ¦2011 ¦ ¦ ¦0513 ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦5/27/ ¦Deposition of Robert Marx in Ingram v NPC and all accompanying ¦ ¦ ¦2011 ¦exhibits ¦ ¦0514 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦7/25/ ¦Deposition of Robert Marx in Rhodes v NPC and all accompanying ¦ ¦ ¦2011 ¦exhibits ¦ ¦0515 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Suzanne ¦ ¦DX- ¦4/16/ ¦ ¦ ¦ ¦2009 ¦Parisian in In re Aredia & Zometa ¦ ¦0516 ¦ ¦ ¦ ¦ ¦ ¦Litigation, Vol I and all accompanying exhibits ¦ +-----+-------+---------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Suzanne ¦ ¦DX- ¦4/17/ ¦ ¦ ¦ ¦2009 ¦Parisian in In re Aredia & Zometa ¦ ¦0517 ¦ ¦ ¦ ¦ ¦ ¦Litigation, Vol II and all accompanying exhibits ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦8/22/ ¦Deposition of Suzanne Parisian in Stevens v. NPC and all ¦ ¦ ¦2009 ¦accompanying exhibits ¦ ¦0518 ¦ ¦ ¦ +-----+-------+---------------------------------------------------------------¦ ¦DX- ¦9/189/ ¦Transcript of the Trial Testimony of Suzanne Parisian in ¦ ¦ ¦22/09 ¦Stevens v. NPC nad all accompanying exhibits ¦ ¦0519 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦Deposition of Suzanne ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Parisian in In re Aredia & Zometa ¦ ¦DX- ¦2/3/ ¦ ¦ ¦ ¦2010 ¦Litigation and ¦ ¦0520 ¦ ¦ ¦ ¦ ¦ ¦all ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦accompanying exhibits ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦7/26/ ¦Deposition of Suzanne Parisian in Bessemer v. NPC and all ¦ ¦ ¦2010 ¦accompanying exhibits ¦ ¦0521 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦2/27/ ¦Deposition of Wayne Ray in In re Aredia & Zometa ¦ ¦ ¦2010 ¦ ¦ ¦0522 ¦ ¦Litigation Vol I and all accompanying exhibits ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦2/20/ ¦Deposition of Wayne Ray in In re Aredia & Zometa ¦ ¦ ¦2009 ¦ ¦ ¦0523 ¦ ¦Litigation Vol I and all accompanying exhibits ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦2/21/ ¦Deposition of Wayne Ray in In re Aredia & Zometa ¦ ¦ ¦2009 ¦ ¦ ¦0524 ¦ ¦Litigation Vol II and all accompanying exhibits ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦9/12/ ¦Deposition of Wayne Ray in Stevens v. NPC and all ¦ ¦ ¦2009 ¦accompanying exhibits ¦ ¦0525 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0526¦4/14/ ¦Transcript of Kemp Hearing in Bessemer v. NPC ¦ ¦ ¦2010 ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0527¦4/23/ ¦Transcript of Kemp Hearing in Bessemer v. NPC ¦ ¦ ¦2010 ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+------+--------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Agreement for Expert Witness Services ¦ ¦0528 ¦ ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX- ¦ ¦Publication listing regarding Prevalence Stratified By Type of¦ ¦ ¦ ¦Cancer ¦ ¦0529 ¦ ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦AAOMS and ASMBR standards ¦ ¦0530 ¦ ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦ADA website print-out re ONJ ¦ ¦0531 ¦ ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Guidance for Industry, Content and format of Investigationa ¦ ¦ ¦ ¦New Drug Applications ¦ ¦DX- ¦11/00/¦ ¦ ¦ ¦1995 ¦(INDs) for ¦ ¦0532 ¦ ¦ ¦ ¦ ¦ ¦Phase 1 studies of drugs, including well-characterized, ¦ ¦ ¦ ¦therapeutic, biotechnology-derived products (Nov. 1995) ¦ +-------+------+--------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Statement of FDA Commisioner Lutter before Congress ¦ ¦0533 ¦ ¦ ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦Transcript excerpts of Dr. Ruggiero's September 2005 ¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦AAOMS ¦ ¦0534 ¦ ¦ ¦ ¦ ¦ ¦Presentation ¦ +-------+------+--------------------------------------------------------------¦ ¦ ¦ ¦U.S. Food and Drug ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Administration: AERS ¦ ¦DX- ¦1/9/ ¦ ¦ ¦ ¦2009 ¦instructions ¦ ¦0535 ¦ ¦ ¦ ¦ ¦ ¦(revised ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦1/9/09) ¦ +-------+------+--------------------------------------------------------------¦ ¦DX-0536¦ ¦21 CFR 1.21 ¦ +-----------------------------------------------------------------------------+

+----------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+---------------------¦ ¦DX-0537¦ ¦21 C.F.R. Part 7 ¦ +-------+----+---------------------¦ ¦DX-0538¦ ¦21 CFR § 56.102(g) ¦ +-------+----+---------------------¦ ¦DX-0539¦ ¦21 CFR § 56.103(a) ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 56.103(b) ¦ ¦0540 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 56.109(a) ¦ ¦0541 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 56.109(f) ¦ ¦0542 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 56.111(a)(1)¦ ¦0543 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 56.111(a)(2)¦ ¦0544 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 56.111(a)(6)¦ ¦0545 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 56.113 ¦ ¦0546 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR part 201 ¦ ¦0547 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR§ 2 02.1 ¦ ¦0548 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 202.10 ¦ ¦0549 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 310.300 ¦ ¦0550 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 310.301 ¦ ¦0551 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR § 312 ¦ ¦0552 ¦ ¦ ¦ +-------+----+---------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦21 CFR part 314 ¦ ¦0553 ¦ ¦ ¦ +----------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date¦Description ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0554¦ ¦21 CFR 316 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0555¦ ¦21 CFR part 601 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0556¦ ¦21 CFR § 812 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0557¦ ¦21 CFR part 814 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0558¦ ¦21 U.S.C. § 321 ¦ +-------+----+----------------------------------------------------------------¦ ¦ ¦ ¦21 U.S.C. § ¦ ¦DX-0559¦ ¦ ¦ ¦ ¦ ¦352(a) ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0560¦ ¦21 U.S.C. § 355 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0561¦ ¦21 U.S.C. § 360 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX-0562¦ ¦42 U.S.C. § 282 ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦American Cancer Society, Cancer Facts & Figures 2000, Atlanta: ¦ ¦ ¦2000¦American Cancer ¦ ¦0563 ¦ ¦ ¦ ¦ ¦ ¦Society (2000) ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦American Cancer Society, Cancer Facts & Figures 2001, Atlanta: ¦ ¦ ¦2001¦American Cancer Society (2001) ¦ ¦0564 ¦ ¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦American Cancer Society, Cancer Facts & Figures 2002, Atlanta: ¦ ¦ ¦2002¦American Cancer Society (2002) ¦ ¦0565 ¦ ¦ ¦ +-------+----+----------------------------------------------------------------¦ ¦DX- ¦ ¦American Cancer Society, Cancer Facts & Figures 2003, Atlanta: ¦ ¦ ¦2003¦American Cancer Society (2003) ¦ ¦0566 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦ ¦American Cancer Society, Cancer Facts & Figures 2004, ¦ ¦ ¦2004 ¦Atlanta: American Cancer Society (2004) ¦ ¦0567 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦American Cancer Society, Cancer Facts & Figures 2005, ¦ ¦DX-0568¦2005 ¦Atlanta: American Cancer ¦ ¦ ¦ ¦ ¦ ¦ ¦ ¦Society (2005) ¦ +-------+-------+-------------------------------------------------------------¦ ¦ ¦ ¦All Exhibits Indentified in ¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Plaintiff's ¦ ¦0569 ¦ ¦ ¦ ¦ ¦ ¦Pretrial Statement and the Exhibits Thereto ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦6/2/ ¦Deposition of Sharon Pfeiffer in White v. NPC and all ¦ ¦ ¦2010 ¦accompanying exhibits ¦ ¦0570 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦12/3/ ¦ ¦ ¦ ¦2008 ¦Expert Report of Dr. David Ettinger ¦ ¦0571 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Current CV of Dr. David Ettinger ¦ ¦0572 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦12/2/ ¦ ¦ ¦ ¦2008 ¦Expert Report of Dr. Alan Felsenfeld ¦ ¦0573 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Current CV of Dr. Alan Felsenfeld ¦ ¦0574 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX-0575¦10/20/ ¦Transcript of De Bene Esse Deposition of Talib Najjar in ¦ ¦ ¦2010 ¦Fussman v. NPC ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦11/4/ ¦Transcript of Trial Testimony of Robert Marx in Fussman v. ¦ ¦ ¦2010 ¦NPC ¦ ¦0576 ¦ ¦ ¦ +-------+-------+-------------------------------------------------------------¦ ¦DX- ¦9/23/ ¦Transcript of Trial Testimony of Robert Marx in Bessemer v. ¦ ¦ ¦2010 ¦NPC ¦ ¦0577 ¦ ¦ ¦ +-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+ ¦Ex. No.¦Date ¦Description ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦9/24/ ¦Transcript of Trial Testimony of Robert Marx in Bessemer v. ¦ ¦ ¦2010 ¦NPC ¦ ¦0578 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦9/29/ ¦Transcript of Trial Testimony of Suzanne Parisian in ¦ ¦ ¦2010 ¦Bessemer v. NPC ¦ ¦0579 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦DX- ¦11/3/ ¦Transcript of Trial Testimony of Suzanne Parisian in Fussman¦ ¦ ¦2010 ¦v. NPC ¦ ¦0580 ¦ ¦ ¦ +-------+--------+------------------------------------------------------------¦ ¦ ¦ ¦TASQ ¦ ¦DX- ¦ ¦ ¦ ¦ ¦ ¦Technology, Inc. / First Data ¦ ¦0581 ¦ ¦ ¦ ¦ ¦ ¦Corporation ¦ +-------+--------+------------------------------------------------------------¦ ¦DX-0582¦ ¦Photographs of William White Produced by Plaintiff ¦ +-----------------------------------------------------------------------------+